NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
NCT03942822,Chia Supplementation and Non Alcoholic Fatty Liver Disease,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease|Dietary Modification,Dietary Supplement: Milled chia seeds,Effect of a chia (Salvia hispanica L.) supplemented diet in patients with non-alcoholic fatty liver|Effect of chia on plasma levels of alpha linolenic acid|Effect of chia on lipid parameters,Instituto Nacional de Cardiologia Ignacio Chavez,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,16-980,1-Sep-16,1-Sep-17,1-Sep-17,8-May-19,null,8-May-19,,,https://ClinicalTrials.gov/show/NCT03942822
NCT03936803,Interval Training Versus Electro Acupuncture on Liver Functions in Patients With Non-alcoholic Fatty Liver Disease,,Recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease,Behavioral: aerobic interval training exercise .|Device: electro acupuncture,body mass index|lab investigations,Cairo University,All,30 Years to 55 Years   (Adult),Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",P.T.REC/012/001579,1-May-17,Jun-19,Jul-19,3-May-19,null,7-May-19,"faculty of physical therapy Cairo university, Cairo, Egypt",,https://ClinicalTrials.gov/show/NCT03936803
NCT03868566,"An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD",,Recruiting,No Results Available,NASH - Nonalcoholic Steatohepatitis,Drug: SNP-612 dose1|Drug: SNP-612 dose2|Drug: SNP-612 dose3,Change in serum ALT|Change in serum AST|Change in serum Alk-P|Change in serum γ-GT|Change in GSP|Change in liver fat content as measured by liver fat fraction (FF) with magnetic resonance imaging method.|Change in serum CK-18 fragment levels|Rate of AE/SAE|Rate of AEs leading to discontinuation at end of treatment,Sinew Pharma Inc.,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,54,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SNP-612-202,4-Aug-17,31-Dec-19,31-Dec-19,11-Mar-19,null,13-Mar-19,"Tri-Service General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT03868566
NCT03791203,Effectiveness and Adherence of Modified Alternate-day Calorie Restriction (MACR) in Non-Alcoholic Fatty Liver Disease,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease,Behavioral: Calorie restriction (MACR),Change from baseline shear wave elastography (SWE) at 8 weeks|Change from baseline liver steatosis at 8 weeks|Concentration of high-density lipoprotein (HDL)|Concentration of low-density lipoprotein (LDL)|Concentration of triglycerides (TG)|Concentration of total cholesterol (TC)|Concentration of fasting blood sugar (FBS)|Concentration of alanine aminotransferase (ALT)|Concentration of aspartate aminotransferase (AST)|Dietary plan adherence,University of Science Malaysia,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,43,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,304/PPSP/61313173,1-Aug-15,31-Jul-17,1-Oct-17,1-Jan-19,null,1-Jan-19,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03791203/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03791203/ICF_001.pdf",https://ClinicalTrials.gov/show/NCT03791203
NCT03774511,Effects of Exercise on Patients With Nonalcoholic Fatty Liver Disease- A Comparative Randomized Controlled Trial,[PTREC],Completed,No Results Available,Nonalcoholic Fatty Liver Disease|Obesity|Exercise,Other: High-Intensity Interval Exercise,peak oxygen uptake (VO2peak),Ahlia University|Cairo University,All,40 Years to 60 Years   (Adult),Not Applicable,30,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",P.T. REC/012/002146,9-Jul-17,10-Aug-18,10-Dec-18,13-Dec-18,null,13-Dec-18,"Dr Sayed Tanatwy, Giza, Egypt",,https://ClinicalTrials.gov/show/NCT03774511
NCT03738358,Clinical Study of 12-week Trehalose Intake in Patients With Fatty Liver Disease,,Completed,No Results Available,Non-alcoholic Fatty Liver,Dietary Supplement: Trehalose|Other: Placebo,"Change in liver fat content scanned by CT|Change in ALT and AST|Change in homeostatic model assessment-insulin resistance (HOMA-IR)|Change in total cholesterol, LDL, HDL, triglyceride (TG) and free fatty acid|Change in BMI|Change in visceral fat and subcutaneous fat levels|Adverse event (AE)",Samsung Medical Center,All,"19 Years to 79 Years   (Adult, Older Adult)",Not Applicable,39,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",2016-02-015,30-Jun-16,20-Mar-18,20-Mar-18,12-Nov-18,null,30-Jan-19,,,https://ClinicalTrials.gov/show/NCT03738358
NCT03725631,"Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD",,Recruiting,No Results Available,Nonalcoholic Fatty Liver|Nonalcoholic Steatohepatitis,Diagnostic Test: Imaging and serologic evaluation of fibrosis and steatosis,Development of scoring system for diagnosis of NASH|Evaluation of hepatic fibrosis using fibroscan|Evaluation of hepatic steatosis using fibroscan|Evaluation of hepatic fibrosis using MRI|Evaluation of hepatic steatosis using MRS|Evaluation of hepatic fibrosis using serologic marker,Korea University Guro Hospital,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,150,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2016GR0302,1-Sep-16,31-Aug-19,31-Aug-19,31-Oct-18,null,31-Oct-18,"Korea University Guro Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03725631
NCT03648086,Intestinal Microbiota Transplantation for Nonalcoholic Fatty Liver Disease,NAFLD,Recruiting,No Results Available,Non-alcoholic Fatty Liver Disease,Other: intestinal microbiota transplantation,The change of CT ratio of liver/spleen|biochemical indicators|Fibroscan E value|Changes of gut microbiota,Zhongshan Hospital Xiamen University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2017005,14-Nov-17,Oct-20,Nov-20,27-Aug-18,null,27-Aug-18,"Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, China","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03648086/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03648086/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03648086
NCT03614039,Effect of Probiotic and Smectite Gel on NAFLD,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease|Fatty Liver|Liver Diseases|Digestive System Diseases|Type2 Diabetes,"Dietary Supplement: ""Symbiter Forte""|Dietary Supplement: Placebo",fatty liver index (FLI)|liver stiffness (LS)|ALT|AST|γ-GT|Total Cholesterol (TC)|Tryglicerides (TG)|LDL-Cholesterol (LDL-C)|VLDL-Cholesterol (VLDL-C)|HDL-Cholesterol (HDL-C)|cytokines levels,Nazarii Kobyliak|Bogomolets National Medical University,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ENDO-3,15-Sep-15,15-Mar-16,20-Apr-16,3-Aug-18,null,7-Aug-18,,,https://ClinicalTrials.gov/show/NCT03614039
NCT03536650,Effect of DMR in the Treatment of NASH,DMR_NASH_001,Recruiting,No Results Available,NASH - Nonalcoholic Steatohepatitis,Device: DMR,"Safety of duodenal mucosal resurfacing characterized by the incidence of all Adverse Device Effects (ADEs), and subsequent adverse events [ Time Frame: 12 months ] in patients with NASH.|Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 6 months in DMR subjects.|Change in NAS score from baseline in the following 12 months in DMR subjects.|Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 6 months in DMR subjects|Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 12 months in DMR subjects|Change in Transient Elastography using Firboscan from baseline in the following at 6 months in DMR subjects|Change in Transient Elastography using Firboscan from baseline in the following at 12 months in DMR subjects|Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 12 months in DMR subjects.|Change in transaminases levels from baseline in the following 6 months in DMR subjects|Change in transaminases levels from baseline in the following 12 months in DMR subjects|Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 6 months in DMR subjects|Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 12 months in DMR subjects|Change in stage of fibrosis from baseline in the following 12 months in DMR subjects","Erasme University Hospital|Fractyl Laboratories, Inc.",All,"28 Years to 75 Years   (Adult, Older Adult)",Not Applicable,12,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,P2017/302,8-Nov-17,30-Jun-18,31-Dec-19,25-May-18,null,28-May-18,"Erasme Hospital, Brussels, Belgium",,https://ClinicalTrials.gov/show/NCT03536650
NCT03528707,Effect of Probiotic Co-administration With Omega-3 Fatty Acids on NAFLD,,Completed,No Results Available,Type2 Diabetes|NAFLD|Probiotic|Omega-3 Fatty Acids,Dietary Supplement: Symbiter-Omega|Dietary Supplement: Placebo,fatty liver index (FLI)|liver stiffness (LS)|ALT|AST|γ-GT|Total Cholesterol (TC)|Tryglicerides (TG)|LDL-Cholesterol (LDL-C)|VLDL-Cholesterol (VLDL-C)|HDL-Cholesterol (HDL-C)|cytokines levels,Bogomolets National Medical University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ENDO-2,14-Apr-15,22-Dec-15,28-Jan-16,18-May-18,null,18-May-18,,,https://ClinicalTrials.gov/show/NCT03528707
NCT03467282,Probiotics in NASH Patients - PROBILIVER TRIAL,NASH,Recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease,Dietary Supplement: Probiotic|Dietary Supplement: Placebo,hepatic fibrosis|diversity of gut microbiota|inflammation by TLR4 expression|inflammation by CK18 expression|inflammation by serum C-reactive protein|metabolic syndrome|change in body composition by DEXA|body composition by bioimpedance|change in hand grip strength|change in physical ability|change in the parameters of sarcopenia by serum myostatin|change in the parameters of sarcopenia by serum testosterone,Hospital de Clinicas de Porto Alegre,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",160438,29-Nov-17,31-Mar-19,20-Dec-21,15-Mar-18,null,27-Feb-19,"Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil",,https://ClinicalTrials.gov/show/NCT03467282
NCT03463967,Effects of Tomato Products in Children With NAFLD,,Recruiting,No Results Available,NAFLD,Dietary Supplement: Lycopene-enriched tomato juice|Other: Energy-restricted diet,Reduction of liver steatosis|Reduction in BMI|Reduction in ALT serum level|Improvement of inflammatory state|Amelioration of oxidative state,Federico II University,All,4 Years to 14 Years   (Child),Not Applicable,61,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,TD1016,Oct-16,Feb-18,Jun-18,13-Mar-18,null,13-Mar-18,"Unit of Hepatology-Dept. of Pediatric Clinic, Naples, Italy",,https://ClinicalTrials.gov/show/NCT03463967
NCT03444233,Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women.,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease|Obesity,Other: Diet,metabolite concentration|fatty liver index|Non-alcoholic fatty liver disease (NAFLD)|Body weight|Blood pressure (systolic and diastolic)|GGT|GOT|GPT|AP|Triglycerides|HDL|LDL|Fasting glucose|BSR|Kreatinine|Uric acid|Urea|Cholesterol|Ghrelin|Leptin,University of Hohenheim,Female,20 Years to 30 Years   (Adult),Phase 4,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Fructose Study,15-Aug-09,15-Oct-09,15-Oct-09,23-Feb-18,null,23-Feb-18,,,https://ClinicalTrials.gov/show/NCT03444233
NCT03439254,Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis,REVERSE,Recruiting,No Results Available,Compensated Cirrhosis|Nonalcoholic Steatohepatitis,Drug: Obeticholic acid (10 mg)|Drug: Obeticholic acid (10 mg to 25 mg)|Drug: Placebo,"Percentage of subjects with improvement in fibrosis by at least 1 stage with no worsening of NASH, using NASH Clinical Research Network (CRN) scoring system|Percentage of subjects with improvement in fibrosis by at least 2 stages, using Ishak scoring criteria|Percentage of subjects with NASH resolution, using the NASH CRN scoring",Intercept Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 3,540,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",747-304,30-Aug-17,Jul-20,Jul-21,20-Feb-18,null,19-Apr-19,"University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States|Digestive Health Specialists of the Southeast, Dothan, Alabama, United States|Objective GI d/b/a North Alabama GI Research Center, Madison, Alabama, United States|Del Sol Research Management, LLC, Chandler, Arizona, United States|The Institute for Liver Health, Chandler, Arizona, United States|The Institute for Liver Health, Chandler, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|The Institute for Liver Health, Tucson, Arizona, United States|Mesquite Surgery Center - Gen1 Research, Tucson, Arizona, United States|Liver Wellness Center, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|Hope Clinical Research, Canoga Park, California, United States|Precision Research Institute, Chula Vista, California, United States|University of California, San Francisco-Fresno, Fresno, California, United States|Scripps Whittier Diabetes Institute, La Jolla, California, United States|University of California, San Diego (Altman Clinical and Translational Research Institute), La Jolla, California, United States|eStudySite, La Mesa, California, United States|Keck Hospital of USC, Los Angeles, California, United States|Cedars-Sinani Medical Center, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|United Medical Doctors, Murrieta, California, United States|Palmtree Clinical Research, INC., Palm Springs, California, United States|Stanford University Medical Center, Palo Alto, California, United States|ASCLEPES Research Centers, Panorama City, California, United States|California Liver Research Institute, Pasadena, California, United States|Havana Research Institute, Pasadena, California, United States|Alliance Clinical Research, Poway, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|Lomita Family Medical Group, Inc., San Diego, California, United States|eStudySite, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Colorado Denver and Hospital, Aurora, Colorado, United States|Peak Gastroenterology Associates, Colorado Springs, Colorado, United States|South Denver Gastroenterology, PC, Englewood, Colorado, United States|Naugatuck Valley Gastroenterology Consultants, LLC - Gen1 Research, Prospect, Connecticut, United States|Innovative Medical Research of South Florida, Inc., Aventura, Florida, United States|Medycal Research, Inc., Brooksville, Florida, United States|Hi Tech and Global Research LLC, Coral Gables, Florida, United States|Top Medical Research, Inc., Cutler Bay, Florida, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|UF Health Jacksonville-Gastroenterology Emerson, Jacksonville, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Borland Groover, Jacksonville, Florida, United States|SIH Research, LLC, Kissimmee, Florida, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Bruce W. Carter, Miami VA Medical Center, Miami, Florida, United States|Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States|Advanced Research Institute Inc., New Port Richey, Florida, United States|Sensible Healthcare, LLC, Ocoee, Florida, United States|Omega Research Maitland, LLC, Orlando, Florida, United States|Innovation Medical Research Center, Palmetto Bay, Florida, United States|Gastroenterology Associates of Pensacola, PA, Pensacola, Florida, United States|Digestive and Liver Center of Florida, Spring Hill, Florida, United States|Tampa General Medical Group, Tampa, Florida, United States|Guardian Angel Research Center, INC, Tampa, Florida, United States|South Florida Center of Gastroenterology LLC, Wellington, Florida, United States|Florida Medical Clinic, P.A, Zephyrhills, Florida, United States|Summit Clinical Research, LLC, Athens, Georgia, United States|AGA, LLC, Atlanta, Georgia, United States|The Emory Clinic (TEC), Atlanta, Georgia, United States|Gastroenterology Associates of Central Georgia, LLC, Macon, Georgia, United States|Gastrointestinal Specialists of Georgia, Marietta, Georgia, United States|Grand Teton Research Group, PLLC, Idaho Falls, Idaho, United States|Northwestern Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Southwest Gastroenterology, New Lenox, Illinois, United States|Aquiant Research, New Albany, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kansas City VA Medical Center, Kansas City, Kansas, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Kansas Medical Clinic, Topeka, Kansas, United States|University of Louisville, Clinical Trials Unit, Louisville, Kentucky, United States|Tandem Clinical Research, LLC, Marrero, Louisiana, United States|Delta Research Partners, LLC, Monroe, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Louisiana Research Center, Shreveport, Louisiana, United States|University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|UMass Memorial Health Care, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center, Wyoming, Michigan, United States|Huron Gastroenterology Associates, Ypsilanti, Michigan, United States|Minnesota Gastroenterology, P.A., Saint Paul, Minnesota, United States|Gulfport Memorial Hospital - Gen1 Research, Gulfport, Mississippi, United States|Southern Therapy and Advanced Research (STAR) LLC, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CHI Health Alegent Creighton Clinic, Omaha, Nebraska, United States|Sierra Clinical Research, Las Vegas, Nevada, United States|eStudySite, Las Vegas, Nevada, United States|Amici GI-LLC, Martinsville, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|CHEAR Center LLC, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|University at Buffalo, Clinical and Translational Research Center, Buffalo, New York, United States|Ichan School of Medicine at Mount Sinai Beth Israel, New York, New York, United States|NYU Langone Health, New York, New York, United States|Ichan School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, North Carolina, United States|Charlotte Gastroenterology & Hepatology, PLLC, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Carolinas Center for Liver Disease/Carolinas HealthCare System, Huntersville, North Carolina, United States|Carolinas Health Care System Center for Liver Disease, Huntersville, North Carolina, United States|Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|Trial Management Associates, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem LLC, Winston-Salem, North Carolina, United States|Dayton Gastroenterology, Inc., Beavercreek, Ohio, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|UC Physicians Company, LLC/Division of Digestive Diseases, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Adult Gastroenterology Associates - Gen1 Research, Tulsa, Oklahoma, United States|Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, United States|Hillmont GI, pc, Flourtown, Pennsylvania, United States|The Pennsylvania State University and the Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Drexel University, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Einstein Healthcare Network, Philadelphia, Pennsylvania, United States|UPMC - Center for Liver Diseases at the Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina, United States|SCTR Research Nexus, Charleston, South Carolina, United States|Rapid City Medical Center LLP, Rapid City, South Dakota, United States|Gastro One, Germantown, Tennessee, United States|Associates in Gastroenterology, PLC, Hermitage, Tennessee, United States|Clinical Research Solutions, Jackson, Tennessee, United States|Johnson City Medical Center, Johnson City, Tennessee, United States|Methodist Healthcare University Hospital, Memphis, Tennessee, United States|Quaility Medical Research, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center - Digestive Disease Center, Nashville, Tennessee, United States|Texas Clinical Research Institute LLC, Arlington, Texas, United States|Austin Center for Clinical Research, Austin, Texas, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Liver Center of Texas, Dallas, Texas, United States|Texas Digestive Disease Consultants, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|San Antonio Military Medical Center, Fort Sam Houston, Texas, United States|Baylor Scott and White All Saints Medical Center, Fort Worth, Texas, United States|Texas Digestive Disease Consultants, Fort Worth, Texas, United States|Baylor College of Medicine - Advanced Liver Therapies, Houston, Texas, United States|Baylor College of Medicine - Ben Taub Hospital, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Liver Associates of Texas, P.A., Houston, Texas, United States|The University of Texas Medical School at Houston, Houston, Texas, United States|Houston Digestive Consultants, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Coastal Medical Group, Houston, Texas, United States|Pinnacle Clinical Research, PLLC, Live Oak, Texas, United States|Centex Studies, Inc., McAllen, Texas, United States|American Research Corporation, San Antonio, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Texas Digestive Disease Consultants, San Marcos, Texas, United States|Mt. Olympus Medical Research, Sugar Land, Texas, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|Maryview Hospital, Inc. d/b/a Bon Secours Liver Institute of Hampton Roads, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bon Secours Richmond Community Hospital, Inc. d/b/a Bon Secours, Richmond, Virginia, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Gastroenterology Consultants of Southwest Virginia, Roanoke, Virginia, United States|Virginia Mason - Seattle Medical Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Organ Transplant and Liver Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|UW Digestive Health Center, Madison, Wisconsin, United States|Nepean Blue Mountains Local Health District, Nepean Hospital, Kingswood, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia|Mater Misericordiae Limited, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Center, Bedford Park, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|University of Calgary Liver Unit (Heritage Medical Research Clinic), Calgary, Alberta, Canada|GI Research, Edmonton, Alberta, Canada|South Edmenton Gastroenterology, Edmonton, Alberta, Canada|LAIR Centre, Vancouver, British Columbia, Canada|Gordon and Leslie Diamond Helath Care Centre, Vancouver, British Columbia, Canada|(G.I.R.I.) GI Research Institute, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|Kent Place, Lindsay, Ontario, Canada|London Health Sciences Centre-University Hospital, London, Ontario, Canada|Office of Dr. Gauthier, North Bay, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|McGill University Health Centre (MUHC), Montreal, Quebec, Canada|Centre de Recherche du Centre Hospitalier de l'Universite' de Montreal (CRCHUM), Montreal, Quebec, Canada|Centre Hospitalier Universitaire d'Angers, Angers, France|Hôpital Beaujon- Service d'Hepatologie, Clichy, France|Center Hospitalier Universitaire Grenoble Alpes, La Tronche, France|Hôpital de la Croix Rousse, Lyon Cedex 04, France|CHU de Nice, Hôpital de l'Archet 2, Nice, France|Hôpital Saint Antoine, Paris, France|Hôpital Pitié-Salpêtrierè, Paris, France|CHU de Bordeaux - GH Sud - Hôpital Haut-Lévêque, Pessac, France|CHU de Rouen-Centre Hospitalier Universitaire, Rouen, France|Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France|Hôpital Hautepierre, Strasbourg, France|Hôpital Purpan, Toulouse, France|CHRU de Nancy - Hôpitaux de Brabois, Vandoeuvre-les-Nancy, France|Hôpital Paul Brousse, Villejuif, France|Universitätsklinik Tübingen, Tübingen, Baden Württemberg, Germany|Univeritätsklinkum Ulm, Ulm, Baden Württemberg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Baden-Würtlemberg, Germany|Univeritätsklinkum Würzburg, Würzburg, Bayern, Germany|Teuber Consulting & Research UG, Frankfurt am main, Hessen, Germany|Katholische Kliniken Ruhrhalbinsel gGmbh, Essen, Nordrhein-Westfalen, Germany|Universitätsmedizin Mainz, Mainz, Rheinland-Pfalz, Germany|EUGASTRO GmbH, Leipzig, Sachsen, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Sachsen, Germany|Gastroenterologisch-Hepatologisches Zentrum Kiel, Kiel, Schleswig-Holstein, Germany|Charité - Universitätsmedzin Berlin, Berlin, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Univeritätsmedizin Mannheim, Mannheim, Germany|Synexus Magyarország Kft. Budapest, Budapest, Hungary|Synexus Magyarorszag Kft. Debrecen A.S., Debrecen, Hungary|Synexus Magyarorszag Kft. Gyula DRS, Gyula, Hungary|Szabolcs - Szatmar - Bereg County Hospitals and University Teaching Hospital, Nyiregyhaza, Hungary|Middlemore Clinical Trials, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Public Hospital, Dunedin, New Zealand|Waikato Hospital, Hamilton, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Synexus Polska Sp. z o.o., Oddział w Częstochowie, Częstochowa, Poland|Synexus Polska Sp. z o.o., Oddział w Katowicach, Katowice, Poland|Synexus Polska Sp. z o.o., Oddział w Poznaniu, Poznań, Poland|Synexus Polska Sp. z o.o., Oddział w Warszawie, Warszawa, Poland|Synexus Polska Sp. z o.o., Oddział w Wrocławiu, Wrocław, Poland|Synexus Polska Sp. z o.o., Oddział w Łodzi, Łódź, Poland|Latin Clinical Trial Center, San Juan, Puerto Rico|Fundación de Investigación de Diego, San Juan, Puerto Rico|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politécnic La Fe, Valencia, Spain|Medical Center of Private High Educational Institue <<Institute of General Practice - Family Medicine>>, Kyiv, Ukraine|Medical Center of LLC Medbud-Clinic, Clinical Diagnostic Department, Kyiv, Ukraine|Kyiv Railway Clinical Hospital №2 of branch ""Health Center"" of the Joint-Stock Company ""Ukranian Railway"", Day treatment department, Kyiv, Ukraine|Royal Cornwall Hospitals NHS Trust, Truro, Cornwall, United Kingdom|Derby Teaching Hospitals NHS Foundation Trust, Derby, Derbyshire, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, England, United Kingdom|Addenbrooke's Hospital, Cambridge, England, United Kingdom|Barts Health NHS Trust Royal London Hospital, London, England, United Kingdom|Royal Free Hospital NHS Foundation Trust, London, England, United Kingdom|King's College Hospital NHS Foundation Trust, London, England, United Kingdom|Imperial College Healthcare NHS Trust, St Mary's Hospital, London, England, United Kingdom|Manchester University Hospitals NHS Foundation Trust, Manchester, England, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom|Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom|Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Abertawe Bro Morganinwg University Local Health Board, Swansea, Wales, United Kingdom|Unversity Hospital Southampton NHS Trust, Southampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT03439254
NCT03400163,A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH),,Completed,No Results Available,Non-Alcoholic Steatohepatitis,Drug: BMS-986036|Drug: Placebo,"Change in percent hepatic fat fraction (%) by Magnetic Resonance Imaging (MRI)|Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) and AEs leading to discontinuation|Number of participants with marked laboratory abnormalities|Number of participants with clinically relevant ECG abnormalities|Number of participants with clinically relevant vital sign abnormalities|Number of participants with injection site reactions|Mean percent change from baseline in Bone Mineral Density by Dual Energy X-Ray Absorptiometry (DXA)|Geometric mean of Trough Observed Plasma Concentration (Ctrough) of BMS-986036 at Day 112|Percentage of participants with positive Anti-BMS-986036 Antibody response at Day 142|Percentage of participants with positive Anti-FGF21 Antibody response at Day 142",Bristol-Myers Squibb,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 2,3,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MB130-045 A,8-May-15,18-Jan-17,19-Jun-17,17-Jan-18,null,19-Jan-18,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Texas Liver Institute, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT03400163
NCT03380416,Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients,MEDEA,Recruiting,No Results Available,Diabetes Type 2|NAFLD,Other: Portfolio Diet|Other: MUFA Diet,Liver fat content|Liver functionality|Blood pressure|Endothelial function|Liver fibrosis|Biochemical parameters|Body composition|lipids|subclinical inflammation|oxidative stress,Federico II University,All,"35 Years to 75 Years   (Adult, Older Adult)",Not Applicable,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",16/17,Apr-16,Mar-19,Dec-19,21-Dec-17,null,15-Feb-19,"Department of Clinical Medicine and Surgery, Naples, Italy",,https://ClinicalTrials.gov/show/NCT03380416
NCT03377140,The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease,,Unknown status,No Results Available,Non Alcoholic Steatohepatitis,Dietary Supplement: Hesperidin|Other: control,liver fibrosis|body mass index,National Nutrition and Food Technology Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",6756,1-Jun-17,1-Feb-18,20-Mar-18,19-Dec-17,null,19-Dec-17,"National Nutrition and Food Technology Research Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT03377140
NCT03377153,The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease,,Unknown status,No Results Available,Non Alcoholic Steatohepatitis,Dietary Supplement: hesperidin and flaxseed|Other: control,liver fibrosis|body mass index,National Nutrition and Food Technology Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,6757,1-Jun-17,1-Feb-18,20-Mar-18,19-Dec-17,null,19-Dec-17,"National Nutrition and Food Technology Research Institute, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT03377153
NCT03375580,Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD,,Recruiting,No Results Available,Nonalcoholic Fatty Liver Disease,Dietary Supplement: TLC|Drug: metformin|Drug: Compound Zhenzhu Tiaozhi capsule|Drug: Simvastatin,Fat attenuation index|Serum triglyceride|Serum cholesterol|Serum lipoproteins|Hydrogen/methane breath testing|Quality of life,The First Affiliated Hospital of Guangdong Pharmaceutical University,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,196,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,U1111-1201-8245,31-Dec-17,30-Aug-19,31-Dec-19,18-Dec-17,null,19-Dec-17,"First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03375580/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03375580/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03375580/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03375580
NCT03375008,Predictable MR Index for Nonalcoholic Steatohepatitis (NASH),,Completed,No Results Available,Nonalcoholic Steatohepatitis,Diagnostic Test: Imaging diagnostic and biopsy,"Radiologic Diagnosis & Criteria of nonalcoholic steatohepatitis(NASH)|Fat imaging : Fat signal fraction measured on magnetic resonance(MR) spectroscopy|Fibrosis imaging(1) : Liver stiffness measured on magnetic resonance elastography(MRE)|Fibrosis imaging(2) : T1 relaxation time measured on T1 mapping|Histologic interpretation(1) : Nonalcoholic fatty liver disease activity score (NAS)|Histologic interpretation(1) : Steatosis, Activity, Fibrosis (SAF) score",Korea University Guro Hospital,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,47,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,KUGH16184,8-Sep-16,7-Aug-18,7-Aug-18,15-Dec-17,null,16-May-19,"Korea University Guro Hospital, Seoul, Guro-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03375008
NCT03373643,Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease,NASHSAS,Recruiting,No Results Available,"Non-alcoholic Fatty Liver Disease|Sleep Apnea, Obstructive",Diagnostic Test: OSA screening,Association between OSA severity marker (apnea hypopnea index per hour on the polysomnography) and significant liver fibrosis (score F3 and F4 of the histological nonalcoholic steatohepatitis [NASH]-CRN classification)|Association between OSA severity marker (apnea hypopnea index per hour on the polysomnography) and significant nonalcoholic steatohepatitis (3 positive criteria on NASH-CRN classification)|Association between OSA severity marker (apnea hypopnea index per hour on the polysomnography) and significant liver steatosis (histological steatosis > 33% or stade 2 or more on NASH-CRN),"University Hospital, Angers",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening,UHAngers,14-Dec-17,14-Dec-19,14-Mar-20,14-Dec-17,null,16-Jan-19,"CHU Angers, Angers, Please Select, France",,https://ClinicalTrials.gov/show/NCT03373643
NCT03371355,"Study of ISIS 703802 in Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease",,Recruiting,No Results Available,"NAFLD|Diabetes Mellitus, Type 2|Hypertriglyceridemia|Fatty Liver, Nonalcoholic",Drug: ISIS 703802|Drug: Placebo,Percent change in fasting TG level from Baseline at the primary analysis time point.|The safety of ISIS 703802 by the incidence of treatment-emergent adverse events|The effect of ISIS 703802 on changes from Baseline at End-of-Treatment on glucose metabolism|The effect of ISIS 703802 on changes from Baseline at End-of-Treatment lipid metabolism|The effect of ISIS 703802 on changes from Baseline at End-of-Treatment on liver fat|Plasma Cmax of ISIS 703802 across different doses and dose regimens|Plasma Tmax of ISIS 703802 across different doses and dose regimens|Plasma AUC values of ISIS 703802 across different doses and dose regimens|The effect of ISIS 703802 on changes from Baseline on biomarkers related to liver inflammation|The effect of ISIS 703802 on changes from Baseline on adipose tissue as related to body composition|The effect of ISIS 703802 on changes from Baseline on WHR (waist-to-hip ratio) as related to body composition.|The effect of ISIS 703802 on changes from Baseline on BMI (Body Mass Index) as related to body composition,"Akcea Therapeutics|Ionis Pharmaceuticals, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,144,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ISIS 703802-CS2,18-Dec-17,28-Feb-19,31-May-19,13-Dec-17,null,26-Sep-18,"Clinical Sites, Chandler, Arizona, United States|Clinical Site, Fountain Hills, Arizona, United States|Clinical Site, Glendale, Arizona, United States|Clinical Site, Mesa, Arizona, United States|Clinical Site, Mesa, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Phoenix, Arizona, United States|Clinical Site, Huntington Park, California, United States|Clinical Site, Los Angeles, California, United States|Clinical Site, Montclair, California, United States|Clinical Site, Panorama City, California, United States|Clinical Site, Boca Raton, Florida, United States|Clinical Site, Jupiter, Florida, United States|Clinical Site, Port Saint Lucie, Florida, United States|Clinical Site, Atlanta, Georgia, United States|Clinical Site, Chicago, Illinois, United States|Clinical Site, Louisville, Kentucky, United States|Clinical Site, Edina, Minnesota, United States|Clinical Site, Bridgeton, New Jersey, United States|Clinical Site, Greensboro, North Carolina, United States|Clinical Site, High Point, North Carolina, United States|Clinical Site, Cincinnati, Ohio, United States|Clinical Site, Cincinnati, Ohio, United States|Clinical Site, Charleston, South Carolina, United States|Clinical Site, Austin, Texas, United States|Clinical Site, Carrollton, Texas, United States|Clinical Site, Dallas, Texas, United States|Clinical Site, Hurst, Texas, United States|Clinical Site, San Antonio, Texas, United States|Clinical Site, San Antonio, Texas, United States|Clinical Site, Layton, Utah, United States|Clinical Site, Hamilton, Ontario, Canada|Clinical Site, Toronto, Ontario, Canada|Clinical Site, Chicoutimi, Quebec, Canada|Clinical Site, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03371355
NCT03369145,"High-fat Overfeeding, Hepatokines and Appetite Regulation",OVEREAT,Completed,No Results Available,Insulin Resistance|Type2 Diabetes Mellitus|Non-Alcoholic Fatty Liver Disease|Obesity,Dietary Supplement: High-fat diet,Leukocyte cell-derived chemotaxin 2 (LECT2)|Fibroblast growth factor 21 (FGF21)|Fetuin-A|Acylated ghrelin|Peptide YY (PYY)|C-Terminal Telopeptide of Type 1 Collagen (CTX)|N-Terminal Propeptide of Type 1 Procollagen (P1NP)|Visual Analogue Scale for Subjective Ratings of Appetite|Subjective food preference|Whole-body insulin sensitivity|Homeostasis model assessment of insulin resistance (HOMA-IR)|Adipose tissue insulin resistance (ADIPO-IR)|Physical activity and sedentary behaviour|Resting Metabolic Rate|Fat Oxidation|Blood pressure|Body weight|Body fat percentage,Loughborough University|Nottingham Trent University|Nottingham University Hospitals NHS Trust,Male,18 Years to 40 Years   (Adult),Not Applicable,12,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,R17-P144,11-Dec-17,31-Jul-18,31-Jul-18,11-Dec-17,null,18-Feb-19,"National Centre for Sport and Exercise Medicine, Loughborough University, Loughborough, Leicestershire, United Kingdom|Clifton Campus, Nottingham Trent University, Nottingham, Nottinghamshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03369145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03369145/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03369145/ICF_002.pdf",https://ClinicalTrials.gov/show/NCT03369145
NCT03357380,A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver,,"Active, not recruiting",No Results Available,Hepatobiliary Disorders|Non-alcoholic Fatty Liver Disease,Drug: Semaglutide|Drug: Placebo,Change in liver stiffness (kPa) assessed by magnetic resonance elastography (MRE)|Change in relative liver fat content (%) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF)|Change in absolute liver fat volume (L) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF)|Proportion of subjects with at least 30% reduction in relative liver fat content assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF)|Proportion of subjects with at least 15% reduction in liver stiffness assessed by magnetic resonance elastography (MRE)|Change in visceral adipose tissue (L) assessed by magnetic resonance imaging (MRI)|Change in abdominal subcutaneous adipose tissue (L) assessed by magnetic resonance imaging (MRI)|Change in Body weight (% and kg)|Change in Waist circumference|Change in Body mass index (BMI)|Number of treatment-emergent adverse events (TEAEs)|Number of treatment-emergent hypoglycaemic episodes,Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,66,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NN9931-4381|2017-001193-42|U1111-1194-3900,28-Nov-17,27-Mar-20,27-Mar-20,29-Nov-17,null,17-Dec-18,"Novo Nordisk Investigational Site, Mainz, Germany|Novo Nordisk Investigational Site, Neuss, Germany",,https://ClinicalTrials.gov/show/NCT03357380
NCT03354247,Lifestyle Intervention in Fatty Liver (NAFLD),FOIEGRAS,Recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease,Behavioral: Lifestyle Intervention,Changes in food intake and Mediterranean diet adherence score|Changes in physical activity level|Changes in body mass index|Changes in abdominal girth|Changes in liver steatosis score according to ultrasonography,University of Bari|European Commission,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,722619,1-Jul-17,30-Jun-20,31-Dec-20,27-Nov-17,null,24-Jan-19,"Department of Biomedical Sciences Human Oncology - Clinica Medica ""A. Murri"", Bari, BA, Italy",,https://ClinicalTrials.gov/show/NCT03354247
NCT03350165,A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD),,Recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease,Drug: K-877|Drug: Placebo,"Efficacy: % Change from baseline to Week 24 in hepatic fat fraction by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)|Safety: Incidence of adverse events and adverse drug reactions that occurred after the administration of the study drug|Change in noninvasive imaging biomarkers (MRI-PDFF in %, MRE in kPa, Transient elastography in kPa)|Change in clinical laboratory tests (AST in IU/L, ALT in IU/L, γ-GTP in IU/L)|Change in noninvasive biomarkers (Cytokeratin 18 in U/L, Hyaluronic acid in ng/mL, Type IV collagen 7S in ng/mL, M2BPGi in no unit)|Change in noninvasive biomarkers (NAFLD fibrosis score)|Change in noninvasive biomarkers (FIB4 index)|Change in noninvasive biomarkers (NAFIC score)|Change in noninvasive biomarkers (ELF test)|Percentage of patients with ≥ 30% reduction in hepatic fat fraction (MRI-PDFF)|Percentage of patients with ≥ 15% reduction in liver stiffness (MRE)","Kowa Company, Ltd.",All,"20 Years and older   (Adult, Older Adult)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",K-877-FL-01,27-Dec-17,Feb-20,May-20,22-Nov-17,null,12-Feb-18,"Aomori Prefectural Central Hospital, Aomori, Aomori, Japan|Asahikawa Medical University, Asahikawa, Hokkaido, Japan|Fukuoka University Hospital, Fukuoka, Fukuoka, Japan|SeireiHamamatsu General Hospital, Hamamatsu, Shizuoka, Japan|Hamamatsu University Hospital, Hamamatsu, Shizuoka, Japan|Iwata City Hospital, Iwata, Shizuoka, Japan|Chutoen General Medical Center, Kakegawa, Shizuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Niigata University Medical & Dental Hospital, Niigata, Niigata, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Shiga University of Medical Science Hospital, Otsu, Shiga, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Yamagata University Hospital, Yamagata, Yamagata, Japan|Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan",,https://ClinicalTrials.gov/show/NCT03350165
NCT03339245,Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease|Obesity,Other: Fructose Solution (75 Grams)|Other: Glucose Solution (75 grams),Difference in the distribution of fecal microbiota in each participant,Rockefeller University|Weill Medical College of Cornell University|National Institutes of Health (NIH),All,"45 Years to 70 Years   (Adult, Older Adult)",Not Applicable,10,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",PHO-0956,5-Dec-17,2-Oct-18,2-Oct-18,13-Nov-17,null,5-Feb-19,"The Rockefeller University, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT03339245
NCT03329885,"A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Patients and Patients With Average to Very Serious Psoriasis",,Terminated,No Results Available,Rheumatoid Arthritis|Psoriasis|Ankylosing Spondylitis|Inflammatory Bowel Diseases|Nonalcoholic Steatohepatitis,Drug: BMS-986251|Other: Placebo,"Number of Serious Adverse Events (SAE)|Number of Adverse Events (AE) leading to study discontinuation|Number of deaths|Number of potentially clinically significant changes in electrocardiogram (ECG) parameters|Number of potentially clinically significant changes in vital signs|Number of potentially clinically significant changes in clinical laboratory parameters|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (tmax)|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)]|Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(0-inf)]|Terminal elimination half-life, calculated as 0.693/kel [t(1/2)]|Apparent (oral) clearance (CL/F)|Apparent volume of distribution at terminal phase [V(z)/F]|Cumulative urinary excretion [Ae(t)]|Amount excreted unchanged in urine (% of dose) [Fe(urine)%]|Renal clearance [CL(R)]|Area under the concentration-time curve over 24 hours (one dosing interval) [AUC(0-24)]|Ratio of AUC(0-24) following last dose to AUC(0-24) following first dose [AR[AUC(0-24)]]|Ratio of Cmax following last dose to Cmax following first dose [AR(Cmax)]|Pre-dose plasma concentration (Cpre)|Maximum observed inhibition [I(max)]|Time of maximum observed inhibition [t(Imax)]|Time of inhibition above 50% [t(I>50%)]|Time of inhibition above 90% [t(I>90%)]|Pre-dose inhibition [I(pre)]|Inhibition at time t [I(t)]",Bristol-Myers Squibb,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IM024-005|2017-003408-38,2-Nov-17,26-Jun-18,26-Jun-18,6-Nov-17,null,23-Jul-18,"Local Institution, Groningen, Netherlands",,https://ClinicalTrials.gov/show/NCT03329885
NCT03332940,An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH,,Completed,No Results Available,Nonalcoholic Steatohepatitis|NASH - Nonalcoholic Steatohepatitis,Drug: Tc 99M Sulfur Colloid|Drug: Tc99m-tilmanocept,Adverse Drug Reaction|Localization of Tc 99m tilmanocept|Localization of Tc 99m sulfur colloid|Localization Distribution Comparison,Navidea Biopharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 1,6,Industry,Interventional,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NAV3-30,6-Dec-17,10-Mar-19,10-Mar-19,6-Nov-17,null,21-Mar-19,"Kettering Medical Center, Kettering, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03332940
NCT03319199,The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver,,Not yet recruiting,No Results Available,"Fatty Liver, Nonalcoholic","Dietary Supplement: ""SLIM WATER""|Other: Placebo - water",The primary outcome is decline in serum levels of Aspartate transaminase (AST) to normal value.|Decline in serum levels of Alanine transaminase (ALT) to normal value.|Improvement in radiological hepatic steatosis .|Improvement in lipid profile.,"RAWI HAZZAN|HaEmek Medical Center, Israel",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",0068-16-EMC,Oct-17,Oct-18,Dec-18,24-Oct-17,null,24-Oct-17,,,https://ClinicalTrials.gov/show/NCT03319199
NCT03308916,Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers,SIPHON,Recruiting,No Results Available,"Liver Diseases, Alcoholic|Fibrosis",Diagnostic Test: transient elastography|Diagnostic Test: Enhanced liver fibrosis test|Diagnostic Test: Indirect serum markers of liver fibrosis|Diagnostic Test: Direct serum markers of liver fibrosis|Diagnostic Test: LiverTRAIL|Diagnostic Test: Cytokeratin 18|Diagnostic Test: Omics markers,Biopsy-verified advanced fibrosis|Liver-related outcomes|Liver related outcomes|Mortality,"Maja Thiele|Horizon 2020 - European Commission|Novo Nordisk A/S|University of Southern Denmark|Esbjerg University Hospital of South-West Jutland|Odense Municipality Alcohol Rehabilitation Unit|Svendborg Municipality Alcohol Rehabilitation Unit|University of Copenhagen|University of Oslo|Nordic Bioscience A/S|VLV Bio, Peviva AB|Manatee APS|Siemens Healthcare A/S|Steno Diabetes Center Copenhagen|Biomedical Research Foundation, Academy of Athens|European Molecular Biology Laboratory, EMBL, University of Heidelberg|Odense University Hospital",All,"30 Years to 75 Years   (Adult, Older Adult)",Not Applicable,4000,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,S-20170087,6-Oct-17,30-Dec-22,30-Oct-32,13-Oct-17,null,13-Oct-17,"Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark",,https://ClinicalTrials.gov/show/NCT03308916
NCT03300661,Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine,SEELN,Recruiting,No Results Available,Non Alcoholic Fatty Liver Disease|Lifestyle|Diet Modification,Behavioral: Mediterranean Style,Weight loss|Body Mass Index (BMI) decrease|Waist Circumference (WC) decrease|Blood sugar level decrease|Blood cholesterol level decrease|Blood triglycerides level dicrease,Università degli Studi di Brescia,All,20 Years to 59 Years   (Adult),Not Applicable,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Ubrescia,13-Jun-17,13-Dec-17,13-Dec-18,3-Oct-17,null,3-Oct-17,"ASST Spedali Civili Brescia, Brescia, Italy",,https://ClinicalTrials.gov/show/NCT03300661
NCT03294941,The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology,,Recruiting,No Results Available,NASH - Nonalcoholic Steatohepatitis,Combination Product: HepQuant SHUNT Liver Diagnostic Kit,Baseline DSI|Change in DSI over study period|Comparing DSI to other tests of liver disease severity,"HepQuant, LLC",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,72,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,HQ-US-SHUNT-1701,8-Dec-17,May-22,May-22,27-Sep-17,null,26-Jan-18,"Schiff Center for Liver Diseases, Miami, Florida, United States|University of PA, Philadelphia, Pennsylvania, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|TX Digestive Disease Consultants, Dallas, Texas, United States|The Texas Liver Institute, San Antonio, Texas, United States|McGuire VA Med Cntr, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washingtion, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03294941
NCT03291249,"Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM",,Not yet recruiting,No Results Available,NASH - Nonalcoholic Steatohepatitis|NAFLD|T2DM (Type 2 Diabetes Mellitus),Drug: Foralumab|Other: placebo|Drug: Omeprazole 20mg,severity and duration for all adverse events|Abnormal laboratory findings|Abnormal physical findings|Change ALT levels|Change in HbA1c levels|change in HOMA/HOMA-IR scores,"Tiziana Life Sciences, PLC",All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",TZLS-0401-001,1-Dec-17,1-Dec-18,1-Jun-19,25-Sep-17,null,26-Sep-17,,,https://ClinicalTrials.gov/show/NCT03291249
NCT03289897,Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan,RADIcAL1,Recruiting,No Results Available,NASH - Nonalcoholic Steatohepatitis|NAFLD,Diagnostic Test: LiverMultiScan,Measuring the cost effectiveness of LiverMultiScan (LMS) as a standardised diagnostic test for liver disease in different EU territories|Improvement in patient satisfaction with the new technology compare to current care pathway.,"Perspectum Diagnostics Ltd|University of Oxford|Leiden University Medical Centre, DEPT of Parasitology, Leiden Holland|University of Coimbra|University of Ulm",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,2000,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,PJM124,4-Sep-17,4-Sep-19,28-Feb-20,21-Sep-17,null,25-Sep-17,"Prof Dr. Matthias Dollinger, Ulm, Baden-Württemberg, Germany|Dr Minneke Coenraad, Leiden, South Holland, Netherlands|Dr Miguel Castelo Branco, Coimbra, Centro, Portugal",,https://ClinicalTrials.gov/show/NCT03289897
NCT03281083,Levothyroxine for Non-Alcoholic Fatty Liver Disease (NAFLD),,Terminated,No Results Available,"Non-Alcoholic Fatty Liver Disease|Diabetes Mellitus, Type 2",Drug: Levothyroxine Sodium,Liver fat content|HbA1c|Lipid profile|Abdominal fat,"Duke-NUS Graduate Medical School|Singapore Clinical Research Institute|Singapore Institute for Clinical Sciences|Singapore Bioimaging Consortium|Tan Tock Seng Hospital|Singapore General Hospital|Ng Teng Fong General Hospital|Changi General Hospital|Khoo Teck Puat Hospital|National University Health System, Singapore",Male,21 Years to 60 Years   (Adult),Phase 2,29,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MRN-01-NAFLD-01,28-Mar-14,28-Jul-16,28-Jul-16,13-Sep-17,null,14-Sep-17,,,https://ClinicalTrials.gov/show/NCT03281083
NCT03261739,"Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)",,Completed,No Results Available,NAFLD,Biological: RYI-018|Biological: Placebo,Clinical evaluation of adverse events|Time to peak serum concentration|Peak serum concentration|Area under the serum concentration versus time curve (AUC)|Apparent volume of distribution|Immunogenicity as determined by the concentration of serum anti-RYI-018 antibodies.,"Bird Rock Bio, Inc.|ProSciento, Inc.|Perspectum Diagnostics Ltd",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,84,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BRB-018-001-US,28-Aug-17,24-Aug-18,24-Aug-18,25-Aug-17,null,14-Mar-19,"BRB Site, Chula Vista, California, United States|BRB Site, Miami, Florida, United States|BRB Site, Orlando, Florida, United States|BRB Site, San Antonio, Texas, United States|BRB Site, Nedlands, Western Australia, Australia|BRB Site, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT03261739
NCT03260543,Efficacy and Safety of Fermented Ginseng Powder on Liver Function,,Completed,No Results Available,"Fatty Liver, Nonalcoholic",Dietary Supplement: fermented ginseng powder|Dietary Supplement: Placebo,Changes of ALT(Alanine Transaminase)|Changes of Liver function index|Changes of fatty liver grade|Changes of lipid metabolism index|Changes of total antioxidant capacity|Changes of imflammation index|Changes of Multidimensional Fatigue Scale,Chonbuk National University Hospital,All,"19 Years to 70 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",GB-LFE-GP,Jul-16,Nov-16,Aug-17,24-Aug-17,null,5-Feb-18,"Clinical Trial Center for Functional Foods Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03260543
NCT03256526,6-week Safety and PD Study in Adults With NAFLD,,Completed,Has Results,Non-alcoholic Fatty Liver Disease,Drug: Placebo|Drug: PF-06835919 Low Dose|Drug: PF-06835919 High Dose,Percent Change From Baseline in Whole Liver Fat at Week 6|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Post-dose Vital Signs Data Meeting Categorical Criteria|Number of Participants With Post-dose ECG Data Meeting Categorical Criteria|Number of Participants With Laboratory Abnormalities,Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,53,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,C1061003,27-Sep-17,30-Mar-18,27-Apr-18,22-Aug-17,4-Apr-19,4-Apr-19,"National Research Institute, Los Angeles, California, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Stand-Up MRI of Miami, Miami, Florida, United States|Avail Clinical Research, LLC, Orange City, Florida, United States|Qps-Mra, Llc, South Miami, Florida, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|WR-ClinSearch LLC, Chattanooga, Tennessee, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|National Clinical Research, Inc, Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03256526/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT03256526/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT03256526
NCT03248882,"Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)",,Completed,No Results Available,Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis,Drug: Placebo|Drug: PF-05221304,Evaluate Dose-Response for Effect on Liver Fat using MRI-PDFF|Evaluate Dose-Response for Effect on ALT|Assessment of treatment-emergent adverse events|Assessment of clinical laboratory tests|Assessment of Vital Signs|Assessment of 12-lead electrocardiograms,Pfizer,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,305,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",C1171002|2017-001156-55,22-Aug-17,26-Feb-19,27-Mar-19,14-Aug-17,null,10-May-19,"Franco Felizarta MD, Bakersfield, California, United States|eStudy Site - Chula Vista, Chula Vista, California, United States|San Diego Imaging Chula Vista, Chula Vista, California, United States|University of California, San Diego (Altman Clinical and Translational Research Institute), La Jolla, California, United States|University of California, San Diego, La Jolla, California, United States|eStudy Site, La Mesa, California, United States|Clinical Trials Research, Lincoln, California, United States|National Research Institute, Los Angeles, California, United States|Stanford University Medical Center, Blake wilbur Building, Palo Alto, California, United States|Stanford University Medical Center, Palo Alto, California, United States|Huntington Medical Research Institute, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Precision Research Institute, San Diego, California, United States|Mission Gastroenterology and Hepatology (fibroscan facility), San Francisco, California, United States|SimonMed, San Francisco, California, United States|Quest Clinical Research, San Francisco, California, United States|South Denver Gastroenterology, P.C., Englewood, Colorado, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Ocean Blue Medical Research Center, Inc, Miami Springs, Florida, United States|Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States|Stand Up MRI of Miami, Miami, Florida, United States|Avail Clinical Research, LLC, Orange City, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Advanced Gastroenterology Associates, LLC, Palm Harbor, Florida, United States|Qps-Mra, Llc, South Miami, Florida, United States|Tampa General Medical Group, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|South Florida Center Of Gastroenterology, PA, Wellington, Florida, United States|Independent Imaging, Wellington, Florida, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|In Vision Imaging, Honolulu, Hawaii, United States|Midwest Institute for Clinical Research, Indianapolis, Indiana, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Ascension Via Christi Imaging at St. Francis, Wichita, Kansas, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic- Main Campus, Rochester, Minnesota, United States|Gastrointestinal Associates, PA, Flowood, Mississippi, United States|Colonnades at Baptist, Jackson, Mississippi, United States|BioTelemetry Research, Rochester, New York, United States|Virtualscopics/ Biotelemetry Research, Rochester, New York, United States|Investigational Drug Service, University of North Carolina Hospitals, Chapel Hill, North Carolina, United States|The University of NC at Chapel Hill, Clinical and Translational Research Center (CTRC), Chapel Hill, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|PMG Research of Wilmington, LLC, Wilmington, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Prime Imaging (Chattanooga Outpatient Center) MRI Imaging Only, Chattanooga, Tennessee, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Touchstone, Austin, Texas, United States|Baylor College of Medicine - Advanced Liver Therapies, Houston, Texas, United States|Pinnacle Clinical Research, Rollingwood, Texas, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|Pinnacle Clinical Research, PLLC, San Antonio, Texas, United States|Clinical Research Advantage, Inc./Wasatch Peak Family Practice, Layton, Utah, United States|National Clinical Research - Richmond, Inc., Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Australian Clinical Research Network, Maroubra, New South Wales, Australia|Spectrum Medical Imaging, Randwick, New South Wales, Australia|Castlereagh Imaging, Westmead, New South Wales, Australia|Storr Liver Centre, Westmead Hospital, Westmead, New South Wales, Australia|Dr. Jones & Partners Medical Imaging, Adelaide, South Australia, Australia|Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, South Australia, Australia|Flinders Medical Centre/Department of Gastroenterology & Hepatology, Adelaide, South Australia, Australia|Radiology SA, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Dr TG Elliott Inc - BC Diabetes, Vancouver, British Columbia, Canada|False Creek Healthcare Centre, Vancouver, British Columbia, Canada|False Creek Healthcare, Vancouver, British Columbia, Canada|LAIR Centre, Vancouver, British Columbia, Canada|Discovery Clinical Services Ltd., Victoria, British Columbia, Canada|West Coast Medical Imaging, Victoria, British Columbia, Canada|Nova Scotia Health Authority, QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority, QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Nova Scotia Health Authority - QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Aggarwal and Associates Limited, Brampton, Ontario, Canada|St. Joseph's Health Care London, London, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Oxford Medical Imaging, Mississauga, Ontario, Canada|LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada|St. Michael's Hospital - MRI Research Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|University Health Network (UHN) - Toronto General Hospital - Toronto Centre for Liver Disease (TCLD), Toronto, Ontario, Canada|University of Toronto - Toronto General Hospital, Toronto, Ontario, Canada|University Health Network (UHN), Toronto, Ontario, Canada|Toronto Liver Centre - Liver Care Centre Corporation, Toronto, Ontario, Canada|Resonance Magnetique du Saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada|Ecogene-21, Chicoutimi, Quebec, Canada|Medpharmgene Inc, Montreal, Quebec, Canada|Clinique de Medecine Urbaine du Quartier Latin, Montreal, Quebec, Canada|Centre de recherche du CHUM, Montreal, Quebec, Canada|Cedar Cancer Center - McGill University Health Centre, Montreal, Quebec, Canada|Chronic Viral Illness Service - Royal Victoria Hospital - McGill University Health Centre (MUHC), Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Research Institute of the MUHC, Montreal, Quebec, Canada|Radiologie Varad, Montreal, Quebec, Canada|Centre Intégré Universitaire de Santé et de Services Sociaux (CIUSSS) de l'Estrie, Sherbrooke, Quebec, Canada|Recherche Medicale St-Jerome Inc, St-Jerome, Quebec, Canada|Radiologie Mailloux, Quebec, Canada|CHU de Quebec - Universite Laval - site Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Canada|Centre de recherche de l'Institut Universitaire de Cardiologie et de pneumologie de Quebec, Quebec, Canada|Centre de recherche Saint-Louis, Quebec, Canada|IRM Québec - Clinique St-Louis, Quebec, Canada|Alpha Recherche Clinique, Quebec, Canada|Clinix, Quebec, Canada|Hillel Yaffe Medical Center, Hadera, Israel|Rambam Health Care Campus, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Hebrew University Medical Center - Ein Kerem, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|Holy Family Hospital, Nazareth, Israel|Rabin Medical Center, Petah Tikva, Israel|The Chaim Sheba Medical Center, Ramat-Gan, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|ClinicMed Badurski i wspolnicy Spolka Jawna, Bialystok, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdansku, Gdansk, Poland|Centrum Badan Klinicznych PI-House Sp. z o.o., Gdansk, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia, Poland|Osrodek Badan Klinicznych, Jaworze, Poland|Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Poland|Silmedic Sp. z o.o. Oddzial w Katowicach, Katowice, Poland|Centrum Medyczne A-Z Clinic, Krakow, Poland|Krakowskie Centrum Medyczne sp. z o.o., Krakow, Poland|Gabinet Lekarski Malgorzata Saryusz-Wolska, Lodz, Poland|Synexus Polska Sp. z o.o Oddzial w Poznaniu, Poznan, Poland|Centrum Medyczne Medyk, Rzeszow, Poland|Synexus Polska Sp. z o. o. Oddzial w Warszawie, Warszawa, Poland|Niepubliczny Zaklad Opieki Zdrowotnej Centrum Badan Klinicznych, Wroclaw, Poland|Synexus Polska Sp. z o.o. Oddzial we Wroclawiu, Wroclaw, Poland|DOBROSTAN - Gabinety Lekarskie, Wroclaw, Poland|Changhua Christian Hospital, Changhua city, Changhua County, Taiwan|Chung-Ho Memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan|National Cheng-Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT03248882
NCT03222206,The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease,,"Active, not recruiting",No Results Available,Non Alcoholic Fatty Liver|Osteo Arthritis,Drug: Salsalate|Other: Placebo,"Change of controlled attenuation parameter|Change of hepatokine as Fetuin-A|Change of pulse wave velocity|Change of adipokine as Adiponectin|Numerical value change of fatty liver index|Numerical value change of hepatic fibrosis as Nonalcoholic Fatty Liver Disease(NAFLD) fibrosis score|Change of saccharometabolic factors as Homeostasis Model Assessment(HOMA)-Insulin Resistance(IR), Homeostasis Model Assessment(HOMA)-B, Fasting glucose, Insulin, C-peptide, HbA1c, Glycated albumin|Change of lipid metabolic factors as Cholesterol, Triglyceride, LDL-cholesterol HDL-cholesterol and liver function test as Aspartate Transaminase(AST) and Alanine Transaminase(ALT)|Change of inflammatory factors as C Reactive Protein(CRP), Tumor Necrosis Factor(TNF)-a|Change of liver fibrosis factors as hyaluronic acid|Change of symptom of osteoarthritis as visual analog score for pain|Change of function of osteoarthritis as WOMAC (The Western Ontario and McMaster Universities Osteoarthritis Index)|Stability comparison like side effect","Korea University Guro Hospital|Kuhnil Pharmaceutical Co., Ltd.",All,"19 Years and older   (Adult, Older Adult)",Phase 4,34,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",KUGH16353,8-Nov-17,22-Feb-19,22-Feb-19,19-Jul-17,null,9-Aug-18,"Korea University Guro Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03222206
NCT03213145,"Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers",,Completed,No Results Available,NASH - Nonalcoholic Steatohepatitis,Drug: intraconazole|Drug: Rifampin|Drug: EDP 305,"Cmax of EDP-305 with and without coadministration with itraconazole|AUC of EDP-305 with and without coadministration with itraconazole|Cmax of EDP-305 with and without coadministration with rifampin|AUC of EDP-305 with and without coadministration with rifampin|Safety measured by adverse events, physical exams, vital signs, 12-lead electrocardiograms (ECGs) and clinical lab results (including chemistry, hematology, and urinalysis).",Enanta Pharmaceuticals,All,18 Years to 55 Years   (Adult),Phase 1,48,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,EDP 305-005,11-Jul-17,10-Aug-17,7-Sep-17,11-Jul-17,null,6-Nov-17,"Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States",,https://ClinicalTrials.gov/show/NCT03213145
NCT03205150,Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients,,Recruiting,No Results Available,Obese Patients With Non-alcoholic Steatohepatitis (NASH),Drug: LIK066|Drug: Placebo,Change from baseline in Alanine aminotransferase (ALT) at week 12|Change from baseline in Aspartate aminotransferase (AST) at week 12|Change from baseline in percent liver fat at week 12|Change from baseline in total body weight at week 12|Change from baseline on non-invasive liver fibrosis markers (Enhanced Liver Fibrosis (ELF) panel) at week 12|Pharmacokinetics of LIK066: Observed maximum time duration of maximum concentration (Tmax) following drug administration|Pharmacokinetics of LIK066: Observed area under the curve up to the last measurable concentration (AUClast) following drug administration|Pharmacokinetics of LIK066: Observed maximum plasma concentration (Cmax) following drug administration|Change from baseline in body mass index (BMI) at week 12|Change from baseline in waist and hip (WTH) ratio at week 12,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,110,Industry,Interventional,"Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CLIK066X2204|2017-002046-71,4-Oct-17,3-Sep-19,1-Oct-19,2-Jul-17,null,28-Feb-19,"Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Live Oak, Texas, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Hong Kong Island, Hong Kong|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, Chia-Yi, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand",,https://ClinicalTrials.gov/show/NCT03205150
NCT03205345,"Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis",ENCORE-LF,"Active, not recruiting",No Results Available,Decompensated Cirrhosis,Drug: Emricasan (25 mg)|Drug: Emricasan (5 mg)|Drug: Placebo,"Comparison of the effect of emricasan on improving event-free survival relative to placebo, based on a composite clinical endpoint|Improvement in MELD score|Improvement in Child-Pugh scores|Reduction of the proportion of subjects with MELD score progression|Decrease in new decompensation events|Decrease in liver transplantation rates|Decrease in all-cause and liver specific mortality|Improvement in health-related quality of life (QOL) as measured by Short Form-36|Improvement in liver metabolic function as measured by Methacetin Breath Test (MBT)",Conatus Pharmaceuticals Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,210,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IDN-6556-17,28-Jun-17,Aug-19,Aug-19,2-Jul-17,null,19-Mar-19,"The Institute for Liver Health, Chandler, Arizona, United States|St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|University of Arizona Liver Research Institute, Tucson, Arizona, United States|University of California, San Francisco-Fresno, Fresno, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Pfleger Liver Institute, Los Angeles, California, United States|California Liver Research Institute, Pasadena, California, United States|Stanford University, Redwood City, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|UC Davis GI/Hepatology Clinical Trials Unit, Sacramento, California, United States|Scripps Clinic - Torrey Pines, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Peak Enterology Associates, Colorado Springs, Colorado, United States|West Haven VA Medical Center, West Haven, Connecticut, United States|UF Hepatology Research at CTRB, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Schiff Center for Liver Disease/University of Miami, Miami, Florida, United States|Florida Hospital Transplant Institute, Orlando, Florida, United States|IMIC Inc., Palmetto Bay, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Piedmont Transplant Institute, Atlanta, Georgia, United States|Gastrointestinal Specialists of Georgia, Marietta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Aquiant Research, Albany, Indiana, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics/ Internal Medicine, Iowa City, Iowa, United States|Delta Research Partners, Bastrop, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center (WRNMMC), Bethesda, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Division of Digestive Diseases, Jackson, Mississippi, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|Northwell Health Inc., Sandra Atlas Bass Center for Liver Diseases., Manhasset, New York, United States|NYU Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center - Center for Liver Disease and Transplantation, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Carolinas Healthcare System, Center for Liver Disease, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina, United States|UC Health/ UCPC LLC, Cincinnati, Ohio, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|GHS Gastroenterology and Liver Center, Greenville, South Carolina, United States|ClinSearch, LLC, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|Methodist Health System Clinical Research Institute, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor Scott & White Research Institute, Fort Worth, Texas, United States|Baylor College of Medicine - Advanced Liver Therapies, Houston, Texas, United States|Liver Associates of Texas, P.A., Houston, Texas, United States|American Research Corporation at the Texas Liver Institue, San Antonio, Texas, United States|Methodist Specialty & Transplant Hospital, San Antonio, Texas, United States|San Antonio Military Medical Center, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Emeritas Research Group LLC, Leesburg, Virginia, United States|Banner University Medical Center - Phoenix Transplant Institute, Newport News, Virginia, United States|Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Swedish Organ Transplant and Liver Center, Seattle, Washington, United States|University of Washington Harborview Medical Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03205345
NCT03203486,Response of NAFLD Patients to Mediterranean Diet,,Completed,No Results Available,NAFLD|Steatosis of Liver,Other: Mediterranean Diet,Regulation of hepatic steatosis|Adherence to MedDiet|Regulation of visfatin|Regulation of oxLDL|Association of single nucleotide polymorphisms to response to dietary treatment,Harokopio University|National and Kapodistrian University of Athens|Greek Secretariat for Research and Technology,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,44,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,09-ΣΥΝ-12-890,Apr-14,Jul-14,Oct-14,29-Jun-17,null,29-Jun-17,,,https://ClinicalTrials.gov/show/NCT03203486
NCT03198572,Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis,EASYBEinNASH,Recruiting,No Results Available,Non-alcoholic Steatohepatitis,Behavioral: Lifestyle intervention|Drug: Placebo|Drug: Berberine,"Improvement in histologic features of nonalcoholic steatohepatitis by NAFLD activity score (NAS)|Improvement in the composites of NAFLD activity scores for steatosis, lobular inflammation, hepatocellular ballooning|Improvement in liver histological fibrosis staging|Resolution of NASH|Change in anthropometric measures|Change in blood biochemistry|Change in liver fat content|Change in serum cytokeratin 18 (CK-18) in U/L","Fudan University|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|The Affiliated Hospital of Hangzhou Normal University|Tianjin Third Central Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Xinjiang Medical University",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2016ZSLC04,16-Aug-17,30-Dec-20,30-Jul-21,26-Jun-17,null,11-Mar-19,"Department of Endocrinology and Metabolism,Shanghai 6th People's Hospital, Shanghai, Shanghai, China|The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Tianjin Third Central Hospital, Tianjin, China|Xinjiang Medical University, Urumqi, China",,https://ClinicalTrials.gov/show/NCT03198572
NCT03186859,Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease),EDISON,Recruiting,No Results Available,"Non-Alcoholic Fatty Liver Disease|Non Alcoholic Fatty Liver|Bariatric Surgery Candidate|Obesity, Morbid",Procedure: Roux-en-Y Gastric Bypass (RYGB) surgery|Procedure: Sleeve Gastrectomy (SG) surgery,"Change in liver fat content|Hepatic fatty acid synthesis|Changes in relative contributions of pathways involved in lipid homeostasis|Changes in fasting and postprandial plasma lipid concentration|Changes in fasting and postprandial plasma glucose concentration|Change in the incorporation of 13C (from dietary fat) into CO2|Expression changes (gene/protein) in adipose tissue biopsies|Change in fat mass|Change in lean mass|Change in functional strength|changes in fasting and post-prandial peptides/proteins (e.g. PYY, GLP-1, insulin)|change in weight|change in body mass index (BMI)|change in status of metabolic diseases (e.g. diabetes) / metabolic disease risk scores|complications, re-operation, mortality|changes in subcutaneous, visceral and pancreatic fat",University of Oxford,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,32,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,219190,9-Jun-17,Aug-19,Aug-19,14-Jun-17,null,11-Oct-18,"University of Oxford, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT03186859
NCT03183193,Fatty Liver in Obesity: Long-lifestyle Follow-up (FLiO),FLiO,Recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease|Obese|Overweight,Other: Control diet|Other: FLiO diet,Change from Baseline Weight at 6 months|Change from 6 month Weight at 12 months|Change from Baseline Weight at 12 months|Change from Baseline Body fat at 6 months|Change from 6 month Body fat at 12 months|Change from Baseline Body fat at 12 months|Change from Baseline Waist circumference at 6 months|Change from 6 month Waist circumference at 12 months|Change from Baseline Waist circumference at 12 months|Change from Baseline handgrip strength at 6 months|Change from 6 month handgrip strength at 12 months|Change from Baseline handgrip strength at 12 months|Change from Baseline Systolic blood pressure at 6 months|Change from 6 month Systolic blood pressure at 12 months|Change from Baseline Systolic blood pressure at 12 months|Change from Baseline Diastolic blood pressure at 6 months|Change from 6 month Diastolic blood pressure at 12 months|Change from Baseline Diastolic blood pressure at 12 months|Change from Baseline lipid metabolism at 6 months|Change from 6 month lipid metabolism at 12 months|Change from Baseline lipid metabolism at 12 months|Change from Baseline uric acid concentration at 6 months|Change from 6 month uric acid concentration at 12 months|Change from Baseline uric acid concentration at 12 months|Change from Baseline homocysteine concentration at 6 months|Change from 6 month homocysteine concentration at 12 months|Change from Baseline homocysteine concentration at 12 months|Change from Baseline glucose metabolism at 6 months|Change from 6 month glucose metabolism at 12 months|Change from Baseline glucose metabolism at 12 months|Change from Baseline insulin concentration at 6 months|Change from 6 month insulin concentration at 12 months|Change from Baseline insulin concentration at 12 months|Change from Baseline Hemoglobin A1c concentration at 6 months|Change from 6 month Hemoglobin A1c concentration at 12 months|Change from Baseline Hemoglobin A1c concentration at 12 months|Change from Baseline liver function at 6 months|Change from 6 month liver function at 12 months|Change from Baseline liver function at 12 months|Change from Baseline fibroblast growth factor 21 (FGF21) concentration at 6 months|Change from 6 month fibroblast growth factor 21 (FGF21) concentration at 12 months|Change from Baseline fibroblast growth factor 21 (FGF21) concentration at 12 months|Change from Baseline cytokeratin-18 (CK18) concentration at 6 months|Change from 6 month cytokeratin-18 (CK18) concentration at 12 months|Change from Baseline cytokeratin-18 (CK18) concentration at 12 months|Change from Baseline C-reactive protein (CRP) concentration at 6 months|Change from 6 month C-reactive protein (CRP) concentration at 12 months|Change from Baseline C-reactive protein (CRP) concentration at 12 months|Change from Baseline interleukin 6 (IL-6) concentration at 6 months|Change from 6 month interleukin 6 (IL-6) concentration at 12 months|Change from Baseline interleukin 6 (IL-6) concentration at 12 months|Change from Baseline tumor necrosis factor-α (TNFα) concentration at 6 months|Change from 6 month tumor necrosis factor-α (TNFα) concentration at 12 months|Change from Baseline tumor necrosis factor-α (TNFα) concentration at 12 months|Change from Baseline leptin concentration at 6 months|Change from 6 month leptin concentration at 12 months|Change from Baseline leptin concentration at 12 months|Change from Baseline adiponectin concentration at 6 months|Change from 6 month adiponectin concentration at 12 months|Change from Baseline adiponectin concentration at 12 months|Change from Baseline LDL-oxidized concentration at 6 months|Change from 6 month LDL-oxidized concentration at 12 months|Change from Baseline LDL-oxidized concentration at 12 months|Change from Baseline Malondialdehyde concentration at 6 months|Change from 6 month Malondialdehyde concentration at 12 months|Change from Baseline Malondialdehyde concentration at 12 months|Change from Baseline plasma antioxidant capacity at 6 months|Change from 6 month plasma antioxidant capacity at 12 months|Change from Baseline plasma antioxidant capacity at 12 months|Change from Baseline Hepatic echography at 6 months|Change from 6 month Hepatic echography at 12 months|Change from Baseline Hepatic echography at 12 months|Change from Baseline Hepatic elastography at 6 months|Change from 6 month Hepatic elastography at 12 months|Change from Baseline Hepatic elastography at 12 months|Change from Baseline Hepatic Magnetic Resonance Imaging at 6 months|Change from 6 month Hepatic Magnetic Resonance Imaging at 12 months|Change from Baseline Hepatic Magnetic Resonance Imaging at 12 months|Change from Baseline White blood cell count at 6 months|Change from 6 month White blood cell count at 12 months|Change from Baseline White blood cell count at 12 months|Change from Baseline blood rheological properties at 6 months|Change from 6 month blood rheological properties at 12 months|Change from Baseline blood rheological properties at 12 months|Change from Baseline Physical activity level at 6 months|Change from 6 months Physical activity level at 12 months|Change from Baseline Physical activity level at 12 months|Change from Baseline Minnesota Physical Activity test at 6 months|Change from 6 month Minnesota Physical Activity test at 12 months|Change from Baseline Minnesota Physical Activity test at 12 months|Change from Baseline number of steps at 6 months|Change from 6 month number of steps at 12 months|Change from Baseline number of steps at 12 months|Change from Baseline chair test at 6 months|Change from 6 month chair test at 12 months|Change from Baseline chair test at 12 months|Change from Baseline sleep quality at 6 months|Change from 6 month sleep quality at 12 months|Change from Baseline sleep quality at 12 months|Change from Baseline Depressive symptoms at 6 months|Change from 6 month Depressive symptoms at 12 months|Change from Baseline Depressive symptoms at 12 months|Change from Baseline Anxiety symptoms at 6 months|Change from 6 month Anxiety symptoms at 12 months|Change from Baseline Anxiety symptoms at 12 months|Single Nucleotide polymorphisms (SNPs)|Change from Baseline DNA methylation at 6 months|Change from 6 month DNA methylation at 12 months|Change from Baseline DNA methylation at 12 months|Change from Baseline microRNAs at 6 months|Change from 6 month microRNAs at 12 months|Change from Baseline microRNAs at 12 months|Change from Baseline Gut microbiota composition at 6 months|Change from 6 month Gut microbiota composition at 12 month|Change from Baseline Gut microbiota composition at 12 month|Change from Baseline metabolites composition of urine at 6 months|Change from 6 month metabolites composition of urine at 12 months|Change from Baseline metabolites composition of urine at 12 months|Change from Baseline metabolites composition of serum at 6 months|Change from 6 month metabolites composition of serum at 12 months|Change from Baseline metabolites composition of serum at 12 months|Change from Baseline dietary intake at 6 months|Change from 6 month dietary intake at 12 months|Change from Baseline dietary intake at 12 months|Assessment of dietary adherence at Baseline|Assessment of dietary adherence at 6 months|Assessment of dietary adherence at 12 months|Change from Baseline satiety index at 6 months|Change from 6 month satiety index at 12 months|Change from Baseline satiety index at 12 months|Change from Baseline life quality index at 6 months|Change from 6 month life quality index at 12 months|Change from Baseline life quality index at 12 months|Change from Baseline Ghrelin concentration at 6 months|Change from 6 month Ghrelin concentration at 12 months|Change from Baseline Ghrelin concentration at 12 months|Change from Baseline glucagon-like peptide-1 (GLP-1) concentration at 6 months|Change from 6 month glucagon-like peptide-1 (GLP-1) concentration at 12 months|Change from Baseline glucagon-like peptide-1 (GLP-1) concentration at 12 months|Change from Baseline Dopamine concentration at 6 months|Change from 6 month Dopamine concentration at 12 months|Change from Baseline Dopamine concentration at 12 months|Change from Baseline Dopac concentration at 6 months|Change from 6 month Dopac concentration at 12 months|Change from Baseline Dopac concentration at 12 months|Change from Baseline Serotonin (5-HT) concentration at 6 months|Change from 6 month Serotonin (5-HT) concentration at 12 months|Change from Baseline Serotonin (5-HT) concentration at 12 months|Change from Baseline Noradrenaline concentration at 6 months|Change from 6 month Noradrenaline concentration at 12 months|Change from Baseline Noradrenaline concentration at 12 months|Change from Baseline 5-hydroxyindoleacetic acetic (5-HIAAC) concentration at 6 months|Change from 6 month 5-hydroxyindoleacetic acetic (5-HIAAC) concentration at 12 months|Change from Baseline 5-hydroxyindoleacetic acetic (5-HIAAC) concentration at 12 months,"Clinica Universidad de Navarra, Universidad de Navarra|Complejo Hospitalario de Navarra",All,"30 Years to 80 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,FLiO,Jun-16,Dec-17,Dec-19,12-Jun-17,null,12-Jun-17,"Centre for Nutrition Research, University of Navarra, Pamplona, Navarra, Spain",,https://ClinicalTrials.gov/show/NCT03183193
NCT03184376,Histological Improvement of NASH With Prebiotic,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease,Dietary Supplement: Prebiotic oligofructose|Dietary Supplement: Placebo maltodextrin,Histological change|Body composition|Body weight|Glucose tolerance|Gut microbiota|Serum total cholesterol|Serum LDL cholesterol|Serum triglycerides|Serum HDL cholesterol|Serum IL-6|Serum TNF-alpha,University of Calgary,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,14,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,E-23936,28-Feb-12,16-Dec-15,30-May-16,12-Jun-17,null,12-Jun-17,,,https://ClinicalTrials.gov/show/NCT03184376
NCT03166735,Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH,,"Active, not recruiting",No Results Available,Non-alcoholic Fatty Liver Disease,Drug: BI 1467335|Drug: Placebo,"Plasma amine oxidase copper-containing 3 (AOC3) activity relative to baseline in percent, 24 h post dose,|Percentage of subjects with adverse reactions|relative ALT change from baseline|relative AST change from baseline|relative AP change from baseline|relative Gamma-GT change from baseline|relative caspase cleaved cytokeratin 18 (M30) change from baseline|relative total cytokeratin 18 (M65) change from baseline",Boehringer Ingelheim,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,114,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1386-0004|2016-000499-83,6-Jun-17,19-Jun-19,19-Jun-19,25-May-17,null,14-May-19,"Southern California Research Center, Coronado, California, United States|University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|National Research Institute, Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|Quest Clinical Research, San Francisco, California, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Genoma Research Group, Inc, Miami, Florida, United States|Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States|Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Northwell Health, Manhasset, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Diabetes and Endocrinology Consultants, PC, Morehead City, North Carolina, United States|Dallas Diabetes and Endocrine Center, Dallas, Texas, United States|Pinnacle Clinical Research, Live Oak, Texas, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Edegem - UNIV UZ Antwerpen, Edegem, Belgium|AZ Maria Middelares, Gent, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|University of Calgary, Calgary, Alberta, Canada|Liver and Intestinal Research Centre, Vancouver, British Columbia, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Clinique Medecine Urbaine Quartier Latin, Montreal, Quebec, Canada|HOP Claude Huriez, Lille, France|HOP La Pitié Salpêtrière, Paris, France|Universitätsklinikum Aachen, AöR, Aachen, Germany|Universitätsklinikum Frankfurt, Frankfurt am Main, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|St James's Hospital, Dublin, Ireland|Academisch Medisch Centrum (AMC), Amsterdam, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Queen Elizabeth Hospital, Birmingham, United Kingdom|Aintree University Hospital, Liverpool, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Royal Stoke University Hospital, Stoke on Trent, United Kingdom",,https://ClinicalTrials.gov/show/NCT03166735
NCT03163810,A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH),,Terminated,No Results Available,Nonalcoholic Steatohepatitis,Device: Erchonia Verju Laser|Device: Erchonia EVRL Laser,Percent (%) change from Baseline to Subject Study Endpoint evaluation in aminoalanine transaminase (ALT) level.,Erchonia Corporation,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,3,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EC_NASH_PILOT,6-Feb-17,13-Dec-17,13-Dec-17,23-May-17,null,18-Dec-17,"Meridian Integrative Medicine, Scottsdale, Arizona, United States",,https://ClinicalTrials.gov/show/NCT03163810
NCT03156881,Global Osteopathic Treatment for Patients With NAFLD,,Unknown status,No Results Available,Non-Alcoholic Fatty Liver Disease,Other: Global Osteopathic Treatment,Global osteopathic treatment will improve liver function in patient's with non-alcoholic fatty liver disease.|Global osteopathic treatment will increase quality of life in patients with non-alcoholic fatty liver disease.|Global osteopathic treatment will increase readiness to change in patients with Non-Alcohoic Fatty Liver Disease using the URICA questionnaire.,Jenna Wilcox|Canadian College of Osteopathy,All,"Child, Adult, Older Adult",Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,CCOsteopathy,Jul-17,Nov-17,May-18,17-May-17,null,17-May-17,,,https://ClinicalTrials.gov/show/NCT03156881
NCT03151798,The Liver Health Study for Patients With NAFLD,,Recruiting,No Results Available,Nonalcoholic Fatty Liver|Nonalcoholic Steatohepatitis|Obesity,Behavioral: Phase II: Lifestyle treatment|Behavioral: Phase II: Control treatment|Other: Phase I: Observational studies,Liver mitochondrial gene expression|Liver mitochondrial fat oxidation|Histology to determine the amount of fibrosis in the liver,University of Missouri-Columbia,All,"22 Years to 65 Years   (Adult, Older Adult)",Not Applicable,90,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,HS IRB #2008258,26-Apr-17,31-May-22,31-May-29,12-May-17,null,3-Aug-18,"University of Missouri, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03151798
NCT03143166,Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan,,Completed,Has Results,Non-alcoholic Fatty Liver Disease,Drug: Dabigatran Etexilate|Drug: Rabeprazol sodium,Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Total Dabigatran (AUC0-tz).|Maximum Concentration of Total Dabigatran in Plasma (Cmax).|Area Under the Plasma Concentration-time Curve From 0 to Time of Last Quantifiable Time Point (tz) of Free Dabigatran (AUC0-tz).|Maximum Concentration of Free Dabigatran in Plasma (Cmax).|Area Under the Concentration-time Curve of Total Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).|Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞).,Boehringer Ingelheim,Male,20 Years to 40 Years   (Adult),Phase 1,36,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1160-0270,22-May-17,27-Jul-17,2-Aug-17,8-May-17,16-Jan-19,16-Jan-19,"Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03143166/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03143166/Prot_001.pdf",https://ClinicalTrials.gov/show/NCT03143166
NCT03135873,Mastiha Treatment for Obese With NAFLD Diagnosis,MAST4HEALTH,Recruiting,No Results Available,Non Alcoholic Fatty Liver Disease,Dietary Supplement: Mastiha|Dietary Supplement: Placebo,LIF score|NAFLD/NASH-related laboratory markers|Anthropometric characteristics|Genetic profile|Metabolomic profile|Metagenomic profile|Epigenetic profile,"Harokopio University|Fondazione C.N.R./Regione Toscana ""G. Monasterio"", Pisa, Italy",All,"18 Years to 67 Years   (Adult, Older Adult)",Early Phase 1,52,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MAST4HEALTH (691042),8-Mar-17,Dec-18,Dec-19,1-May-17,null,2-Aug-18,"Harokopio University, Athens, Attica, Greece",,https://ClinicalTrials.gov/show/NCT03135873
NCT03118310,Treatment of NAFLD With Two Different Diets,TREND,Recruiting,No Results Available,NAFLD,Behavioral: 5:2 diet|Behavioral: LCHF|Behavioral: Placebo diet,Liver fat,Karolinska University Hospital,All,"Child, Adult, Older Adult",Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Dnr 2017/258-31,6-Apr-17,31-Dec-20,30-Jun-21,18-Apr-17,null,26-Feb-19,"Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT03118310
NCT03082703,Impact of Text Messaging in the Management of Non-alcoholic Fatty Liver Disease,,Completed,No Results Available,NAFLD and NASH,Behavioral: Text Messaging,Change in weight,"Ashwani Singal,MD|University of Alabama at Birmingham",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,X150420005,24-Mar-16,1-Dec-16,1-Mar-17,17-Mar-17,null,17-Mar-17,,,https://ClinicalTrials.gov/show/NCT03082703
NCT03073343,"A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine",,Recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease|Non Insulin Dependent Diabetes|ALT,Dietary Supplement: Betaine (trimethyglycine),Change in alanine aminotransferase (ALT) level in all study participants|Compare changes in alanine aminotransferase (ALT) level in both cohorts,Southern California Institute for Research and Education,All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,48,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Betaine 2,12-Nov-13,30-Jun-20,30-Jun-20,8-Mar-17,null,21-Sep-18,"VA Long Beach Healthcare System, Long Beach, California, United States",,https://ClinicalTrials.gov/show/NCT03073343
NCT03067428,Effects of Fructose Restriction on Liver Steatosis,FRUITLESS,Recruiting,No Results Available,Nonalcoholic Fatty Liver Disease|Glucose Metabolism Disorders|Endothelial Dysfunction,Dietary Supplement: Glucose|Dietary Supplement: Fructose,Change in intrahepatic triglyceride content|Change in arterial stiffness|Change in endothelial function|Change in glucose metabolism,Maastricht University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",162034,31-Jan-17,1-Apr-19,1-Apr-19,1-Mar-17,null,15-Aug-18,"Maastricht University Medical Center, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT03067428
NCT03068065,Antidiabetic Effects on Intrahepatic Fat,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease|Type2 Diabetes,Drug: Liraglutide|Drug: Metformin|Drug: Gliclazide,Intrahepatic fat|Liver function|Lipid|Plasma glucose in standard meal tolerance test|Plasma insulin in standard meal tolerance test|Glucose control|HbA1c|Body composition|Weight|WC,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,All,"17 Years to 80 Years   (Child, Adult, Older Adult)",Phase 4,87,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ChiCTR-TRC-14004660,May-14,Nov-14,Oct-15,1-Mar-17,null,1-Mar-17,"at Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China",,https://ClinicalTrials.gov/show/NCT03068065
NCT03068078,A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes,ReDuCtion,Recruiting,No Results Available,Type2 Diabetes|Nonalcoholic Steatohepatitis|Non-Alcoholic Fatty Liver Disease|Atherosclerosis|Dyslipidemias,Dietary Supplement: Low carbohydrate diet high in monounsaturated fats,"Glycemic control, dyslipidemia and metabolic markers|Endothelial function|Non-Alcoholic Fatty Liver Disease (NAFLD)|Quality of life|Gut dysbiosis",Odense University Hospital|Danish Diabetes Academy|Region of Southern Denmark|Odense Patient Data Explorative Network|Novo Nordisk A/S|University of Southern Denmark,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,135,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,S-20150217,Nov-16,Dec-19,Dec-20,1-Mar-17,null,13-Mar-19,"Odense University Hospital, Odense, Denmark",,https://ClinicalTrials.gov/show/NCT03068078
NCT03059446,Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis,,Enrolling by invitation,No Results Available,Nonalcoholic Steatohepatitis|Liver Cirrhosis|Non-alcoholic Fatty Liver Disease,Drug: Cenicriviroc,Number of Participants with Treatment-emergent Adverse Events (AE),"Tobira Therapeutics, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,560,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,3152-201-002|2016-004754-15,14-Feb-17,27-Nov-29,1-Jul-30,23-Feb-17,null,9-May-19,"Digestive Health Specialists of the Southeast - Dothan, Dothan, Alabama, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Adobe Clinical Research, LLC, Tucson, Arizona, United States|University of California, San Diego (UCSD), La Jolla, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|University of California, San Diego (UCSD) - Medical Center, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|Rocky Mountain Clinical Research, LLC - Littleton, Littleton, Colorado, United States|University of Miami - Schiff Center for Liver Diseases, Miami, Florida, United States|Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital, Tampa, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Louisville School of Medicine, Louisville, Kentucky, United States|Tandem Clinical Research LLC, Marrero, Louisiana, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Mercy Medical Center - Baltimore, Maryland, Baltimore, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Minnesota Gastroenterology, P.A., Saint Paul, Minnesota, United States|Gastrointestinal Associates, P.A - Jackson, Flowood, Mississippi, United States|Digestive Health Specialists, Tupelo, Mississippi, United States|University of Buffalo - Erie County Medical Center, Buffalo, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center (DUMC), Durham, North Carolina, United States|Wake Research Associates, LLC - Raleigh, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Consultants for Clinical Research - Cincinnati, Cincinnati, Ohio, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|The University of Texas - Health Science Center & Medical School at Houston, Houston, Texas, United States|Pinnacle Clinical Research, Live Oak, Texas, United States|The Texas Liver Institute, San Antonio, Texas, United States|Brooke Army Medical Center, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Virginia Commonwealth University Medical College of Virginia, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|Australian National University, Garran, Australian Capital Territory, Australia|Royal Brisbane Hospital and Women's Hospital, Herston, Queensland, Australia|Central Adelaide Local Health Network Inc - Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|UCL Saint Luc Bruxelles, Brussel, Belgium|University Hospital Erasmus (Brussels), Bruxelles, Belgium|Antwerp University Hospital (UZA), Edegem, Belgium|University Hospital Leuven, Leuven, Belgium|CHU Angers, Angers Cedex 09, France|Hopital Saint Antoine, Paris, France|Hospital Pitie Salpetriere, Paris, France|Purpan CHU Toulouse, Toulouse, cedex 9, France|Uniklinik RWTH Aachen, Aachen, Germany|Charite - University Hospital Berlin - Campus Virchow - Hospital, Berlin, Germany|Universitaetsklinikum Hamburg-Eppendorf - I. Medizinische Klinik und Poliklinik, Hamburg, Germany|Universitaetsklinikum Heidelberg - Innere Medizin IV, Heidelberg, Germany|Uniklinik Koeln, Poliklinik fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP), Koeln, Germany|Eugastro GmbH, Leipzig, Germany|University Hospital Giessen and Marburg GmbH, Marburg, Germany|Prince of Wales Hospital, Shatin, Hong Kong|Policlinico S. Orsola-Malpighi, Bologna, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy|AOU Policlinico Paolo Giaccone di Palermo, Palermo, Italy|Clinical Institute Humanitas - Humanitas Foundation for Research, Rozzano (MI), Italy|ID Clinic, Myslowice, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Sp. p., Wroclaw, Poland|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Barts and The London NHS Trust, London, United Kingdom|Nottingham NHS Treatment Centre, Nottingham, United Kingdom|Queen Alexandra Hospital, Portsmouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT03059446
NCT03060538,A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease,,Recruiting,No Results Available,"Diabetes Mellitus, Type 2|Non-Alcoholic Fatty Liver Disease",Drug: BFKB8488A|Other: Placebo,Percentage of Participants with Adverse Events (AE)|Serum BFKB8488A Concentration|Change from Baseline in Percentage of Participants with Anti-Therapeutic Antibodies (ATAs),"Genentech, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,136,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GC39547,5-Mar-17,7-Jun-19,7-Jun-19,23-Feb-17,null,23-Apr-19,"Pinnacle Research Group Cullman, Anniston, Alabama, United States|Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States|Southern California Research Center, Inc., Coronado, California, United States|National Research Inst., Los Angeles, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Northern California Research, Sacramento, California, United States|Stanford Health Care, Stanford, California, United States|Diabetes Research Center, Tustin, California, United States|MD Clinical, Hallandale Beach, Florida, United States|Premier Research Associate, Inc, Miami, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|MidWest Clinical Research, Overland Park, Kansas, United States|Hassman Research Institute, Berlin, New Jersey, United States|Diabetes Endocrinology Center of WNY, Buffalo, New York, United States|High Point Clinical Trials Center, High Point, North Carolina, United States|Carolina Research Center at Jones Family Practice, Shelby, North Carolina, United States|New Orleans Center for Clinical Research, Knoxville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Dallas Diabetes & Endocrine Center, Dallas, Texas, United States|Clinical Trials of Texas Incorporated, San Antonio, Texas, United States|Northeast Clinical Research of San Antonio LLC, San Antonio, Texas, United States|Consano Clinical Research, Shavano Park, Texas, United States|inVentiv Health Clinical, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT03060538
NCT03061721,Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis,EVIDENCES IV,"Active, not recruiting",No Results Available,Non-Alcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis,Drug: Saroglitazar magnesium 1 mg|Drug: Saroglitazar magnesium 2 mg|Drug: Saroglitazar magnesium 4 mg|Drug: Placebos,Percentage change from baseline in serum ALT levels at Week 16|Change in liver fat content as measured by magnetic resonance imaging-derived proton density-fat fraction (MRI-PDFF)|Proportion of patients with sustain decrease in serum ALT levels|Changes in cytokeratin-18|Changes in enhanced liver fibrosis|Change in aspartate aminotransferase-to-platelet ratio index|Pharmacokinetics of Saroglitazar Magnesium: maximum plasma concentration (Cmax)|Time to reach maximum plasma concentration (Tmax)|Terminal half life (t1/2)|Area under the curve from the time of dosing to the last measurable concentration (AUC0-t)|Area under the curve from the time of dosing to the infinity (AUC 0-inf)|Elimination rate constant (λz)|Apparent volume of distribution (Vd/F)|Apparent clearance (CL/F)|Change in quality of life assessed by the Short-Form 36 Health Survey|Safety and tolerability of Saroglitazar Magnesium,Zydus Discovery DMCC,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,106,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SARO.16.005.03.PROT,6-Apr-17,Sep-19,Nov-19,23-Feb-17,null,13-May-19,"Precision Research, Chula Vista, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Catalina Research Institute, Montclair, California, United States|California liver research institute, Pasadena, California, United States|Precision Research, San Diego, California, United States|Medical Associates Research Group, San Diego, California, United States|University of Florida, Gainesville, Florida, United States|Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States|Avail Clinical Research, Orange City, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Awasty Research Network, LLC, Marion, Ohio, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|Gastro One, Germantown, Tennessee, United States|AIG Research, Hermitage, Tennessee, United States|Liver Consultants, Dallas, Texas, United States|The Liver Institute, San Antonio, Texas, United States|Swedish Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03061721
NCT03053050,Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis,STELLAR 3,"Active, not recruiting",No Results Available,Nonalcoholic Steatohepatitis,Drug: SEL|Drug: Placebo,Proportion of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis According to the NASH Clinical Research Network (CRN) Classification Without Worsening of NASH|Event-Free Survival (EFS) at Week 240 as Assessed by Time to the First Clinical Event|Proportion of Participants Who have Progression to Cirrhosis by Week 48|Proportion of Participants Who have a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 240|Proportion of Participants Who Have a ≥ 1-Stage Improvement in Fibrosis at Week 48|Proportion of Participants Who Have a ≥ 1-Stage Improvement in Fibrosis at Week 240|Proportion of Participants Who Have NASH Resolution Without Worsening of Fibrosis at Week 48|Proportion of Participants Who Have NASH Resolution Without Worsening of Fibrosis at Week 240,Gilead Sciences,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,808,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",GS-US-384-1943|2016-004374-18,13-Feb-17,Feb-23,Feb-23,14-Feb-17,null,21-Jan-19,"Institute of Liver Health, Chandler, Arizona, United States|Banner University Medical Center-Phoenix, Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Baptist Medical Center, Little Rock, Arkansas, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|eStudySite, Chula Vista, California, United States|Southern California Liver Centers, Coronado, California, United States|United Gastroenterologists, Costa Mesa, California, United States|TriWest Research Associates, LLC, El Cajon, California, United States|Fresno Clinical Research Center, Fresno, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|Ruane Clinical Research Group, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System, Los Angeles, California, United States|eStudySite, Oceanside, California, United States|California Liver Institute, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|Medical Associates Research Group, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|California Pacific Medical Center - Sutter Pacific Medical Foundation San Francisco Center for Liver Disease Dept. of Transplant, San Francisco, California, United States|Mission Gastroenterology and Hepatology, San Francisco, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|Silicon Valley Research Institute, San Jose, California, United States|University of Colorado, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|UF Hepatology Research at CTRB, Gainesville, Florida, United States|UF Health Jacksonville-Gastroenterology Emerson, Jacksonville, Florida, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Sunrise Medical Research, Inc, Lauderdale Lakes, Florida, United States|Sunrise Research Institute, Miami, Florida, United States|Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States|Genoma Research Group, Inc, Miami, Florida, United States|Advanced Research Institute, New Port Richey, Florida, United States|Avail Clinical Research, LLC, Orange City, Florida, United States|South Florida Center of Gastroenterology, PA, Wellington, Florida, United States|Florida Medical Clinic, PA, Zephyrhills, Florida, United States|Digestive Healthcare of Georgia, Atlanta, Georgia, United States|Piedmont Transplant Institute, Atlanta, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Northwestern Memorial Hospital; Clinical Research Unit, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|NorthShore University Healthsystem, Glenview, Illinois, United States|Indiana University Health - University Hospital, Indianapolis, Indiana, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Gastroenterology Associates of Hazard, Hazard, Kentucky, United States|Delta Research Partners, LLC, Bastrop, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ocshner Medical Center, New Orleans, Louisiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Gastroenterology Associates of Western Michigan, P.L.C., Wyoming, Michigan, United States|Huron Gastroenterology Associates/Center for Digestive Care, Ypsilanti, Michigan, United States|University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Southern Therapy and Advanced Research LLC (STAR), Ridgeland, Mississippi, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Kansas City Gastroenterology and Hepatology, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|eStudySite, Las Vegas, Nevada, United States|Rutgers New Jersey Medical School- Doctors Office Center, Newark, New Jersey, United States|University of Buffalo, Clinical and Translational Research Center, Buffalo, New York, United States|Northwell Health - Sandra Atlas Bass Center for Liver Diseases, Manhasset, New York, United States|Icahn School of Medicine at Mount Sinai Beth Israel, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina at Chapel Hill / UNC School of Medicine, Chapel Hill, North Carolina, United States|Duke University Medical Center - Duke South Clinics, Durham, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Triad Clinical Trials LLC, Greensboro, North Carolina, United States|Piedmont HealthCare, d/b/a Carolinas Center for Liver Disease, Huntersville, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|Piedmont HealthCare, d/b/a Carolinas Center for Liver Disease, Statesville, North Carolina, United States|Digestive Health Specialists, PA, Winston-Salem, North Carolina, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|UC Health/Holmes Hospital, Cincinnati, Ohio, United States|Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, United States|Hospital of the University of Pennsylvania- Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|UPMC - Center for Liver Diseases at the Thomas E. Starlz Institute, Pittsburgh, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|eStudySite, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, PC, Sayre, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Health System - Gastroenterology and Liver Center, Greenville, South Carolina, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Quality Medical Research PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center - Digestive Disease Center, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Pinnacle Clinical Research, PLLC, Austin, Texas, United States|Austin Center for Clinical Research, Austin, Texas, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Texas Digestive Disease Consultants, Dallas, Texas, United States|Baylor Scott & White All Saints Medical Center, Fort Worth, Texas, United States|Kelsey-Seybold Clinic, Houston, Texas, United States|Baylor College of Medicine - Advanced Liver Therapies, Houston, Texas, United States|VAMC & Baylor College, Houston, Texas, United States|Pinnacle Clinical Research, PLLC, Live Oak, Texas, United States|American Research Corporation, The Texas Liver Institute, San Antonio, Texas, United States|Intermountain Liver Disease and Transplant Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Verity Research, Inc., Fairfax, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Emeritas Research Group, Lansdowne Town Center, Virginia, United States|Bon Secours St. Mary's Hospital of Richmond, Inc. d/b/a Bon Secours Liver Institute of Virginia, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bon Secours St. Mary's Hospital of Richmond, Inc. d/b/a Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason, Seattle, Washington, United States|Swedish Organ Transplant and Liver Center, Seattle, Washington, United States|Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Instituto Oulton, Córdoba, Argentina|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|St. George's Hospital, Kogarah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Health, Monash Medical Centre, Clayton, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|The Alfred Hospital, Alfred Health, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Medizinische Universitat Graz, Universitatsklinik fue Innere Medizin, Graz, Austria|Allgemeines Krankenhaus Wien, Vienna, Austria|CUB Hopital Erasme, Brussels, Belgium|UZ Brussel, Brussel, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Hospital das Clínicas da Faculdade de Medicina de Botucatu - FMB/Universidade Estadual Paulista Julio de Mesquita Filho - UNESP, Botucatu, Brazil|Hospital de Clínicas de Porto Alegre - HCPA/UFRGS, Porto Alegre, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo, São Paulo, Brazil|Universidade Federal de São Paulo / Unidade Ambulatorial de Pesquisa Clínica - I (UAPC-I), São Paulo, Brazil|University of Calgary Liver Unit (Heritage Medical Research Clinic), Calgary, Alberta, Canada|University of Alberta Hospital - Walter C. Mackenzie Health Sciences Centre (WMC), Edmonton, Alberta, Canada|LAIR Centre, Vancouver, British Columbia, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada|(G.I.R.I.) GI Research Institute, Vancouver, British Columbia, Canada|PerCuro Clinical Research Ltd., Victoria, British Columbia, Canada|South Shore Medical Arts, Bridgewater, Nova Scotia, Canada|William Osler Health System-Brampton Civic Hospital, Brampton, Ontario, Canada|South Shore Medical Arts, London, Ontario, Canada|Toronto Center for Liver Diseases (TCLD), Toronto General Hospital, Toronto, Ontario, Canada|Chronic Viral Illness Service/Royal Victoria Hospital/McGill University Health Centre (MUHC), Montréal, Quebec, Canada|Centre Hospitalier Universitaire d'Angers, Angers, France|Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, France|Hopital Henri Mondor, Créteil, France|CHU de Grenoble- Hopital Michallon, Grenoble, France|Centre Hospitalier Regional Universitaire- Hopital Claude Huriez, Lille, France|CHU de Limoges- Hopital Dupuytren- Federation Hepatologie, Limoges, France|Hopital de la Croix Rousse, Lyon, France|Hôpital Saint Joseph, Marseille, France|Centre Hospitalier Universitaire de Nice- Hopital l'Archet 2, Nice, France|Hopital Cochin, Paris, France|Hopital Beaujon, Pessac, France|Centre Hospitalier Universitaire de Bordeaux, Pessac, France|Centre Hospitalier Universitaire de Strasbourg- Nouvel Hopital Civil, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse- Hopital Purpan, Toulouse, France|Hopital Paul Brousse, Villejuif, France|Uniklinik RWTH Aachen, Medizinische Klinik III, Aachen, Germany|Zentrum fur Infektiologie Berlin Prenzlauer Berg GmbH (zibp), Berlin, Germany|Universitatsklinikum Bonn (AoR), Bonn, Germany|Universitatsklinikum Frankfurt der Goethe-Universitat, Frankfurt, Germany|Medizinische Hochschule Hannover, Hanover, Germany|Uniklinikum des Saarlandes- Klinik fur Innere Medizin II, Homburg, Germany|Gastroenterologisch- Hepatologisches Zentrum Kiel, Kiel, Germany|Eugastro Gmbh, Leipzig, Germany|Johannes Gutenberg-Universitat, Mainz, Germany|Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong|Tuen Mun Hospital, Tuen Mun, Hong Kong|Midas Multispecialty Hospital, Nagpur, Maharashtra, India|Institute of Post Graduate Medical Education and Research / SSKM Hospital, Kolkata, India|Kasturba Medical College (KMC) Hospital, Mangalore, India|Global Hospital-Super Speciality & Transplant Centre (A Unit of Centre for Digestive and Kidney Diseases (India) Pvt. Ltd.), Mumbai, India|Maharaja Agrasen Hospital, New Delhi, India|All India Institute of Medical Sciences, New Delhi, India|Fortis Flt. Lt. Rajan Dhall Hospital, New Delhi, India|Institute of Liver & Biliary Sciences, New Delhi, India|Rambam Health Care Campus, Haifa, Israel|The Lady Davis Carmel Medical Center, Haifa, Israel|Holy Family hospital, Nazaret, Israel|The Chaim Sheba Medical Center, Ramat Gan, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|IRCCS Ospedale Casa Sollievo Della Soferrenza, San Giovanni Rotondo, Italy|Chiba University Hospital, Chiba, Japan|Fukui-Ken Saiseikai Hospital, Fukui-shi, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Hiroshima University Hospital, Hiroshima, Japan|Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan|Juntendo University Shizuoka Hospital, Izunokuni, Japan|Kagoshima University Medical And Dental Hospital, Kagoshima, Japan|Kanazawa University Hospital, Kanagawa, Japan|Nara Medical University Hospital, Kashihara, Japan|Toranomon Hospital Kajigaya, Kawasaki, Japan|Shinkokura Hospital, Kitakyushu, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Kurume University Hospital, Kurume, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|Shinshu University Hospital, Matsumoto, Japan|Toranomon Hospital, Minato, Japan|Miyazaki Medical Center Hospital, Miyazaki, Japan|Japanese Red Cross Musashino Hospital, Musashino, Japan|Aichi Medical University Hospital, Nagakute, Japan|Heart Life Hospital, Nakagami, Japan|Nara City Hospital, Nara, Japan|Hyogo College of Medicine Hospital, Nishinomiya, Japan|Kawasaki Medical School General Medical Center, Okayama, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Saga University Hospital, Saga, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital, Sapporo, Japan|Tohoku Rosai Hospital, Sendai, Japan|National Center for Global Health and Medicine Hospital, Shinjuku-ku, Japan|Saiseikai Suita Hospital, Suita, Japan|Kagawa Prefectural Central Hospital, Takamatsu, Japan|Mie University Hospital, Tsu, Japan|Ehime University Hospital, Tōno, Japan|Yamagata University Hospital, Yamagata, Japan|Yokohama City University Hospital, Yokohama, Japan|National Hospital Organization Nagasaki Medical Center, Ōmura, Japan|Hirakata Kohsai Hospital, Ōsaka, Japan|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|National Health Insurance Service- Ilsan Hospital, Goyang-si, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|Yonsei University Wonju Severance Christian Hospital, Wŏnju, Korea, Republic of|Hospital Selayang, Batu Caves, Malaysia|University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Phylasis Clinicas Research S. de RL de CV., Cuautitlán, Mexico|Consultorio Médico, Mexico City, Mexico|Investigaciones Medicas Cisneros SC, Monterrey, Mexico|University Medical Center Utrecht, Utrecht, Netherlands|Auckland City Hospital, Grafton, New Zealand|Szpital Specjalistyczny Nr 1 w Bytomiu, Oddzial Obserwacyjno-Zakazny i Hepatologii, Bytom, Poland|Wojewodzki Specjalistyczny Szpital im. W. Bieganskiego, Łódź, Poland|Centro Hospitalar de Tras-os-Montes e Alto Douro, E.P.E, Vila Real, Portugal|Klinical Investigations Group, LLC, San Juan, Puerto Rico|VA Caribbean Healthcare System, San Juan, Puerto Rico|Fundacion de Investigacion de Diego, San Juan, Puerto Rico|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Changi General Hospital Pte Ltd., Singapore, Singapore|Khoo Teck Puat Hospital, Singapore, Singapore|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Puerto de Hierro Majadahonda, Majadahonda, Spain|CHOP_Complejo Hospitalrio Universitario de Pontevedra, Pontevedra, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Universitätsklinik für Viszerale Chirurgie und Medizin, Inselspital, Hepatologie, Bern, Switzerland|Istituto Cantonale di Patologia Locarno, Lugano, Switzerland|Changhua Christian Hospital, Chang-hua, Taiwan|Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|E-DA Hospital, Kaohsiung, Taiwan|Chang Gung Medical Foundation, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospitalv, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Cathay General Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Derby Teaching Hospitals NHS FT, Derby, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Edgbaston, United Kingdom|King's College Hospital NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom|Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Abertawe Bro Morgannwg University Health Board, Swansea, United Kingdom",,https://ClinicalTrials.gov/show/NCT03053050
NCT03053063,Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH),STELLAR 4,Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: SEL|Drug: Placebo,Proportion of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis According to the NASH Clinical Research Network (CRN) Classification Without Worsening of NASH|Event-Free Survival (EFS) at Week 240 as Assessed by Time to the First Clinical Event|Proportion of Participants Who have a ≥ 1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 240|Proportion of Participants Who Have a ≥ 1-Stage Improvement in Fibrosis at Week 48|Proportion of Participants Who Have a ≥ 1-Stage Improvement in Fibrosis at Week 240|Proportion of Participants Who Have NASH Resolution at Week 48|Proportion of Participants Who Have NASH Resolution at Week 240,Gilead Sciences,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,883,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",GS-US-384-1944|2016-004148-13,30-Jan-17,30-Apr-19,30-Apr-19,14-Feb-17,null,9-May-19,"Institute of Liver Health, Chandler, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic, Phoenix, Arizona, United States|Baptist Medical Center, Little Rock, Arkansas, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|Southern California Research Center, Coronado, California, United States|Fresno Clinical Research Center, Fresno, California, United States|Scripps Clinical Research Services, La Jolla, California, United States|University of California, San Diego (Altman Clinical and Translational Research Center), La Jolla, California, United States|Ruane Clinical Research Group, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Veterans Affair Greater Los Angeles Healthcare System, West Los Angeles VA Medical Center, Los Angeles, California, United States|California Liver Research Institute, Pasadena, California, United States|Huntington Medical Research Institutes (HMRI) Liver Center, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|Research and Education, Inc., San Diego, California, United States|Medical Associates Research Group, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|California Pacific Medical Center - Sutter Pacific Medical Foundation San Francisco Center for Liver Disease Dept. of Transplant, San Francisco, California, United States|eStudySite, San Francisco, California, United States|University of California, San Francisco-Liver Clinic, San Francisco, California, United States|Island View Gastroenterology Associates- Ventura, Ventura, California, United States|University of Colorado Denver and Hospital, Aurora, Colorado, United States|South Denver Gastroenterology, PC, Englewood, Colorado, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|University of Florida Hepatology Research at CTRB, Gainesville, Florida, United States|Clinical Research of Homestead, Homestead, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States|Florida Hospital Transplant Institute, Orlando, Florida, United States|IMIC Inc, Palmetto, Florida, United States|South Florida Center of Gastroenterology, PA, Wellington, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Florida Medical Clinic, PA, Zephyrhills, Florida, United States|Digestive Healthcare of Georgia, Atlanta, Georgia, United States|Piedmont Transplant Institute, Atlanta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Gastroenterology Associates of Central Georgia, LLC, Macon, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Northwestern Memorial Hospital; Clinical Research Unit, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|NorthShore University HealthSystem - Glenbrook ACC, Glenview, Illinois, United States|Indiana University Health - University Hospital, Indianapolis, Indiana, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|Iowa Digestive Disease Center, P.C., Clive, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Gastroenterology Associates of Hazard, Hazard, Kentucky, United States|University of Louisville Clinical Trials Unit, Louisville, Kentucky, United States|Delta Research Partners, Bastrop, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ocshner Medical Center, New Orleans, Louisiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Gastroenterology Associates of Western Michigan, P.L.C., Wyoming, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Southern Therapy and Advanced Research LLC (STAR), Ridgeland, Mississippi, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Rutgers New Jersey Medical School- Doctors Office Center, Newark, New Jersey, United States|AccumetRx Clinical Research, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|University of Buffalo, Clinical and Translational Research Center, Buffalo, New York, United States|Northwell Health - Sandra Atlas Bass Center for Liver Diseases, Manhasset, New York, United States|Icahn School of Medicine at Mount Sinai Beth Israel, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|NC TraCS Institute- CTRC, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas HealthCare System Center for Liver Disease, Charlotte, North Carolina, United States|Duke University Medical Center - Duke South Clinics, Durham, North Carolina, United States|Cumberland Research Associates LLC, Fayetteville, North Carolina, United States|Piedmont HealthCare, d/b/a Carolinas Center for Liver Disease, Huntersville, North Carolina, United States|PMG Research of Rocky Mount, LLC, Rocky Mount, North Carolina, United States|Piedmont Healthcare, Statesville, North Carolina, United States|Digestive Health Specialists, PA, Winston-Salem, North Carolina, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Penn State University, The Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania- Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC - Center for Liver Diseases at the Thomas E. Starlz Institute, Pittsburgh, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Medical University of South Carolina, University Hospital, Charleston, South Carolina, United States|Greenville Health System Gastroenterology and Liver Center, Greenville, South Carolina, United States|WR-ClinSearch, LLC, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Methodist University Hospital/University of Tennessee Health Science Center, Office of Clinical Research, Memphis, Tennessee, United States|Quality Medical Research PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center - Digestive Disease Center, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Pinnacle Clinical Research, PLLC, Austin, Texas, United States|Austin Center for Clinical Research, Austin, Texas, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Texas Digestive Disease Consultants, Dallas, Texas, United States|Kelsey-Seybold Clinic, Houston, Texas, United States|Baylor College of Medicine - Advanced Liver Therapies, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Liver Associates of Texas, P.A., Houston, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|Smith Clinic, Houston, Texas, United States|Pinnacle Clinical Research, Live Oak, Texas, United States|DHAT Research Institute, Richardson, Texas, United States|American Research Corporation, The Texas Liver Institute, San Antonio, Texas, United States|Intermountain Liver Disease and Transplant Clinic, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Bon Secours St. Mary's Hospital of Richmond, Inc. d/b/a Bon Secours Liver Institute of Virginia, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason, Seattle, Washington, United States|Swedish Organ Transplant and Liver Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|St. George's Hospital, Kogarah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|The Alfred Hospital, Alfred Health, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Medizinische Universitat Graz, Universitatsklinik fue Innere Medizin, Graz, Austria|Allgemeines Krankenhaus Wien, Vienna, Austria|UZ Brussel, Brussels, Belgium|Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium|CUB Hopital Erasme, Bruxelles, Belgium|Az Maria Middelares Ghent, Ghent, Belgium|UZ Leuven, Leuven, Belgium|University of Calgary Liver Unit (Heritage Medical Research Clinic), Calgary, Alberta, Canada|GI Research, Edmonton, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada|LAIR Centre, Vancouver, British Columbia, Canada|Gordon and Leslie Diamond Health Care Centre, Vancouver General Hospital, UBC Division of Gastroenterology, Vancouver, British Columbia, Canada|PerCuro Clinical Research Ltd., Victoria, British Columbia, Canada|University of Manitoba, Health Sciences Centre, John Buhler Research Centre, Winnipeg, Manitoba, Canada|South Shore Medical Arts, Bridgewater, Nova Scotia, Canada|William Osler Health System-Brampton Civic Hospital, Brampton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|McMaster University Medical Centre, Hamilton, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Toronto Center for Liver Diseases (TCLD), Toronto General Hospital, Toronto, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Chronic Viral Illness Service/Royal Victoria Hospital/McGill University Health Centre (MUHC), Montréal, Quebec, Canada|CHU Amiens Picardie, Amiens, France|Centre Hospitalier Universitaire d'Angers, Angers, France|Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, France|Hopital Henri Mondor, Créteil, France|CHU de Grenoble- Hopital Michallon, Grenoble, France|Centre Hospitalier Regional Universitaire- Hopital Claude Huriez, Lille, France|CHU de Limoges- Hopital Dupuytren- Federation Hepatologie, Limoges, France|Hopital de la Croix Rousse, Lyon, France|Hôpital Saint Joseph, Marseille, France|CHU de Montpellier, Hopital St Eloi, Montpellier, France|Centre Hospitalier Universitaire de Nice- Hopital l'Archet 2, Nice, France|Hopital Cochin, Paris, France|Groupe Hospitalier Universitaire La Pitie Salpetriere, Paris, France|Hopital Beaujon, Pessac, France|Centre Hospitalier Universitaire de Strasbourg- Nouvel Hopital Civil, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse- Hopital Purpan, Toulouse, France|Uniklinik RWTH Aachen, Medizinische Klinik III, Aachen, Germany|Universitatsklinikum Bonn (AoR), Bonn, Germany|Universitatsklinikum Frankfurt der Goethe-Universitat, Frankfurt am main, Germany|Universitatsklinikum Leipzig AoR, Leipzig, Germany|Johannes Gutenberg-Universitat, Mainz, Germany|Prince of Wales Hospital, Sha Tin, Hong Kong|Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong|Department of Hepatology PGIMER Chandigarh, Chandigarh, India|Global Clinical Reseaech Services PVT LTD, Hyderabad, India|Institute of Post Graduate Medical Education and Research (IPGMER), Kolkata, India|Dayanand Medical College & Hospital, Ludhiana, India|Kasturba Medical College Hospital, Mangalore, India|Institute of Liver Diseases, HPB Surgery and Transplant Global Hospitals, Mumbai, India|Midas Multispecialty Hospital, Nagpur, India|All India Institute of Medical Sciences, New Delhi, India|Fortis Flt. Lt. Rajan Dhall Hospital, New Delhi, India|Institute of Liver & Biliary Sciences, New Delhi, India|Emek Medical Center, Afula, Israel|Rambam Health Care Campus, Haifa, Israel|The Lady Davis Carmel Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Rabin Medical Center, Petaẖ Tiqwa, Israel|The Chaim Sheba Medical Center, Ramat Gan, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|IRCCS Istituto Clinico Humanitas, Rozzano, Italy|Fukui-Ken Saiseikai Hospital, Fukui, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Juntendo University Shizuoka Hospital, Izunokuni, Japan|Kanazawa University Hospital, Kanazawa, Japan|Nara Medical University Hospital, Kashihara, Japan|Toranomon Hospital Kajigaya, Kawasaki, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Kurume University Hospital, Kurume, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|Shinshu University Hospital, Matsumoto, Japan|Toranomon Hospital, Minato, Japan|Miyazaki Medical Center Hospital, Miyazaki, Japan|Aichi Medical University Hospital, Nagakute, Japan|Nara City Hospital, Nara, Japan|Kawasaki Medical School General Medical Center, Okayama, Japan|Okayama University Hospital, Okayama, Japan|Hirakata Kohsai Hospital, Osaka, Japan|Saga University Hospital, Saga, Japan|Hokkaido University Hospital, Sapporo, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital, Sapporo, Japan|Tokyo Womens Medical University Hospital, Shinjuku, Japan|Saiseikai Suita Hospital, Suita, Japan|Osaka University Hospital, Suita, Japan|Mie University Hospital, Tsu, Japan|Ehime University Hospital, Tōno, Japan|Yamagata University Hospital, Yamagata, Japan|Yokohama City University Hospital, Yokohama, Japan|National Hospital Organization Nagasaki Medical Center, Ōmura, Japan|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|National Health Insurance Service- Ilsan Hospital, Goyang-si, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Consultorio Médico, Mexico City, Mexico|Accelerium S. de R.L. de C.V., Monterrey, Mexico|Auckland City Hospital, Auckland, New Zealand|Southern District Health Board - Dunedin Hospital, Dunedin, New Zealand|Szpital Specjalistyczny Nr 1 w Bytomiu, Oddzial Obserwacyjno-Zakazny i Hepatologii, Bytom, Poland|ID Clinic Arkadiusz Pisula, Mysłowice, Poland|Wojewodzki Specjalistyczny Szpital im. W. Bieganskiego, Łódź, Poland|Klinical Investigations Group, LLC, San Juan, Puerto Rico|VA Carribean Healthcare System, San Juan, Puerto Rico|Fundacion de Investigacion de Diego, San Juan, Puerto Rico|National University Health System, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Changi General Hospital Pte Ltd., Singapore, Singapore|Hospital Universitario Fundacion Alcorcon, Alcorcón, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital del Mar - Parc de Salut, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerto de Hierro Majadahonda, Majadahonda, Spain|CHOP_Complejo Hospitalario Universitario de Pntevedra, Pontevedra, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Universitätsklinik für Viszerale Chirurgie und Medizin, Inselspital, Hepatologie, Bern, Switzerland|Istituto Cantanale di Patologia Locarno, Lugano, Switzerland|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-LinKou Branch, Taoyuan, Taiwan|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|Barts Health NHS Trust, London, United Kingdom|King's College Hospital NHS Foundation Trust, London, United Kingdom|St. George's Hospital, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Plymouth Hospitals NHS Trust, Plymouth, United Kingdom|Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Abertawe Bro Morgannwg University Health Board, Swansea, United Kingdom",,https://ClinicalTrials.gov/show/NCT03053063
NCT03042767,Anti-LPS Antibody Treatment for Pediatric NAFLD,,Recruiting,No Results Available,Nonalcoholic Fatty Liver Disease (NAFLD),Biological: IMM-124E|Other: Placebo,Percent Change in Alanine Aminotransferase (ALT) Level|Change in Fasting Glucose Level|Change in Fasting Insulin Level|Change in Hemoglobin A1C Level|Change in Adipose Tissue Insulin Resistance (Adipo-IR)|Change in Triglyceride/HDL (TG/HDL) Ratio|Change in Blood Glucose Level|Change in Insulin Levels|Change in Body Mass Index (BMI) Z-Score|Change in Visceral Adiposity|Change in Hepatic Fat Percent|Change in Waist Circumference|Change in PROMIS Fatigue Questionnaire Score|Change in PROMIS Depression Questionnaire Score|Change in PROMIS Anxiety Questionnaire Score|Composite Metabolic Improvement,"Miriam Vos, MD|Advanced MR Analytics AB|Immuron Ltd.|Emory University",All,"6 Years to 19 Years   (Child, Adult)",Phase 2,40,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB00084686,1-Feb-17,May-19,May-19,3-Feb-17,null,6-Sep-18,"Children's Healthcare of Atlanta, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT03042767
NCT03028740,AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH,,Recruiting,No Results Available,Nonalcoholic Steatohepatitis,Drug: Cenicriviroc|Drug: Placebo,"Superiority of CVC compared to placebo on liver histology at Month 12 relative to the Screening biopsy|Superiority of CVC compared to placebo on the composite endpoint of histopathologic progression to cirrhosis, liver-related clinical outcomes, and all-cause mortality|Effect of CVC compared to placebo on liver histology at Month 60 relative to the Screening biopsy for the proportion of subjects with improvement in fibrosis by at least 1 stage AND no worsening of steatohepatitis","Tobira Therapeutics, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,2000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",3152-301-002|2016-004566-26|1001,20-Apr-17,14-Oct-21,28-Oct-28,23-Jan-17,null,29-Mar-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialists of the Southeast, Dothan, Alabama, United States|Objective GI D/B/A North Alabama GI Research Center, Madison, Alabama, United States|The Institute for Liver Health, Chandler, Arizona, United States|Adobe Gastroenterology Research, Tucson, Arizona, United States|Liver Wellness Center, Little Rock, Arkansas, United States|Anaheim Clinical Trials, Anaheim, California, United States|Franco Felizarta MD, Bakersfield, California, United States|GW Research, Chula Vista, California, United States|Precision Research Institute, Chula Vista, California, United States|Southern California Research Center, Coronado, California, United States|University of California, San Francisco Fresno, Fresno, California, United States|Fresno Clinical Research Center, Fresno, California, United States|National Research Institute, Huntington Park, California, United States|University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|AV Pediatrics, Allergy and Family Medicine, Lancaster, California, United States|Ruane Medical and Liver Health Institute, Los Angeles, California, United States|Cedars-Sinai Medical Group, Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|GastroIntestinal Biosciences, Los Angeles, California, United States|Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, United States|eStudySite, Oceanside, California, United States|Stanford School of Medicine, Center for Clinical Sciences Research, Palo Alto, California, United States|National Research Institute, Panorama City, California, United States|Pasadena Liver Center, Pasadena, California, United States|Alliance Clinical Research, Poway, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|TriWest Research Associates, San Diego, California, United States|Precision Research Institute, San Diego, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|Veteran's Administration Hospital, San Diego, California, United States|UCSF School of Medicine, San Francisco, California, United States|Southern California Permanente Medical Group, San Marcos, California, United States|Upland Clinical Research, Upland, California, United States|Island View Gastroenterology Associates, Ventura, California, United States|South Denver Gastroenterology, Englewood, Colorado, United States|Mesa Research, LLC, Grand Junction, Colorado, United States|Rocky Mountain Gastroenterology Associates - Lakewood Endoscopy, Wheat Ridge, Colorado, United States|Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Gastroenterology Consultants of Clearwater, Clearwater, Florida, United States|Optimus Clinical Research, Coral Gables, Florida, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Mayo Clinic College of Medicine, Jacksonville, Florida, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Meridien Research, Maitland, Florida, United States|Bruce W. Carter Department of Veterans Affairs Medical Center, Miami, Florida, United States|University of Miami Hospital, Miami, Florida, United States|Regenerate Clinical Trials, Miami, Florida, United States|IMIC Research, Miami, Florida, United States|Genoma Research Group, Miami, Florida, United States|Medical Professional Clinical Research Center, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Bioclinical Research Alliance, Orlando, Florida, United States|Omega Research Maitland, LLC, Orlando, Florida, United States|Objective GI d/b/a Pensacola GI Research Center, Pensacola, Florida, United States|Advanced Medical Research, Port Orange, Florida, United States|Sensible Healthcare, Summerfield, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|South Florida Center of Gastroenterology, PA, Wellington, Florida, United States|Florida Medical Clinic, Zephyrhills, Florida, United States|Digestive Healthcare of Georgia - Atlanta, Atlanta, Georgia, United States|Gastroenterology Associates of Central Georgia, Macon, Georgia, United States|GI Specialists of Georgia, Marietta, Georgia, United States|Peak Gastroenterology Associates, Savannah, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Gen1 Research - Southwest Gastroenterology, New Lenox, Illinois, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|Aquiant Research, New Albany, Indiana, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Kansas Medical Clinic-Gastroenterology, Topeka, Kansas, United States|University of Louisville Physicians, Louisville, Kentucky, United States|Gastroenterology Associates of Central Georgia, Bastrop, Louisiana, United States|Tandem Clinical Research, Marrero, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Louisiana Research Center, Shreveport, Louisiana, United States|Mercy Medical Center-McAuley Plaza, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Woodholme Gastroenterology Associates, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Digestive Disease Associates, Catonsville, Maryland, United States|Chevy Chase Clinical Research, Chevy Chase, Maryland, United States|Gastro Center of Maryland, Columbia, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Infectious Diseases and The Research Institute, Springfield, Massachusetts, United States|Umass Memorial Medical Center, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Minnesota Gastroenterology, Maplewood, Minnesota, United States|GastroIntestinal Associates, Flowood, Mississippi, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CHI Health Research, Omaha, Nebraska, United States|eStudySite - Las Vegas, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|SIH Research, Madison, New Jersey, United States|Amici Clinical Research, Martinsville, New Jersey, United States|New York Methodist Hospital, Brooklyn, New York, United States|The State University of New York, University at Buffalo, Buffalo, New York, United States|Sing Chan, MD, Flushing, New York, United States|Digestive Disease Care PC, New Hyde Park, New York, United States|Beth Israel Medical Center, New York, New York, United States|Concorde Medical Group, New York, New York, United States|NYU Langone Medical Center - Tisch Hospital - Pulmonary and Critical Care Associates, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cumberland Research Associates, Fayetteville, North Carolina, United States|High Point Clinical Trials Center, High Point, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Options Health Research, Tulsa, Oklahoma, United States|Gastroenterology Specialists, Inc., Tulsa, Oklahoma, United States|Adult Gastroenterology Associates, Tulsa, Oklahoma, United States|Carolina Research, Tulsa, Oklahoma, United States|Northeast Clinical Research Centers, Bethlehem, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|University Medical Group, North Providence, Rhode Island, United States|University Gastroenterology, Providence, Rhode Island, United States|ClinSearch, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Digestive Health Research, Hermitage, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|Austin Center for Clinical Research, Austin, Texas, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|ACRC Trials, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|San Antonio Military Medical Center, Fort Sam Houston, Texas, United States|Baylor Scott & White All Saints Medical Center - Fort Worth, Fort Worth, Texas, United States|Texas Digestive Disease Consultants - Fort Worth, Fort Worth, Texas, United States|Therapeutic Concepts, Houston, Texas, United States|Liver Associates of Texas, P.A., Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Michael E. DeBakey VA Medical Center (MEDVAMC), Houston, Texas, United States|St. Luke's Health Baylor College of Medicine Medical Center, Houston, Texas, United States|Centex Studies, Houston, Texas, United States|Pioneer Research Solutions, Houston, Texas, United States|Pinnacle Clinical Research, Live Oak, Texas, United States|Centex Studies, McAllen, Texas, United States|Digestive Health Associates of Texas-Rockwall, Richardson, Texas, United States|American Research Corporation, San Antonio, Texas, United States|Clinical Trials of Texas Inc, San Antonio, Texas, United States|Diabetes and Glandular Disease Clinic, San Antonio, Texas, United States|Gastrointestinal and Liver disease consultants, Sugar Land, Texas, United States|Bay Area Gastroenterology, Webster, Texas, United States|Wichita Falls Gastroenterology Associates, Wichita Falls, Texas, United States|Physician's Research Options, Draper, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States|Gastroenterology Associates of Northern Virginia, Fairfax, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Liver Institute of Virginia-Bremo, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, Virginia, United States|VCU Medical Center, Richmond, Virginia, United States|Gastroenterology Consultants of Southwest Virginia, Roanoke, Virginia, United States|Virginia Mason Hospital, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|West Virginia University, Clinical Trials Research Unit, Huntington, West Virginia, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States|hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|DIM Clinica Privada, Ramos Mejia, Buenos Aires, Argentina|Hospital Provincial del Centenario, Rosario, Santa Fe, Argentina|Centro de Hepatologia S.A., Buenos Aires, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|Saint George Hospital, Kogarah, New South Wales, Australia|Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Center, Bedford Park, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Medizinische Universität Graz, Graz, Styria, Austria|Medizinische Universität Innsbruck, Innsbruck, Tyrol, Austria|Klinikum Wels-Grieskirchen, Weis, Upper Austria, Austria|Wilhelminenspital der Stadt Wien, Wien, Vienna, Austria|Universitair Ziekenhuis Antwerpen, Edegem, Antwerpen, Belgium|Algemeen Ziekenhuis Maria Middelares, Gent, Oost-Vlaanderen, Belgium|Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen, Belgium|Hôpital Erasme, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Hospital Universitário Professor Edgard Santos, Salvador, Bahia, Brazil|Hospital São Rafael-Monte Tabor, Salvador, Bahia, Brazil|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva, Goiânia, Goias, Brazil|Hospital Universitário Gafrée e Guinle, Tijula-Rio De Janeiro, Rio De Janeiro, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clínicas da Faculdade de Medicina da Riberao Preto da Universidade de São Paulo, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina de São José do Rio Preto Hospital de Base, São José do Rio Preto, Sao Paulo, Brazil|UNIFESP Universidade Federal De São Paulo, São Paulo, Sao Paulo, Brazil|Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil|University of Calgary Liver Unit, Calgary, Alberta, Canada|Bailey Health Clinic, Edmonton, Alberta, Canada|LAIR Centre, Vancouver, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|GI Research (GIRI), Vancouver, British Columbia, Canada|William Osler Health Centre, Brampton Memorial Hospital Campus, Brampton, Ontario, Canada|London Health Sciences Centre University Hospital, London, Ontario, Canada|Toronto Center for Liver Disease - Toronto Western Hospital Liver Clinic, Toronto, Ontario, Canada|Hospital Universidad Católica de Chile, Area Metropolitana, Santiago, Chile|Hospital Clinico San Borja Arriaran, Santiago de Chile, Santiago, Chile|Centro de Investigaciones Clínicas Viña del Mar, Viña del Mar, Valparaiso, Chile|CHU de Strasbourg, Strasbourg cedex, Alsace, France|Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, Aubergne, France|Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre, Caen, Basse-Normandie, France|Hopital Pontchaillou, Rennes, Bretagne, France|Centre Hospitalier Regional et Universitaire de Besançon Hôpital Jean-Minjoz, Besançon cedex, Franche-Comte, France|Hôpital Jean Verdier Bondy, Bondy, Ile-De-France, France|Hôpital Beaujon, Clichy, Ile-De-France, France|Hôpital Beaujon, Clichy, Ile-De-France, France|Centre Hospitalier Universitaire Hopital Henri Mondor, Creteil Cedex, Ile-De-France, France|Hôpital Saint Antoine, Paris Cedex 12, Ile-de-France, France|Groupe Hospitalier - Hôpitaux Universitaires Pitie-Salpetriere - Charles-Foix - Pitie-Salpetriere, Paris Cedex 13, Ile-De-France, France|Centre Médical Odysseum, Montpellier cedex 2, Languedoc-Roussillon, France|CHU de Montpellier, Montpellier cedex 5, Languedoc-Roussillon, France|Center Hospitalier Universitaire d'Angers, Angers, Pays De La Loire, France|CHU Amiens-Picardie, Amiens Cedex 1, Picardie, France|Centre Hospitalier Universitaire de Nice Hôpital l'Archet, Nice Cedex 3, Provence Alpes Cote D'Azur, France|Centre Hospitalier Universitaire Grenoble, Grenoble Cedex 09, Rhone-Alpes, France|Institut Bergonié, Bordeaux, France|Medizinische Universitätsklinik IV (Krehl Klinik) Abt. Gastroenterologie und Infektionskrankhen, Heidelberg, Baden-Wuerttemberg, Germany|Universitätsklinikum Tübingen, Tübingen, Baden-Wuerttemberg, Germany|Philipps-Universität und Universitätsklinikum Gießen und Marburg GmbH, Marburg, Hessen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universität Bonn, Bonn, Nordhein-Westfalen, Germany|Gastroenterologische Gemeinschaftspraxis, Herne, Nordhein-Westfalen, Germany|Uniklinik RWTH Aachen, Aachen, Nordrhein-Westfalen, Germany|Uniklinik Köln, Köln, Nordrhein-westfalen, Germany|Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany|Universitätsklinikum des Saarlandes, Homburg, Saarland, Germany|EUGASTRO GmbH, Leipzig, Sachsen, Germany|Universitätsklinikum Leipzig, Berlin, Germany|Praxis Driesener Strasse, Berlin, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|University Hospital of Ioannina, Ioannina, Epirus, Greece|General Hospital of Thessaloniki PAPAGEORGIOU, Thessaloniki, Macedoni, Greece|Hippokratio Hospital, Thessaloniki, Macedoni, Greece|University General Hospital of Patras Panagia I Voithia, Patra, Peloponnese, Greece|University General Hospital of Alexandroupolis, Alexandroupoli, Thrace, Greece|Humanity and Health Research Centre, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Dept. of Medicine and Therapeutics, Hong Kong, Hong Kong|Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong|Tuen Mun Hospital, Tuen Mun, Hong Kong|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Somogy, Hungary|Egyesitett Szent Istvan es Szent Laszlo Korhaz - Rendelointezet; Szent Laszlo Korhaz, Budapest, Hungary|Pécsi Tudományegyetem, Klinikai Központ, I.sz.Belgyógyászati Klinika, Pécs, Hungary|Sunshine Hospitals, Secunderabad, Andhra Pradesh, India|Surat Institute of Digestive Sciences, Surat, Gujarat, India|BAPS Pramukh Swami Hospital, Surat, Gujarat, India|Artemis Hospitals, Gurgaon, Haryana, India|Victoria Hospital (Bangalore Medical College), Bangalore, Karnataka, India|KLES Prabhakar Kore Hospital and Medical Research Centre, Belgaum, Karnataka, India|Kasturba Medical College Hospital, Mangalore, Karnataka, India|Global Hospital - Super Speciality and Transplant Centre, Mumbai, Maharashtra, India|B.J. Medical College and Sassoon General Hospital, Pune, Maharashtra, India|Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Punjab, India|Sawai Man Singh Hospital, Jaipur, Rajashthan, India|KRM Hospital and Research Center, Lucknow, Uttar Pradesh, India|Om Research Center, Om Surgical Center and Maternity Home, Varanasi, Uttar Pradesh, India|EMMS MC, Nazareth, Jerusalem, Israel|Rambam Health Care Campus - Rambam Medical Center, Haifa, Israel|Carmel Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Galilee Medical Center, Nahariya, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Sheba Medical Center at Tel Hashomer, Tel-Hashomer, Israel|Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy|Polo Universitario - L'Azienda Ospedaliera Luigi Sacco, Milan, Milano, Italy|Istituto Clinico Humanitas, Rozzano, Milano, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliera S. Orsola - Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Ente Ospedaliero Ospedali Galliera, Genova, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Giuseppe, Milano, Italy|Ospedale San Raffaele, Milano, Italy|ASST Santi Paolo e Carlo, Milano, Italy|Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milano, Italy|Azienda Ospedaliero-Universitaria ""Maggiore della Carità"", Novara, Italy|Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone, Palermo, Italy|Fondazione Policlinico Tor Vergata, Roma, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Policlinico Umberto I di Roma, Roma, Italy|Consultorio Médico Dr. Alma Laura Ladron de Guevara, Mexico, Distrito Federal, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, México City, Distrito Federal, Mexico|Consultorio Rosario Arechavaleta, Guadalajara, Jalisco, Mexico|JM Research - Cuernavaca, Cuernavaca, Morelos, Mexico|Investigaciones Medicas Cisneros, Monterrey, Nuevo Leon, Mexico|Consultorio Dra. Maria Sarai Gonzalez Huezo, Metepec, Mexico|Hospital Punta Sur, Queretaro, Mexico|Auckland City Hospital, Grafton, Auckland, New Zealand|Middlemore Clinical Trials, Papatoetoe, Auckland, New Zealand|Bay of Plenty Clinical School, Tauranga, Bay Of Plenty, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Oslo Universitetssykehus-Ullevål Hospital, Oslo, Norway|Hospital Nacional Arzobispo Loayza, Cercado De Lima, Lima, Peru|SANNA - Clínica San Borja, Distrito De Lima, Lima, Peru|Hospital Nacional Guillermo Almenara Irigoyen, La Victoria, Lima, Peru|Clínica Delgado, Miraflores, Lima, Peru|Hospital Nacional Dos de Mayo, Lima, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Centrum Badan Klinicznych Piotr Napora Lekarze Spólka Partnerska, Wroclaw, Dolnoslaskie, Poland|VitaMED, Bydgoszcz, Kujawsko-Pomorskie, Poland|Wojewódzki Specjalistyczny Szpital im. dr Wl. Bieganskiego w Lodzi, Lódz, Lodzkie, Poland|Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych i Administracji w Warszawie, Warszawa, Mazowieckie, Poland|Specjalistyczna Praktyka Lekarska WAMED Zawiercie, Jaworze, Slaskie, Poland|Niepubliczny Zaklad Opieki Zdrowotnej All-Medicus, Katowice, Slaskie, Poland|Centrum Medycyny i Stomatologii Silesia Med, Katowice, Slaskie, Poland|ID Clinic Arkadiusz Pisula, Myslowice, Slaskie, Poland|Hospital Professor Doutor Fernando Fonseca, Amadora, Lisboa, Portugal|Hospital da Senhora da Oliveira - Guimarães, Guimaraes, Portugal|Centro Hospitalar Lisboa Central - Hospital Capuchos, Lisboa, Portugal|Centro Hospitalar de São João, Porto, Portugal|Hospital de São Bernardo, Setúbal, Portugal|Hospital Santa Luzia de Viana do Castelo, Viana do Castelo, Portugal|Centro Hospitalar de Trás-os-Montes e Alto Douro EPE, Vila Real, Portugal|Clinical Research Puerto Rico, San Juan, Puerto Rico|Fundacion de Investigacion De Diego, San Juan, Puerto Rico|Institutul Regional de Gastroenterologie si Hepatologie Prof. Dr. O Fodor, Cluj-Napoca, Cluj, Romania|Centrul Medical Tuculanu SRL, Timisoara, Timis, Romania|Policlinica Dr. Citu, Timisoara, Timis, Romania|Spitalul Clinic Jude¿ean de Urgen¿a Cluj-Napoca, Cluj, Romania|Clinic of Professor Gorbakov, Krasnogorsk, Moscow, Russian Federation|Infection Center, Koltsovo, Novosibirsk, Russian Federation|Clinical Hospital #1-Smolensk, Smolensk, Solensk, Russian Federation|I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation|Modern Medicine Clinic, Moscow, Russian Federation|Sklifosovsky Scientific Research Institution of Emergency Care, Moscow, Russian Federation|Novosibirsk State Regional Clinical Hospital, Novosibirsk, Russian Federation|Stavropol State Medical University, Novosibirsk, Russian Federation|Union Clinic, Saint Petersburg, Russian Federation|ECO Bezopasnost, Saint Petersburg, Russian Federation|Research Institute of Influenza, Saint-Petersburg, Russian Federation|Stavropol Regional Clinical Hospital, Stavropol, Russian Federation|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Khoo Teck Puat Hospital, Singapore, Singapore|Univerzitetni klinicni center Ljubljana (University Clinical Center Ljubljana), Ljubljana, Slovenia|Univerzitetni klinicni center Maribor, Maribor, Slovenia|Splošna bolnišnica Dr. Franca Derganca Nova Gorica, Šempeter pri Gorici, Slovenia|Hospital Universitario Donostia, San Sebastian, Guipuzcoa, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramón Y Cajal, Madrid, Spain|Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Consorci Hospital General Universitari de València, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Kantonspital Sankt Gallen, St. Gallen, Saint Gallen, Switzerland|Chia-Yi Christian Hospital, Chiayi City, Chiayi, Taiwan|China Medical University Hospital, Taichung, Taichung City, Taiwan|National Cheng Kung University Hospital, Tainan, Tainan City, Taiwan|National Taiwan University Hospital, Taipei, Taipei City, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Cathay General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-LinKou Branch, Taoyuan, Taiwan|University Hospitals Birmingham NHS Foundation Trust, Birmingham, England, United Kingdom|Addenbrookes Hospital, Cambridge, England, United Kingdom|Hull and East Yorkshire Hospitals NHS Trust, Hull, England, United Kingdom|Royal Free London NHS Foundation Trust, London, England, United Kingdom|Guy's and Saint Thomas' NHS Foundation Trust, London, England, United Kingdom|Kings College Hospital NHS Foundation Trust, London, England, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust, London, England, United Kingdom|University Hospital of South Manchester NHS Foundation Trust, Manchester, England, United Kingdom|Newcastle Upon the Tyne Hospitals, Newcastle, England, United Kingdom|Plymouth Hospitals NHS Trust, Plymouth, England, United Kingdom|Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom|University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, England, United Kingdom|Luton and Dunstable Hospital NHS Foundation Trust, Luton, United Kingdom|Nottingham Digestive Diseases Biomedical Research Unit, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT03028740
NCT03022630,Palliative Care for Non-Malignant Diseases (COMPASS Trial),COMPASS,Terminated,No Results Available,Liver Diseases|Liver Cirrhosis|NASH (Non-Alcoholic Steatohepatitis),Other: Comprehensive Palliative Care services|Other: Usual hepatic care,Time to first hospital readmission within 1-year post randomization|Days alive out of hospital|Total days in hospital|Total days in ICU|Number of hospital readmissions|Median length of hospital stay per admission|Hospice Referral|Time to Hospice Placement|Chronic Liver Disease Questionnaire (CLDQ)|EQ-5D-5L|PROMIS Emotional Distress - Anxiety - Short Form 4a|PROMIS Emotional Distress - Depression - Short Form 4a|Satisfaction with Care (Quality of End-of-Life Care: Questionnaire for Patient)|Kingston Caregiver Stress Scale|Satisfaction with Care (Quality of End-of-Life Care: Questionnaire for Patient adapted for Caregiver)|Liver Transplant Status|MELD Score|Completed Liver Transplants|Physical symptoms|Presence of Advance Directives|Survival|Provider Satisfaction,Vanderbilt University Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,63,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,160746,6-Feb-17,21-Jun-18,21-Jun-18,16-Jan-17,null,10-Oct-18,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT03022630
NCT03008070,Phase 2b Study in NASH to Assess IVA337,NATIVE,Recruiting,No Results Available,Non-Alcoholic Steatohepatitis (NASH),Drug: IVA337|Drug: Placebo,"Responder analysis based on the improvement of the SAF (steatosis: S, activity : A, and fibrosis: F) activity score.|Percent of patients with resolution of NASH from baseline to end of treatment|Percent of patients with a change in components of SAF score from baseline to end of treatment : Steatosis, Lobular inflammation, Ballooning, Fibrosis|Immunohistochemistry: change in the semi quantitative score of ballooning and stellate cell activation from baseline to end of treatment|Change in fibrosis score on a 4-points scale (SAF score) from baseline to end of treatment|Change in fibrosis score on modified Ishak score from baseline to end of treatment|Change in fibrosis area assessed by morphometry (Collagen Proportionate Area, CPA) from baseline to end of treatment|Liver enzymes change from baseline to end of treatment|Inflammatory markers change from baseline to end of treatment|Glucose metabolism change from baseline to end of treatment|Main plasma lipids levels change from baseline to end of treatment|Adiponectin change from baseline to end of treatment|Number of participants with adverse events (AE) as a measure of safety|ECG data change from baseline to end of treatment|Vital signs parameters change from baseline to end of treatment",Inventiva Pharma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,225,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IVA_01_337_HNAS_16_002|2016-001979-70,7-Feb-17,Dec-19,Jan-20,2-Jan-17,null,25-Mar-19,"North Alabama GI Research Center, Madison, Alabama, United States|ACTRI, La Jolla, California, United States|National Research Institute, Los Angeles, California, United States|Palmetto Research, LLC, Hialeah, Florida, United States|Florida Digestive Health Specialists, LLP, Lakewood Ranch, Florida, United States|Northeast GI Research Division, Concord, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Carolina's Center for Liver Disease/CHG, Huntersville, North Carolina, United States|Jefferson University hospital, Philadelphia, Pennsylvania, United States|Digestive Health Research, LLC, Hermitage, Tennessee, United States|The Texas Liver Institute, San Antonio, Texas, United States|Digestive Health Research, LLC, San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Flinders Medical Centre Department of Hepatology, Bedford Park, Australia|Monash Medical Centre, Clayton, Australia|Lyell McEwin Hospital & The University of Adelaide, Elizabeth Vale, Australia|Royal Brisbane and Women's Hospital, Herston, Australia|Fiona Stanley Hospital, Murdoch, Australia|Medizinische Universität Graz, Graz, Austria|Medical University Vienna, Vienna, Austria|Antwerp University Hospital, Antwerp, Belgium|Hopital Erasme, Brussels, Belgium|Clinique Universitaire Saint-luc, Brussels, Belgium|Ziekenhuis Oost Limburg, Genk, Belgium|UZ Gent, Gent, Belgium|""DCC Alexandrovska"", EOOD, Sofia, Bulgaria|Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria|Acibadem City Clinic University Hospital EOOD, Sofia, Bulgaria|MHAT ""Sveta Anna"" Sofia, Sofia, Bulgaria|Military Medical Academy - MHAT, Sofia, Bulgaria|UMHAT ""Sv. Ivan Rilski"", Sofia, Bulgaria|UMHAT ""Tsaritsa Yoanna-ISUL"", Sofia, Bulgaria|University of Calgary, Calgary, Canada|The Bailey Health Clinic, Edmonton, Canada|CISSS de la Montérégie Centre, Greenfield Park, Canada|University of Western Ontario, London Health Sciences Centre, London, Canada|McGill University Health Centre (MUHC), Montréal, Canada|Medpharmgene, Inc, Montréal, Canada|LAIR Centre, Vancouver, Canada|Researchsite S.R.O., Plzen, Czechia|Klin Med S.R.O., Praha, Czechia|Institut klinické a experimentální medicíny, IKEM, Praha, Czechia|Hôpital Sud- CHU Amiens, Amiens, France|CHU Angers, Angers, France|CHRU Besançon, Besancon, France|Centre Hospitalier de Bordeaux, Bordeaux, France|CHU Henri Mondor, Créteil, France|CHU de Grenoble, Grenoble, France|Hôpital de La Croix Rousse, Lyon, France|Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France|CHU de Nice, Nice, France|Hôpital Saint Antoine, Paris, France|Hôpital La Pitié Salpétrière, Paris, France|Hôpital Beaujon, Paris, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Hôpital de Hautepierre, Strasbourg, France|Hôpital Purpan - Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France|RWTH University Hospital, Aachen, Germany|Innere Medizin II - Universitätsklinik Freiburg, Freiburg, Germany|Hannover Medical School, Hannover, Germany|Medizinischen Klinik IV, Heidelberg, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Universitätsmedizin Mainz, I. Med. Klinik, Mainz, Germany|Universitätsklinikum Münster, Münster, Germany|University Hospital Würzburg, Wurzburg, Germany|Ospedali Riuniti di Ancona-Università Politecnica delle Marche, Ancona, Italy|Granda Ospedale Maggiore Policlinico - Università di Milano, Milano, Italy|Pol. Giaccone, Palermo, Italy|Fondazione Policlinico Agostino Gemelli, Roma, Italy|Poliambulatorio Giovanni Paolo II, San Giovanni Rotondo, Italy|A.O. Città della Salute e della Scienza di Torino, Torino, Italy|CAP Research, Phoenix, Mauritius|Klinika Chorób Zakaźnych i Hepatologii Uniwersytetu Medycznego w Białymstoku, Bialystok, Poland|Oddzial Gastroenterologii Hepatologii UCK, Katowice, Poland|Katedra i Klinika Chorób Zakaźnych i Hepatologii Uniwersytetu Medycznego w Łodzi, Lodz, Poland|Klinika Chorób Zakaźnych, Lublin, Poland|Centrum Badan Klinicznych, Wrocław, Poland|Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal|CHU Réunion - Site Sud, Saint-Pierre, Réunion|General hospital Celje, Celje, Slovenia|General Hospital Murska Sobota, Murska Sobota, Slovenia|Vall d'Hebron Hospital, Barcelona, Spain|Hospital Puerta de Hierro MAJADAHONDA, Madrid, Spain|Virgen de la Victoria University Hospital, Malaga, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Universitätsklinik für Viszerale Chirurgie und Medizin, Bern, Switzerland|Hôpitaux Universitaire de Genève, Geneve, Switzerland|Epatocentro Ticino, Lugano, Switzerland|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Freeman Hospital, Newcastle University, Newcastle, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT03008070
NCT02992470,Crassostrea Gigas for Liver Health,,Unknown status,No Results Available,Nonalcoholic Fatty Liver,Dietary Supplement: Hydrolyzed oyster extract|Dietary Supplement: Placebo,"Change of serum alanine aminotransferase (ALT)|Change of serum aspartate aminotransferase (AST)|Change of gamma-glutamyl transferase (GGT)|Rate of participants with normalized ALT, AST and GGT|Change of serum bilirubin|Change of multi-dimensional fatigue inventory|Change of serum lipid profiles (triglyceride, total cholesterol, High-density lipoprotein and low-density lipoprotein cholesterol)|Change of antioxidant enzymes (superoxide dismutase, malondialdehyde, glutathione peroxidase)",Korean Medicine Hospital of Pusan National University,All,"19 Years and older   (Adult, Older Adult)",Not Applicable,96,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",2016_11_Crassostrea gigas,Dec-16,Dec-17,null,14-Dec-16,null,14-Dec-16,,,https://ClinicalTrials.gov/show/NCT02992470
NCT02983669,The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease,ThymeLiv,Completed,No Results Available,"Fatty Liver|Fatty Liver, Nonalcoholic",Dietary Supplement: Thyme|Other: Placebo,Change in ALT (Alanin aminotransferase) level|Change in grade of fatty liver in sonography by use of Saverymuttu Scoring System|Change in AST (Aspartate aminotransferase) level|Fasting blood sugar (FBS)|Change in Gama GT (γ-glutamyl transpeptidase) level|Fasting insulin level|Body weight|Waist circumference|Hip circumference|Number of patients with adverse events,Shiraz University of Medical Sciences,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,86,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",94-7648,Jan-17,20-Apr-17,10-May-17,6-Dec-16,null,4-Oct-17,"Shahid Motahhari Clinic, Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02983669
NCT02974374,Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: PF-06835919|Other: Placebo,Number of Subjects experiencing an Adverse Event|Maximum Observed Plasma Concentration (Cmax) for PF-06835919|Time to Reach Maximum Observed Concentration for PF-06835919|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06835919|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for PF-06835919|Plasma Decay Half-Life (t1/2) for PF-06835919 (as permitted)|Apparent Total Body Clearance (CL/F) for PF-06835919 (as permitted)|Apparent Volume of Distribution (Vz/F) for PF-06835919 (as permitted),Pfizer,All,18 Years to 55 Years   (Adult),Phase 1,16,Industry,Interventional,"Allocation: Randomized|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",C1061001,Oct-16,Jan-17,Jan-17,28-Nov-16,null,15-Dec-17,"Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT02974374
NCT02972567,"Evaluation of the Effects of a L.Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease",PROSIR,Unknown status,No Results Available,Metabolic Syndrome X,Dietary Supplement: Lactobacillus spp|Dietary Supplement: Control,"Change from basal plasma lipopolysaccharide (LPS) at 12 weeks|Change from basal Blood pressure at 12 weeks|Change from basal HOMA ( homeostatic model assessment ) index at 12 weeks|Change from basal plasma cholesterol level (total, LDL and HDL) at 12 weeks|Change from basal plasma Inflammatory markers (sVCAM, sICAM, myeloperoxidase selectin, adiponectin, plasminogen activator inhibitor and resistin, and interleukines Il-6, Il-8, tumor necrosis factor, HGF, leptin and Multicopper oxidase-1) at 12 weeks|Change from basal Hepatic Steatosis markers (arginase, prolidase and RBP-4(Retinol binding protein-4)) at 12 weeks|Changes from basal fecal microbiota at 12 weeks",Biosearch S.A.|Universidad de Granada|Complejo Hospitalario de Jaen,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,60,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P3600,May-16,Feb-17,Jun-17,23-Nov-16,null,23-Nov-16,"Complejo Hospitalario Universitario de Jaen, Jaen, Spain",,https://ClinicalTrials.gov/show/NCT02972567
NCT02970942,Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.,,"Active, not recruiting",No Results Available,Hepatobiliary Disorders|Non-alcoholic Steatohepatitis,Drug: Semaglutide|Drug: Placebo,NASH (non-alcoholic steatohepatitis) resolution without worsening of fibrosis|At least one stage of liver fibrosis improvement with no worsening of NASH|Non-alcoholic fatty liver disease (NAFLD) activity score (NAS) (0-8)|Stage of fibrosis according to the Kleiner fibrosis classification (0-4)|Activity component of steatosis-activity-fibrosis (SAF) score (0-4)|Fasting plasma glucose (FPG)|Glycosylated haemoglobin A1c (HbA1c)|Serum enhanced liver fibrosis (ELF),Novo Nordisk A/S,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,320,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",NN9931-4296|2016-000685-39|U1111-1179-7464,30-Nov-16,27-Nov-19,2-Apr-20,22-Nov-16,null,15-May-19,"Novo Nordisk Investigational Site, Birmingham, Alabama, United States|Novo Nordisk Investigational Site, Chandler, Arizona, United States|Novo Nordisk Investigational Site, Glendale, Arizona, United States|Novo Nordisk Investigational Site, Tucson, Arizona, United States|Novo Nordisk Investigational Site, Coronado, California, United States|Novo Nordisk Investigational Site, Costa Mesa, California, United States|Novo Nordisk Investigational Site, La Mesa, California, United States|Novo Nordisk Investigational Site, Los Angeles, California, United States|Novo Nordisk Investigational Site, Northridge, California, United States|Novo Nordisk Investigational Site, Panorama City, California, United States|Novo Nordisk Investigational Site, Rialto, California, United States|Novo Nordisk Investigational Site, Boca Raton, Florida, United States|Novo Nordisk Investigational Site, Gainesville, Florida, United States|Novo Nordisk Investigational Site, Jacksonville, Florida, United States|Novo Nordisk Investigational Site, Lakewood Ranch, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Miami, Florida, United States|Novo Nordisk Investigational Site, Ocoee, Florida, United States|Novo Nordisk Investigational Site, Monroe, Louisiana, United States|Novo Nordisk Investigational Site, Baltimore, Maryland, United States|Novo Nordisk Investigational Site, Detroit, Michigan, United States|Novo Nordisk Investigational Site, Rochester, Minnesota, United States|Novo Nordisk Investigational Site, Omaha, Nebraska, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Las Vegas, Nevada, United States|Novo Nordisk Investigational Site, Manhasset, New York, United States|Novo Nordisk Investigational Site, Danville, Pennsylvania, United States|Novo Nordisk Investigational Site, Pittsburgh, Pennsylvania, United States|Novo Nordisk Investigational Site, Hermitage, Tennessee, United States|Novo Nordisk Investigational Site, Austin, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Dallas, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Houston, Texas, United States|Novo Nordisk Investigational Site, Rollingwood, Texas, United States|Novo Nordisk Investigational Site, San Antonio, Texas, United States|Novo Nordisk Investigational Site, Burlington, Vermont, United States|Novo Nordisk Investigational Site, Richmond, Virginia, United States|Novo Nordisk Investigational Site, Seattle, Washington, United States|Novo Nordisk Investigational Site, Camperdown, New South Wales, Australia|Novo Nordisk Investigational Site, Kingswood, New South Wales, Australia|Novo Nordisk Investigational Site, Westmead, New South Wales, Australia|Novo Nordisk Investigational Site, Box Hill, Victoria, Australia|Novo Nordisk Investigational Site, Fitzroy, Victoria, Australia|Novo Nordisk Investigational Site, Graz, Austria|Novo Nordisk Investigational Site, Salzburg, Austria|Novo Nordisk Investigational Site, Wien, Austria|Novo Nordisk Investigational Site, Brussels, Belgium|Novo Nordisk Investigational Site, Bruxelles, Belgium|Novo Nordisk Investigational Site, Edegem, Belgium|Novo Nordisk Investigational Site, Gent, Belgium|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Sofia, Bulgaria|Novo Nordisk Investigational Site, Calgary, Alberta, Canada|Novo Nordisk Investigational Site, Winnipeg, Manitoba, Canada|Novo Nordisk Investigational Site, Halifax, Nova Scotia, Canada|Novo Nordisk Investigational Site, Brampton, Ontario, Canada|Novo Nordisk Investigational Site, Hamilton, Ontario, Canada|Novo Nordisk Investigational Site, London, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Toronto, Ontario, Canada|Novo Nordisk Investigational Site, Montreal, Quebec, Canada|Novo Nordisk Investigational Site, Aarhus N, Denmark|Novo Nordisk Investigational Site, Hvidovre, Denmark|Novo Nordisk Investigational Site, Helsinki, Finland|Novo Nordisk Investigational Site, Besançon, France|Novo Nordisk Investigational Site, Clermont-Ferrand, France|Novo Nordisk Investigational Site, Lyon Cedex 4, France|Novo Nordisk Investigational Site, MARSEILLE cedex 08, France|Novo Nordisk Investigational Site, Montpellier, France|Novo Nordisk Investigational Site, NICE cedex 3, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Paris, France|Novo Nordisk Investigational Site, Pessac, France|Novo Nordisk Investigational Site, Toulouse, France|Novo Nordisk Investigational Site, Venissieux, France|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Athens, Greece|Novo Nordisk Investigational Site, Goudi, Athens, Greece|Novo Nordisk Investigational Site, Larissa, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Thessaloniki, Greece|Novo Nordisk Investigational Site, Asahikawa-shi, Hokkaido, Japan|Novo Nordisk Investigational Site, Fukui-shi, Fukui, Japan|Novo Nordisk Investigational Site, Kamigyo-ku, Kyoto, Japan|Novo Nordisk Investigational Site, Kumamoto-shi, Kumamoto, Japan|Novo Nordisk Investigational Site, Nagakute-shi, Aichi, Japan|Novo Nordisk Investigational Site, Nara-shi, Nara, Japan|Novo Nordisk Investigational Site, Nishinomiya-shi, Hyogo, Japan|Novo Nordisk Investigational Site, Osaka-shi, Osaka, Japan|Novo Nordisk Investigational Site, Otsu-city, Shiga, Japan|Novo Nordisk Investigational Site, Saga-shi, Saga, Japan|Novo Nordisk Investigational Site, Shimonoseki-shi, Yamaguchi, Japan|Novo Nordisk Investigational Site, Suita-shi, Osaka, Japan|Novo Nordisk Investigational Site, Suita-shi, Osaka, Japan|Novo Nordisk Investigational Site, Takamatsu-shi, Kagawa, Japan|Novo Nordisk Investigational Site, Toyoake-shi, Aichi, Japan|Novo Nordisk Investigational Site, Alkmaar, Netherlands|Novo Nordisk Investigational Site, Amstelveen, Netherlands|Novo Nordisk Investigational Site, Amsterdam, Netherlands|Novo Nordisk Investigational Site, Delft, Netherlands|Novo Nordisk Investigational Site, Groningen, Netherlands|Novo Nordisk Investigational Site, Leiden, Netherlands|Novo Nordisk Investigational Site, Maastricht, Netherlands|Novo Nordisk Investigational Site, Nijmegen, Netherlands|Novo Nordisk Investigational Site, San Juan, Puerto Rico|Novo Nordisk Investigational Site, Barnaul, Russian Federation|Novo Nordisk Investigational Site, Kazan, Russian Federation|Novo Nordisk Investigational Site, Kemerovo, Russian Federation|Novo Nordisk Investigational Site, Krasnoyarsk, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Moscow, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Novosibirsk, Russian Federation|Novo Nordisk Investigational Site, Penza, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Saratov, Russian Federation|Novo Nordisk Investigational Site, Stavropol, Russian Federation|Novo Nordisk Investigational Site, Stavropol, Russian Federation|Novo Nordisk Investigational Site, Tomsk, Russian Federation|Novo Nordisk Investigational Site, Ulianovsk, Russian Federation|Novo Nordisk Investigational Site, Yoshkar-Ola, Russian Federation|Novo Nordisk Investigational Site, Madrid, Spain|Novo Nordisk Investigational Site, Majadahonda, Spain|Novo Nordisk Investigational Site, Santander, Spain|Novo Nordisk Investigational Site, Santiago de Compostela, Spain|Novo Nordisk Investigational Site, Sevilla, Spain|Novo Nordisk Investigational Site, Valencia, Spain|Novo Nordisk Investigational Site, Göteborg, Sweden|Novo Nordisk Investigational Site, Malmö, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Stockholm, Sweden|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Birmingham, United Kingdom|Novo Nordisk Investigational Site, Bolton, United Kingdom|Novo Nordisk Investigational Site, Cambridge, United Kingdom|Novo Nordisk Investigational Site, Derby, United Kingdom|Novo Nordisk Investigational Site, Dundee, United Kingdom|Novo Nordisk Investigational Site, Edinburgh, United Kingdom|Novo Nordisk Investigational Site, Glasgow, United Kingdom|Novo Nordisk Investigational Site, Hull, United Kingdom|Novo Nordisk Investigational Site, Leeds, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, London, United Kingdom|Novo Nordisk Investigational Site, Nottingham, United Kingdom|Novo Nordisk Investigational Site, Portsmouth, United Kingdom|Novo Nordisk Investigational Site, Swansea, United Kingdom",,https://ClinicalTrials.gov/show/NCT02970942
NCT02964715,The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes,,Unknown status,No Results Available,Type2 Diabetes|NAFLD,Drug: Empagliflozin,Change in histological Grade as evaluated with Non-alcoholic Steatohepatitis Clinical Research Network Scoring System|Change in serum FGF 21|Change in fibroscan and elastography measure of liver stiffness|Change in Liver enzymes|Change in steatosis|Change in lobular inflammation|Change in ballooning|Change in fibrosis|Change in metabolic outcome -HbA1c|Change in metabolic outcome - fasting NEFA|Change in metabolic outcome - fasting Tg|Change in serum FGF 19|Change in serum adiponectin|Change in serum IL-6|Change in serum TNF alpha|Change in serum uric acid|Change in MRI features of NASH,University of Malaya,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,25,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ERF-4,Nov-16,Nov-18,Nov-18,16-Nov-16,null,31-May-17,"University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia",,https://ClinicalTrials.gov/show/NCT02964715
NCT02962297,Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis,,"Active, not recruiting",No Results Available,NASH (Non-Alcoholic Steatohepatitis),Drug: Vitamin E softgel|Drug: Placebo,Improvement in hepatic histology,"Zhejiang Medicine Co., Ltd.|R&G Pharma Studies Co.,Ltd.|The Affiliated Hospital of Hangzhou Normal University",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,120,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VENS,Dec-16,Jan-21,May-21,11-Nov-16,null,10-Jan-19,"Beijing Ditan Hospital Capital Medical University, Beijin, Beijing, China|302 Military Hospital of China, Beijing, China|Beijing YouAn Hospital Capital Medical Univercity, Beijing, China|West China Hospital, Sichuan university, Chengdu, China|The first Affiliated Hospital, Sun Yat-sen University, Guangdong, China|Guangdong Provincial Chinese Medicine Hospital, Guangzhou, China|Nanfang Hospital, Guangzhou, China|The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China|Southwest Medical University Affiliated, Luzhou, China|The Second Hospital of Nanjing, Nanjing, China|The First Hospital of China Medical University, Shenyang, China|The second people's Hospital of Tianjin, Tianjin, China|The First Affiliated Hospital of Medical University, Urumqi, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhu, China|General Hospital Ningxia Medical, Yinchuan, China",,https://ClinicalTrials.gov/show/NCT02962297
NCT02960204,"Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension",ENCORE-PH,"Active, not recruiting",No Results Available,Cirrhosis|Portal Hypertension|Non-alcoholic Steatohepatitis,Drug: Emricasan|Drug: Placebo,Mean Change in Hepatic Venous Pressure Gradient (HVPG)|Improvement of HVPG response using a 20% reduction from baseline|Caspase 3/7|Alanine aminotransferase (ALT)|The Number of Subjects with Treatment Emergent Adverse Events,Conatus Pharmaceuticals Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,240,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IDN-6556-14,17-Oct-16,Oct-18,Apr-19,9-Nov-16,null,30-Apr-18,"California Liver Research Institute, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|IMIC Inc., Palmetto Bay, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|Digestive and Liver Disease Specialists; Mercy Medical Center, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Minnesota Gastroenterology, PA, Saint Paul, Minnesota, United States|Kansas City Gastroenterology and Hepatology, Kansas City, Missouri, United States|Duke University Medical Center, Duke South Clinics, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Einstein Healthcare Network, Philadelphia, Pennsylvania, United States|Gastro One, Germantown, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|Advanced Liver Therapies - Baylor College of Medicine, Houston, Texas, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Pinnacle Clinical Research, San Antonio, Texas, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|McGuire VA Medical Center, Richmond, Virginia, United States|University of Washington Harborview Medical Center, Seattle, Washington, United States|Universitätsklinikum Bonn, Bonn, Germany|Universitatsklinikum Halle (Saale), Halle (Saale), Germany|Eugastro GmbH, Leipzig, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Münster, Münster, Germany|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Spain|Hospital Universitario de Donostia, San Sebastian, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02960204
NCT02951546,"Study on Metabolic Flexibility and Gut Microbiota Composition in Obese Subjects With NAFLD, Taking Into Account PNPLA3 and TM6SF2 Polymorphisms. Effects of Nutritional Intervention Combined to Exercise",,Unknown status,No Results Available,Non-alcoholic Fatty Liver Disease|Obesity,Dietary Supplement: Mediterranean diet|Dietary Supplement: Low fat diet|Other: Aerobic exercise,metabolic flexibility variation in lipid profile;|metabolic flexibility variation in glucidic profile,University of Roma La Sapienza|Bambino Gesù Hospital and Research Institute|Università degli studi di Roma Foro Italico|Göteborg University,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RIF.CE:4119,Oct-16,Sep-17,Jan-18,1-Nov-16,null,3-Nov-16,"Stefano Ginanni Corradini, Rome, Italy|Department of Clinical Medicine, Sapienza University of Rome, Umberto I Hospital, Rome, Italy",,https://ClinicalTrials.gov/show/NCT02951546
NCT02948647,Healthy Eating Through Reduction Of Excess Sugar,HEROES,Recruiting,No Results Available,NAFLD,Other: Standard of care plus sugar-reduction education,"Total liver fat fraction by Magnetic resonance imaging (MRI) at baseline|Total liver fat fraction by Magnetic resonance imaging (MRI) at 12 weeks|Change in total liver fat fraction by Magnetic resonance imaging (MRI) from baseline to 12 weeks|Liver fibrosis by Magnetic Resonance Enterography (MRE) at baseline|Liver fibrosis by Magnetic Resonance Enterography (MRE) at 12 weeks|Change in Liver fibrosis by Magnetic Resonance Enterography (MRE) from baseline to 12 weeks|Total body fat, soft lean tissue, and bone mineral content by dual-energy x-ray absorptiometry (DXA) at baseline|Total body fat, soft lean tissue, and bone mineral content by dual-energy x-ray absorptiometry (DXA) at 12 weeks|Change in total body fat, soft lean tissue, and bone mineral content by dual-energy x-ray absorptiometry (DXA) from baseline to 12 weeks|Liver enzymes by fasting blood analysis at baseline|Liver enzymes by fasting blood analysis at 12 weeks|Change in liver enzymes by fasting blood analysis from baseline to 12 weeks|Fasting glucose at baseline|Fasting glucose from 12 weeks|Change in fasting glucose from baseline to 12 weeks|Insulin and glucose response to an oral glucose challenge at baseline|Insulin and glucose response to an oral glucose challenge at 12 weeks|Change in insulin and glucose response to an oral glucose challenge at baseline and 12 weeks|Lipids at baseline|Lipids at 12 weeks|Change in lipids from baseline to 12 weeks|Adipokines at baseline|Adipokines at 12 weeks|Change in adipokines from baseline to 12 weeks|Inflammatory markers at baseline|Inflammatory markers at 12 weeks|Change in inflammatory markers from baseline to 12 weeks|Hormones at baseline|Hormones 12 weeks|Change in hormones from baseline to 12 weeks|Blood pressure at baseline|Blood pressure at 12 weeks|Change in blood pressure from baseline to 12 weeks|Resting heart rate at baseline|Resting heart rate at 12 weeks|Change in resting heart rate from baseline to 12 weeks",University of Southern California|Children's Hospital Los Angeles,All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",HS-11-00446,Nov-16,Apr-20,Apr-21,28-Oct-16,null,16-Apr-19,"Diabetes & Obesity Research Institute, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02948647
NCT02941549,Safety And Efficacy Study Of Orally Administered DS102 In Patients With NAFLD,,Recruiting,No Results Available,Non Alcoholic Fatty Liver Disease,Other: Placebo capsules|Drug: DS102,Change in serum ALT (alanine aminotransferase) from baseline to week 16|Number of Treatment Emergent Adverse Events (TEAEs) in each treatment group leading to discontinuation,Afimmune,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,69,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DS102A-02|2016-000311-33,24-Nov-16,Dec-18,Dec-18,21-Oct-16,null,28-Jun-18,"JSC ""Evex Medical Corporation"", Kutaisi, Georgia|JSC ""Saint Nikolozi Surgery Center"", Kutaisi, Georgia|National Center for Diabetes Research, Tbilisi, Georgia|Hospital Universitario de Burgos/ Burgos University Hospital Burgos,, Burgos, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Virgen del Rocío, Sevilla, Spain|State Institution Institute of Gastroenterology of NAMS of Ukraine, Department of Stomach and Duodenum Diseases, Dietology and Therapeutic Nutrition, State Institution Dnipropetrovsk Medical Academy of the MoH of Ukraine, Dnipro, Ukraine|Government Institution ""L.V.Malaya Therapy National Institute of the National academy of Medical Sciences of Ukraine"", Kharkiv, Ukraine|Kyiv City Clinical Hospital #6, Gastroenterology Department with Endocrinology beds profile, Diabetology Department P.L. Shupik NMAPE, Kyiv, Ukraine|Department of Gastroenterology, Dietology and Endoscopy, Shupyk National Medical academy of Post-graduate education, Kyiv City Clinical Hospital No. 8, Kyiv, Ukraine|Royal Victoria Hospital, Belfast, UK, United Kingdom|University Hospital Birmingham, Birmingham, UK, United Kingdom|Birmingham Heartlands Hospital, Birmingham, UK, United Kingdom|Royal Liverpool University Hospital, Liverpool, UK, United Kingdom|Royal London Hospital, London, UK, United Kingdom|Norfolk and Norwich University NHS Hospital Trust, Norwich, UK, United Kingdom|John Radcliffe Hospital, Oxford, UK, United Kingdom|Derriford Hospital, Plymouth, UK, United Kingdom|Queen Alexandra Hospital, Portsmouth, UK, United Kingdom",,https://ClinicalTrials.gov/show/NCT02941549
NCT02930161,Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome,,Terminated,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Runihol|Other: Placebo,"Proportion of responders to treatment|Severity of dyslipidemia|The insulin resistance index (HOMA-IR)|Transaminases|cholestasis markers (alkaline phosphatase, GGT)|Bilirubin|Body mass index|ultrasound signs of hepatic steatosis",POLYSAN Scientific & Technological Pharmaceutical Company,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,35,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",RUN-II-2015,30-May-16,10-Oct-18,10-Oct-18,12-Oct-16,null,8-Feb-19,"Company ""Clinic of professor Gorbakov"" Ltd., Krasnogorsk, Russian Federation|City Hospital of the Holy Martyr Elizabeth, Saint-Petersburg, Russian Federation|Medical Company ""Hepatologist"" Ltd., Samara, Russian Federation",,https://ClinicalTrials.gov/show/NCT02930161
NCT02929901,"The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes",,Completed,No Results Available,Type 2 Diabetes Nonalcoholic Fatty Liver,Dietary Supplement: caffeine and chlorogenic acid|Dietary Supplement: caffeine|Dietary Supplement: chlorogenic acid|Dietary Supplement: placebo,Hepatic steatosis|Glucose|Glycated hemoglobin (HBA1C)|alanine aminotransferase (ALT)|aspartate aminotransferase (ALS)|High sensitive C reactive protein ( hs- CRP)|gut microbiota,National Nutrition and Food Technology Institute,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,200,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",147,Dec-16,Sep-18,Mar-19,11-Oct-16,null,1-May-19,"NNFTRI clinic, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02929901
NCT02927314,A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease,,Recruiting,No Results Available,Non-alcoholic Steatohepatitis (NASH),Drug: CF102|Drug: Placebo,"Efficacy of CF102 as determined by change in serum alanine aminotransferase (ALT) levels|Nature, frequency, and severity of adverse events in this patient population|Efficacy of CF102 as determined by change in magnetic resonance imaging-determined hepatic steatosis|Body weight in subjects with NAFLD|Waist circumference in subjects with NAFLD|HDL cholesterol levels in subjects with NAFLD|Normalization of serum ALT levels|Serum aspartate aminotransaminase (AST) levels in subjects with NAFLD|Hemoglobin A1c levels and degree of insulin resistance|Pharmacokinetics (PK) of CF102 in this population|Peripheral blood expression of the A3 adenosine receptor (A3AR).",Can-Fite BioPharma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CF102-211LD,27-Nov-17,Dec-18,Dec-18,7-Oct-16,null,4-Apr-18,"Can-Fite Investigational Site #318, Jerusalem, Israel|Can-Fite Investigational Site #319, Nazareth, Israel|Can-Fite Investigational Site #311, Petach Tikva, Israel",,https://ClinicalTrials.gov/show/NCT02927314
NCT02927184,Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease,,"Active, not recruiting",No Results Available,Hyperlipidemia|NAFLD,Drug: VK2809|Drug: Placebo,Change in LDL-C in patients receiving VK2809 compared to placebo,"Viking Therapeutics, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,59,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VK2809-201,28-Sep-16,28-Dec-18,28-Jun-19,6-Oct-16,null,30-Oct-18,"Radiant Research, Inc., Chandler, Arizona, United States|SC Clinical Research, Garden Grove, California, United States|ACTCA, Los Angeles, California, United States|Catalina Research Institute, Montclair, California, United States|North America Research, Inc, Pomona, California, United States|Orange County Research Center, Tustin, California, United States|Research Institute of South Florida, Miami, Florida, United States|Research Institute of South Florida, Miami, Florida, United States|Avant Research Associates, LLC, Crowley, Louisiana, United States|HCI- MetroMedic Walk-in, New Bedford, Massachusetts, United States|HCI- MetroMedic Walk-in, New Bedford, Massachusetts, United States|Flint Clinical Research, PLLC, Flint, Michigan, United States|CHEAR Center, LLC, Bronx, New York, United States|Mid Hudson Medical, Hopewell Junction, New York, United States|Wake Research Associcates, LLC., Raleigh, North Carolina, United States|Avant Research, Beaumont, Texas, United States|Clinical Trials of Texas, INC, San Antonio, Texas, United States|Radiant Research, Inc., San Antonio, Texas, United States|Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States",,https://ClinicalTrials.gov/show/NCT02927184
NCT02923804,Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients,,Completed,No Results Available,Non Alcoholic Fatty Liver,Dietary Supplement: Omega-3|Dietary Supplement: Olive oil,• The primary endpoint is the difference in mean percent changes from baseline (Week 24 each with baseline subtracted) between placebo and omega-3 groups|• Difference in mean percent change from baseline to end-of-treatment in RBC EPA and RBC DHA (percentage of lipids and quantitative measurements)|• Difference in mean percent change from baseline to end of treatment in omega-6: omega-3 ratios.|To assess the impact of omega-3 on changes in liver fat as determined by MRI-PDFF,Pronova BioPharma|Nutrasource Diagnostics Inc.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,172,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1051-001-PRO-19012015,Oct-15,1-Dec-17,1-Dec-17,5-Oct-16,null,4-Apr-18,"Hialeah, Hialeah, Florida, United States|Lake Worth, Lake Worth, Florida, United States|Lauderdale Lakes, Lauderdale Lakes, Florida, United States|Miami, Miami, Florida, United States|Greenville, Greenville, South Carolina, United States|Arlington, Arlington, Texas, United States|Arlington, Arlington, Texas, United States",,https://ClinicalTrials.gov/show/NCT02923804
NCT02923154,Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH),,"Active, not recruiting",No Results Available,NASH,Drug: MT-3995|Drug: Placebo,Percent change from baseline in ALT|Change from baseline in ALT|Adverse events,Mitsubishi Tanabe Pharma Corporation,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MT-3995-J07,Sep-16,Mar-18,Apr-19,4-Oct-16,null,2-Dec-17,"Investigational site, Kanagawa, Japan|Investigational site, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT02923154
NCT02918929,A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD,,Completed,No Results Available,Presumptive NAFLD,Drug: EDP 305|Drug: Placebo,"Safety data including but not limited to adverse events, physical exams, vital signs, 12-lead ECGs and clinical lab results (including chemistry, hematology, and urinalysis).|Cmax|AUC",Enanta Pharmaceuticals|Pharmaceutical Research Associates,All,18 Years to 55 Years   (Adult),Phase 1,146,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",EDP 305-001,Sep-16,Jun-17,Jun-17,29-Sep-16,null,21-Aug-17,"Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States",,https://ClinicalTrials.gov/show/NCT02918929
NCT02912260,Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH),,"Active, not recruiting",No Results Available,Non-alcoholic Steatohepatitis,Drug: MGL-3196|Drug: Placebo,Change from baseline in hepatic fat fraction assessed by MRI-PDFF|Two-point reduction in Non-alcoholic fatty liver disease NASH CRN (NAFLD) activity score (NAS)|Resolution of Non-alcoholic steatohepatitis (NASH) (ballooning = 0; inflammation = 0 to 1) as determined by the NASH CRN NAS score|Improvement in fibrosis by at least 1 stage with no worsening of steatohepatitis|Change from baseline in hepatic fat fraction|Safety and tolerability of MGL-3196 based on Adverse Events and Changes in Laboratory Values|Effect on high-sensitivity C-reactive protein (hsCRP)|Effect on serum alanine aminotransferase (ALT)|Effect on aspartate aminotransferase (AST)|Effect on lipid parameters|Effect on NASH and fibrosis biomarkers,"Madrigal Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,125,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MGL-3196-05,Sep-16,Oct-17,Apr-18,23-Sep-16,null,19-Dec-17,"Madrigal Research Site, Dothan, Alabama, United States|Madrigal Research Site, Tucson, Arizona, United States|Madrigal Research Site, Coronado, California, United States|Madrigal Research Site, Los Angeles, California, United States|Madrigal Research Site, Rialto, California, United States|Madrigal Research Site, San Diego, California, United States|Madrigal Research Site, Ventura, California, United States|Madrigal Research Site, Englewood, Colorado, United States|Madrigal Research Site, Boca Raton, Florida, United States|Madrigal Research Site, Lakewood Ranch, Florida, United States|Madrigal Research Site, Lauderdale Lakes, Florida, United States|Madrigal Research Site, Miami, Florida, United States|Madrigal Research Site, New Port Richey, Florida, United States|Madrigal Research Site, Kansas City, Kansas, United States|Madrigal Research Site, Monroe, Louisiana, United States|Madrigal Research Site, Baltimore, Maryland, United States|Madrigal Research Site, Jackson, Mississippi, United States|Madrigal Research Site, Saint Louis, Missouri, United States|Madrigal Research Site, Albuquerque, New Mexico, United States|Madrigal Research Site, New York, New York, United States|Madrigal Research Site, Durham, North Carolina, United States|Madrigal Research Site, Rapid City, South Dakota, United States|Madrigal Research Site, Live Oak, Texas, United States|Madrigal Research Site, San Antonio, Texas, United States|Madrigal Research Site, Charlottesville, Virginia, United States|Madrigal Research Site, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02912260
NCT02913105,"Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH",,"Active, not recruiting",No Results Available,Non-alcoholic Steatohepatitis NASH,Drug: LMB763|Drug: Placebo,Adverse event profile and safety endpoints of LMB763 in patients with NASH|Change in Transaminase levels|Change from baseline in % of fat in the liver assessed using MRI|Change from baseline in anthropometric assessments (BMI in kg/m^2)|Change from baseline on non-invasive liver fibrosis markers (Enhanced Liver Fibrosis (ELF) panel)|Severity of itch sensation based on a visual analog scale (VAS) rating|Change from baseline on fasting lipid profile|Pharmacokinetics of LMB763 in plasma: Cmax maximum plasma concentration at steady state|Pharmacokinetics of LMB763 in plasma: Tmax time to reach the maximum concentration after drug administration|Pharmacokinetics of LMB763 in plasma: AUC area under the concentration-time curve|Pharmacokinetics of LMB763 in plasma: Racc the accumulation ratio|Pharmacokinetics of LMB763 in plasma: T1/2 the effective half-life based on drug accumulation at steady state,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,192,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CLMB763X2201,24-Oct-16,20-Dec-19,20-Dec-19,23-Sep-16,null,26-Feb-19,"Novartis Investigative Site, Culver City, California, United States|Novartis Investigative Site, Cypress, California, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Miami Springs, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, High Point, North Carolina, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Newport News, Virginia, United States|Novartis Investigative Site, New Lambton, New South Wales, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Tbilisi, Georgia|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Papatoetoe, Auckland, New Zealand|Novartis Investigative Site, Auckland, New Zealand|Novartis Investigative Site, Christchurch, New Zealand|Novartis Investigative Site, Tauranga, New Zealand|Novartis Investigative Site, Wellington, New Zealand|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Geneve 14, Switzerland|Novartis Investigative Site, Lugano, Switzerland|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Portsmouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT02913105
NCT02907684,The Impact of Almond Nut Consumption on Markers of CVD & Metabolic Health,Almonds,"Active, not recruiting",No Results Available,Cardiovascular Disease,Dietary Supplement: Almonds|Dietary Supplement: Muffins/Crackers,Endothelium-dependent vasodilation|Liver fat %|Pancreatic fat|Abdominal fat|Muscle fat|Body composition: body weight|Body composition: body mass index|Body composition: Waist circumference|Body composition: Hip circumference|Blood pressure|24 hour ambulatory blood pressure|24 hour heart rate variability|Fecal short chain fatty acids|Gut microbiota|Fasting insulin|Fasting glucose|Fasting non esterified fatty acids (NEFA)|Plasma Total cholesterol|Plasma LDL cholesterol|Plasma HDL cholesterol|Plasma HDL:LDL ratio|Plasma triglyceride concentration|Homeostasis model assessment estimated insulin resistance (HOMA-IR)|Plasma adiponectin|Plasma resistin|Plasma leptin,King's College London|Almond Board of California,All,"30 Years to 70 Years   (Adult, Older Adult)",Not Applicable,108,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,ABC RFP-DHW001,29-Mar-17,30-Apr-19,30-Apr-19,20-Sep-16,null,27-Feb-19,"King's College London, Diabetes and Nutritional Sciences Division, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02907684
NCT02908152,Curcumin Supplement in Nonalcoholic Fatty Liver Patients With Type 2 Diabetes,,Unknown status,No Results Available,Type 2 Diabetes|Nonalcoholic Fatty Liver,Dietary Supplement: curcumin|Dietary Supplement: placebo,Hepatic steatosis|Glucose|HBA1C|ALT|AST,National Nutrition and Food Technology Institute,All,"30 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",467,Feb-17,Jul-17,Oct-17,20-Sep-16,null,20-Sep-16,"Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02908152
NCT02891408,Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function,HI,Completed,No Results Available,Nonalcoholic Steatohepatitis (NASH),Drug: Firsocostat|Drug: Fenofibrate,"PK Parameter: AUClast of firsocostat or fenofibrate (and their metabolites, as applicable)|PK Parameter: AUCinf of firsocostat or fenofibrate (and their metabolites, as applicable)|PK Parameter: Cmax of firsocostat or fenofibrate (and their metabolites, as applicable)|PK Parameter: %AUCexp of firsocostat or fenofibrate (and their metabolites, as applicable)|PK Parameter: Tmax of firsocostat or fenofibrate (and their metabolites, as applicable)|PK Parameter: Clast of firsocostat or fenofibrate (and their metabolites, as applicable)|PK Parameter: Tlast of firsocostat or fenofibrate (and their metabolites, as applicable)|PK Parameter: λz of firsocostat or fenofibrate (and their metabolites, as applicable)|PK Parameter: CL/F of firsocostat or fenofibrate (and their metabolites, as applicable)|PK Parameter: Vz/F of firsocostat or fenofibrate (and their metabolites, as applicable)|PK Parameter: t1/2 of firsocostat or fenofibrate (and their metabolites, as applicable)|Incidence of adverse events|Incidence of laboratory abnormalities",Gilead Sciences,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,74,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-426-3988,23-Sep-16,5-May-19,13-May-19,7-Sep-16,null,20-May-19,"Tustin, California, United States|Miami, Florida, United States|Orlando, Florida, United States|Minneapolis, Minnesota, United States|San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT02891408
NCT02880189,EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity,,Completed,Has Results,Obesity|Non-Alcoholic Steatohepatitis,Device: Orbera Intragastric Balloon|Procedure: Endoscopic Ultrasound Guided Core Liver Biopsy,Weight Loss Achieved With Intragastric Balloon (IGB)|Diagnosis of NASH and Early Fibrosis by Endoscopic Ultrasound (EUS) Guided Liver Core Biopsies,Mayo Clinic,All,"22 Years to 69 Years   (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,15-009262,Dec-16,13-Mar-18,13-Mar-18,26-Aug-16,18-Apr-19,18-Apr-19,,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02880189/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02880189
NCT02875392,Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD),,Unknown status,No Results Available,Non-alcoholic Fatty Liver Disease,Other: 275mg Oligo Fucoidan + 275mg HS Fucoxanthin|Other: placebo pills,improvement on AST|improvement on ALT,Taipei Medical University WanFang Hospital,All,"20 Years to 75 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",N201605071,Nov-16,Nov-17,Dec-17,23-Aug-16,null,8-Feb-17,"WanFangH, Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT02875392
NCT02875821,Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone,,Completed,No Results Available,Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD),Drug: Ipragliflozin|Drug: metformin with pioglitazone,changes in visceral fat area|Changes in subcutaneous fat area|Changes in liver fat,Yonsei University,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 4,44,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-2015-1115,26-Apr-16,7-Jun-17,7-Jun-17,23-Aug-16,null,23-Jun-17,"Yonsei University College of Medicine, Department of internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02875821
NCT02863393,Diaphragmatic Breathing Exercise Improves Non-alcoholic Fatty Liver Disease,,Withdrawn,No Results Available,Non-alcoholic Fatty Liver Disease,Other: Diaphragmatic breathing exercise,AST and ALT,Taipei Medical University WanFang Hospital,All,"20 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,N201603004,29-Aug-17,Jan-18,Mar-18,11-Aug-16,null,30-Aug-17,,,https://ClinicalTrials.gov/show/NCT02863393
NCT02856555,GS-0976 in Adults With Nonalcoholic Steatohepatitis,,Completed,No Results Available,Nonalcoholic Steatohepatitis (NASH),Drug: GS-0976|Drug: Placebo,Overall Safety Profile of GS-0976 assessed as the percentage of participants experiencing treatment-emergent adverse events,Gilead Sciences,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,127,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GS-US-426-3989,8-Aug-16,18-Jul-17,18-Jul-17,5-Aug-16,null,11-Jul-18,"Coronado, California, United States|Foster City, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Rialto, California, United States|San Diego, California, United States|San Diego, California, United States|San Francisco, California, United States|San Francisco, California, United States|Miami, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Kansas City, Missouri, United States|New York, New York, United States|Durham, North Carolina, United States|Statesville, North Carolina, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Germantown, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Live Oak, Texas, United States|San Antonio, Texas, United States|Murray, Utah, United States|Falls Church, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Richmond, Virginia, United States|Richland, Washington, United States|Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02856555
NCT02855164,Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH),FLIGHT-FXR,Recruiting,No Results Available,Non-alcoholic Steatohepatitis (NASH),Drug: Tropifexor (LJN452)|Drug: Placebo,Adverse event profile of different doses of tropifexor (LJN452) in patients with NASH|Change in Transaminase levels|Change from baseline in % of fat in the liver assessed using MRI|Change from baseline in weight|Change from baseline in biomarker FGF19|Change from baseline on on markers of liver fibrosis|Change from baseline on gamma-glutamyl transferase (GGT)|Change from baseline on fasting lipid profile|Determine Ctrough of LJN452|Itch based on a visual analog scale (VAS) rating scale|Change from baseline in BMI|Change from baseline in waist-to-hip (WTH) ratio|Change from baseline in biomarker C4|Determine C2h of LJN452|Effects on above mentioned primary outcome measures in a subset of patients with history of biopsy data,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",Phase 2,345,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CLJN452A2202|2015-005215-33,1-Aug-16,31-Jul-19,3-Apr-20,4-Aug-16,null,19-Feb-19,"Novartis Investigative Site, Madison, Alabama, United States|Novartis Investigative Site, North Little Rock, Arkansas, United States|Novartis Investigative Site, Coronado, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Pasadena, California, United States|Novartis Investigative Site, Rialto, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Lonetree, Colorado, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Lakewood Ranch, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Pensacola, Florida, United States|Novartis Investigative Site, Georgia, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Catonsville, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Worcester, Massachusetts, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Bellevue, Nebraska, United States|Novartis Investigative Site, Morehead City, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Hermitage Nashville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Norfolk, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Bs As, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Kingswood, New South Wales, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Gurgaon, Haryana, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Roma, Italy|Novartis Investigative Site, Hatsukaichi-city, Hiroshima, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Saga-city, Saga, Japan|Novartis Investigative Site, Izumo-city, Shimane, Japan|Novartis Investigative Site, Seoul, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Dongjak Gu, Seoul, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Banska Bystrica, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Nitra, Slovakia|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Kaoshiung, Taiwan|Novartis Investigative Site, Keelung City, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan",,https://ClinicalTrials.gov/show/NCT02855164
NCT02854605,"Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)",,Completed,Has Results,Nonalcoholic Steatohepatitis (NASH),Drug: GS-9674|Drug: Placebo to match GS-9674,Overall Safety of GS-9674 as Assessed By Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)|Overall Safety of GS-9674 as Assessed By Percentage of Participants With Treatment-Emergent Laboratory Abnormalities,Gilead Sciences,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,140,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GS-US-402-1852|2016-002496-10,26-Oct-16,9-Jan-18,9-Jan-18,3-Aug-16,29-Jan-19,29-Jan-19,"Ruane Clinical Research Group Inc., Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Clinical Research of South Florida, Coral Gables, Florida, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|Northwestern Memorial Hospital, Clinical Research Unit, Chicago, Illinois, United States|Crescent Clinical Research Center, LLC, Metairie, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Concorde Medical Group, PLLC, New York, New York, United States|Duke University Medical Center, Duke South Clinics, Durham, North Carolina, United States|Carolinas Center for Liver Disease/Carolinas HealthCare System, Durham, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Gastro One, Germantown, Tennessee, United States|Quality Medical Research, PC, Nashville, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Texas Digestive Disease Consultants, Dallas, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Pinnacle Clinical Research, Live Oak, Texas, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|Intermountain Liver Disease and Transplant Center, Murray, Utah, United States|Bon Secours St. Mary's Hospital of Richmond, Inc d/b/a Bon Secours Liver Institute of Virginia, Newport News, Virginia, United States|Bon Secours St. Mary's Hospital of Richmond, Inc. d/b/a Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Swedish Organ Transplant and Liver Center, Seattle, Washington, United States|University of Calgary, Calgary, Alberta, Canada|LMC Clinical Research Inc (Bayview), Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Liver Center, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Inc., Vaughan, Ontario, Canada|Princess Margaret Hospital, Kowloon, Hong Kong|The Chinese University of Hong Kong, Sha Tin, Hong Kong|Auckland Clinical Studies, Auckland, New Zealand|Universitatsspital Bern, Inselspital, Universitatsklinik fur Viszerale Chirurgie und Medizin, Hepatologie, Bern, Switzerland|Universitatsspital Zurich, Zurich, Switzerland|Addenbrooke's Hospital, Cambridge, United Kingdom","""Study Protocol: Original"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02854605/Prot_000.pdf|""Study Protocol: Amendment 1"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02854605/Prot_001.pdf|""Study Protocol: Amendment 2"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02854605/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT02854605/SAP_003.pdf",https://ClinicalTrials.gov/show/NCT02854605
NCT02826525,AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.,,"Active, not recruiting",No Results Available,T2DM With NAFLD,Drug: AZD4076|Drug: Placebo,The safety and tolerability of AZD4076 by assessing the number of participants with adverse events|The safety and tolerability of AZD4076 by assessment of blood pressure|The safety and tolerability of AZD4076 by assessment of pulse|The safety and tolerability of AZD4076 by assessment of oral temperature|The safety and tolerability of AZD4076 by assessment of electrocardiogram readings|The safety and tolerability of AZD4076 by assessment of digital electrocardiogram readings|The safety and tolerability AZD4076 by assessment of physical examination|The safety and tolerability of AZD4076 by assessing the injection site|The safety and tolerability of AZD4076 by assessing the number of adverse events|The safety and tolerability of AZD4076 by assessing hematology|The safety and tolerability of AZD4076 by assessing clinical chemistry|The safety and tolerability of AZD4076 by assessing urinalysis|Glucose infusion rate at hyperinsulinemic clamp|Reduction in liver fat content (%) per MRI|24 hour glucose area under the curve|HOMA-IR|Fasting Endogenous Glucose Production|AUCt of AZD4076 and longmer and shortmer metabolites|Matsuda Index|AUC0-24 of AZD4076 and longmer and shortmer metabolites|Cmax of AZD4076 and longmer and shortmer metabolites|Tmax of AZD4076 and longmer and shortmer metabolites|CLR of AZD4076 and longmer and shortmer metabolites|fe% of AZD4076 and longmer and shortmer metabolites|Ae of AZD4076 and longmer and shortmer metabolites,AstraZeneca,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,14,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,D5590C00002,18-Jul-16,28-Dec-20,28-Dec-20,11-Jul-16,null,1-Mar-19,,,https://ClinicalTrials.gov/show/NCT02826525
NCT02820285,Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH,,Completed,No Results Available,Non Alcoholic Fatty Liver Disease,Other: Evaluation of the staging of fibrosis liver|Other: Determine the expression level of semaphorin|Other: Determination of the composition of immunity cells,Evaluation of the staging of liver fibrosis|Determination of the expression of level of semaphorin|Determination of the composition of immunity cells,Centre Hospitalier Universitaire de Nice,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,148,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11-PP-10,Mar-13,Sep-16,Sep-16,30-Jun-16,null,5-Oct-17,"Service d'Hépato-Gastroentérologie - Hôpital de l'Archet, Nice, France",,https://ClinicalTrials.gov/show/NCT02820285
NCT02808312,Pharmacokinetics and Pharmacodynamics of GS-9674 in Adults With Normal and Impaired Hepatic Function,,Completed,No Results Available,Nonalcoholic Steatohepatitis (NASH),Drug: GS-9674 (30 mg)|Drug: GS-9674 (10 mg),Pharmacokinetic (PK) Parameter: AUClast of GS-9674|PK Parameter: AUCinf of GS-9674|PK Parameter: Cmax of GS-9674|PK Parameter: %AUCexp of GS-9674|PK Parameter: Clast of GS-9674|PK Parameter: Tmax of GS-9674|PK Parameter: Tlast of GS-9674|PK Parameter: λz of GS-9674|PK Parameter: CL/F of GS-9674|PK Parameter: Vz/F of GS-9674|PK Parameter: t1/2 of GS-9674|Incidences of Adverse Events|Changes from Baseline in Pharmacodynamic (PD) Markers such as FGF19 and C4,Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 1,57,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-402-3885,13-Jul-16,16-Oct-18,16-Oct-18,21-Jun-16,null,30-Oct-18,"Miami, Florida, United States|Orlando, Florida, United States|Knoxville, Tennessee, United States|San Antonio, Texas, United States|Auckland, New Zealand",,https://ClinicalTrials.gov/show/NCT02808312
NCT02787304,Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH),,Terminated,No Results Available,Non-Alcoholic Steatohepatitis,Drug: SHP626|Drug: Placebo,Number of Subjects Achieving Binary Response on Liver Histology Between Volixibat (SHP626) and Placebo at Week 48|Change From Baseline to Week 48 on Liver Histology|Change From Baseline to Week 48 on Hepatic Steatosis|Change from baseline to Week 48 on liver histology|Resolution of NASH at Week 48|Change from baseline to Week 48 on Serum Liver-related Biochemistry|Change From Baseline to Week 48 on Metabolic Indicators|Change From Baseline to Week 48 on Serum Lipids,"Mirum Pharmaceuticals, Inc.",All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,197,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",SHP626-201|2016-000203-82,24-Oct-16,27-Jul-18,27-Jul-18,1-Jun-16,null,18-Mar-19,"Southern California Research Center, Coronado, California, United States|Fresno Clinical Research Center, Fresno, California, United States|Ceders-Sinai Medical Center, Los Angeles, California, United States|California Liver Research Institute, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|South Denver Gastroenterology, PC, Englewood, Colorado, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|George Washington (GW) Medical Faculty Associates, Washington, District of Columbia, United States|Schiff Center for Liver Diseases, Miami, Florida, United States|South Florida Center of Gastroenterology, Wellington, Florida, United States|Internal Medicine Associates of Wellstar Atlanta Medical, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Gastrointestinal Specialists of Georgia, Marietta, Georgia, United States|The Queen's Medical Center - Liver Center, Honolulu, Hawaii, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Liver Research Center, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Digestive Disease Associates, Catonsville, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Henry Ford Health System, Novi, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Northwell Health Inc., Manhasset, New York, United States|Concorde Medical Group PLLC, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Center for Liver Disease, Charlotte, North Carolina, United States|DUMC-Gastroenterology, Durham, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Carolinas Center for Liver Disease, Statesville, North Carolina, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Clinsearch, LLC, Chattanooga, Tennessee, United States|University of TN Health Science Center, Memphis, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Austin Center for Clinical Research, Austin, Texas, United States|Methodist Health Systems Clinical, Dallas, Texas, United States|Baylor College of Medicine - Advanced Liver Therapies, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|DHAT Research Institute, Richardson, Texas, United States|UVM Medical Center, Burlington, Vermont, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|UW Digestive Health Center (DHC), Madison, Wisconsin, United States|University of Calgary Liver Unit, Calgary, Alberta, Canada|LAIR Centre, Vancouver, British Columbia, Canada|Vancouver ID Research and Care Centre Society, Vancouver, British Columbia, Canada|Nova Scotia Heath Authority, Halifax, Nova Scotia, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|CRCHUM, Montreal, Quebec, Canada|UPR: Medical Sciences Campus, San Juan, Puerto Rico|University Hospital Birmingham, West Midlands, Birmingham, United Kingdom|NHS Tayside, Taysdie, Dundee City, United Kingdom|Royal Free Hospital, Hampstead, London, United Kingdom|Norfolk & Norwich University Hospital, Norwich, Norfolk, United Kingdom|John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom|Royal London Hospital, London, United Kingdom|Nottingham Digestive Diseases Centre and Biomedical Research Unit, Nottingham, United Kingdom|Abertawe Bro Morgannwg University, Swansea, United Kingdom|York Clinical Research Facility, York, United Kingdom",,https://ClinicalTrials.gov/show/NCT02787304
NCT02787668,A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease|Childhood Obesity|Insulin Resistance,"Other: Carbohydrate-restricted diet|Other: Control, low-fat diet",Change in hepatic lipid assessed via magnetic resonance imaging (MRI and magnetic resonance spectroscopy (MRS).|Change in body composition via dual-energy X-ray absorptiometry (DXA).|Change in liver enzymes via fasting blood draw|Change in fasting glucose via blood draw|Change in fasting insulin via blood draw,University of Alabama at Birmingham,All,9 Years to 17 Years   (Child),Not Applicable,27,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,F160218006,May-16,Apr-18,Apr-18,1-Jun-16,null,20-Apr-18,"University of Alabama at Birmingham, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT02787668
NCT02784444,"A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH",EMMINENCE,"Active, not recruiting",No Results Available,Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis|NASH - Nonalcoholic Steatohepatitis,Drug: MSDC-0602K|Drug: Placebo,"Hepatic histological improvement in NAS defined as a decrease of at least 2 points with no worsening of fibrosis stage at 12 months.|Proportion of subjects with resolution of NASH with no worsening of fibrosis at 12 months.|Proportion of subjects with improvement of fibrosis (CRN staging score) by at least 1 stage with no worsening of NASH at 12 months.|Mean change from baseline in NAFLD activity score (NAS) and each one of its components (steatosis, inflammation and ballooning) at 12 months.|Mean change from baseline in fibrosis score at 12 months.","Cirius Therapeutics, Inc.|Chiltern International Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,380,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MSDC-0602K-C009NASH,Jul-16,Jun-19,Jun-19,27-May-16,null,21-May-18,"Chandler, Arizona, United States|Tucson, Arizona, United States|Chula Vista, California, United States|Fresno, California, United States|Garden Grove, California, United States|Huntington Park, California, United States|La Mesa, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Poway, California, United States|Rialto, California, United States|San Diego, California, United States|Englewood, Colorado, United States|Gainesville, Florida, United States|Hialeah, Florida, United States|Inverness, Florida, United States|Lakewood Ranch, Florida, United States|Miami Lakes, Florida, United States|Wellington, Florida, United States|Marietta, Georgia, United States|Indianapolis, Indiana, United States|Bastrop, Louisiana, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|West Monroe, Louisiana, United States|Flowood, Mississippi, United States|Las Vegas, Nevada, United States|Brooklyn, New York, United States|New York, New York, United States|Fayetteville, North Carolina, United States|Greenville, North Carolina, United States|Statesville, North Carolina, United States|Providence, Rhode Island, United States|Germantown, Tennessee, United States|Hermitage, Tennessee, United States|Arlington, Texas, United States|Dallas, Texas, United States|Fort Sam Houston, Texas, United States|Houston, Texas, United States|Live Oak, Texas, United States|Rollingwood, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02784444
NCT02781584,"Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)",,"Active, not recruiting",No Results Available,Nonalcoholic Steatohepatitis (NASH),Drug: SEL|Drug: Firsocostat|Drug: Cilofexor|Drug: Fenofibrate,Incidence of Treatment-Emergent Adverse Events|Incidence of Treatment-Emergent Serious Adverse Events|Incidence of Treatment-Emergent Laboratory Abnormalities,Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 2,154,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-384-3914,13-Jul-16,Jul-19,Jul-19,24-May-16,null,17-Apr-19,"Los Angeles, California, United States|Palo Alto, California, United States|San Diego, California, United States|Florida Research Institute, Lakewood Ranch, Florida, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Live Oak, Texas, United States|San Antonio, Texas, United States|Grafton, Auckland, New Zealand",,https://ClinicalTrials.gov/show/NCT02781584
NCT02769091,A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes,NASH,Withdrawn,No Results Available,Nonalcoholic Steatohepatitis|Type 2 Diabetes Mellitus,Drug: TEV-45478|Drug: Placebo,"serum Alanine Transaminase (ALT) levels response, defined as ALT value within reference range of <35 IU/L for women and <40 IU/L for men|liver fat response, defined as a reduction of ≥6% at week 24 compared to screening by the MRI-Proton Density Fat Fraction (PDFF)|Percentage of Participants with Adverse Events|percent change from baseline in ALT|percent change from baseline in Aspartate Aminotransferase (AST)|change from baseline in AST|change from baseline in ALT|Change from baseline in glycosylated hemoglobin ((HbA1c)|Change from baseline in liver fibrosis measured using transient elastography (with Fibroscan)","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TV45478-IMM-20019,30-Sep-16,31-Jan-18,28-Feb-18,11-May-16,null,4-Jan-18,,,https://ClinicalTrials.gov/show/NCT02769091
NCT02764047,Probiotics in the Treatment of NAFLD,,Recruiting,No Results Available,"Non-alcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Fatty Liver, Nonalcoholic|NAFLD",Dietary Supplement: Probiotic,Hepatic changes (histological)|Hepatic changes (enzymatic)|Lipid profile|Alterations in gut microbiota,Federal University of Health Science of Porto Alegre|Irmandade Santa Casa de Misericórdia de Porto Alegre,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",852.771,Jan-15,Dec-17,Jan-18,6-May-16,null,6-Oct-17,"Irmandade Santa Casa de Misericórdia, Porto Alegre, RS, Brazil",,https://ClinicalTrials.gov/show/NCT02764047
NCT02728765,Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease,,Completed,No Results Available,Obstructive Sleep Apnea|Non-alcoholic Fatty Liver Disease,Device: Continuous positive airway pressure (CPAP),Changes in intrahepatic triglyceride content (IHTG)|Changes in Epworth Sleepiness Score|Transient elastography by fibroscan|Serum cytokeratin-18 fragment|Change in non-alcoholic fatty liver disease(NAFLD) activity score,Chinese University of Hong Kong,All,"20 Years to 80 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",Fatty liver/OSA/2016,5-Jul-16,30-Mar-19,30-Mar-19,5-Apr-16,null,7-May-19,"Prince of Wales Hospital, Hong Kong, Hong Kong",,https://ClinicalTrials.gov/show/NCT02728765
NCT02726542,Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents,,Recruiting,No Results Available,NAFLD,Drug: somatropin,Change in hepatic fat|Change in aspartate aminotransferase (AST)|Change in alanine aminotransferase (ALT)|Change in gamma glutamyl transferase|Change in visceral adipose tissue,Massachusetts General Hospital,All,18 Years to 29 Years   (Adult),Early Phase 1,24,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2016p-000657,3-May-17,Sep-19,Sep-19,1-Apr-16,null,22-Oct-18,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02726542
NCT02721264,Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.,,Recruiting,No Results Available,Non Alcoholic Steatohepatitis,Biological: Fecal Microbiota Transplant|Other: Standard Medical Treatment,"Reduction in Hepatic Venous Pressure Gradient in the two groups from baseline.|Improvement in liver function test as compared to baseline.|Improvement in Liver Stiffness Measurement as compared to baseline.|Assess improvement in insulin resistance (Fasting plasma and insulin levels, HOMA-IR)|Incidence of new onset upper gastrointestinal bleed in both groups|development of new onset of ascites in both groups.|Number of Spontaneous Bacterial peritonitis cases in both groups.|ACLF (Acute on Chronic Liver failure) cases in both groups.|Reduction in hepatic and systemic inflammatory markers like TNF-α in both groups|Reduction in hepatic and systemic inflammatory markers like C Reactive Protein in both groups|Reduction in hepatic and systemic inflammatory markers like serum endotoxins in both groups.|Histological and permeability changes in the duodenal biopsy in both groups.","Institute of Liver and Biliary Sciences, India",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,112,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ILBS-NASH-03,1-Mar-16,30-Jun-18,30-Jun-18,29-Mar-16,null,15-Feb-18,"Institute of Liver & Biliary Sciences, New Delhi, Delhi, India",,https://ClinicalTrials.gov/show/NCT02721264
NCT02704403,Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH),RESOLVE-IT,Recruiting,No Results Available,Nonalcoholic Steatohepatitis (NASH) With Fibrosis,Drug: Elafibranor|Drug: Placebo,"Proportion of Elafibranor treated patients relative to placebo achieving resolution of NASH without worsening of fibrosis|Composite long-term outcome composed of all-cause mortality, cirrhosis, and liver-related clinical outcomes|Proportion of Elafibranor treated patients relative to placebo achieving improvement of fibrosis|Proportion of Elafibranor treated patients relative to placebo achieving improvement in histological scores in NASH|Proportion of Elafibranor treated patients relative to placebo with improvement in cardiometabolic and liver markers and liver markers|Proportion of Elafibranor treated patients relative to placebo having a liver-related death",Genfit,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,2000,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GFT505-315-1|2015-005385-38,Mar-16,Dec-21,null,10-Mar-16,null,1-Apr-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialists of the Southeast, Dothan, Alabama, United States|The Institute for Liver Health, Chandler, Arizona, United States|The Institute for Liver Health, Glendale, Arizona, United States|Banner University Medical Center Phoenix, Phoenix, Arizona, United States|Dignity Health St. Joseph's Hospital, Phoenix, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Adobe Clinical Research, LLC, Tucson, Arizona, United States|The University of Arizona College of Medicine Liver Research Institute, Tucson, Arizona, United States|Liver Wellness Center, Little Rock, Arkansas, United States|GW Research, Inc., Chula Vista, California, United States|Southern California Research Center, Coronado, California, United States|Fresno Clinical Research Center, Fresno, California, United States|University of California, San Francisco, Fresno Community Regional Medical Center, Fresno, California, United States|Scripps Clinic Torrey Pines, La Jolla, California, United States|University of California - San Diego, La Jolla, California, United States|Loma Linda University Medical Center - Transplantation Insitute, Loma Linda, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|Keck Hospital of USC, Los Angeles, California, United States|Ruane Clinical Research Group Inc., Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Gastrointestinal Biosciences Clinical Trials LLC, Los Angeles, California, United States|Veterans Affaires Greater Los Angeles Healthcare System, West LA VA Medical Center, Los Angeles, California, United States|Alliance Clinical Research, Oceanside, California, United States|National Research Institute, Panorama City, California, United States|Alliance Clinical Research, Poway, California, United States|University of California, Davis Medical Center, Sacramento, California, United States|Medical Associates Research Group, Inc., San Diego, California, United States|VA San Diego HealthCare System, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|Sutter West Bay Hospitals dba California Pacific Medical Center, San Francisco, California, United States|University of California, San Francisco, Medical Center at Parnassus, San Francisco, California, United States|Ventura Clinical Trials, Ventura, California, United States|South Denver Gastroenterology, Englewood, Colorado, United States|Yale University SCHOOL OF MEDICINE, SECTION OF DIGESTIVE DISEASES, New Haven, Connecticut, United States|Georgetown University Hospitals, Washington, District of Columbia, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States|Integrity Clinical Research LLC, Doral, Florida, United States|University of Florida, Gainesville, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Mayo Clinic Hospital, Jacksonville, Florida, United States|Atlantic Gastroenterology Associates, LLC, Lakewood Ranch, Florida, United States|University of Miami - Miller School of Medicine, Miami, Florida, United States|University of Miami - Schiff Center for Liver Diseases, Miami, Florida, United States|South Florida Center of Gastroenterology, PA, Wellington, Florida, United States|Florida Medical Clinic, PA, Zephyrhills, Florida, United States|Summit Clinical Research, Athens, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Atlanta Medical Center, Inc., Atlanta, Georgia, United States|The Queen's Medical Center, Honolulu, Hawaii, United States|Northwestern Memorial Hospital - Arkes Family Pavilion, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Gastroenterology Associates of Hazard, Hazard, Kentucky, United States|University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States|University of Louisville Medical / Dental Complex, Louisville, Kentucky, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Kaiser Permanente Shady Grove Medical Center, Rockville, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Henry Ford Health System, Division of Gastroenterology & Hepatology, Detroit, Michigan, United States|Gastrointestinal Associates & Endoscopy Center, Flowood, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|St. Luke's Liver Transplant & Specialist, Kansas City, Missouri, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Saint Louis University School of Medicine, Saint Louis, Missouri, United States|Amici Clinical Research LLC, Martinsville, New Jersey, United States|Rutgers, Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Rutgers, New Jersey Medical School, Newark, New Jersey, United States|Southwest Gastroenterology Associates, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|University at Buffalo, Clinical and Translational Research Center, Buffalo, New York, United States|Hofstra Northwell School of Medicine, Manhasset, New York, United States|Concorde Medical Group, New York, New York, United States|New York University Langone Medical Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|New York-Presbyterian Hospital - Columbia University Medical Center, New York, New York, United States|Beth Israel Medical Center, New York, New York, United States|Premier Medical Group, Poughkeepsie, New York, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|UNC Health Care System, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke Gastroenterology, Durham, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Wake Research Associates, Raleigh, North Carolina, United States|Piedmont Healthcare, Statesville, North Carolina, United States|Trial Management Associates, Wilmington, North Carolina, United States|Ohio Gastroenterology & Liver Institute, Cincinnati, Ohio, United States|University of Cincinnati Physicians Company , LLC, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Drexel University, College of Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Temple University Health System, Philadelphia, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|UPMC Montefiore, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States|Medical University of South Carolina (MUSC), Charleston, South Carolina, United States|Associates in Gastroenterology, PLC, Hermitage, Tennessee, United States|Methodist University Hospital, Memphis, Tennessee, United States|Quality Medical Research, PLLC, Nashville, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|Liver Center of Texas, Dallas, Texas, United States|Baylor All Saints Medical Center - Baylor Research Institute, Fort Worth, Texas, United States|DHAT Research Institute, Garland, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Liver Associates of Texas, P.A., Houston, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|Centex Studies Inc., Houston, Texas, United States|Gulf Coast Research Group LLC, Houston, Texas, United States|Brooke Army Medical Center, Houston, Texas, United States|Gastroenterology Consultants of San Antonio, Live Oak, Texas, United States|Centex Studies Inc, McAllen, Texas, United States|Pinnacle Clinical Research, PLLC, Rollingwood, Texas, United States|The Texas Liver Institute, Inc., San Antonio, Texas, United States|Texas Digestive Consultants (TDDC), Southlake, Texas, United States|Victoria Gastroenterology, Victoria, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Inova Fairfax Medical Campus - Center for Liver Disease, Falls Church, Virginia, United States|Bon Secours Liver Institute of Virginia - Newport News, Newport News, Virginia, United States|Bon Secours Liver Institute of Virginia - Richmond, Richmond, Virginia, United States|Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Kaiser Permanente Springfield Medical Center, Springfield, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Organ Transplant and Liver Center, Seattle, Washington, United States|Sanatorio Güemes, Caba, Buenos Aires, Argentina|Axismed S.R.L, Caba, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas San Nicolas SRL, San Nicolas, Buenos Aires, Argentina|Hospital Alemán, Buenos Aires, Argentina|Centro de Investigación y Prevención Cardiovascular SA (CIPREC), Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Británico de Buenos Aires, Buenos Aires, Argentina|Centro De Hepatologia Ciudad de La Plata, La Plata, Argentina|Hospital Universitario Austral, Pilar, Argentina|Dim Clinica Privada, Ramos Mejía, Argentina|Hospital Provincial del Centenario, Rosario, Argentina|Instituto Medico Alas, Salta, Argentina|Flinders Medical Centre, Bedford Park, Australia|Box Hill Hospital, Boxhill, Australia|Monash Medical Centre Clayton, Clayton, Australia|Concord Repatriation General Hospital, Concord, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Australia|Austin Hospital, Heidelberg, Australia|Nepean Hospital, Kingswood, Australia|The St George Hospital, Kogarah, Australia|The Alfred Hospital, Melbourne, Australia|Fiona Stanley Hospital, Murdoch, Australia|Sir Charles Gairdner Hospital (SCGH), Nedlands, Australia|Westmead Hospital, Westmead, Australia|Hôpital Erasme, Bruxelles, Belgium|Universitair Ziekenhuis Brussel, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|Centre Hospitalier de Wallonie Picardie (CHWAPI), Tournai, Belgium|Hospital das Clínicas da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Instituto do Fígado e Transplantes de Pernambuco, Recife, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, Brazil|Hospital Universitário Clementino Fraga Filho (HUCFF), Rio de Janeiro, Brazil|Universidade Federal da Bahia - Hospital Universitário Professor Edgard Santos (HUPES), Salvador, Brazil|Faculdade de Medicina de São Jose do Rio Preto, Sao Jose do Rio Preto, Brazil|Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo - UNIFESP, São Paulo, Brazil|Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil|Dr John Farley Inc, Abbottsford, Canada|University of Calgary, Cumming School of Medicine, Calgary, AB, Canada|Queen Elizabeth Ii Health Sciences Centre, Nova Scotia Health Authority, Halifax, Canada|McGill University Health Centre (MUHC), Montreal, Canada|Toronto Western Hospital, Toronto, ON, Canada|Toronto Liver Centre, Toronto, ON, Canada|LAIR Centre, Vancouver, BC, Canada|Vancouver General Hospital (VGH) - Gordon and Leslie Diamond Health Care Centre, Vancouver, BC, Canada|Dr John Farley Inc, Vancouver, BC, Canada|University of Manitoba, Winnipeg, MB, Canada|Hospital de La Serena, La Serena, Chile|Alta Salud, Los Ángeles, Chile|Hospital Clínico UC, Santiago, Chile|Hospital Clínico Universidad de Chile, Santiago, Chile|Centro de Estudios Clinicos Barros Luco SPA (Patients seen, Fibroscan stored and Drug Shipment), Santiago, Chile|Clínica Reñaca, Vina Del Mar, Chile|Solano&Terront Servicios Médicos LTDA - Unidad Integral de Endocrinologia UNIENDO, Bogota D.C, Colombia|Fundación Cardio Infantil - Instituto de Cardiología, Bogotá, Colombia|Fundación Santa Fe de Bogotá Centro de Estudios e Investigación en Salud (CEIS), Bogotá, Colombia|Centro Medico Imbanaco, Cali, Colombia|Fundación Valle del Lili, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Hospital Universitario de San Vicente Fundación, Medellin, Colombia|Fundacion Hospitalaria San Vicente de Paul, Medellín, Colombia|Fakultní Nemocnice Brno, Brno, Czechia|Research Site, s.r.o, Plzen, Czechia|KlinMed s.r.o., Praha 2, Czechia|Aarhus University Hospital, Aarhus, Denmark|Helsinki University Central Hospital, Helsinki, Finland|CHU Amiens Picardie, Amiens, France|CHU Angers, Angers, France|Hôpital Antoine-Béclère, Clamart, France|Hôpital Beaujon, Clichy, France|Hôpital Henri Mondor, Créteil, France|CHU Limoges - Hôpital Dupuytren, Limoges, France|Hôpital de la Croix-Rousse, Lyon, France|Hôpital Saint Joseph, Marseille, France|CHRU Montpellier- Hôpital Saint Eloi, Montpellier, France|CHU de Nantes - Hôpital Laennec, Nantes, France|CHU de Nice- Hôpital de l'Archet II, Nice, France|Hôpital Saint-Antoine, Paris, France|Hopital Pitie-Salpetriere, Paris, France|Hôpital Cochin, Paris, France|Hôpital Haut-Lévêque, Pessac, France|CHU Toulouse - Hôpital Purpan, Toulouse, France|CHU Nancy - Hôpital Brabois, Vandoeuvre Les Nancy, France|Hôpital Paul Brousse, Villejuif, France|Universitätsklinikum RWTH Aachen, Aachen, Germany|Liver Center, Berlin, Germany|Gastroenterologie am Bayerischen Platz/ Gastro-Studien, Berlin, Germany|Universitätsklinikum Bonn, Bonn, Germany|Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum Frankfurt - Goethe Universität, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover (MHH), Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Köln, Köln, Germany|EUGASTRO GmbH, Leipzig, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsklinikum Magdeburg, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Ospedaliera di Rilievo Nazionale ""A. Cardarelli"", Napoli, Italy|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy|Policlinico Tor Vergata, Roma, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale Casa Sollievo della Sofferenza I.R.C.C.S., San Giovanni Rotondo, Italy|Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino - Ospedale Molinette, Torino, Italy|Centro de Investigación Clínica del Pacífico, S.A de C.V., Acapulco, Mexico|Hospital Maria Auxiliadora, Guadalajara, Mexico|Médica Sur, Mexico City, Mexico|Consultorio Medico, Mexico City, Mexico|Accelerium S de RL de C.V., Monterrey, Mexico|Vrije Universiteit Medical Center, Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Maastricht UMC+, Maastricht, Netherlands|Radboud UMC, Nijmegen, Netherlands|Centro Hospitalar e Universitário de Coimbra, EPE - Hospitais da Universidade de Coimbra, Coimbra, Portugal|Centro Hospitalar Lisboa Central, EPE - Hospital Santo António dos Capuchos, Lisboa, Portugal|Centro Hospitalar de Lisboa Norte, EPE - Hospital Santa Maria, Lisboa, Portugal|Centro Hospitalar de São João, EPE - Hospital de São João, Porto, Portugal|Centro Hospitalar de São João, Porto, Portugal|Centro Hospita de Tras-os-Montes e Alto Douro, EPE, Vila Real, Portugal|Caparra Internal Medicine Research Center, Rio Grande, Puerto Rico|Klinical Investigations Group, LLC, San Juan, Puerto Rico|Fundacion de Investigacion de Diego, San Juan, Puerto Rico|Institutul National de Boli Infectioase ""Prof. Dr. Matei Bals"", Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|SC Cabinet Particular Policlinic Algomed SRL, Timisoara, Romania|Spitalul Clinic Judetean de Urgenta ""Pius Brinzeu"" Timisoara, Timisoara, Romania|FSBRI ""Federal Research Center of nutrition and biotechnology, Moscow, Russian Federation|I. M. Sechenov - First Moscow State Medical University, Moscow, Russian Federation|M. F. Vladimirsky - Clinical Research Institution of Moscow Region, Moscow, Russian Federation|Military medical academy n. a. S.M. Kirov, Saint Petersburg, Russian Federation|St Petersburg State Budgetary Healthcare Institution City Clinical Hospital N°31, Saint Petersburg, Russian Federation|City Clinical Hospital No. 31, St. Petersburg, Russian Federation|Tiervlei Trial Centre, Cape Town, South Africa|Mediclinic Constantiaberg, Cape Town, South Africa|Phoenix Pharma (Pty) Ltd, Port Elizabeth, South Africa|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Campus Hospital Universitario Virgen del Rocío - Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|INSELSPITAL, University Hospital Bern, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Kantonsspital St. Gallen, Saint Gallen, Switzerland|UniversitätsSpital Zürich, Zurich, Switzerland|Ankara Üniversitesi Tıp Fakültesi, Ankara, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Capa/Istanbul, Turkey|Bezmiâlem Vakıf Üniversitesi, Fatih Istanbul, Turkey|Ege Üniversitesi, Izmir, Turkey|Marmara Üniversitesi Eğitim ve Araştırma Hastanesi, Pendik Istanbul, Turkey|Sağlık Bilimleri Üniversitesi Ümraniye Eğitim ve Araştırma Hastanesi, Umraniye /Istanbul, Turkey|University Hospitals Birmingham NHS foundation Trust, Birmingham, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Frimley Park Hospital NHS Foundation Trust, Frimley, United Kingdom|The Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom|Hull and East Yorkshire Hospitals NHS Trust - Hull Royal Infirmary, Hull, United Kingdom|Bart Health NHS Trust- Royal London Hospital, London, United Kingdom|The Royal Free London NHS Foundation Trust - The Royal Free Hospital, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust - St Thomas' Hospital, London, United Kingdom|St George's University Hospitals NHS Foundation Trust - St George's Hospital, London, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital, Newcastle upon Tyne, United Kingdom|Nottingham University Hospitals NHS FoundationTrust - Queen's Medical Centre, Nottingham, United Kingdom|Plymouth Hospitals NHS Trust - Derriford Hospital, Plymouth, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT02704403
NCT02696941,SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis,SMASH,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Metformin|Drug: SGLT2 inhibitor,Hepatic steatosis|% contribution of newly synthesised lipid to circulating triglyceride levels|Global insulin sensitivity|Hepatic insulin sensitivity|Intrabdominal fat,University of Oxford,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,11693,Feb-16,1-Apr-18,1-Apr-18,2-Mar-16,null,4-May-18,"University of Oxford, Oxford, United Kingdom",,https://ClinicalTrials.gov/show/NCT02696941
NCT02690792,Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease,,Completed,No Results Available,Healthy|NAFLD (Non-Alcoholic Fatty Liver Disease)|NASH (Non-Alcoholic Steatohepatitis),Other: NAFLD/NASH - Placebo|Dietary Supplement: NAFLD/NASH - Vitamin E,Change in Measurement of percentage of Liver Fat by MRI|Change in Measurement of Insulin Sensitivity via Hyperinsulinemic glucose clamp|Change in Measurement of glucose metabolism turnover by non-radioactive isotopic infusion and recovery,Jeffrey Browning|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Texas Southwestern Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,70,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",102010-180|R01DK087977-01A1,Dec-09,Dec-16,Dec-16,24-Feb-16,null,16-Nov-18,"University of Texas Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02690792
NCT02686476,Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes,E-LIFT,Completed,No Results Available,Non Alcoholic Fatty Liver Disease,Drug: Empagliflozin,Change in Liver Fat|Pancreatic fat content|visceral fat|subcutaneous fat,"Medanta, The Medicity, India",All,"40 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MMELIFT01,Mar-16,Sep-17,Dec-17,19-Feb-16,null,14-Mar-18,"Division Of Endocrinology , Medanta The Medicity Sec 38, Gurgaon, Haryana, India",,https://ClinicalTrials.gov/show/NCT02686476
NCT02686762,"Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis",ENCORE-NF,"Active, not recruiting",No Results Available,Non-alcoholic Steatohepatitis|Fibrosis|Liver Diseases,Drug: Emricasan (5 mg)|Drug: Emricasan (50 mg)|Drug: Placebo,Fibrosis improvement by at least one stage without worsening of steatohepatitis|Steatohepatitis resolution (based on liver biopsy)|Improvement in the Non-alcoholic fatty liver disease (NAFLD) Activity Score|Caspase 3/7 Relative Light Units and Alanine aminotransferase (ALT),Conatus Pharmaceuticals Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,330,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IDN-6556-12,26-Jan-16,Dec-18,Jan-19,19-Feb-16,null,30-Apr-18,"University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona Clinical and Translational Sciences Research Center, Tucson, Arizona, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Fresno Clinical Research Center, Freestone, California, United States|UCLA The Pfleger Liver Institute, Los Angeles, California, United States|Gastrointestinal Biosciences, Los Angeles, California, United States|Surinder Singh Saini, M.D., Inc., Newport Beach, California, United States|California Liver Research Institute, Pasadena, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|University of California Davis Medical Center, Sacramento, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|UF Hepatology Research at CTRB, Gainesville, Florida, United States|Florida Digestive Health Specialist, Lakewood Ranch, Florida, United States|Miami Veterans Administration Healthcare System, Miami, Florida, United States|University of Miami/Schiff Center for Liver Diseases, Miami, Florida, United States|Florida Hospital Orlando Transplant Institute, Orlando, Florida, United States|Tampa General Medical Group, Tampa, Florida, United States|iResearch Atlanta LLC, Decatur, Georgia, United States|Gastrointestinal Specialists of Georgia, Marietta, Georgia, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Aquiant Research, New Albany, Indiana, United States|Iowa Digestive Disease Center, P.C, Clive, Iowa, United States|UnityPoint Clinic Center For Liver Disease, Des Moines, Iowa, United States|University of Louisville, Louisville, Kentucky, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Washington University School of Medicine-Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Doctors Office Center, Newark, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|State University of New York, Buffalo, New York, United States|Northwell Health, Inc., Manhasset, New York, United States|Mount Sinai Beth Israel Medical Center, New York, New York, United States|NYU Langone Medical Center, New York, New York, United States|Columbia University Medical Center (CUMC), New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States|Carolinas Healthcare System, Center for Liver Disease, Charlotte, North Carolina, United States|Duke University Medical Center, Duke South Clinics, Durham, North Carolina, United States|Rex Healthcare, Raleigh, North Carolina, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Options Health Research, LLC, Tulsa, Oklahoma, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|PMG Research at Charleston, Charleston, South Carolina, United States|ClinSearch, LLC, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Methodist University Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center - Digestive Disease Center, Nashville, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor All Saints Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Liver Associates of Texas, P.A., Houston, Texas, United States|Research Specialists of Texas, Houston, Texas, United States|Pinnacle Clinical Research, PLLC, Live Oak, Texas, United States|American Research Corporation at the Texas Liver Institue, San Antonio, Texas, United States|Brooke Army Medical Center, San Antonio, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|University of Vermont, Burlington, Vermont, United States|Bon Secours Richmond Health System, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|McGuire VA Medical Center, Richmond, Virginia, United States|University of Washington Harborview Medical Center, Seattle, Washington, United States|Universitätsklinikum der RWTH Aachen, Aachen, North Rhine-Westphalia, Germany|Universitätsklinikum Bonn, Bonning, North Rhine-Westphalia, Germany|Universitätsklinikum Münster, Munster, North Rhine-Westphalia, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Eugastro GmbH, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Spain|Hospital Universitario de Donostia, San Sebastian, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT02686762
NCT02684591,Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy,ARRIVE,Completed,No Results Available,Nonalcoholic Fatty Liver Disease|HIV,Drug: Aramchol|Drug: Placebo,Efficacy of Aramchol 600 mg vs. placebo in improving hepatic steatosis assessed by magnetic resonance imaging in patients with HIV-associated NAFLD|Efficacy of aramchol 600 mg orally daily versus placebo in improving serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with HIV-associated NAFLD,"University of California, San Diego",All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",ARRIVE,Jan-16,Feb-18,Feb-18,18-Feb-16,null,13-Jun-18,"University of California, San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT02684591
NCT02682173,Magnetic Resonance Imaging (MRI) Fat Quantification of the Liver,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease|Obesity,Other: MR Abdomen,Liver fat quantification|Visceral fat quantification|Subcutaneous fat quantification,"University Hospital, Basel, Switzerland",All,18 Years to 60 Years   (Adult),Not Applicable,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,MRI Fat quantification,Mar-13,Jul-17,Jul-17,15-Feb-16,null,27-Jul-17,"University Hospital, Basel, Switzerland",,https://ClinicalTrials.gov/show/NCT02682173
NCT02681055,Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects,,Completed,No Results Available,Non-alcoholic Steatohepatitis|Hypertriglyceridemia|Non-alcoholic Fatty Liver Disease|Hypercholesterolemia,Drug: MN-001,To measure the change from baseline at 12 weeks of MN-001 on Cholesterol Efflux Capacity in NASH subjects with hypertriglyceridemia|To measure the change from baseline at 12 weeks of MN-001 on serum triglyceride levels in NASH subjects with hypertriglyceridemia|To measure the safety and tolerability of MN-001 by assessing the number of treatment-related adverse events.|To measure blood the concentration of MN-001/MN-002 (metabolite) change from pre-dose after 24 hours|To measure the effect of MN-001 on serum lipid panel|To measure the effect of MN-001/002 on liver enzymes|To measure the effect of MN-001/002 on percentage of fat in the liver by MRI from baseline to Week 12,MediciNova,All,"18 Years and older   (Adult, Older Adult)",Phase 2,19,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MN-001-NATG-201,Mar-16,30-May-18,14-Jan-19,12-Feb-16,null,18-Jan-19,"Southern California Research Center, Coronado, California, United States|Scripps Research, La Jolla, California, United States|Harborview Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02681055
NCT02679417,The Effects of Type of Exercise in Non-alcoholic Fatty Liver Disease,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Behavioral: exercise,"Hepatic fat content as assessed by the controlled attenuation parameter.|Hepatic inflammation as assessed by serum levels of aspartate aminotransferase, alanine aminotransferase, ferritin and c-reactive protein.|Liver fibrosis as assessed by vibration-controlled transient elastography.|Metabolic profiles assessed with the measurement of lipid profiles, plasma glucose, insulin and oral glucose tolerance test.|Anthropometry and bioelectrical impedance assessed by a bioelectrical fat analyzer.|Cardiorespiratory fitness as assessed with maximal oxygen uptake under treadmill test.",Mahidol University,All,18 Years to 60 Years   (Adult),Not Applicable,38,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,183/2558(EC1),Aug-15,Sep-16,Sep-16,10-Feb-16,null,14-Sep-16,"Faculty of Medicine Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT02679417
NCT02654002,"Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674, and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics",,Completed,No Results Available,Nonalcoholic Steatohepatitis (NASH),Drug: GS-9674|Drug: Placebo,Single-dose PK Parameter: AUClast of GS-9674|Single-dose PK Parameter: AUCinf of GS-9674|Single-dose PK Parameter: Cmax of GS-9674|Multiple-dose plasma PK parameter: AUCtau of GS-9674|Multiple-dose plasma PK parameter: Cmax of GS-9674|Multiple-dose plasma PK parameter: Ctau of GS-9674|Incidence of Adverse Events|Proportion of Participants with 12-lead ECG Abnormalities|Proportion of Participants with Clinical Laboratory Abnormalities|Measurement of PD Biomarker Level of Fibroblast Growth Factor 19 (FGF19)|Measurement of PD Biomarker Level of Bile Acids|Measurement of PD Biomarker Level of C4,Gilead Sciences,All,18 Years to 45 Years   (Adult),Phase 1,120,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GS-US-402-1851,Jan-16,Jul-16,Jul-16,13-Jan-16,null,27-Jul-16,"SeaView Research, Inc, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02654002
NCT02654665,"Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults",CGH-LiNASH,Recruiting,No Results Available,Non-alcoholic Fatty Liver Disease (NAFLD)|Weight Loss|Non-alcoholic Steatohepatitis (NASH),Behavioral: Lifestyle modification|Drug: Liraglutide,Improvement in NASH,Changi General Hospital,All,"21 Years to 65 Years   (Adult, Older Adult)",Phase 3,36,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CGH-LiNASH,Mar-14,Dec-17,Dec-18,13-Jan-16,null,30-Jan-18,"Changi General Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT02654665
NCT02654977,CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy,,"Active, not recruiting",No Results Available,Familial Partial Lipodystrophy|Nonalcoholic Steatohepatitis|NAFLD,Drug: Metreleptin,Improvement in Non alcoholic fatty liver disease|Improvement in triglyceride levels|Improvement in hemoglobin A1c values,University of Michigan,All,"5 Years and older   (Child, Adult, Older Adult)",Phase 2,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HUM00093399,Apr-15,Feb-25,Feb-25,13-Jan-16,null,22-Oct-18,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02654977
NCT02649465,SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD,,Recruiting,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Tofogliflozin|Drug: Glimepiride,"The improvement in histologic features of NAFLD|Change from baseline in liver enzymes|Change from baseline in body composition|Change from baseline in fasting plasma glucose level and glucose metabolism assessed with arginine tolerance test|Changes from baseline in organ-specific insulin sensitivity and glucagon response during a euglycemic hyperinsulinemic clamp study|Change from baseline in lipid profile|Change from baseline in renal function and electrolyte balances|Change from baseline in oxidative stress|Change from baseline in cytokine (TNF-alpha, leptin, adiponectin) levels|Change from baseline in hepatokine (Selenoprotein P, LECT2) levels|Change from baseline in organ-specific fat accumulation|Change from baseline in oxidative and non-oxidative glucose disposal|Change from baseline in respiratory quotients|Change from baseline in energy expenditure|Change from baseline in autonomic nerve function.|Changes from baseline in minerals and bone metabolism|Changes from baseline in endothelial functions|Changes from baseline in fatty acids profiles|19. Factors associated with the changes in autonomic nerve function, organ-specific fat accumulation, and glucagon response.|Changes from baseline in gene expression profiles in the liver and blood cells|Changes from baseline in microRNAs and exosome contents|Epigenomic changes from baseline in genes of the liver and blood cells","Kanazawa University|Kowa Company, Ltd.",All,"20 Years and older   (Adult, Older Adult)",Phase 4,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-033,Jan-16,Sep-20,Sep-20,7-Jan-16,null,7-Jan-16,"Department of Disease Control and Homeostasis, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan",,https://ClinicalTrials.gov/show/NCT02649465
NCT02647294,Polyunsaturated Fatty Acids in Patients With NAFLD.,,"Active, not recruiting",No Results Available,NAFLD,Dietary Supplement: Maxicor|Other: Placebo,Number of patients with decreased liver fat content.|Number of patients with progression of liver fibrosis.,"General University Hospital, Prague",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",15-28745A,Feb-16,Dec-19,Dec-19,6-Jan-16,null,28-Sep-18,"General University Hospital, Prague, Prague 2, Czechia",,https://ClinicalTrials.gov/show/NCT02647294
NCT02644239,Impact of Ketogenic Diet on Lipoproteins in Refractory Epilepsy,Ketonutri,Recruiting,No Results Available,Epilepsy|Cardiovascular Disease|Non-alcoholic Fatty Liver Disease|Quality of Life,Dietary Supplement: ketogenic diet,Socioeconomic and clinical profile|Body Mass Index|Fat mass|Fat free mass|Phase angle,University of Sao Paulo,All,"1 Year to 19 Years   (Child, Adult)",Not Applicable,60,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,Faculdade de Saúde Pública USP,Jun-12,Jul-20,Jul-20,31-Dec-15,null,31-Dec-15,"Nagila Raquel Teixeira Damasceno, Sao Paulo, SP, Brazil",,https://ClinicalTrials.gov/show/NCT02644239
NCT02642172,Prebiotics in Patients With Non-alcoholic Liver Disease,,Recruiting,No Results Available,Non-alcoholic Fatty Liver Disease|Metabolic Syndrome,Dietary Supplement: ITF (Inulin/OFS 75/25)|Dietary Supplement: Placebo,Change from baseline in the severity of NAFLD|Change from baseline of gut microbiota composition.|Change from baseline in glycemic control|Change from baseline in insulin sensitivity|Change from baseline in lipid profile,Kaplan Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",PN-837-CTIL,Jan-16,Jan-20,Jan-20,30-Dec-15,null,28-Aug-18,"Kaplan Medical Center, Rechovot, Israel",,https://ClinicalTrials.gov/show/NCT02642172
NCT02637973,"Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes",EmLiFa,Completed,No Results Available,Type 2 Diabetes|Non-alcoholic Fatty Liver Disease,Drug: Empagliflozin|Drug: Placebo,Change in liver fat content,The Deutsche Diabetes Forschungsgesellschaft e.V.|Boehringer Ingelheim|German Diabetes Center,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,84,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EmLiFa001,Dec-15,Aug-18,Aug-18,22-Dec-15,null,14-Jan-19,"Charite Universitaetsmedizin Berlin, Berlin, Germany|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany|German Diabetes Center, Dusseldorf, Germany|University Clinic Heidelberg, Heidelberg, Germany|University Clinic Tübingen, Tübingen, Germany",,https://ClinicalTrials.gov/show/NCT02637973
NCT02633956,Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL),CONTROL,Completed,Has Results,Nonalcoholic Steatohepatitis,Drug: Obeticholic Acid|Drug: Atorvastatin|Drug: Placebo,The Effect of Obeticholic Acid on Low-density Lipoprotein (LDL) Concentration (Least Squares Mean Change From Baseline at Week 16)|The Effect of Obeticholic Acid on LDL Particle Size (Least Squares Mean Change From Baseline at Week 16)|The Effect of Obeticholic Acid on LDL Particle Concentration (Total) (Least Squares Mean Change From Baseline at Week 16),Intercept Pharmaceuticals,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 2,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",747-209,4-Dec-15,21-Mar-17,12-Mar-18,17-Dec-15,4-Jun-18,4-Jun-18,"St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Scripps Clinic, La Jolla, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|Nature Coast Clinical Research, Inverness, Florida, United States|University of Miamai, Schiff Center for Liver Diseases, Miami, Florida, United States|South Florida Center of Gastroenterology, Wellington, Florida, United States|Florida Medical Clinic, P.A., Zephyrhills, Florida, United States|The Queen's Medical Center - Liver Center, Honolulu, Hawaii, United States|Mercy Medical Center, Institute for Digestive Health & Liver Disease, Baltimore, Maryland, United States|Kansas City Research Institute, Kansas City, Missouri, United States|St. Louis University, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University Gastroenterology Liver Center, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|ClinSearch, Chattanooga, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Liver Associates of Texas, P.A., Houston, Texas, United States|American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States|McGuire DVAMC, Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02633956/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT02633956/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02633956
NCT02612662,A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects,,"Active, not recruiting",No Results Available,Non-alcoholic Steatohepatitis (NASH),Drug: AZD4076|Drug: Placebo,"The safety and tolerability of AZD4076 by assessment of blood pressure|The safety and tolerability of AZD4076 by assessment of pulse|The safety and tolerability of AZD4076 by assessment of oral temperature|The safety and tolerability of AZD4076 by assessment of electrocardiogram readings|The safety and tolerability of AZD4076 by assessment of digital electrocardiogram readings|The safety and tolerability of AZD4076 by assessment of cardiac telemetry|The safety and tolerability of AZD4076 by assessment of physical examination|The safety and tolerability of AZD4076 by assessing hematology|The safety and tolerability of AZD4076 by assessing the injection site|The safety and tolerability of AZD4076 by assessming the number of adverse events|The safety and tolerability of AZD4076 by assessing clinical chemistry|The safety and tolerability of AZD4076 by assessing urinalysis|The safety and tolerability of AZD4076 by assessing the number of participants with adverse events|Observed maximum plasma concentration, taken directly from the individual concentration-time curve [Cmax] assessed for AZD4076 from the plasma data|Time to reach maximum concentration, taken directly from the individual concentration-time curve [tmax] assessed for AZD4076 from the plasma data|Terminal elimination half-life, estimated as (ln2)/λz [t1/2λz ] assessed for AZD4076 from the plasma data|Area under the plasma concentration-curve from time zero to 72h after drug administration [AUC(0-72h)] assessed for AZD4076 from the plasma data|Area under the plasma concentration-curve from time zero to the time of last quantifiable concentration [AUC(0-last)] assessed for AZD4076 from the plasma data|Area under plasma concentration-time curve from time zero extrapolated to infinity [AUC] assessed for AZD4076 from the plasma data|Apparent total clearance, estimated as dose divided by AUC [CL/F] assessed for AZD4076 from the plasma data|Mean Residence Time [MRT] assessed for AZD4076 from the plasma data|Apparent volume of distribution at terminal phase, estimated by dividing the apparent clearance (CL/F) by λz [Vz/F] assessed for AZD4076 from the plasma data|Dose normalized maximum plasma concentration divided by dose, calculated by dividing Cmax by the dose administered for [Cmax/D] assessed for AZD4076 from the plasma data|Dose normalized area under the plasma concentration-time curve from time zero to time of last quantifiable concentration, calculated by dividing AUC(0-last) by the dose administered [AUC(0 last)/D] assessed for AZD4076 from the plasma data|Dose normalized area under the plasma concentration-time curve from time zero extrapolated to infinity divided by dose, calculated by dividing AUC by the dose administered [AUC/D] assessed for AZD4076 from the plasma data|Lag-time, taken directly from the individual concentration-time curve [tlag] assessed for AZD4076 from the plasma data|Cumulative amount of analyte excreted in urine from time zero to the last sampling interval (72 hours) [Ae(0-t)] assessed for AZD4076 from the urine data|Percentage of dose excreted unchanged into the urine from time zero to the last sampling interval (72 hours), estimated by dividing Ae(0-t) by dose [fe(0-t)] assessed for AZD4076 from the urine data|Renal clearance, estimated by dividing Ae(0-t) by AUC(0-72) [CLR] assessed for AZD4076 from the urine data|Cmax assessed for AZD4076 metabolites from the plasma data|tmax assessed for AZD4076 metabolites from the plasma data|t1/2λz assessed for AZD4076 metabolites from the plasma data|AUC(0-last) assessed forAZD4076 metabolites from the plasma data|AUC(0-72h) assessed for AZD4076 metabolites from the plasma data|MRT assessed for AZD4076 metabolites from the plasma data|tlag assessed for AZD4076 metabolites from the plasma data|Vz/F assessed for AZD4076 metabolites from the plasma data|Cmax/D assessed for AZD4076 metabolites from the plasma data|[AUC(0-last)/D assessed for AZD4076 metabolites from the plasma data|AUC/D assessed for AZD4076 metabolites from the plasma data|Ae(0-t) assessed for AZD4076 metabolites from the urine data|fe(0-t) assessed for AZD4076 metabolites from the urine data|CLR assessed for AZD4076 metabolites from the urine data|AUC assessed for AZD4076 metabolites from the plasma data|CL/F assessed for AZD4076 metabolites from the plasma data",AstraZeneca,Male,18 Years to 50 Years   (Adult),Phase 1,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,D5590C00001,25-Nov-15,4-Nov-17,28-Dec-20,24-Nov-15,null,8-May-19,"Research Site, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02612662
NCT02605616,Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD),,Recruiting,No Results Available,Non-alcoholic Fatty Liver Disease (NAFLD)|Non-alcoholic Steatohepatitis (NASH),Drug: AZ compound|Other: Placebo,Change in Liver Fat Fraction (LFF)|Change in Liver Enzymes Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)|Change in Liver Fibrosis|Change in Total Insulin Sensitivity (Si) and Hepatic Insulin Sensitivity (Si liver),Mayo Clinic|AstraZeneca,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 2,100,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",15-000013,Nov-15,Dec-19,Dec-19,16-Nov-15,null,9-Nov-17,"University of Virginia, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02605616
NCT02599038,Serine Supplementation for Obese Subjects With Fatty Liver Disease,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Dietary Supplement: Serine supplementation,Liver fat content|Triglycerides|Cholesterol fractions,"Hanns-Ulrich Marschall|Sahlgrenska University Hospital, Sweden",All,"20 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,10,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,Serine-NAFLD,Oct-15,Oct-16,Oct-16,6-Nov-15,null,18-Oct-16,"Hanns-Ulrich Marschall, Göteborg, Sweden|Sahlgrenska Academy, Göteborg, Sweden",,https://ClinicalTrials.gov/show/NCT02599038
NCT02574325,A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis,,Unknown status,No Results Available,Nonalcoholic Steatohepatitis,Drug: Placebo|Drug: ARI-3037MO,"Efficacy as measured by change in intra hepatic fat content|Efficacy as measured by change in plasma ALT levels|Efficacy as measured by change in plasma TG levels|Safety as measured by the occurrence of flushing (number of episodes) and itching (number of episodes)|Safety as measured by effect of ARI-3037MO on on glycemic control|Safety as measured by effect of ARI-3037MO on serum bilirubin, alkaline phosphatase, Prothrombin time and plasma albumin levels|Safety as measured by effect of ARI-3037MO on gastrointestinal systems; episodes of nausea, vomiting and diarrhea",Arisaph Pharmaceuticals Inc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,11,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ARI-3037MO-006,Oct-15,Oct-16,Dec-16,12-Oct-15,null,8-Aug-16,"Gastroenterology & Hepatology CRU, St Louis University, St Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02574325
NCT02571192,A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose,,Completed,No Results Available,Non-Alcoholic Steatohepatitis,Drug: SHP626|Radiation: 5.95 μCi RAD,"Pharmacokinetic parameters will be determined from the plasma and blood concentration time data of total radioactivity and from the plasma concentration-time data for SHP626 by non-compartmental analysis.|Total radioactivity (RAD) in whole blood and plasma|To determine the total RAD in urine and feces.|Maximum plasma concentration (Cmax) of 50mg [14C]-SHP626 and RAD occurring at time of maximum observed concentration (tmax)|Area under the plasma concentration curve (AUC0-t) of 50mg [14C]-SHP626 and RAD from the time of dosing to the last measurable concentration|Area under the plasma concentration curve (AUC0-∞ ) of 50mg [14C]-SHP626 and RAD extrapolated to infinity, calculated using the observed value of the last non-zero plasma concentration|First order rate constant associated with the terminal portion of the plasma curve terminal half-life (t½) for 50mg [14C]-SHP626 and RAD|Total body clearance (CL/F ) of 50mg [14C]-SHP626 and RAD for extravascular administration divided by the fraction of dose absorbed|Volume of distribution (Vz/F ) of 50mg [14C]-SHP626 and RAD associated with the terminal slope following extra-vascular administration divided by the fraction of dose absorbed|Cumulative amount (Aef )of RAD recovered in stool over the dosing interval|Excreted Percent of RAD recovered in stool over the dosing interval|Cumulative amount (Aeu ) of RAD recovered in urine over the dosing interval|Excreted Percent of RAD recovered in urine over the dosing interval|Renal Clearance (CLR ) of 50mg [14C]-SHP626|Characterize and identify metabolites of [14C]-SHP626 in plasma by accelerator mass spectrometry for radioactivity quantification|Characterize and identify metabolites of [14C]-SHP626 in urine by accelerator mass spectrometry for radioactivity quantification|Characterize and identify metabolites of [14C]-SHP626 in feces by liquid scintillation counting|Assess the safety and tolerability of [14C]-SHP626 by adverse events (AEs) defined as changes, including changes from baseline in physical examination findings|Changes from baseline in vital signs|Changes from baseline in ECGs|Changes from baseline in hematology|Changes from baseline in coagulation|Changes in baseline in urinalysis|Changes in baseline in chemistry","Mirum Pharmaceuticals, Inc.",Male,18 Years to 50 Years   (Adult),Phase 1,8,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,SHP626-102,1-Oct-15,1-Oct-15,1-Oct-15,8-Oct-15,null,1-May-19,"Covance Madison Clinical Research Unit, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02571192
NCT02568605,Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease,,Recruiting,No Results Available,Non-alcoholic Fatty Liver Disease,Dietary Supplement: Prebiotic fibre|Dietary Supplement: Placebo|Behavioral: Weight Loss,"Change in Liver Fat|Change in Liver Fibrosis|Change in Liver Injury|Change in Glucose Tolerance|Change in Glycemic Control|Change in Subjective Appetite|Change in Satiety Hormones|Change in Body Composition|Change in Quality of Life|Dietary Adherence|Examine mechanisms related to prebiotic-induced changes in gut microbiota, their metabolic byproducts, and de novo lipogenesis",University of Calgary|Canadian Institutes of Health Research (CIHR),All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UC-REB14-2464,May-15,Jul-19,Aug-20,6-Oct-15,null,19-Sep-18,"University of Calgary, Calgary, Alberta, Canada",,https://ClinicalTrials.gov/show/NCT02568605
NCT02568787,The Effect of an RBAC Supplement (BRM4) on NAFLD,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease,Dietary Supplement: rice bran arabinoxylan compound (RBAC)|Dietary Supplement: Placebo,Change from baseline in liver function test|Change from baseline in metabolic markers|Change from baseline in immunological markers|Change from baseline in systolic blood pressure|Change from baseline in Diastolic blood pressure|Pulse|Change from Baseline in Quality of Life,University of Miami|Daiwa Health Development,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,23,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",20150512,May-16,10-Jun-17,10-Jun-17,6-Oct-15,null,14-Jun-17,"University of Miami Miller School of Medicine, Soffer Clinical Research Center, Department of Psychiatry & Behavioral Sciences, Miami, Florida, United States",,https://ClinicalTrials.gov/show/NCT02568787
NCT02564679,Sleeve Gastrectomy in Adolescents With Complicated Morbid Obesity and NAFLD,,Completed,No Results Available,Morbid Obesity|NAFLD,Procedure: Laparoscopic Sleeve gastrectomy (LSG)|Behavioral: Lifestyle Intervention,Improvement of metabolic parameters|Improvement of liver parameters|Improvement of liver histology,Bambino Gesù Hospital and Research Institute,All,13 Years to 17 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LSG_metabolic profile,Jul-14,Jul-15,Sep-15,1-Oct-15,null,1-Oct-15,,,https://ClinicalTrials.gov/show/NCT02564679
NCT02558530,Resolution of Liver Fat in Non-alcoholic Fatty Liver Disease,,"Active, not recruiting",No Results Available,NAFLD,Other: Low carbohydrate diet,Liver fat percent by nuclear magnetic resonance imaging|De novo lipogenesis measured as Incorporation of new fatty acids (%) to very-low density lipoprotein triglycerides|Gut microbiota measured as change in microbiome profile from baseline,"Helsinki University Central Hospital|Sahlgrenska University Hospital, Sweden|Göteborg University",All,"20 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Atkins,Jan-15,Nov-19,Apr-20,24-Sep-15,null,8-Mar-19,"RPU Diabetes and Obesity, Biomedicum, Helsinki, Finland|Wllenberg Laboratory, Gothenburg, Sweden",,https://ClinicalTrials.gov/show/NCT02558530
NCT02548351,Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment,REGENERATE,Recruiting,No Results Available,Non Alcoholic Steatohepatitis (NASH),Drug: Obeticholic Acid|Drug: Placebo,To evaluate the effect of Obeticholic Acid compared to placebo on liver histology in non-cirrhotic nonalcoholic steatohepatitis (NASH) subjects with stage 2 or 3 fibrosis by assessing the following primary endpoints|To evaluate the effect of Obeticholic Acid compared to placebo on all-cause mortality and liver-related clinical outcomes as measured by the time to first occurrence of any of the listed adjudicated events (clinical outcomes composite endpoint)|To evaluate the effect of Obeticholic Acid compared to placebo on liver histology in NASH|To evaluate the effect of Obeticholic Acid compared to placebo on liver biochemistry and markers of liver function,Intercept Pharmaceuticals,All,"18 Years to 85 Years   (Adult, Older Adult)",Phase 3,2370,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",747-303,Sep-15,Oct-22,Oct-22,14-Sep-15,null,31-Jan-19,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Digestive Health Specialists of the Southeast, Dothan, Alabama, United States|University of South Alabama, Mobile, Alabama, United States|The Institute for Liver Health, Chandler, Arizona, United States|Banner - Advanced Liver Disease and Transplant Center, Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic, Phoenix, Arizona, United States|Liver Wellness Center, Little Rock, Arkansas, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, United States|GW Research Inc., Chula Vista, California, United States|Precision Research Institute, Chula Vista, California, United States|eStudy Site, Chula Vista, California, United States|Southern California Research Center, Coronado, California, United States|TriWest Research Associates, El Cajon, California, United States|UCSF Fresno Clinical Research Center, Fresno, California, United States|Fresno Clinical Research Center (FCRC), Fresno, California, United States|Citrus Valley Gastroenterology, Glendora, California, United States|Scripps Clinic, La Jolla, California, United States|University of California, San Diego, La Jolla, California, United States|Loma Linda University, Loma Linda, California, United States|Loma Linda Veterans Association for Research & Education, Loma Linda, California, United States|Keck Medical Center of USC, Los Angeles, California, United States|Ruane Medical and Clinical Research Institute, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|National Research Institute, Wilshire, Los Angeles, California, United States|Gastrointestinal Biosciences, Los Angeles, California, United States|VA Greater Los Angeles Health Care System, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Surinder Saini, M.D., Inc, Newport Beach, California, United States|Stanford University, Palo Alto, California, United States|Inland Empire Liver Foundation, Rialto, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Medical Associates Research Group, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|University of California San Francisco (UCSF) / San Francisco General Hospital, San Francisco, California, United States|California Pacific Medical Center, San Francisco, California, United States|Quest Clinical Research, San Francisco, California, United States|University of California San Francisco, San Francisco, California, United States|Silicon Valley Research Institute, San Jose Gastroenterology, San Jose, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|South Denver Gastroenterology, PC, Englewood, Colorado, United States|Rocky Mountain Clinical Research, LLC, Wheat Ridge, Colorado, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Integrity Clinical Research, LLC, Doral, Florida, United States|University of Florida (UF) Hepatology Research at CTRB, Gainesville, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|University of Florida Health - Jacksonville, Jacksonville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Florida Digestive Health Specialist Research Institute, Lakewood Ranch, Florida, United States|Sunrise Medical Research, Inc, Lauderdale Lakes, Florida, United States|Meridien Research, Inc., Maitland, Florida, United States|Bruce W. Carter Miami VA Medical Center, Miami, Florida, United States|University of Miami, Schiff Center for Liver Disease, Miami, Florida, United States|Gastro Health, Miami, Florida, United States|ProLive Medical Research, Miami, Florida, United States|Janus Clinical Research, Miami, Florida, United States|Florida Hospital Transplant Institute, Orlando, Florida, United States|South Florida Center of Gastroenterology, PA, Wellington, Florida, United States|Cleveland Clinic Florida, Weston, Florida, United States|Florida Medical Clinic, PA, Zephyrhills, Florida, United States|Summit Clinical Research, LLC, Athens, Georgia, United States|Atlanta Gastroenterology Associates (AGA), LLC, Atlanta, Georgia, United States|Digestive Healthcare of Georgia, Atlanta, Georgia, United States|Piedmont Transplant Institute, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States|Georgia Clinical Research, LLC, Snellville, Georgia, United States|The Queen's Medical Center - Liver Center, Honolulu, Hawaii, United States|Grand Teton Research Group, Idaho Falls, Idaho, United States|Norhwestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University (IU) Health University Hospital, Indianapolis, Indiana, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Gastroenterology Associates of Hazard, Hazard, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|Investigative Clinical Research, Annapolis, Maryland, United States|Mercy Medical Center, Institute for Digestive Health and Liver Disease, Baltimore, Maryland, United States|John Hopkins Hospital, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Commonwealth Clinical Studies, Brockton, Massachusetts, United States|Lahey Hospital & Medical Center, Burlington, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|West Michigan Clinical Research, Wyoming, Michigan, United States|Huron Gastroenterology Associates, Ypsilanti, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Minnesota Gastroenterology, P.A., Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|VA Medical Center Kansas City, Kansas City, Missouri, United States|Kansas City Research Institute, Kansas City, Missouri, United States|St. Louis University, Gastroenterology and Hepatology, Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CHI Research Center, Omaha, Nebraska, United States|AGA Clinical Research Associates, LLC, Egg Harbor Township, New Jersey, United States|Amici Clinical Research, Martinsville, New Jersey, United States|Rutgers University New Jersey Medical School, Newark, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|The Gastroenterology Group of South Jersey, Vineland, New Jersey, United States|AccumetRx Clinical Research, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|University of Buffalo, Buffalo, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|Concorde Medical Group PLLC, New York, New York, United States|New York University (NYU) Langone Medical Center, New York, New York, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Premier Medical Group of the Hudson Valley, PC, Poughkeepsie, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Charlotte Gastroenterology & Hepatology, P.L.L.C, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Piedmont Healthcare, Carolinas Center for Liver Disease, Statesville, North Carolina, United States|Digestive Health Specialists, PA, Winston-Salem, North Carolina, United States|Consultants for Clinical Research, Cincinnati, Ohio, United States|University of Cincinnati Physicians Company, LLC/Division of Digestive Diseases, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|The Ohio State University (OSU) Wexner Medical Center, Columbus, Ohio, United States|Center for Digestive Health, Mentor, Ohio, United States|Clinical Research Solutions, Middleburg Heights, Ohio, United States|INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University (OHSU), Portland, Oregon, United States|Central Bucks Specialists-Gastroenterology, Doylestown, Pennsylvania, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|Main Line Gastroenterology Associates, Perkasie, Pennsylvania, United States|Hahnemann University Hospital/Drexel University Hospital, Philadelphia, Pennsylvania, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Einstein Healthcare Network, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University Gastroenterology, Liver Center, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|Innovative Clinical Research, Rapid City, South Dakota, United States|ClinSearch, LLC, Chattanooga, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Methodist Healthcare, University Hospital, Memphis, Tennessee, United States|Nashville Medical Research Institute, Nashville, Tennessee, United States|Quality Medical Research, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center - Digestive Disease Center, Nashville, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|Austin Center for Clinical Research, Austin, Texas, United States|The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas, United States|Liver Center of Texas, Dallas, Texas, United States|Texas Digestive Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|MedResearch, Inc., El Paso, Texas, United States|Brooke Army Medical Center (Geneva Foundation), Fort Sam Houston, Texas, United States|Baylor All Saints Medical Center, Fort Worth, Texas, United States|VA Medical Center Houston, Houston, Texas, United States|Baylor College of Medicine - Ben Taub Hospital, Houston, Texas, United States|Baylor St. Luke's Medical Center, Advanced Liver Therapies, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Liver Associates of Texas, P.A., Houston, Texas, United States|University of Texas Health Science Center, Houston, Houston, Texas, United States|Centex Studies, Inc., Houston, Texas, United States|Gulf Coast Research Group, Houston, Texas, United States|Gastroenterology Consultants of San Antonio, Live Oak, Texas, United States|Centex Studies - McAllen, McAllen, Texas, United States|American Research Corporation, The Texas Liver Institute, San Antonio, Texas, United States|Texas Digestive Disease Consultants- San Marcos, San Marcos, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|The University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|McGuire DVAMC, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Organ Transplant and Liver Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|University of Wisconsin, School of Medicine, Madison, Wisconsin, United States|Royal Adelaide Hospital, Adelaide, Australia|Flinders Medical Centre, Bedford Park, Australia|The Royal Brisbane Hospital, Brisbane, Australia|Gallipoli Medical Research Foundation, Brisbane, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|Monash Medical Centre, Clayton, Australia|Concord Repatriation General Hospital, Concord, Australia|Austin Hospital, Heidelberg, Australia|Nepean Hospital, Kingswood, Australia|Fiona Stanley Hospital, Murdoch, Australia|Royal Melbourne Hospital, Parkville, Australia|The Alfred Hospital, Prahran, Australia|Westmead Hospital, Westmead, Australia|Medizinische Universität Innsbruck, Innsbruck, Austria|Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria|Krankenhaus der Elisabethinen Linz, Linz, Austria|Medizinische Universität Wien - AKH, Wien, Austria|Universitair Ziekenhuis Antwerpen (UZA), Edegem, Antwerp, Belgium|CUB Hôpital Erasme, Brussels, Brabant, Belgium|University Hospitals Leuven, KU Leuven, Leuven, Vlaams-Brabant, Belgium|AZ Sint-Jan Brugge Oostende, Brugge, Belgium|UCL Saint-Luc, Brussels, Belgium|Ziekenhuis Oost-Limburg, Genk, Belgium|UZ Ghent, Ghent, Belgium|Gastroenterologie AZ Nikolaas, Sint-Niklaas, Belgium|University of Alberta, Edmonton, Alberta, Canada|University of Calgary, Calgary, Canada|GI Medical Research, Edmonton, Canada|London Health Sciences Centre - University Hospital, London, Canada|Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Montreal, Canada|The Research Institute of the McGill University Health Centre, Montreal, Canada|Toronto Center for Liver Disease, Toronto, Canada|Toronto Liver Centre, Toronto, Canada|LAIR Centre, Vancouver, Canada|Gordon & Leslie Diamond Health Care Centre, Vancouver, Canada|GI Research Institute (GIRI), Vancouver, Canada|PerCuro Clinical Research, Victoria, Canada|University of Manitoba, Winnipeg, Canada|Aalborg University Hospital, Aalborg, Denmark|Aarhus Universitetshospital, Aarhus C, Denmark|Copenhagen University Hospital Hvidovre, Hvidovre, Denmark|Odense University Hospital, Odense, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Turku University Hospital, Turku, Finland|CHU Amiens Picardie, Amiens, France|CHU Angers, Angers, France|Centre Endoscopie Nord Isere, Bourgoin-Jallieu, France|CHU Caen, Hôpital Côte de Nacre, Caen, France|Hôpital Beaujon, Clichy, France|Henri Mondor Hospital, Creteil, France|CHU Grenoble, Grenoble, France|Hôpital Claude Huriez CHRU Lille, Lille, France|Hôpital de la Croix Rousse, Lyon, France|Hôpital Saint Joseph, Marseille, France|CHU de Nice, Nice, France|CHU Orléans, Orléans, France|Hôpital Saint-Antoine, Paris, France|Hospital Cochin, Paris, France|Hôpital de la pitié Salpétrère, Paris, France|CHU de Bordeaux - Hôpital du Haut-Lévêque, Pessac, France|CHU de Rouen, Hôpital C Nicole, Rouen, France|CHU de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Nancy, Vandoeuvre-Lès-Nancy, France|Hopital Paul Brousse, Villejuif, France|Universitatsklinikum Heidelberg, Heidelberg, Baden-Wurttemberg, Germany|Friedrich Alexander Universitat Erlangen, Erlangen, Bavaria, Germany|Klinikum der Johann-Wolfgang Goethe Universitat, Frankfurt, Hesse, Germany|Universitatsmedizin Mainz, Mainz, Rhineland-Palatinate, Germany|Universitatsklinikum Leipzig, Leipzig, Saxony, Germany|Universitätsklinikum Aachen, Aachen, Germany|Charite Universitätsmedizin Campus Virchow, Berlin, Germany|St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany|Universitätskliniken Bonn AöR, Bonn, Germany|University of Düsseldorf, Düsseldorf, Germany|Katholische Kliniken Ruhrhalbinsel GmbH, Essen, Germany|University Hospital Essen, Essen, Germany|Ifi- Studien und Projekte GmbH, Hamburg, Germany|Universitätsklinikum Hamburg- Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Gastroenterologische Gemeinschaftspraxis, Herne, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Hepato-Gastroenterology Center Kiel, Kiel, Germany|Universitätsklinik Köln, Köln, Germany|EUGASTRO GmbH, Leipzig, Germany|Universitatsklinikum Mannheim, Mannheim, Germany|Krankenhaus Barmherzige Brueder Munich, Munich, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Szent László Kórház - Központi Felnőtt Szakrendelő, Budapest, Hungary|Kenézy Gyula Kórház és Rendelőintézet, Infektológia és Hepatológiai Centrum, Debrecen, Hungary|University of Debrecen, Debrecen, Hungary|University of Pécs, Pécs, Hungary|Carmel Medical Center, Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|West Galilee Hospital, Nahariya, Israel|Holy Family Hospital, Nazareth, Israel|AOU Pol. S.Orsola-Malpighi di Bologna, Bologna, Italy|Università de Bologna, Bologna, Italy|Università degli Studi di Firenze, Firenze, Italy|Azienda Ospedaliera San Paolo Polo Universitario Milano, Milano, Italy|Fondazione IRCCS Ca' Granda, Milano, Italy|Humanitas Research Hospital, Milan, Italy|Ospedale san Giuseppe Multimedica, Milan, Italy|ASL di Modena, Modena, Italy|University of Naples, Naples, Italy|University of Padova, Padova, Italy|Azienda Ospedaliera Universitaria Policlinico ""Paolo Giaccon"", Palermo, Italy|University of Tor Vergata (Roma), Roma, Italy|Università Cattolica del Sacro Cuore, Roma, Italy|A.O.U. Città della Salute e della Scienza di Torino - Dipartimento di scienze mediche, Torino, Italy|Vrije Universiteit Medisch centrum, Amsterdam, Netherlands|University of Amsterdam, Amsterdam, Netherlands|Radboud University Nijmegen Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Auckland City Hospital, Grafton, Auckland, New Zealand|Middlemore Clinical Trials, Auckland, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok, Poland|Centrum Badań Klinicznych, Gdansk, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny im. prof. Kornela Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland|Klinika Chorob Zakaznych i Hepatologii UM Oddzial Chorob Zakaznych, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1, Lublin, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin, Poland|Centrum Badań Klinicznych Piotr Napora lekarze spółka partnerska, Wroclaw, Poland|Centro Hospitalar do Baixo Vouga, EPE, Aveiro, Portugal|Hospital José Joaquim Fernandesin, Beja, Portugal|Centro Hosipitalar e Universitário de Coimbra, Coimbra, Portugal|Hospital de Santo Antonio, Douro, Portugal|Hospital da Senhora da Oliveira - Guimarães, Guimarães, Portugal|CHLC, EPE - Hospital de Santo António dos Capuchos, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal|CHLN - Hospital de Santa Maria, Lisbon, Portugal|Centro Hospitalar Trás-os-Montes e Alto Douro, EPE, Lordelo, Portugal|Centro Hospitalar São João, EPE -Hospital de São João, Porto, Portugal|University of Puerto Rico, Ponce, Puerto Rico|Klinical Investigations Group, LLC, San Juan, Puerto Rico|Hospital Auxilio Mutuo, San Juan, Puerto Rico|Fundacion de Investigacion, San Juan, Puerto Rico|Klinički Centar Srbije, Belgrade, Serbia|Kliničko Bolnički Centar Zvezdara, Belgrade, Serbia|University Hospital Center Bezanijska Kosa, Belgrade, Serbia|University Hospital Center Zemun, Belgrade, Serbia|Clinical Center Nis, Nis, Serbia|Hospital Universitari Son Espases, Palma de Mallorca, Baleares, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Universitario Fundación Alcorcon, Alcorcon, Spain|Hospital General y Universitario de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario de León, Leon, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Clinica Universidad de Navarra, Pamplona, Spain|Hospital Universitario Donostia, San Sebastian, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Clínico de Santiago de Compostela, Santiago de Compostela, Spain|Hospital (Universitario) Virgen del Rocio, Sevilla, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|La Fe Hospital, Valencia, Spain|Hospital Clinico Universitario Zaragoza, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Sahlgrenska University Hospital, Gothenburg, Sweden|Magtarmmedicinska mottagningen Universitetssjukhuset, Linkoping, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|University of Bern, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Epatocentro Ticino SA, Lugano, Switzerland|Kantonsspital St.Gallen, St.Gallen, Switzerland|USZ Universitätsspital Zürich, Zürich, Switzerland|Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|Royal Devon & Exeter Hospital, Exeter, Devon, United Kingdom|The Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom|Norfolk & Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk, United Kingdom|Oxford University Hospital NHS Trust, Headington, Oxford, United Kingdom|Royal Surrey County Hospital NHS Trust, Guildford, Surrey, United Kingdom|University of Birmingham, Birmingham, United Kingdom|Bradford Teaching Hospitals Foundation Trust, Bradford, United Kingdom|Royal Alexander Children's Hospital (CIRU), Brighton, United Kingdom|University Hospital Bristol NHS Foundation Trust, Bristol, United Kingdom|Cambridge University Hospital NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom|Royal London Hospital, Barts Health NHS Trust, London, United Kingdom|The Royal Free Hospital, London, United Kingdom|Guys and St. Thomas NHS Foundation Trust, London, United Kingdom|Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom|Central Manchester University Hospital NHS Foundation Trust Manchester Royal Infirmary, Manchester, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom|Queens Medical Centre, Nottingham University Hospitals, Nottingham, United Kingdom|Derriford Hospital, Plymouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT02548351
NCT02546609,The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease,,Completed,Has Results,NAFLD,Drug: Leu-Met-Sil 0.5|Drug: Leu-Met-Sil 1.0|Drug: Placebo,Change in Hepatic Fat|Change in Serum AlanineAaminotransferase (ALT) Levels|Change in Circulating Cytokeratin 18 Fragments (M30)|Change in Heamoglobin A1c (HbA1c)|Change in Fasting Glucose|Change in Insulin|Change in Blood Lipids (Cholesterol)|Change in Blood Lipids (High Density Lipoprotein:HDL)|Change in Low Density Lipoproteins (LDL)|Change in Triglycerides|Change in C-reactive Protein|Change in Insulin Sensitivity (HOMA-IR),NuSirt Biopharma,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,91,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NS-0200-01,19-Nov-15,30-Nov-16,31-Jan-17,11-Sep-15,2-May-18,2-May-18,"Catalina Research Institute, Chino, California, United States|University of California San Diego, San Diego, California, United States|Rocky Mountain Research, Wheat Ridge, Colorado, United States|Atlanta Gastroenterology Associates, Atlanta, Georgia, United States|GI Specialists of Georgia, Marietta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States|Sterling Research, Cincinnati, Ohio, United States|Premier Clinical Research, Clarksville, Tennessee, United States|Gastro One, Germantown, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02546609
NCT02541045,Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis,,Suspended,No Results Available,Non-alcoholic Steatohepatitis,Drug: metadoxine|Other: placebo,improvement in the degree of non-alcoholic fatty liver disease score (NAS)|improvement in liver steatosis measured on a scale from 0 to 3|improvement in lobular inflammation measured on a scale from 0 to 3|improvement in ballooning measured on a scale from 0 to 2|improvement in alanine aminotransferase serum levels|improvement in aspartate aminotransferase serum levels|improvement in the degree of liver fibrosis measured on a scale from 0 to 2|to compare the occurrence of adverse effects between groups,Hospital General de Mexico,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,108,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DI/15/108/03/48,Aug-15,Aug-19,Aug-19,4-Sep-15,null,21-Sep-18,"Hospital General de México, Mexico City, DF, Mexico",,https://ClinicalTrials.gov/show/NCT02541045
NCT02535195,Effect of Ginger Supplement on Non-alcoholic Fatty Liver,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Dietary Supplement: Ginger supplement|Dietary Supplement: Placebo (starch),Serum levels of the ALT liver enzyme|Serum levels of the AST liver enzyme|controlled attenuation parameter(CAP) score,Dr Azita Hekmatdoost|National Nutrition and Food Technology Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",93-03-161-27265,Mar-13,Feb-14,Aug-15,28-Aug-15,null,28-Aug-15,,,https://ClinicalTrials.gov/show/NCT02535195
NCT02530138,"The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver",,Unknown status,No Results Available,Non Alcoholic Steatohepatitis,Dietary Supplement: synbiotic|Dietary Supplement: Placebo,Alaninaminotransferase (ALT) (UL)|hepatic steatosis (cap score)|Body Mass Index (BMI) (kg/m2),National Nutrition and Food Technology Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",563,Aug-14,Feb-16,null,20-Aug-15,null,20-Aug-15,"NNFTRI clinic, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02530138
NCT02528305,The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis,,Completed,Has Results,Non-alcoholic Steatohepatitis|Non-alcoholic Fatty Liver Disease,Other: High-intensity Interval Training,"Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)|Oral Glucose Tolerance Test|AST: ALT Ratio|FIB-4|Body Fat Mass Estimated Via Bioimpedance|Blood Pressure|General Well-being as Assessed by SF-36 Questionnaire|Short-term Memory Recall|Estimated VO2 Max|Physical Function-""Get up and go"" Test|Ankle Brachial Pressure Index (ABPI)|Long-term Memory Recall|Executive Function (Verbal Fluency Test)",University of Bath|Abertay University,All,20 Years to 59 Years   (Adult),Not Applicable,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015CM,Oct-15,Jun-16,Jun-16,19-Aug-15,4-May-18,4-May-18,"Abertay University, Dundee, United Kingdom|Ninewells Hospital, Dundee, United Kingdom",,https://ClinicalTrials.gov/show/NCT02528305
NCT02526732,Hepatic Inflammation and Physical Performance in Patients With NASH,HELP,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Other: individual training program,Change in physical performance|Change in liver inflammation,Priv.-Doz. Dr. J. Schattenberg|Johannes Gutenberg University Mainz,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,44,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,2015_04_001_HELP,Sep-15,20-Dec-17,20-Dec-17,18-Aug-15,null,5-Sep-18,"University Medical Center of the Johannes Gutenber Univeristy, Mainz, Germany",,https://ClinicalTrials.gov/show/NCT02526732
NCT02513121,Dietary Treatment Study of Pediatric NAFLD,DTS,Completed,No Results Available,Nonalcoholic Fatty Liver Disease,Other: Dietary modification,Change of fat in the liver measured by proton density fat fraction (PDFF)|Change in alanine aminotransferase (ALT)|Change in aspartate aminotransferase (AST)|Change in gamma-glutamyl transferase (GGT)|Change in weight|Change in body mass index (BMI)|Change in waist circumference,"University of California, San Diego|Emory University|Nutrition Science Initiative",Male,11 Years to 16 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015-4405,Jul-15,31-Aug-17,31-Aug-17,31-Jul-15,null,11-Jan-18,"University of California, San Diego, San Diego, California, United States|Emory University, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02513121
NCT02510599,Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis,,Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: solithromycin,To evaluate effects on hepatic histology in patients with NASH|Changes in Steatosis on liver biopsy|Changes in hepatocellular ballooning score on liver biopsy|Changes in inflammation on liver biopsy,"Melinta Therapeutics, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,10,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CE01-205,Dec-15,27-Jan-17,28-Feb-17,29-Jul-15,null,21-Mar-17,"Case Western University Hospitals, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02510599
NCT02500147,Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS),,Recruiting,No Results Available,Polycystic Ovary Syndrome|Non-Alcoholic Fatty Liver Disease|Metabolic Syndrome,Drug: Metformin|Drug: Placebo,"Difference in percentage liver fat between Metformin arm and Placebo arm in adolescents and young adults with PCOS and with elevated percentage liver fat (>/=4.8%)|Proportion of PCOS subjects with the PNPLA3 allele comparing those with elevated percentage liver fat (>/=4.8%) and those with normal percentage liver fat (<4.8%) by magnetic resonance spectroscopy|The association of percentage liver fat by magnetic resonance spectroscopy with insulin resistance as measured by HOMA-IR in adolescents with PCOS|The association of percentage liver fat with triglycerides|The association of percentage liver fat with visceral adipose tissue|The association of percentage liver fat with total body adipose tissue|The association of percentage liver fat with pancreatic polypeptide|The association of percentage liver fat with M30, a hepatic apoptosis marker",Columbia University,Female,"13 Years to 25 Years   (Child, Adult)",Phase 4,46,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AAAF4452,Jul-13,Jun-19,Jun-20,16-Jul-15,null,4-Nov-16,"Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02500147
NCT02498990,Low Calorie Diet and Diabetes,LCD,Enrolling by invitation,No Results Available,Diabetes Mellitus Type 2|Dyslipidemia|Non-alcoholic Fatty Liver Disease|Obesity,Behavioral: Low calorie diet followed by life style intervention,"Change from Baseline in HbA1c (mmol/mol) at 12 and 24 months|Change from Baseline in BMI (kg/m2) at 7 weeks, 6,12, and 24 months|Change from Baseline in Liver Fat (Controlled Attenuation Parameter, db/m) at 7 weeks, 6, 12 and 24 months|Change from Baseline in Cholesterol (mmo/l) and Triglycerides (mmol/l) at 7 weeks, 6, 12 and 24 months|Change from Baseline in 2-hour Glucose (mmol/l) and Insulin (mU/l) by Glucose tolerance test at 7 weeks, 6, 12 and 24 months",Karolinska University Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2015/628-31,Aug-15,Feb-19,Aug-19,15-Jul-15,null,25-Aug-17,"Karolinska University Hospital, Stockholm, Sweden",,https://ClinicalTrials.gov/show/NCT02498990
NCT02496390,Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD,FMT,Completed,No Results Available,Diabetes Mellitus|Non-alcoholic Fatty Liver Disease,Biological: Autologous|Biological: Allogeneic,Improvement in Homeostasis model assessment [HOMA] score.|Fat reduction|Reducing body fat|Gut permeability|Microbiome modulation|Modulation of lipid and hormone metabolism,Lawson Health Research Institute,All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IDFMT - 001,Jun-16,Apr-18,Dec-18,14-Jul-15,null,11-Dec-18,"Michael Silverman, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02496390
NCT02491905,Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: HL tablet|Drug: Placebo,To assess the change of hepatic fat by Magnetic Resonance spectroscopy (MRS) after administration of HL tablet compared with baseline|Changes in Alanine Transaminase (ALT)|Changes in Asparate Transaminase (AST)|Changes in cholesterol|Changes in triglyceride|Changes in free fatty acid|Changes in insulin resistance|Changes in Body Mass Index (BMI),"Huons Co., Ltd.",All,"19 Years to 75 Years   (Adult, Older Adult)",Phase 2,69,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12-HS-HP-09-1,Nov-13,May-15,May-15,8-Jul-15,null,8-Jul-15,"Huons, Ansan, Kyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02491905
NCT02491229,"""Hepafast"" in Non-alcoholic Fatty Liver Disease (NAFLD)",,Completed,No Results Available,Non-alcoholic Fatty Liver Disease (NAFLD)|Obesity,Other: Hepafast|Other: LOGI diet,"change from baseline in hepatorenal index at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in fatty liver index at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in the classification of non-alcoholic fatty liver disease (NAFLD) based on ultrasound at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in body weight at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in blood pressure (systolic and diastolic) at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in GGT at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in GOT at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in GPT at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in AP at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in triglycerides at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in HDL cholesterol at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in LDL cholesterol at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in fasting glucose at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in insulin at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in HbA1c at two weeks, six weeks and twelve weeks after starting a defined way of nutrition|change from baseline in hsCRP at two weeks, six weeks and twelve weeks after starting a defined way of nutrition",University of Hohenheim|Bodymed AG,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ZKES HEPA V2.0,Jan-15,May-15,Dec-15,7-Jul-15,null,14-Jan-16,"University of Hohenheim, Stuttgart, Germany",,https://ClinicalTrials.gov/show/NCT02491229
NCT02469272,Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study,,Recruiting,No Results Available,Nonalcoholic Fatty Liver Disease,Drug: Fecal Microbiota Transplantation,degree of hepatic steatosis as determined by MRI|Liver Function Tests|Markers of insulin sensitivity,Lifespan,All,"18 Years and older   (Adult, Older Adult)",Phase 1,5,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Committee # 2014-15,May-15,Jun-18,Jun-18,11-Jun-15,null,1-Nov-17,"Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT02469272
NCT02466516,"Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3",,Completed,No Results Available,Non-Alcoholic Steatohepatitis (NASH),Drug: GS-4997|Biological: SIM,Adverse event profile of GS-4997|Percentage of participants who prematurely discontinued study drug or study due to adverse events,Gilead Sciences,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,72,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GS-US-384-1497,Jun-15,Oct-16,Oct-16,9-Jun-15,null,27-Feb-17,"Stanford University Medical Center, Palo Alto, California, United States|University of California San Diego, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburg Medical Center, Pittsburg, Pennsylvania, United States|Texas Clinical Research Institute, Arlington, Texas, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|CHI St. Luke's Health Baylor College of Medicine, Houston, Texas, United States|Brooke Army Medical Center Ft. Sam, Houston, Texas, United States|Digestive Research Center, Live Oak, Texas, United States|American Research Corporation at Texas Liver Institute, San Antonio, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Mary Immaculate Hospital, Newport News, Virginia, United States|St. Mary's Hospital, Richmond, Virginia, United States|Virginia Commonwealth University Health System, Richmond, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|University of Calgary, Calgary, Alberta, Canada|Toronto Liver Centre, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT02466516
NCT02461212,Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Procedure: Magnetic Resonance Imaging (MRI),Correlation between HepaFat-Scan and pathology based assessment of steatosis|Correlation of HepaFat-Scan measurement with magnetic resonance spectroscopy (MRS) and computerized steatosis|Correlation of HepaFat-Scan measurement with magnetic resonance spectroscopy (MRS) and grade of pathology of assessment|Repeatability of HepaFat-Scan,Emory University|Resonance Health,All,"7 Years to 18 Years   (Child, Adult)",Not Applicable,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,IRB00078470,1-Jul-15,17-Mar-17,17-Mar-17,3-Jun-15,null,10-Apr-17,"Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02461212
NCT02458586,Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD),UFOP-2,Unknown status,No Results Available,NAFLD|Obesity|Prediabetes|Dyslipoproteinemia,Dietary Supplement: Dietary intervention / counseling,change in liver fat content|change in hepatic insulin sensitivity,German Institute of Human Nutrition|ufop: Union zur Förderung von Oel- und Proteinpflanzen e.V.,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment",UFOP-2,May-15,May-17,Nov-17,1-Jun-15,null,22-Nov-16,"German Institut for Human Nutrition; Department for Clinical Nutrition, Nuthetal, Brandenburg, Germany",,https://ClinicalTrials.gov/show/NCT02458586
NCT02457286,Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study,,Withdrawn,No Results Available,Non-alcoholic Fatty Liver Disease (NAFLD),Drug: Metformin|Behavioral: Lifestyle modifications|Device: Fibroscan device (Echosens),Improvement in NAFLD as measured by ALT levels|Incidence of metabolic syndrome (insulin resistance)|Incidence of NAFLD fibrosis scores after 12 months of treatment as measured by Fibroscan,Northwell Health,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 1,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB# 13-204,Jun-15,Jul-17,Jul-17,29-May-15,null,28-Jul-17,"North Shore Hospital, Manhasset, New York, United States",,https://ClinicalTrials.gov/show/NCT02457286
NCT02442687,JKB-121 for the Treatment of Nonalcoholic Steatohepatitis,,Completed,Has Results,Nonalcoholic Steatohepatitis,Drug: JKB-121: 5 mg twice daily|Drug: JKB-121: 10 mg twice daily|Drug: Placebo,Analysis of MRI-PDFF Change From Baseline to Week 24 (Per Protocol Population)|Analysis of MRI-PDFF Change From Baseline to Week 12 (Per Protocol Population)|Analysis of ALT Change From Baseline to Week 24 (Per Protocol Population)|Analysis of ALT Change From Baseline to Week 12 (Per Protocol Population)|Time to Remission (in Weeks)|Change in BMI (Body Mass Index)|Change in Hemoglobin A1C|Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)|Percent Change in Cholesterol|Percent Change in Triglycerides|Percent Change in Low Density Lipoprotein (LDL) Cholesterol|Percent Change in High Density Lipoprotein (HDL)|Mean Serum Aspartate Aminotransferase (AST)|Mean Serum Alanine Aminotransferase (ALT)|Mean Serum Gamma-glutamyl Transpeptidase (GGT)|Number of Subjects With ALT in Normal Range at Week 24|Maximum Observed Concentrations (Cmax)|Minimum Observed Concentration (Cmin)|Area Under Concentration-time (AUC)|Half-life,Manal Abdelmalek|Duke University,All,"18 Years and older   (Adult, Older Adult)",Phase 2,65,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00062677,1-Aug-15,24-Sep-17,24-Sep-17,13-May-15,7-Jan-19,7-Jan-19,"Digestive Disease Specialists of the Southeast, Dothan, Alabama, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Digestive Associates, Las Vegas, Nevada, United States|Duke University, Durham, North Carolina, United States|Digestive Disease Specialists, Cincinnati, Ohio, United States|Brook Army Medical Center, Houston, Texas, United States|University of Virginia Health Systems, Charlottesville, Virginia, United States|Medical College of Virginia, Richmond, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02442687/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT02442687/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT02442687
NCT02443116,Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH),,Recruiting,No Results Available,Nonalcoholic Steatohepatitis (NASH),Biological: NGM282|Other: Placebo,Change in absolute liver fat content as measured by MRI from Baseline to Week 24|Change in percentage liver fat content as measure by MRI from Baseline to Week 24,"NGM Biopharmaceuticals, Inc|NGM Biopharmaceuticals Australia Pty Ltd",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,250,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",15-0105,May-15,Sep-19,Sep-19,13-May-15,null,5-Jun-18,"NGM Clinical Study Site 922, Chandler, Arizona, United States|NGM Clinical Study Site 923, Tucson, Arizona, United States|NGM Clinical Study Site 924, Los Angeles, California, United States|NGM Clinical Study Site 901, San Diego, California, United States|NGM Clinical Study Site 902, Denver, Colorado, United States|NGM Clinical Study Site 917, Lakewood Ranch, Florida, United States|NGM Clinical Study Site 906, Chicago, Illinois, United States|NGM Clinical Study Site 918, Kansas City, Missouri, United States|NGM Clinical Study Site 903, Durham, North Carolina, United States|NGM Clinical Study Site 921, Germantown, Tennessee, United States|NGM Clinical Study Site 910, Dallas, Texas, United States|NGM Clinical Study Site 920, Rollingwood, Texas, United States|NGM Clinical Study Site 905, San Antonio, Texas, United States|NGM Clinical Study Site 909, San Antonio, Texas, United States|NGM Clinical Study Site 904, Charlottesville, Virginia, United States|NGM Clinical Study Site 911, Richmond, Virginia, United States|NGM Clinical Study Site 908, Seattle, Washington, United States|NGM Clinical Study Site 703, Sydney, New South Wales, Australia|NGM Clinical Study Site 704, Adelaide, South Australia, Australia|NGM Clinical Study Site 701, Melbourne, Victoria, Australia|NGM Clinical Study Site 705, Melbourne, Victoria, Australia|NGM Clinical Study Site 916, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT02443116
NCT02427087,Sedentary Postmenopausal Women With Nonalcoholic Fatty Liver Disease (NAFLD) Submitted to Physical Activity,,Completed,No Results Available,Fatty Liver,Behavioral: Continuous Aerobic Training twice|Behavioral: Healthy Diet,Efficacy in reduce inflammatory component of NASH for transient elastography liver|Inflammatory systemic profile,University of Sao Paulo General Hospital,Female,"35 Years to 75 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",9022,Jan-13,Dec-14,Dec-14,27-Apr-15,null,27-Apr-15,"University of Sao Paulo School of Medicine, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02427087
NCT02421094,Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis,NASH-FX,Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: GR-MD-02|Drug: Placebo,Mean change in liver fibrosis of corrected T1 (cT1) mapping (LiverMultiScan -LMS)|Baseline-adjusted change in liver stiffness with MR-elastography (MRE)|Baseline-adjusted change in liver stiffness by FibroScan®,Galectin Therapeutics Inc.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,30,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GT-028,Sep-15,27-Sep-16,27-Sep-16,20-Apr-15,null,11-Jul-17,"Brooke Army Medical Center, Fort Sam Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02421094
NCT02420054,Short Term Intermittent Fasting and Insulin Resistance,IFAST,Unknown status,No Results Available,Diabetes Mellitus|Non-alcoholic Fatty Liver Disease|Metabolic Syndrome|Obesity,Behavioral: Intermittent fasting|Other: Time control,Change from Baseline in Insulin Sensitivity after 20 days of intermittent fasting.|Change of insulin secretion|Glycogen Content in Skeletal Muscle after a Day of Eating and after a Day of Fasting|Change from Baseline in Fat Content in the Liver and Visceral Fat after 20 Days of Intermittent Fasting|Insulin signalling cascade proteins,University of Copenhagen|Herlev Hospital,Male,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Intermittent Fasting,Apr-15,Jul-17,Apr-18,17-Apr-15,null,18-May-17,"Xlab, Department of Biomedical Sciences, University of Copenhagen, Copenhagen N, Denmark",,https://ClinicalTrials.gov/show/NCT02420054
NCT02412540,Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH,,Recruiting,No Results Available,Obesity|Nonalcoholic Steatohepatitis|Nonalcoholic Fatty Liver Disease,Behavioral: Comprehensive Lifestyle Intervention,"Histology Endpoint: Proportion of subjects achieving greater than 2 point reduction in NASH activity score (NAS)|Biomarker Endpoint|Resolution of NASH: Proportion of subjects achieving ""not NASH"" histological diagnosis|Reduction in mean NAS|Decrease in steatosis|Composite decrease in weight|Composite Quality of Life (QOL) Measures|Liver enzymes","Children's Hospital Medical Center, Cincinnati",All,"12 Years to 19 Years   (Child, Adult)",Not Applicable,70,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NASH ABC,Apr-15,Jun-20,Jun-20,9-Apr-15,null,3-Sep-18,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02412540
NCT02413372,A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH),,Completed,No Results Available,Non-Alcoholic Steatohepatitis,Drug: BMS-986036|Drug: Placebo,"Change in percent hepatic fat fraction (%) by Magnetic Resonance Imaging (MRI)|Safety, as measured by adverse events (AEs)|Safety, as measured by clinical laboratory tests|Safety, as measured by vital signs|Safety, as measured by electrocardiograms|Safety, as measured by physical examinations|Safety, as measured by bone mineral density|BMS-986036 observed concentration by Ctrough|Anti-BMS-986036 antibodies|Anti-FGF21 antibodies",Bristol-Myers Squibb,All,"21 Years to 75 Years   (Adult, Older Adult)",Phase 2,202,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",MB130-045,8-May-15,18-Jan-17,19-Jun-17,9-Apr-15,null,30-Apr-19,"Inland Empire Liver Foundation, Rialto, California, United States|University Of California, San Diego, San Diego, California, United States|Indiana University Health - University Hospital, Indianapolis, Indiana, United States|Saint Louis University, Saint Louis, Missouri, United States|Unc Hospitals And Clinics, Chapel Hill, North Carolina, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Upmc Center For Liver Diseases, Pittsburgh, Pennsylvania, United States|Gastro One, Germantown, Tennessee, United States|Quality Medical Research PLLC, Nashville, Tennessee, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|St. Luke'S Episcopal Hospital - Baylor College Of Medicine, Houston, Texas, United States|Texas Liver Institute, San Antonio, Texas, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02413372
NCT02400099,Protein-rich Diet and NAFLD in Bariatric Surgery,,Unknown status,No Results Available,Obesity|Non-alcoholic Fatty Liver Disease,Dietary Supplement: High-protein low calorie diet|Dietary Supplement: Control low calorie diet|Other: Anthropometrical measurements|Other: Body composition|Other: 8-h metabolic profile|Other: Liver biopsy,Liver fat content assessment|Insulin sensitivity assessment|fat free mass assessment,Catholic University of the Sacred Heart|Federico II University,All,20 Years to 60 Years   (Adult),Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,UCSC-2015,Jun-15,Jun-16,null,26-Mar-15,null,26-Mar-15,"Catholic University School of Medicine, Rome, Italy",,https://ClinicalTrials.gov/show/NCT02400099
NCT02395900,The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease,,Completed,No Results Available,Non Alcoholic Steatohepatitis,Dietary Supplement: Flaxseed|Other: control,Alaninaminotransferase (ALT)|Liver fibrosis|Body Mass Index (BMI),National Nutrition and Food Technology Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,567,Mar-14,Aug-14,Jan-15,24-Mar-15,null,22-Mar-16,,,https://ClinicalTrials.gov/show/NCT02395900
NCT02394353,Impact of Bariatric Surgery on the Evolution of Nonalcoholic Fatty Liver Disease: a Comparative Clinical Trial Between Sleeve Gastrectomy and Gastric Bypass,,Completed,No Results Available,Obesity|Fatty Liver,Device: Transient hepatic elastography,Measure of fatty liver disease by transient hepatic elastography|Transversal study comparing comorbidities and transient hepatic elastography,"Ministry of Health, Brazil",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,Interventions,Jan-13,May-15,Feb-16,20-Mar-15,null,7-Mar-16,"Fluminense Federal University, Niteroi, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT02394353
NCT02383485,Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children,SMART,Completed,No Results Available,Overweight and Obesity|Non-alcoholic Fatty Liver Disease,Behavioral: Exercise|Behavioral: After-school program,"Change in Liver Fat|Change in Arterial Stiffness|Change in Liver Fibrosis|Change in Liver Inflammation|Change in Quality of Life|Associations among Liver Fat, Fibrosis and Inflammation, Arterial Stiffness, and Other Cardiovascular Risk Indices","Augusta University|National Heart, Lung, and Blood Institute (NHLBI)",All,8 Years to 11 Years   (Child),Not Applicable,175,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,R01HL087923-02S1,May-08,May-13,Apr-14,9-Mar-15,null,9-Mar-15,"Georgia Prevention Institute, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02383485
NCT02369536,Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD),NUTRAFAST,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Dietary Supplement: nutraceutical mixture|Dietary Supplement: placebo,change of hematic levels of hepatic enzymes|Change of hepatic function|Levels of circulating Inflammation markers|Measures of the haemostatic function|Metabolic syndrome parameters|Apoptosis parameters,Neuromed IRCCS,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,127,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Neuromed-Nutrafast-PON2015,18-Aug-15,15-Sep-16,15-Sep-16,24-Feb-15,null,5-Feb-18,"IRCCS Neuromed, Pozzilli, Isernia, Italy",,https://ClinicalTrials.gov/show/NCT02369536
NCT02367742,Effect of Physical Activity on NAFLD,,Completed,No Results Available,NAFLD,Behavioral: Endurance Activity (EA)|Behavioral: EA + Resistance Training (RT),Change from Baseline in NAFLD score at three and six months|Change from Baseline in Indirect calorimetry at three and six months|Percentage Change from Baseline in Bioimpedenziometry at three and six months,Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NUTRIEPATT,Jan-13,Sep-13,Dec-13,20-Feb-15,null,24-Mar-15,,,https://ClinicalTrials.gov/show/NCT02367742
NCT02366052,"Nutritional Counseling vs. Nutritional Supplements for NASH - a Randomized Prospective, Open Label Pilot Study",NucesNASH,Completed,No Results Available,"Non-alcoholic Fatty Liver Disease|Fatty Liver, Nonalcoholic",Behavioral: Nutritional Counseling|Dietary Supplement: Lactobacillus casei shirota (LCS)|Other: Nutritional Counseling and LCS,Reduction of the M30 antigen in the serum|Change in indicators of hepatocellular injury and fibrosis|Change in metabolic risk factors|Saftey and tolerability,Johannes Gutenberg University Mainz|University of Jena,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NUCES_NASH-JGU|SCHA 1015/5-1,1-Feb-15,10-May-17,10-May-17,19-Feb-15,null,16-May-17,"Institut für Ernährungswissenschaften, University Jena, Jena, Germany|University Medical Center of the Johannes Gutenber Univeristy, Mainz, Germany",,https://ClinicalTrials.gov/show/NCT02366052
NCT02365233,Fatty Liver Study in Patients With Type II Diabetes,,Terminated,Has Results,Type II Diabetes|Nonalcoholic Fatty Liver,Drug: DPP4 inhibitor|Drug: Pioglitazone|Drug: Lantus insulin,Change in Hepatic Lipid Content From Baseline Visit to Six Month Follow up Visit,"The University of Texas Medical Branch, Galveston",All,"18 Years and older   (Adult, Older Adult)",Phase 4,5,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-021,1-May-13,31-Dec-16,31-Dec-16,18-Feb-15,31-Jul-18,31-Jul-18,"University of Texas Medical Branch -Galveston, Galveston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02365233
NCT02358928,Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome,NAFLD,"Active, not recruiting",No Results Available,NAFLD|Fatty Liver|Obesity|Metabolic Syndrome,Other: Diet Intervention,HepaticTrigylceride Content quantified on proton magnetic spectroscopy (H-MRS)|BMI Z-score|Cytokeratin-18|ALT (alanine transaminase),University of Texas Southwestern Medical Center,All,11 Years to 17 Years   (Child),Not Applicable,54,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STU 082013 020,Jul-14,Mar-17,Dec-19,9-Feb-15,null,27-Feb-19,"UTexasSouthwestern/Childrens Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02358928
NCT02354976,A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.,,Completed,Has Results,Non-alcoholic Fatty Liver Disease (NAFLD|Hypertriglyceridemia,Drug: Placebo|Drug: Omega-3 carboxylic acid|Drug: Fenofibrate 200mg,Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Placebo)|Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Fenofibrate),AstraZeneca,All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 2,78,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",D5881C00007,1-Sep-15,26-May-16,26-May-16,3-Feb-15,25-Sep-18,25-Sep-18,"Research Site, Göteborg, Sweden|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",,https://ClinicalTrials.gov/show/NCT02354976
NCT02347696,Diet and Physical Activity on NAFLD and Erytrocyte Membrane Lipid Profile.,,Unknown status,No Results Available,NAFLD,Behavioral: Control|Behavioral: LGIMD|Behavioral: Endurance Activity (EA)|Behavioral: EA+Resistance Training (RT)|Behavioral: LGIMD+EA|Behavioral: LGIMD+EA/RT,Non-Alcoholic Fatty liver Disease (NAFLD) score|Lipid composition of erythrocyte membrane|Sierical lipid profile,Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis,All,30 Years to 60 Years   (Adult),Not Applicable,240,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",NUTRIATT,Mar-15,Dec-16,Dec-16,27-Jan-15,null,26-Jul-16,"Laboratory of Epidemiology and Biostatistics-IRCCS Saverio de Bellis, Castellana Grotte, BA, Italy",,https://ClinicalTrials.gov/show/NCT02347696
NCT02337660,Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Procedure: Liver biopsy|Other: Pancreatic clamp,Endogenous glucose production|Amino acid metabolism|Degree of steatosis|Total RNA sequencing of liver biopsies,"University Hospital, Gentofte, Copenhagen|The Novo Nordisk Foundation Center for Basic Metabolic Research",All,"25 Years to 80 Years   (Adult, Older Adult)",Not Applicable,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,SIRG-1,Jan-15,Jan-16,Jan-16,13-Jan-15,null,16-Nov-18,"Center for Diabetes Research, Gentofte, Denmark",,https://ClinicalTrials.gov/show/NCT02337660
NCT02331589,Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis,,Completed,Has Results,Fatigue,Drug: KRG (Korea Red ginseng)|Drug: Placebo (for KRG),Liver Enzymes|Fatigue as Measured by KRUPP's Fatigue Severity Scale|Pro-inflammatory Cytokine|Adiponectin,Chuncheon Sacred Heart Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,AFEKRG,Aug-11,Apr-12,Apr-12,6-Jan-15,10-Feb-15,10-Feb-15,,,https://ClinicalTrials.gov/show/NCT02331589
NCT02330549,ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD,,Completed,No Results Available,Prediabetic State|Non-alcoholic Fatty Liver Disease|Type 2 Diabetes Mellitus,Drug: Cenicriviroc 150 mg|Drug: Matching placebo,Changes in Insulin Sensitivity Measured by Peripheral and Adipose Tissue|Degree of Macrophage Infiltration in Subcutaneous Adipose Tissue|Expression of Chemokine Receptors Types 2 (CCR2) and 5 (CCR5) in Subcutaneous Adipose Tissue|Changes from Baseline in Peripheral Monocyte Subsets (CD14/CD16)|Changes in Non-invasive Imaging by Multiparametric Magnetic Resonance Imaging (MRI) for Liver Disease (LiverMultiScan™)|Correlation of Non-invasive Liver Imaging Findings with Histology Results|Changes from Baseline in Liver Transaminases|Changes from Baseline in Serum Biomarker Panel|Changes from Baseline in Metabolic Parameters|Number and Percentage of Subjects with Adverse Events over 24 Weeks|Changes from Baseline in Physical Examination over 24 Weeks|Changes from Baseline in Vital Signs over 24 Weeks|Changes from Baseline in 12 Lead ECG over 24 weeks|Pharmacokinetics (PK) of CVC in a population PK analysis,"Tobira Therapeutics, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,45,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",652-2-204,29-Jun-15,26-Aug-16,8-Sep-16,5-Jan-15,null,27-Sep-17,"Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Gastroenterology Consultants of San Antonio, Live Oak, Texas, United States|Fundación de Investigación, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT02330549
NCT02329405,The Effects of PXR Activation on Hepatic Fat Content,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Rifampicin|Drug: Placebo,Hepatic fat fraction,University of Oulu|Oulu University Hospital,All,18 Years to 40 Years   (Adult),Phase 4,16,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,Rifa-Stea|2014-003422-41,Dec-14,Jan-17,Jan-17,31-Dec-14,null,1-Nov-17,"Oulu University Hospital, Oulu, Finland",,https://ClinicalTrials.gov/show/NCT02329405
NCT02316717,A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis,,Completed,No Results Available,Non-alcoholic Steatohepatitis (NASH),Biological: IMM-124E|Other: Placebo,"Body Temperature|Percentage Fat Content of the Liver|Adverse Events|Respiratory Rate|Pulse Rate|Systolic Blood Pressure|Diastolic Blood Pressure|Hematology, Coagulation, Clinical Chemistry, Serum Lipids, Blood Glucose and Urinalysis|Serum Alanine Aminotransaminase (ALT)|Peak serum concentration (Cmax)|Minimum serum concentration (Cmin)|Area Under the Concentration Time Curve (AUC)|Elimination Half Life (T1/2)|Body Mass Index (BMI)|Waist Circumference|Waist:Hip Ratio|Hemoglobin (HB)A1C|Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)|Total Cholesterol|Triglycerides|Low density lipoprotein (LDL)|High Density Lipoprotein (HDL)|Serum Aspartate Aminotransaminase (AST)|Bilirubin|Albumin|Gamma Glutamyl Transpeptidase (GGT)",Immuron Ltd.,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,133,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IMM-124E-2001,Dec-14,30-Oct-17,30-Oct-17,15-Dec-14,null,21-Nov-17,"eStudySite, Chula Vista, California, United States|University of California San Diego, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|University of Florida Hepatology Research at CTRB, Gainesville, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Duke Liver Centre, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Baylor St Lukes Medical Centre, Houston, Texas, United States|Brooke Army Medical Centre, Houston, Texas, United States|Pinnacle Clinical Research, Live Oak, Texas, United States|University of Virginia Medical Centre, Charlottesville, Virginia, United States|Mary Immaculate Hospital, Newport News, Virginia, United States|Bon Secours St Marys Hospital, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Swedish Medical Centre, Seattle, Washington, United States|The Nepean Hospital, Penrith, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|The Alfred Hospital, Prahran, Victoria, Australia|Hadassah Medical Centre, Jerusalem, Israel|Sourasky Medical Center (Ichilov), Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT02316717
NCT02314026,BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH,,Completed,Has Results,Non-Alcoholic Steatohepatitis,Device: Suspected NASH BreathID test with 13C-Octanoate|Device: Suspected NASH Breath test with 13C Methacetin,Number of Participants With Biopsy Proven Non-Alcoholic Steatohepatitis|Liver Decompensation as Measured by Area Under Receiver Operating Curve,Exalenz Bioscience LTD.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,140,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NASH-EX-1114,Mar-15,Jun-17,Jun-17,10-Dec-14,19-Mar-19,19-Mar-19,"Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States|San Antonio Military Medical Center, Forts Sam Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Liver Associates, Houston, Texas, United States|Texas Liver Institute, San Antonio, Texas, United States|Mary Immaculate Hospital, Newport News, Virginia, United States|St. Mary's Hospital, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Antwerp University Hospital (UZA), Edegem, Belgium|Hôpital Pitié Salpêtrière, Paris, France|Freeman Hospital, New Castle, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02314026/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02314026
NCT02307344,Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis,NASH NAFLD,Unknown status,No Results Available,Nonalcoholic Steatohepatitis|Liver Steatosis,Dietary Supplement: Nigella Sativa|Dietary Supplement: Placebo,Effect of Nigella Sativa on Liver Triglyceride Concentration|Effect of Nigella Sativa on Improvement in NASH Activity Index|Effect of Nigella Sativa on Fibrosis Staging,Hillel Yaffe Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,0002-14-HYMC,Jan-15,Jan-17,Jan-17,4-Dec-14,null,4-Dec-14,"Hillel Yaffe Medical Center, Hadera, Israel",,https://ClinicalTrials.gov/show/NCT02307344
NCT02303730,Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes,,Unknown status,No Results Available,"Diabetes Mellitus, Type 2|Non-alcoholic Fatty Liver Disease",Drug: Exenatide|Drug: insulin glargine,"Change in liver fat content（%） measured by MRS|Change in intra-abdominal visceral fat content (cm2), abdominal subcutaneous fat content (cm2), and ratio between intra-abdominal visceral fat and subcutaneous fat area by MRI|Change in glucose metabolism (fasting blood glucose, postprandial plasma glucose, HbA1c)|Change in blood lipid profile (total cholesterol, triglyceride, HDL, LDL)|Change in body weight,waist circumference and hip circumference",Fudan University|Huadong Hospital|Shanghai Minhang Central Hospital|Shanghai 6th People's Hospital|Shanghai Changzheng Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,76,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ESR-14-10096,Mar-15,Nov-16,May-17,1-Dec-14,null,13-Sep-16,"Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China|Department of Endocrinology and Metabolism, Shanghai Minhang Central Hospital, Shanghai, Shanghai, China|Department of Endocrinology and Metabolism,Huadong Hospital, Shanghai, Shanghai, China|Department of Endocrinology and Metabolism,Shanghai 6th People's Hospital, Shanghai, Shanghai, China|Department of Endocrinology and Metabolism,Shanghai Changzheng Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT02303730
NCT02303314,Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Trigonella Foenum-graecum Seed Extract|Drug: Drug: Placebo,Liver stiffness change,Shiraz University of Medical Sciences,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,35,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CT-P-9362-6352|IRCT2013102015083N1,Nov-14,Aug-17,Sep-17,27-Nov-14,null,25-Sep-17,"Shiraz University of Medical Sciences, Shiraz, Fars, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02303314
NCT02290106,Effects of Pitavastatin on Insulin Sensitivity and Liver Fat,,Completed,No Results Available,"Obesity|Fatty Liver, Nonalcoholic",Drug: pitavastatin|Other: PLACEBO,Insulin-stimulated glucose uptake|Liver fat|alanine aminotransferase (ALT)|aspartate aminotransferase (AST)|hepatic insulin sensitivity|hemoglobin A1c (HbA1c)|quantitative insulin sensitivity check index (QUICKI),Massachusetts General Hospital,Male,"40 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014p-002117,2-Mar-15,30-Apr-18,30-Apr-18,13-Nov-14,null,15-Aug-18,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02290106
NCT02287779,Safety and Tolerability Study of SHP626 in Overweight and Obese Adults,,Completed,Has Results,Non-Alcoholic Steatohepatitis,Drug: SHP626|Drug: Placebo,"Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Standard Hematology|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Fat Soluble Vitamins (Vitamin A, D, & E)|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Lipid Panel|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Thyroid Hormone Panel|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Coagulation|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Standard Chemistry|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Urinalysis Parameters|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital Signs|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Electrocardiogram (12-lead)|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs)|Number of Participants With Treatment-emergent Adverse Events (TEAEs) Who Discontinued From the Study|Average Total Fecal Bile Acid (FBA) Concentration|Mean Serum 7- Alpha-hydroxy-4-cholesten-3-one (C4) Concentration|Number of Participants With Stool Hardness Using Bristol Stool Chart|Maximum Observed Plasma Concentration (Cmax) of Volixibat|Area Under the Plasma Concentration-Time Curve (AUC) of Volixibat (SHP626)","Mirum Pharmaceuticals, Inc.",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,84,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SHP626-101,19-Jan-15,19-Jun-15,19-Jun-15,11-Nov-14,7-Dec-16,26-Mar-19,"New Orleans Center for Clinical Research, Knoxville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02287779
NCT02285205,"A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD",,Completed,No Results Available,Type 2 Diabetes|Non-alcoholic Fatty Liver Disease,Drug: Oral administration of Lobeglitazone,changes from baseline in controlled attenuation parameters (CAP),Yonsei University,All,"20 Years and older   (Adult, Older Adult)",Phase 4,38,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,4-2014-0778,Nov-14,Nov-15,Nov-15,6-Nov-14,null,2-Feb-16,"Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02285205
NCT02283710,The Effect of Pentoxifylline on Liver Function Tests in Fatty Liver Disease,,Completed,No Results Available,Fatty Liver,Drug: Pentoxifylline|Behavioral: Lifestyle modification,Change from baseline serum alanine aminotransferase at 6 months|Change from baseline serum aspartate aminotransferase at 6 months,Tehran University of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",9011160012,May-13,May-14,May-14,5-Nov-14,null,6-Nov-14,"Gastroenterology clinic, Sina Hospital, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02283710
NCT02279407,A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients,EFFECTII,Completed,Has Results,T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin),Drug: placebo|Drug: Omega-3 carboxylic acids|Drug: Dapagliflozin|Drug: Placebo,Change From Baseline to Week 12 in % Liver Fat as Assessed by MRI (Comparison Versus Placebo)|Change From Baseline to Week 12 in % Liver Fat (Comparison Between Active Treatment Groups),"AstraZeneca|Uppsala Clinical Research, Uppsala, Sweden",All,"40 Years to 75 Years   (Adult, Older Adult)",Phase 2,223,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D5883C00004,Jan-15,Dec-15,Dec-15,31-Oct-14,27-Jan-17,17-Mar-17,"Research Site, Göteborg, Sweden|Research Site, Linkoping, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Örebro, Sweden",,https://ClinicalTrials.gov/show/NCT02279407
NCT02279524,A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH,Aramchol_005,Completed,No Results Available,Fatty Liver,Drug: Aramchol,% change in the liver triglycerides concentration measured by NMRS between Aramchol treated arms and placebo arm at start and end of the study.|Proportion (%) of subjects with CRN Fibrosis Score Improvement without worsening of NASH|Proportion (%) of subjects with NAS Score Improvement (>=2 points) without worsening of CRN Fibrosis Score|Proportion (%) of subjects with SAF Activity Score Improvement (>=2 points) without worsening of CRN Fibrosis Score|Proportion (%) of subjects with NASH Resolution (ballooning 0; inflammation 0 or 1) without worsening of CRN Fibrosis Score|Change from Baseline to Week 52/Termination in ALT,"Galmed Pharmaceuticals Ltd|Sharp Clinical Services|Diamond Pharma Services Regulatory Affairs Consultancy|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|ClinIntel|Itamar-Medical, Israel|One Way Liver OWL|Medical University of Graz|Tel-Aviv Sourasky Medical Center|DSG EDC|TransPerfect|Clinical Reference Laboratory",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2|Phase 3,247,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Aramchol005,Jan-15,22-May-18,22-May-18,31-Oct-14,null,26-Jun-18,"Profil Institue for Clinical Research Inc., Chula Vista, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Liver Research Institute, Pasadena, California, United States|Inland Empoire Liver Foundation, Rialto, California, United States|University of California Department of Medicine Division of Gastroenterology, San Diego, California, United States|Orange County Research Center, Tustin, California, United States|Indiana University, Indianapolis, Indiana, United States|Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Research, Raleigh, North Carolina, United States|Texas Digestive Disease Consultants, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Gastroenterology Consultants of San Antonio, Live Oak, Texas, United States|Texas Liver Institute San Antonio, San Antonio, Texas, United States|Clinical Trials of Texas, San Antonio, Texas, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States|Biomedica Research Group, Santiago, Chile|Centro de Investigacion Clinica CEIC, Santiago, Chile|Hospital Clinico Universidad de Chile, Santiago, Chile|Pontificia Universidad Catolica de Chile, Santiago, Chile|Centro de Investigaciones Clinicas Vina del Mar, Vina del Mar, Chile|Centre Hospitalier Universitaire (CHU) d'Angers, Angers, France|Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France|San Joseph Service Hepato Gastro Entrologie, Marseille, France|Hospital Saint Eloi, Montpellier, France|CHU Centre Hospiatalier Universitaire de Rennes, Paris, France|Hospital Pitie-Salpetriere, Paris, France|Hospital Saint-Antoine AP-HP, Paris, France|Hopital Paul Brousse, Villejuif, France|Unimed Adjara, Batumi, Georgia|Clinic Cortex, Tbilisi, Georgia|David Tatishvili Medical Center, Tbilisi, Georgia|LTD Diacor, Tbilisi, Georgia|Research Institute of Clinical Medicine, Tbilisi, Georgia|Medizinische Hochschule, Hannover, Germany|EUGASTRO GmbH, Leipzig, Germany|Universitat Leipzig Medizinische Fakultat, Leipzig, Germany|Humanity & Health Medical Centre, Central, Hong Kong|Carmel Medical Center, Haifa, Israel|Rambam Medical Center, Haifa, Israel|Hadassah Ein Karem Medical Cente, Jerusalem, Israel|Naharia Medical Center, Nahariya, Israel|The Holy family Medical Center, Nazareth, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel-Aviv Saurasky Medical Center, Tel-Aviv, Israel|Asaf Harofeh Medical Center, Zrifin, Israel|Spedali Civili di Brescia, Brescia, Italy|A.O. San Paolo, Milano, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|A.O. U. ""Federico II"" di Napoli, Napoli, Italy|Azienda Ospedaliera di Rilievo Nazionale ""A.Cardarelli"", Napoli, Italy|Azienda Ospidaliera Universitaria Seconda Universita di Napoli, Napoli, Italy|A.O.U. Maggiore della Carità, Novara, Italy|""Ospedale Cristo Re"" dell'Istituto Figlie di N.S. al Monte Calvario, Roma, Italy|Fondazione Policlinico di Tor Vergata, Roma, Italy|Ospedale San Camillo, Roma, Italy|Policlinico A. Gemelli, Roma, Italy|Policlinico Umberto I Di Roma, Roma, Italy|Policlinico Univestitario Campus Biomedico, Roma, Italy|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|Klaipeda University Hospital, Klaipeda, Lithuania|Vilinius University Hospital Santariskiu Klinikos, Vilnius, Lithuania|Unidad de Hígado Hospital Universitario Dr. José Eleuterio González, Monterrey, Nuevo León, Mexico|JM Research, Cuernavaca, Mexico|Consultorio Médico, Metepec, Mexico|Torre de Consultorios Clinica Londres, Mexico City, Mexico|Consultorio Medico, Mexico City, Mexico|Instituto de Ciencias Medicas y de la Nutricion Salvador Zubiran, Mexico City, Mexico|Torre de Consultorios Clinica Londres, Mexico Distrito Federal, Mexico|Accelerium Clinical Research, Monterrey, Mexico|Consultorio Medico del Dr. Mauricio Castillo Barradas, México Distrito Federal, Mexico|""Angeles Valle oriente"" Hospital, San Pedro Garza Garcia, Mexico|Clinical Institute Colentina, Bucharest, Romania|The National Institute for Infectious Diseases ""Prof. Dr. Matei Bals"", Clinical Department for Adults II, Bucharest, Romania|Cluj County Emergency Hospital, Cluj Napoca, Romania|TVM Medical, Cluj Napoca, Romania|County Hospital Mures-Gastroenterology Department, Targu Mures, Romania",,https://ClinicalTrials.gov/show/NCT02279524
NCT02265276,"A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease",GLAZED,Unknown status,No Results Available,Fatty Liver,Drug: Saroglitazar|Drug: Pioglitazone,Change in the NAFLD fibrosis score|Change in body composition|Change in insulin resistance|Change in lipid profile|Change in HbA1c,"Command Hospital, India",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,ENDO/2014/4,Oct-14,Sep-15,Sep-15,15-Oct-14,null,16-Oct-14,"Command Hospital, Panchkula, Haryana, India",,https://ClinicalTrials.gov/show/NCT02265276
NCT02263677,Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI,,Withdrawn,No Results Available,Type 2 Diabetes|Non-alcoholic Fatty Liver Disease,Drug: Sitagliptin,Change in Liver steatosis,University of Missouri-Columbia,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MERCK-9938,Mar-14,Dec-15,Jan-16,13-Oct-14,null,5-Oct-16,"University of Missouri-Columbia: Diabetes Center, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02263677
NCT02258126,Effect of Exercise on Hepatic Fat in Overweight Children,EFIGRO,Completed,No Results Available,Non-alcoholic Fatty Liver Disease|Obesity|Metabolic Syndrome,Other: Multidisciplinary intervention program,changes in hepatic fat|Changes in Insulin sensitivity|Changes in serum lipid profile|Changes in liver enzymes|Changes in dietary habits|Changes in physical activity|Changes in body composition|Changes in other cardiometabolic risk factors,Basque Country University,All,8 Years to 12 Years   (Child),Not Applicable,115,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PI13/01335,Nov-14,Nov-17,Jan-18,7-Oct-14,null,1-Apr-19,"Pediatric Endocrinology Unit of the University Hospital of Araba (HUA), Vitoria-Gasteiz, Araba, Spain",,https://ClinicalTrials.gov/show/NCT02258126
NCT02244944,Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD,,Terminated,Has Results,Nonalcoholic Fatty Liver Disease (NAFLD),Drug: EZ-Urso combination therapy,Reduction in Serum Alanine Transaminase (ALT)|Increase in Plasma Lathosterol|Reduction in Hepatic Fat Fraction,"Gregory Graf, PhD|University of Kentucky",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,2,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,13-0972-F1V,Sep-14,Sep-15,Sep-15,19-Sep-14,7-Feb-18,7-Feb-18,"University of Kentucky Medical Center, Lexington, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT02244944
NCT02242149,Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects,DGCLFT2DM,Completed,No Results Available,"Diabetes Mellitus, Type 2|Non-alcoholic Fatty Liver Disease",Drug: Diacerein|Drug: Placebo,Evidence of improvement in glycemic control and improvement in liver steatosis|Improvement of microalbuminuria|Changes of adipocytokines and cytokeratin-18,Universidade Federal do Rio de Janeiro|Rio de Janeiro State Research Supporting Foundation (FAPERJ),All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 3,84,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",30194914.3.0000.5257,14-Oct-14,31-Jan-17,31-Jan-18,16-Sep-14,null,3-May-18,"Program of Arterial Hypertension, University Hospital Clementino Fraga Filho, Rio de Janeiro, Brazil",,https://ClinicalTrials.gov/show/NCT02242149
NCT02235233,Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin,,Completed,No Results Available,Non-alcoholic Steatohepatitis,Drug: Technetium Tc 99M Mebrofenin,Hepatic exposure (AUC0→∞)|Systemic exposure (AUC0 →∞)|Cmax (hepatic)|Tmax (hepatic)|Xurine|CLuptake|CLrenal,"University of North Carolina, Chapel Hill|National Institute of General Medical Sciences (NIGMS)",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,21,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,13-3362|2R01GM041935,Apr-15,Jul-16,Jul-16,9-Sep-14,null,5-May-17,"UNC Hospitals, Chapel Hill, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT02235233
NCT02231333,The Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis,,Unknown status,No Results Available,Non-alcoholic Steatohepatitis,Drug: S-adenosylmethionine (SAMe)|Drug: pentoxiphylline (PTX),Biochemical improvement in the form of AST/ALT|Improvement in LSM (Liver Stiffness Measurement) & CAP (Controlled Attenuation Parameter)|Metabolic response in form of anthropometry.|Fasting lipid profiles|Reduction in uric acid levels|Reduction in pro- inflammatory cytokines|Histological outcome in the form of improvement or non- progression in hepatocyte injury and fibrosis.,"Institute of Liver and Biliary Sciences, India",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ILBS-NASH-01,Jun-14,Jun-16,Jun-16,4-Sep-14,null,24-Mar-15,"Institute of Liver & Biliary Sciences, New Delhi, Delhi, India",,https://ClinicalTrials.gov/show/NCT02231333
NCT02216552,Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents,,Completed,No Results Available,NAFLD|TYPE 2 DIABETES|METABOLIC SYNDROME,Dietary Supplement: Resveratrol|Dietary Supplement: Placebo,Safety/ Adverse Event Outcome|Efficacy Outcome,"University of Manitoba|DSM Nutritional Products, Inc.",All,"13 Years to 18 Years   (Child, Adult)",Phase 2|Phase 3,10,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",2013-01-15-RESV,Aug-15,1-Jan-17,20-Mar-17,15-Aug-14,null,5-May-17,"Children's Hospital Research Institute of Manitoba/University of Manitoba, Winnipeg, Manitoba, Canada",,https://ClinicalTrials.gov/show/NCT02216552
NCT02217345,Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease,NAFLD,Recruiting,No Results Available,Nonalcoholic Fatty Liver Disease (NAFLD),Drug: Growth hormone|Drug: Placebo,Intrahepatic lipid content as measured by 1H-MRS|Inflammatory Markers,Massachusetts General Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2014P001680,Sep-15,Jan-21,Jan-21,15-Aug-14,null,29-Jan-19,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02217345
NCT02217475,Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis,CENTAUR,Completed,Has Results,Nonalcoholic Steatohepatitis,Drug: Cenicriviroc|Drug: Placebo,"Number of Participant With Hepatic Histological Improvement in NAS by ≥ 2 Points With at Least 1-Point Reduction in Either Lobular Inflammation or Hepatocellular Ballooning and no Concurrent Worsening of Fibrosis at Year 1|Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage and Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1|Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage and Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 2|Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage at Year 1|Number of Participants With Complete Resolution of Steatohepatitis With no Concurrent Worsening of Fibrosis Stage at Year 2|Number of Participants With Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 1|Number of Participants With Improvement in Fibrosis by at Least 1 Stage (NASH CRN System) and no Worsening of Steatohepatitis at Year 2|Number of Participants With Deaths, Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs Leading Study Drug to Discontinuation|Number of Participants With Clinically Significant Changes in Vital Signs|Number of Participants With Clinical Laboratory Abnormalities|Number of Participants With Clinically Abnormal in Electrocardiogram (ECG) Findings|Number of Participants With Hepatic Histological Improvement in NAS at Year 2|Change From Baseline in the 3 Categorical Features of NAS (Steatosis, Lobular Inflammation, Hepatocellular Ballooning) at Year 1|Change From Baseline in the 3 Categorical Features of NAS (Steatosis, Lobular Inflammation, Hepatocellular Ballooning) at Year 2|Number of Participants With Hepatic Histological Improvement With a Minimum 2-Point Improvement in NAS With at Least a 1-Point Improvement in More Than 1 Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 1|Number of Participants With Hepatic Histological Improvement With a Minimum 2-Point Improvement in NAS With at Least a 1-point Improvement in More Than 1 Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 2|Number of Participants With Resolution of NASH Using a Modified Definition Based on Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 1|Number of Participants With Resolution of NASH Using a Modified Definition Based on Categorical Features of NAS and no Concurrent Worsening of Fibrosis Stage at Year 2|Change From Baseline in Morphometric Quantitative Collagen on Liver Biopsy at Year 1|Change From Baseline in Morphometric Quantitative Collagen on Liver Biopsy at Year 2|Change From Baseline in Hepatic Tissue Fibrogenic Protein Alpha-Smooth Muscle Actin (α-SMA) at Year 1|Change From Baseline in Hepatic Tissue Fibrogenic Protein Alpha-Smooth Muscle Actin (α-SMA) at Year 2|Change From Baseline in Morphometric Quantitative Fat Content on Liver Biopsy at Year 1|Change From Baseline in Morphometric Quantitative Fat Content on Liver Biopsy at Year 2|Change From Baseline in Histologic Fibrosis Stage (NASH CRN System and Ishak Scale Score) at Year 1|Change From Baseline in Histologic Fibrosis Stage (NASH CRN System and Ishak Scale Score) at Year 2|Change From Baseline in Portal Inflammation Grade on Liver Biopsy at Year 1|Change From Baseline in Portal Inflammation Grade on Liver Biopsy at Year 2|Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Aspartate Aminotransferase to Platelet Count Ratio Index (APRI) at Months 3, 6 and 12|Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Aspartate Aminotransferase to Platelet Count Ratio Index (APRI) at Months 15, 18 and 24|Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Fibrosis-4 (FIB-4) at Months 3, 6 and 12|Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Fibrosis-4 (FIB-4) at Months 15, 18 and 24|Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Hyaluronic Acid at Months 6 and 12|Change From Baseline in Non-invasive Marker of Hepatic Fibrosis: Hyaluronic Acid at Months 18 and 24|Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score (NFS) at Months 3, 6 and 12|Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: NAFLD Fibrosis Score (NFS) at Months 15, 18 and 24|Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Enhanced Liver Fibrosis Test (ELF) Score at Months 6 and 12|Change From Baseline in Non-invasive Markers of Hepatic Fibrosis: Enhanced Liver Fibrosis Test (ELF) Score at Months 18 and 24|Change From Baseline in Biomarkers of Hepatocyte Apoptosis: Caspase Cleaved (CK-18 [M-30]) Levels and Total M-65 (CK-18 [M-65]) Levels at Months 3, 6 and 12|Change From Baseline in Biomarkers of Hepatocyte Apoptosis: Caspase Cleaved (CK-18 [M-30]) Levels and Total M-65 (CK-18 [M-65]) Levels at Months 15, 18 and 24|Change From Baseline in Weight at Months 3, 6 and 12|Change From Baseline in Weight at Months 15, 18 and 24|Change From Baseline in Body Mass Index (BMI) at Months 3, 6 and 12|Change From Baseline in Body Mass Index (BMI) at Months 15, 18 and 24|Change From Baseline in Waist Circumference at Months 3, 6 and 12|Change From Baseline in Waist Circumference at Months 15, 18 and 24|Change From Baseline in Hip Circumference at Months 3, 6 and 12|Change From Baseline in Hip Circumference at Months 15, 18 and 24|Change From Baseline in Forearm Circumference at Months 3, 6 and 12|Change From Baseline in Forearm Circumference at Months 15, 18 and 24|Change From Baseline in Tricep Skinfold Thickness at Months 3, 6 and 12|Change From Baseline in Tricep Skinfold Thickness at Months 15, 18 and 24","Tobira Therapeutics, Inc.",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,289,Industry,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",652-2-203|2016-004754-15,18-Sep-14,30-Jun-16,22-Jun-17,15-Aug-14,10-May-19,10-May-19,"Dothan, Alabama, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Rialto, California, United States|San Diego, California, United States|San Diego, California, United States|San Francisco, California, United States|Littleton, Colorado, United States|Miami, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Chevy Chase, Maryland, United States|Lutherville, Maryland, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Ann Arbor, Michigan, United States|Saint Paul, Minnesota, United States|Flowood, Mississippi, United States|Jackson, Mississippi, United States|Tupelo, Mississippi, United States|Buffalo, New York, United States|New York, New York, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Chattanooga, Tennessee, United States|Germantown, Tennessee, United States|Houston, Texas, United States|Houston, Texas, United States|Live Oak, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Garran, Australian Capital Territory, Australia|Herston, Queensland, Australia|Adelaide, South Australia, Australia|Bedford Park, South Australia, Australia|Clayton, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Brussels, Belgium|Brussels, Belgium|Edegem, Belgium|Leuven, Belgium|Angers, France|Lyon cedex 04, France|Montpellier Cedex 5, France|Paris, France|Paris, France|Pessac Cedex, France|Toulouse, France|Vandoeuvre-les Nancy, France|Villejuif, France|Heidelberg, BW, Germany|Marburg, HE, Germany|Hamburg, HH, Germany|Hannover, Niedersachsen, Germany|Aachen, NRW, Germany|Koeln, NRW, Germany|Leipzig, Sachsen, Germany|Leipzig, SN, Germany|Heidelberg, VIC, Germany|Berlin, Germany|Lubeck, Germany|Shatin, New Territories, Hong Kong|Bologna, BO, Italy|Milan, MI, Italy|Rozzano, MI, Italy|Palermo, PA, Italy|Chorzow, Poland|Lodz, Poland|Myslowice, Poland|Rzeszow, Poland|Wroclaw, Poland|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Portsmouth, Hampshire, United Kingdom|London, United Kingdom|London, United Kingdom|Newcastle, United Kingdom|Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT02217475
NCT02213224,Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease,NF-NAFLD,Unknown status,No Results Available,Nonalcoholic Fatty Liver Disease (NAFLD),Drug: Perindopril|Drug: Telmisartan|Drug: Amlodipine,Cap value of FibroScan （dB/m）|Angiotensin II|IL-18，IL-1β|aminotransferase|lipids|HOMA-IR|computed tomography value of liver,Nanfang Hospital of Southern Medical University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,180,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,NAFLD20140805,Aug-14,Sep-16,Sep-17,11-Aug-14,null,11-Aug-14,"Nanfang Hospital, Southern Medical University, GuangZhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02213224
NCT02210715,Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients,,Unknown status,No Results Available,HIV|Fatty Liver|Nonalcoholic Steatohepatitis,Drug: Isentress.|Other: Continue usual antiretroviral therapy,improvement of fatty liver or liver fibrosis|Difference in serum CK-18 levels|Difference in transaminases levels|Difference in metabolic markers,McGill University Health Center|Merck Sharp & Dohme Corp.,All,"18 Years and older   (Adult, Older Adult)",Phase 4,58,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening,switchMerck,Mar-15,Sep-17,Mar-18,7-Aug-14,null,25-Apr-17,"McGill University Health Center, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02210715
NCT02201160,Potential Role of n-3 Fatty Acids in the Treatment of NAFLD in Pediatric Patients,,Unknown status,No Results Available,Non Alcoholic Fatty Liver Disease (NAFLD),Dietary Supplement: omega 3,Efficacy of omega 3 PUFA supplementation in NAFLD subjects compared to placebos|A composite mesures regarding the improvement of metabolic profile of NAFLD patients,St. Justine's Hospital|Nutrisanté Canada,Male,"8 Years to 18 Years   (Child, Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,NAFLD-2188,Jan-09,Dec-13,Dec-15,25-Jul-14,null,25-Jul-14,"CHU Ste-Justine, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT02201160
NCT02196831,Tesamorelin Effects on Liver Fat and Histology in HIV,,"Active, not recruiting",No Results Available,Human Immunodeficiency Virus (HIV)|Nonalcoholic Fatty Liver Disease (NAFLD)|Nonalcoholic Steatohepatitis (NASH),Drug: tesamorelin|Drug: Placebo,Liver fat as measured by 1-H Magnetic resonance spectroscopy|Nonalcoholic fatty liver disease activity score|alanine aminotransferase (ALT)|aspartate aminotransferase (AST)|liver stiffness measured by FibroScan,Massachusetts General Hospital|National Institute of Allergy and Infectious Diseases (NIAID),All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,61,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",1U01AI115711|U01AI115711,1-Jul-15,16-Jan-19,Jul-19,22-Jul-14,null,11-Mar-19,"National Institutes of Health, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02196831
NCT02193867,Clinical Trial in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency,,"Active, not recruiting",No Results Available,Lysosomal Acid Lipase Deficiency,Drug: sebelipase alfa,Long-term safety|Survival at 12 months of age|Survival beyond 12 months of age|Growth|Hematological parameters|Characterize the PK of sebelipase alfa,Alexion Pharmaceuticals,All,up to 8 Months   (Child),Phase 2,10,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LAL-CL08,Jun-14,Apr-18,Apr-18,18-Jul-14,null,6-Sep-17,"Irvine, California, United States|Naples, Italy|Birmingham, United Kingdom|Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT02193867
NCT02194894,The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients,,Withdrawn,No Results Available,Non-alcoholic Fatty Liver Disease (NAFLD),Drug: Acetaminophen,This pilot study will seek to answer the question of whether or not NAFLD patients are more prone to APAP toxicity and whether or not lower doses should be recommended.|Exploring possible mechanism of acetaminophen liver injury in NAFLD patients,University of Southern California,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,HS-13-00771,Jun-14,19-Mar-15,19-Mar-15,18-Jul-14,null,30-Mar-17,"USC, Los Angeles, California, United States|USC HCC II (Fatty Liver Clinic), Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02194894
NCT02178839,The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease,,Unknown status,No Results Available,Non Alcoholic Fatty Liver Disease,Dietary Supplement: β- glucan|Dietary Supplement: Maltodextrin,Liver Echogenicity|Liver Enzymes|Anthropometric Measurement WHtR|Appetite|Insulin Resistance|Anthropometric Measurement WC|Anthropometric Measurement WHR|Anthropometric Measurement BMI|Peptide YY (PYY) Hormone|Cholecystokinin (CKK) Hormone|Fasting Blood Sugar,Urmia University of Medical Sciences,All,18 Years to 55 Years   (Adult),Not Applicable,48,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",umsu.rec.1393.48,Jul-14,Mar-15,null,1-Jul-14,null,1-Jul-14,"Shekh-al- rais Clinic, Tabriz, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT02178839
NCT02147925,Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects,LIGHT-ON,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Liraglutide combined with metformin|Drug: Insulin glargine combined with metformin|Drug: Sitagliptin combined with metformin,Intrahepatic lipids (IHL)|Change of abdominal subcutaneous adipose tissue(SAT)|Change of visceral adipose tissue(VAT)|Change in hemoglobin A1c(HbA1c),Sun Yat-sen University,All,"30 Years to 75 Years   (Adult, Older Adult)",Phase 4,75,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IIS201404,Aug-14,Apr-17,Apr-17,28-May-14,null,18-May-18,"The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02147925
NCT02134522,The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease,,Terminated,Has Results,Non Alcoholic Fatty Liver Disease,Device: Continuous positive airway pressure (CPAP).,Changes in Hepatic Fat Content|Changes in Two Hour Glucose,Yale University|American Heart Association,All,"9 Years to 21 Years   (Child, Adult)",Not Applicable,1,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1404013732,Jun-14,Apr-17,Apr-17,9-May-14,8-Jun-18,8-Jun-18,"Yale University, New Haven, Connecticut, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT02134522/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT02134522
NCT02132442,"Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes",VDLS,Completed,No Results Available,Type 2 Diabetes|Nonalcoholic Fatty Liver Disease|Vitamin D Deficiency,"Dietary Supplement: Ergocalciferol, placebo",Change in hepatic triglyceride content (HTGC)|Hemoglobin A1c,"University of Massachusetts, Worcester",All,"10 Years to 50 Years   (Child, Adult)",Phase 3,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC Docket # H00002866,Mar-14,Oct-16,Oct-16,7-May-14,null,10-Jan-17,"University of Massachusetts Medical School, Worcester, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02132442
NCT02126306,Beta Glucosylceramide for Treatment of NASH,,Completed,Has Results,Compliance Behavior,Drug: Beta Glucosylceramide|Drug: Placebo,Number of Participants With a Decrease of 2 Points in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS) Analysis is Per Protocol,Hadassah Medical Organization,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,23,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",YI1958,Jan-06,Dec-10,Dec-10,30-Apr-14,18-Aug-14,30-Oct-14,,,https://ClinicalTrials.gov/show/NCT02126306
NCT02117700,Fatty Liver Disease in Obese Children,,Unknown status,No Results Available,Obesity|Nonalcoholic Fatty Liver Disease|Cardiovascular Disease,Dietary Supplement: N-acetyl cysteine 600 mg once/day|Dietary Supplement: N-acetyl cysteine 600mg twice/day|Other: Placebo twice/day,Change in liver fat (MRI) and ALT levels from baseline and at 16 weeks,Nemours Children's Clinic,All,"7 Years to 18 Years   (Child, Adult)",Phase 2,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NemoursCC|American Diabetes Association,Apr-15,Dec-16,Dec-17,21-Apr-14,null,31-Mar-15,"Nemours Children's Clinic/Alfred I duPont Hospital, Jacksonville, Florida, United States",,https://ClinicalTrials.gov/show/NCT02117700
NCT02116192,Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents,NAFLD,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,"Behavioral: Experimental: Low-fructose, reduced carbohydrate diet|Behavioral: General Healthy Diet",Hepatic triglyceride content measured by Magnetic resonance (MR) PDFF|Metabolic biomarkers|PNPLA3 genotype|Novel free breathing hepatic MR PDFF protocol,"University of Wisconsin, Madison",All,11 Years to 17 Years   (Child),Not Applicable,28,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,K12HD055894,Apr-14,Jul-16,Oct-17,16-Apr-14,null,11-Oct-18,"Research Park Clinic, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02116192
NCT02098317,DHA and Vitamin D in Children With Biopsy-proven NAFLD,VitD_DHA,Completed,No Results Available,NAFLD|Non Alcoholic Steatohepatitis (NASH),Drug: DHA plus Vitamin D|Drug: Placebo,"Improvement in NAFLD Activity Score (NAS)|improvement of laboratory parameters of metabolic syndrome, such as lipids and gluco-insulinemic profile|safety",Bambino Gesù Hospital and Research Institute,All,4 Years to 16 Years   (Child),Phase 3,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VD3_DHA_NAFLD,Jan-14,May-15,Sep-15,28-Mar-14,null,14-Jan-16,"Bambino Gesù Children Hospital, Rome, Italy",,https://ClinicalTrials.gov/show/NCT02098317
NCT02086708,Ultrasound Method to Measure Fibrosis of the Liver in Children,,Terminated,Has Results,Chronic Liver Disease|Non-Alcoholic Fatty Liver Disease|HCV Coinfection|HBV|Drug-Induced Liver Injury,Device: Shear Wave sonoelastography,Measure Liver Elasticity Value Using Sonoelastography.,Massachusetts General Hospital,All,"1 Year to 21 Years   (Child, Adult)",Not Applicable,24,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2010P000705,Jun-10,Mar-15,Mar-15,13-Mar-14,1-Feb-17,1-Feb-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02086708
NCT02077374,A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases,NAFLD,Completed,Has Results,Nonalcoholic Steatohepatitis|Non-alcoholic Fatty Liver Disease,Drug: IDN-6556|Other: Placebo,Change in Alanine Aminotransferase (ALT)|Relative Percent Change in Alanine Aminotransferase (ALT)|Change in Aspartate Aminotransferase (AST)|Levels of cCK18/M30|Levels of Caspase 3/7 RLU|Levels of flCK18/M65,Conatus Pharmaceuticals Inc.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,38,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IDN-6556-06,Mar-14,Mar-15,Mar-15,4-Mar-14,21-Jul-16,30-Aug-16,"University of Miami, Miami, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Mary Immaculate Hospital, Newport News, Virginia, United States|Bon Secours St. Mary's Hospital, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02077374
NCT02075164,Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD,,Recruiting,No Results Available,Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis,Dietary Supplement: Fructose|Dietary Supplement: Glucose,Intrahepatic total fat and ipid composition assessed by Magnetic resonance spectroscopy,"Prof. Michael Trauner, MD|Wiener Wissenschafts-, Forschungs- und Technologiefonds|Medical University of Vienna",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,56,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",Fru2.0,May-13,Jun-19,Dec-19,3-Mar-14,null,17-Jul-18,"Medical University of Vienna, General Hospital of Vienna Vienna, Vienna, Austria 1090, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT02075164
NCT02068339,Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis,,Completed,No Results Available,Non-alcholic Fatty Liver Disease,Drug: Oltipraz 1 (90mg)|Drug: Placebo|Drug: Oltipraz 2 (120mg),"MRS(magnetic resonance spectroscopy)|change in liver fat concentration|change in BMI|change in NAFLD Fibrosis score (NFS)|change in ALT, AST, γ-GT|change in Cholesterol (total, LDL, HDL, VLDL), Triglyceride (TG)|change in HOMA-IR|change in waist circumference",PharmaKing,All,"19 Years to 75 Years   (Adult, Older Adult)",Phase 3,283,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",PMK-N01GI1_Phase 3,Feb-14,Feb-16,Mar-16,21-Feb-14,null,30-Mar-16,"NHUS Ilsan Hospital, Ilsan-ro Ilsan-donggu, Goyang-si, Korea, Republic of|Inje University Ilsan Paik Hospital, Dahwa-dong, Ilsanseo-gu, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Daehak-ro Jongno-gu, Seoul, Korea, Republic of|Korea University Guro hospital, Gurodong-ro, Seoul, Korea, Republic of|Boramae Hospital, Sindaebang-dong Dongjak-gu, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02068339
NCT02051842,Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis,,Recruiting,No Results Available,NAFLD|Pre-diabetes,Drug: Metadoxine,Oxidative stress,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GAS-1081-13/14-1,Jan-16,Jan-20,Dec-20,31-Jan-14,null,31-Jan-19,"Instituto Nacional de Ciencias Médicas y Nutrición ""Salvador Zubirán"", Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT02051842
NCT02038387,"Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)",,Unknown status,No Results Available,Chronic Hepatitis C Virus|Non Alcoholic Fatty Liver Disease,Behavioral: normocaloric low cholesterol diet,Evaluation of the immune Th17 mediated cell response modulation in subjects with chronic HCV infection vs NAFLD subjects administered with a 30-day low cholesterol diet,University of Roma La Sapienza,All,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,717/12,Jul-12,Dec-13,null,16-Jan-14,null,16-Jan-14,"Departemnt of Internal Medicine, La Sapienza University, Rome, Italy",,https://ClinicalTrials.gov/show/NCT02038387
NCT02030977,The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis,,Completed,No Results Available,Non Alcoholic Fatty Liver,Dietary Supplement: Resveratrol|Other: placebo,Alaninaminotransferase(ALT),Dr Azita Hekmatdoost|National Nutrition and Food Technology Institute,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2|Phase 3,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",46468,Jun-12,Feb-13,Mar-13,9-Jan-14,null,9-Jan-14,,,https://ClinicalTrials.gov/show/NCT02030977
NCT02029586,Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis,,Terminated,No Results Available,Nonalcoholic Fatty Liver Disease,Drug: MB12066 200mg|Drug: Placebo,Change in hepatic steatosis(%)|Proportion of subjects with more than 1 point in total NAFLD Activity Score (NAS)|Change in fibrosis score|Change in steatosis score|Change in lobular inflammation score|Change in ballooning score|Change in lipid profile,"Yungjin Pharm. Co., Ltd.",Male,"20 Years and older   (Adult, Older Adult)",Phase 2,18,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MB12066_201,Jan-13,Nov-14,Nov-14,8-Jan-14,null,21-Dec-17,"Seoul St. Mary's Hospital, Seoul, Banpo-daero Seocho-gu, Korea, Republic of|Uijeongbu St. Mary's Hospital, Uijeongbu, Cheonbo-ro Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Daehak-ro Jongno-gu, Korea, Republic of|Keimyung University Donsan Medical Center, Daegu, Dalseong-ro Jung-gu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Dongdeok-ro Jung-gu, Korea, Republic of|Chung-ang University Hospital, Seoul, Heukseok-dong Dongjak-gu, Korea, Republic of|ASAN Medical Center, Seoul, Olympic-ro 43-gil, Songpa-gu, Korea, Republic of|Boramae Hospital, Seoul, Sindaebang-dong Dongjak-gu, Korea, Republic of|Hanyang University Medical Center, Seoul, Wangsimni-ro Seongdong-gu, Korea, Republic of|Severance Hospital, Seoul, Yonsei-ro Seodaemun-gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02029586
NCT02018237,High Fructose Corn Syrup,Fructose,Completed,No Results Available,Nonalcoholic Fatty Liver Disease|Obesity,Behavioral: High fructose corn syrup diet|Behavioral: Standard diet (low in high fructose corn syrup),Change in intrahepatic triglyceride (IHTG) content|Hepatic lipid metabolism|Multi-organ insulin sensitivity|Uric acid metabolism,Washington University School of Medicine,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,47,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,2011-12111,Mar-12,Mar-16,Mar-16,23-Dec-13,null,27-Mar-17,"Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02018237
NCT02009592,Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients,,Completed,No Results Available,Fatty Liver|Steatohepatitis,Drug: Rifaximin,Drop in the levels of pro-inflammatory cytokines and increase in anti-inflammatory cytokines,Bezmialem Vakif University,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,42,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18245212-108-99/164,Jun-13,Jan-14,Feb-14,12-Dec-13,null,16-May-14,"Bezmialem Vakif University, Istanbul, Turkey",,https://ClinicalTrials.gov/show/NCT02009592
NCT02006329,Treatment of Non Alcoholic Fatty Liver Disease With Lifestyle Modification and Acupuncture,,Unknown status,No Results Available,NAFLD|Accupuncture,Device: acupuncture,Fibroscan test,Ziv Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0089-13-ziv,Jan-14,Nov-14,null,10-Dec-13,null,10-Dec-13,"Ziv Medical Center, Safed, Israel",,https://ClinicalTrials.gov/show/NCT02006329
NCT02006498,Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD),,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Sillymarin|Drug: Placebo,To assess the efficacy of Silymarin as defined by an improvement in non-alcoholic steatosis (NAS) activity score by at least 30% from baseline compared to placebo|To assess the safety and adverse event profile of Silymarin compared to placebo,University of Malaya|Rottapharm,All,"18 Years and older   (Adult, Older Adult)",Phase 2,99,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LE13T0.01,Jun-12,Dec-15,Dec-15,10-Dec-13,null,8-Jan-16,"University Malaya Medical Centre, Kuala Lumpur, Federal Territory, Malaysia",,https://ClinicalTrials.gov/show/NCT02006498
NCT01999101,Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients,,Completed,No Results Available,Non Alcoholic Fatty Liver Disease,Drug: Px-104,Safety|Change of hepatocellular lipid content|Changes in oral glucose tolerance test (oGTT)|Change from baseline in fibroblast growth factor 19 (FGF-19)|Change from baseline in plasma bile acid concentration|Pharmacokinetics of Px-104 and conjugates,Phenex Pharmaceuticals AG|Medical University of Vienna,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,12,Industry|Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PHS-Px-104-II-01,Oct-13,Jan-15,Jun-16,3-Dec-13,null,29-Sep-16,"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT01999101
NCT01997424,ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES MELLITUS,,Unknown status,No Results Available,Non-alcoholic Fatty Liver Disease (NAFLD),"Device: Controlled Attenuation Parameter (CAP), Echosens, Paris, France|Device: FibroScan, Echosens, Paris, France",Steatosis|Fibrosis|Steatosis (serum),Johann Wolfgang Goethe University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,340,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,JWGUHMED1-007,May-13,Sep-14,Dec-14,28-Nov-13,null,28-Nov-13,"University Hospital Frankfurt, Frankfurt am Main, Hessen, Germany",,https://ClinicalTrials.gov/show/NCT01997424
NCT01992809,Omega 3 Supplementation in Fatty Liver,OMEGA 3 NASH,Completed,No Results Available,Fatty Liver,Dietary Supplement: Omega 3,Efficacy in reduce inflammatory component of NASH for NAS score|Inflammatory systemic profile,University of Sao Paulo General Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",0681/09CAPPESQ,Sep-09,Jun-11,Jun-11,25-Nov-13,null,25-Nov-13,"University of Sao Paulo School of Medicine, Sao Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT01992809
NCT01987310,Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment,,Withdrawn,No Results Available,Non Alcoholic Fatty Liver Disease,Drug: atorvastatin|Behavioral: lifestyle counseling,Change from baseline in liver steatosis at 6 months|change from baseline in liver fibrosis at 6 months|endothelial function in Non-Alcoholic Fatty Liver Disease (NAFLD) patients|relationship between blood parameters and liver steatosis and fibrosis|relationship between blood parameters and endothelial function|change from baseline in endothelial function at 6 months,Sheba Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SHEBA-13-0694-ZBE-CTIL,Dec-15,Dec-15,Dec-15,19-Nov-13,null,27-Apr-17,"Sheba Medical Center, Ramat Gan, Israel",,https://ClinicalTrials.gov/show/NCT01987310
NCT01985009,"Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.",,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Device: FibroScan® examination.,"Performance of CAP will be assessed using ROC analysis for the detection of steatosis above 5% - 10% - 30% and 60% using liver biopsy as the reference.|Clinical, histological and biological factors associated CAP will be assessed using multivariate correlation.",Echosens,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,450,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,M118,Jan-14,17-Jan-17,17-Jan-17,15-Nov-13,null,27-Jul-17,"Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Royal Free Hospital, London, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Queen's Medical Centre Nottingham, Nottingham, United Kingdom|John Radcliffe Hopsital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom",,https://ClinicalTrials.gov/show/NCT01985009
NCT01975935,Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients,,Completed,Has Results,Diabetes Mellitus Type 2|Non-alcoholic Fatty Liver Disease|Obesity,Drug: Amlexanox|Drug: Placebo,Difference in Hemoglobin A1c Values|Hepatic Steatosis as Measured by MRI|Change in Weight,University of Michigan,All,"18 Years and older   (Adult, Older Adult)",Phase 2,42,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",HUM00079381,Jan-14,25-Apr-16,18-Aug-17,5-Nov-13,9-May-17,7-Nov-18,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01975935
NCT01963845,Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease,,Completed,Has Results,Non-alcoholic Fatty Liver Disease,Drug: Sitagliptin|Drug: Placebo,"Percentage Change in Liver Fat Relative to Baseline Assessed by MRI-PDFF|AST, Aspartate Aminotransferase|ALT, Alanine Aminotransferase|LDL, Low-density Lipoprotein|HOMA-IR, Homeostatic Model Assessment of Insulin Resistance","University of California, San Diego",All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",Sitagliptin-NAFLD,Jan-14,Jan-16,Jan-16,16-Oct-13,20-Oct-16,20-Oct-16,"University of California, San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01963845
NCT01956825,The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver,,Unknown status,No Results Available,Non Alcoholic Fatty Liver Disease,"Dietary Supplement: ""slim water""",effect of LCARNITINE and magnesium treatment on the liver fat content|effect of L-CARNITINE and magnesium treatment on the metabolic panel,Meir Medical Center,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MMC13023-13CTIL,Jan-14,Apr-14,Apr-14,8-Oct-13,null,8-Oct-13,"Meir Hospital, Kfar Saba, Israel",,https://ClinicalTrials.gov/show/NCT01956825
NCT01950884,Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis,,Unknown status,No Results Available,•Non-alcoholic Steatohepatitis (NASH),Drug: Ezetimibe|Behavioral: Lifestyle,HISTOLOGICAL IMPROVEMENT IN THE SEVERITY OF NASH|Changes in individual components of NAS score,University of Palermo,All,"18 Years and older   (Adult, Older Adult)",Phase 4,45,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LISTEN|2013-003465-33,Oct-13,Oct-14,Dec-14,26-Sep-13,null,26-Sep-13,"Dipartimento Biomedico di Medicina Interna e Specialistica Di.Bi.M.I.S., Palermo, Italy",,https://ClinicalTrials.gov/show/NCT01950884
NCT01940263,Purified Anthocyanin and Nonalcoholic Fatty Liver Disease,,Completed,No Results Available,Nonalcoholic Fatty Liver Disease,Dietary Supplement: Anthocyanin|Dietary Supplement: Placebo,Biomarkers related to oxidative stress|Biomarkers related to inflammation,Shaoguan University|Sun Yat-sen University,All,"18 Years to 65 Years   (Adult, Older Adult)",Early Phase 1,63,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",SGU-02|81372994,Jun-13,Jan-14,Jun-14,12-Sep-13,null,1-Aug-14,"Shaoguan University, Shaoguan, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01940263
NCT01934777,"Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis",,Completed,No Results Available,Fatty Liver|Liver Fibrosis|Obesity|Metabolic Syndrome|Nonalcoholic Fatty Liver Disease,Drug: Docosahexaenoic Acid plus Vitamin E plus choline|Drug: placebo pearls,"Improvement in NAFLD Activity Score (NAS)|Improvement of serum alanine transferase levels, lipid profile, glico-insulinemic profile (all parameters of metabolic syndrome) and bright liver at ultrasonography",Bambino Gesù Hospital and Research Institute,All,4 Years to 16 Years   (Child),Phase 3,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OPBG-DHA, VIT E, CHOLINE",Oct-13,Oct-14,Jul-15,4-Sep-13,null,14-Jan-16,"Bambino Gesù Hospital and Research Institute, Rome, Rome, Italy, Italy",,https://ClinicalTrials.gov/show/NCT01934777
NCT01930123,"Impact of Fructose on Metabolism, Energy Homeostasis and MR Biomarkers in NAFLD",,Recruiting,No Results Available,Nonalcoholic Fatty Liver Disease (NAFLD),Other: intravenous fructose challenge,Change in metabolism|Change in energy homeostatic|Change in MR Biomarkers,Duke University,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,Pro00031687,Oct-13,Aug-19,Aug-19,28-Aug-13,null,6-Nov-18,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01930123
NCT01919294,Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS),TEREPINS,Completed,No Results Available,Nonalcoholic Steatohepatitis|Hypogonadism,Drug: testosterone undecanoate,steatosis histology|Proportion of patients in whom liver inflammation improves|Proportion of patients in whom liver ballooning improves|Proportion of patients in whom liver fibrosis improves|Change in fat content of liver|Change in HOMA index|Change in serum liver enzymes|Adverse events,Sheffield Teaching Hospitals NHS Foundation Trust|Bayer,Male,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,3,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STH16037|2012-002564-27,Jul-13,30-Jan-17,30-Jan-17,9-Aug-13,null,26-Apr-17,"Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom",,https://ClinicalTrials.gov/show/NCT01919294
NCT01913470,Study of Losartan in the Treatment of NAFLD in Children,,Completed,Has Results,NAFLD,Drug: Losartan,Change in Alanine Aminotransferase (ALT) From Baseline to End of Treatment (8 Weeks of Treatment)|Change in Cholesterol Levels From Baseline to End of Treatment (8 Weeks of Treatment)|Change in Triglyceride Levels From Baseline to End of Treatment (8 Weeks of Treatment)|Change in Fatty Acid Levels From Baseline to End of Treatment (8 Weeks of Treatment)|Changes in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) Between Baseline and End of Treatment (8 Weeks of Treatment)|Changes in Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations Between Baseline and End of Treatment,"Miriam Vos, MD|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Children's Healthcare of Atlanta|Emory University",All,"11 Years to 19 Years   (Child, Adult)",Phase 2,12,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IRB00062895|1R03DK096157-01A1|1R03DK096157-01,Jul-13,Dec-15,Dec-15,1-Aug-13,15-May-17,15-May-17,"Emory University / Children's Healthcare of Atlanta, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01913470
NCT01899859,Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis,,Completed,No Results Available,Non-Alcoholic Steatohepatitis (NASH),Drug: GR-MD-02|Drug: Placebo,"Primary objective is to characterize safety for GR-MD-02 administered intravenously to subjects w/ biopsy-proven NASH w/ advanced liver fibrosis. Specifically assessed by number of subjects experiencing TEAEs.|A secondary objective is to characterize the first-dose PK profile of GR-MD-02. The PK profile is assessed by the AUC (area under the plasma concentration versus time curve) and Cmax (peak plasma concentration) of GR-MD-02.|A secondary objective for the study is to characterize the PK profile and serum level accumulation of GR-MD-02 following administration of 3 subsequent weekly doses given by IV infusion beginning 28 days after the first dose.|A secondary objective is to evaluate change in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), ratio of AST:ALT, alkaline phosphatase, and gamma glutamyl transpeptidase (GGTP); change in AST/platelet ratio index.|A secondary objective for this study is to evaluate changes in exploratory pharmacodynamic biomarkers in serum",Galectin Therapeutics Inc.,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 1,31,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GT-020,Jul-13,Feb-15,Feb-15,16-Jul-13,null,23-Feb-15,"Brooke Army Medical Ctr., San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01899859
NCT01894438,Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease (NAFLD)|Non-alcoholic Steatohepatitis (NASH),Behavioral: Mediterranean lifestyle|Behavioral: Mediterranean Diet,Serum levels of alanine aminotransferase (ALT)|Gamma-glutamyl transpeptidase (GGT)|Liver stiffness|Inflammatory and oxidative stress markers,Harokopio University|University of Athens,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,63,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,LD-0098,Apr-13,May-17,May-17,10-Jul-13,null,3-Aug-17,"Harokopio University, Kallithea, Attiki, Greece",,https://ClinicalTrials.gov/show/NCT01894438
NCT01875978,Effect of Phytosterols on Nonalcoholic Fatty Liver Disease,,Completed,Has Results,Non-alcoholic Fatty Liver Disease,Dietary Supplement: Phytosterols & placebo,Metabolic Effect of Phytosterols on Patients With Nonalcoholic Fatty Liver Disease|Anti-oxidative Capacity of Phytosterols on Patients With Fatty Liver Disease|Insulin-like Growth Factor-1 Effect of Phytosterols on Patients With Nonalcoholic Fatty Liver Disease|Endothelial Protective Effect of Phytosterols on Patients With Non-alcoholic Fatty Liver Disease,China Medical University Hospital,All,"25 Years to 80 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",DMR101-IRB2-036,Oct-12,Dec-12,Jul-13,12-Jun-13,11-Jun-14,11-Jun-14,"China Medical University Hospital, Taichung, Taiwan",,https://ClinicalTrials.gov/show/NCT01875978
NCT01876108,The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease,,Completed,No Results Available,Fatty Liver|Liver Dysfunction|Insulin Resistance,"Drug: H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)",Change from baseline liver fat content at 6 months|Change from baseline liver function tests at 6 months,Tehran University of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",1392/3/11- 589,Jul-12,Jul-13,Jul-13,12-Jun-13,null,8-Jul-13,"Gastroenterology clinic, Sina Hospital, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01876108
NCT01874249,Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease,,Completed,No Results Available,Non Alcoholic Fatty Liver Disease,Other: Electronic detailed information|Other: NAFLD Score|Other: Transient elastography,Advanced Fibrosis by any diagnostic modality|Specialized care,Fundación Clínica Médica Sur,All,"18 Years to 69 Years   (Adult, Older Adult)",Not Applicable,1200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,FAFLD,Jul-12,Aug-15,Aug-16,11-Jun-13,null,9-Aug-18,"Medica Sur Clinic & Foundation, Mexico City, DF, Mexico",,https://ClinicalTrials.gov/show/NCT01874249
NCT01854463,The Effect of Vitamin D Supplementation in Type 2 Diabetes,VD2000,Completed,No Results Available,DIABETES MELLITUS,Drug: Vitamin D3|Drug: placebo,glycemic control|arterial stiffenss,Chuncheon Sacred Heart Hospital|Korean Diabetes Association,All,"30 Years to 69 Years   (Adult, Older Adult)",Phase 4,158,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CSHH2011-64|KDA2010,Dec-11,Oct-12,Feb-13,15-May-13,null,15-May-13,"Chuncheon Sacred Heart Hospital, Chuncheon, Gangwon-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01854463
NCT01849081,Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver,,Unknown status,No Results Available,Non-alcoholic Fatty Liver Disease,Device: CPAP|Behavioral: LIfestyle,Steatosis by MRS,Massachusetts General Hospital|National Institutes of Health (NIH),All,"18 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,40,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2013P000688,Jul-16,Jul-17,Jul-18,8-May-13,null,1-Nov-16,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01849081
NCT01842282,Amlexanox for Type 2 Diabetes and Obesity,,"Active, not recruiting",No Results Available,Diabetes Mellitus Type 2|Non Alcoholic Fatty Liver Disease|Obesity,Drug: Amlexanox,HbA1c|hepatic steatosis by MRI|Weight,University of Michigan,All,18 Years to 59 Years   (Adult),Phase 2,15,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HUM00065177,19-Jul-13,Oct-19,Dec-19,29-Apr-13,null,22-Oct-18,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01842282
NCT01834300,The Effect of Exercise Intervention on Insulin Resistance in Non-alcoholic Fatty Liver Disease (NAFLD),,Unknown status,No Results Available,Non Alcoholic Fatty Liver Disease,Behavioral: Unsupervised exercise training|Behavioral: Supervised exercise training,Reduction in liver and muscle fat|Changes in liver function tests|Changes in lipid profiles|Changes in body weight and anthropometric measurements|Hepatic insulin sensitivity|VLDL-TG kinetics,University of Liverpool|Royal Liverpool University Hospital|University of Surrey|Imperial College London|Royal Surrey County Hospital,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,09/H1008/1,Feb-09,Apr-13,Jun-15,17-Apr-13,null,17-Sep-14,"Royal Surrey County Hospital, Guildford, Surrey, United Kingdom|University of Surrey, Guildford, Surrey, United Kingdom|John Moores University, Liverpool, United Kingdom|University of Liverpool, Liverpool, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Liverpool University, Liverpool, United Kingdom|Imperial College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01834300
NCT01811472,"Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients",,Completed,Has Results,Non-alcoholic Fatty Liver Disease (NAFLD),Drug: LCQ908|Drug: placebo,"Change From Baseline in Percentage of Fat in the Liver as Assessed Using MRI at Week 24|Change From Baseline in Percentage of Fat in the Liver as Assessed Using MRI at Week 12|Percentage of Responders at Week 12|Percentage of Responders at Week 24|Change From Baseline Values for Alanine Aminotransferase (ALT) , Aspartate Aminotransferase (AST) and Gamma-glutamyl Transpeptidase (GGT) to Week 6|Change From Baseline Values for Alanine Aminotransferase (ALT) , Aspartate Aminotransferase (AST) and Gamma-glutamyl Transpeptidase (GGT) to Week 12|Change From Baseline Values for Alanine Aminotransferase (ALT) , Aspartate Aminotransferase (AST) and Gamma-glutamyl Transpeptidase (GGT) to Week 24|Percentage of Patients With Normalized Liver Enzymes|Percent Change From Baseline in Fasting Triglycerides|Post-prandial Peak Triglycerides Over 0 - 8 Hours|Change From Baseline in Body Weight|Change From Baseline in Waist Circumference|Number of Patients With Adverse Events, Serious Adverse Events (SAEs) and Death as Assessment of Safety and Tolerability",Novartis Pharmaceuticals|Novartis,All,"18 Years to 74 Years   (Adult, Older Adult)",Phase 2,52,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CLCQ908A2216|2013-000049-38,Jun-13,Sep-14,Sep-14,14-Mar-13,4-Feb-16,4-Feb-16,"Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Tamarac, Florida, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Tupelo, Mississippi, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Plano, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01811472
NCT01807910,ER Stress in NAFLD,,Withdrawn,No Results Available,Obesity|NAFLD,Drug: methyl-D9-choline,Net hepatic phospholipid production|Kinetics of secretory lipoprotein phospholipids,Vanderbilt University,Female,30 Years to 60 Years   (Adult),Early Phase 1,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,ER stress,Oct-13,Oct-17,Apr-18,8-Mar-13,null,23-Oct-13,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT01807910
NCT01798719,Effect of Mediterranean Diet on Non-alcoholic Fatty Liver Disease,Nutriepa,Completed,No Results Available,NAFLD,Behavioral: Low Glycemic Index Mediterranean Diet|Behavioral: General Advice,Non-alcoholic Fatty Liver Disease Ultrasonography Score,Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,50,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPINUT3,Feb-11,Oct-11,Nov-11,26-Feb-13,null,27-Feb-13,"Laboratory of Epidemiology and Biostatistics, IRCCS Saverio de Bellis, Castellana Grotte, BA, Italy",,https://ClinicalTrials.gov/show/NCT01798719
NCT01791959,The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis,,Completed,No Results Available,Non Alcoholic Steatohepatitis,Dietary Supplement: synbiotic|Other: placebo,Alaninaminotransferase (ALT)|Liver fibrosis|Body Mass Index (BMI),National Nutrition and Food Technology Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,54,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",46466,Mar-12,Oct-12,Jan-13,15-Feb-13,null,15-Feb-13,,,https://ClinicalTrials.gov/show/NCT01791959
NCT01792115,Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E,,"Active, not recruiting",No Results Available,Fatty Liver,Drug: Vitamin E 200 IU/d|Drug: Vitamin E 400 IU/d|Drug: Vitamin E 800 IU/d|Behavioral: Diet and Exercise,"Biochemical: Percent of patients with normal transaminases at end of treatment.|Percent and relative change in transaminases and GGT. Percent change in liver fat content.|Changes in hepatic and adipose tissue gene expression, oxidative stress and NH/NKT cell phenotype in response to treatment.",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 2,38,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,130002|13-DK-0002,13-Feb-13,1-Aug-19,1-Aug-19,15-Feb-13,null,16-May-19,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01792115
NCT01790984,How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?,CHOT,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Other: High sugar low starch diet|Other: Low sugar high starch diet,Plasma concentration of triglyceride (mmol/l) in the post-absorptive state (after 12 hour fast)|Very low density lipoprotein (VLDL) kinetics: Fractional catabolic and production rates of large and small VLDL glycerol (2H-5 deuterated glycerol) and apoprotein B (1-C-13 leucine).|De novo lipogenesis (synthesis of liver fat)|C-13 palmitate kinetics|Percentage of intra-hepatocellular lipid (IHCL),Bruce A. Griffin|Imperial College London|University of Cambridge|University of Surrey,Male,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,27,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,RN0172 A/B|BB/G009899/1,Apr-09,Aug-11,Sep-12,13-Feb-13,null,13-Feb-13,"University of Surrey, Guildford, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT01790984
NCT01787591,Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome,,Completed,Has Results,Non-alcoholic Fatty Liver|Metabolic Syndrome,Other: Fat-Free Milk|Other: Low-Fat Milk|Other: Full-Fat Milk|Other: Soy Milk,Area Under the Curve 0-72 h (Deuterium Labeled Alpha-tocopherol)|Cmax|Tmax|Elimination Rate|Estimated Absorption (% Dose),Ohio State University,All,18 Years to 40 Years   (Adult),Not Applicable,21,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",2012H0344,Apr-13,Jan-15,Dec-15,8-Feb-13,22-Nov-16,22-Nov-16,"Ohio State University, Columbus, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01787591
NCT01766713,Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis,,Completed,Has Results,Non Alcoholic Steatohepatitis,Drug: Ezetimibe,Change in Liver Fat as Measured by MRI-PDFF,"University of California, San Diego",All,"18 Years and older   (Adult, Older Adult)",Phase 2,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",EZE,Jan-13,Aug-14,Sep-14,11-Jan-13,18-Dec-14,18-Dec-14,"University of California, San Diego, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01766713
NCT01761370,Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH),,Completed,No Results Available,Non Alcoholic Steatohepatitis,Procedure: AHA diet plus exercise with BIB placement|Procedure: AHA diet plus exercise with sham BIB placement,Change in liver histology,"National University Hospital, Singapore",All,"21 Years to 65 Years   (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,D/05/338,Nov-05,Sep-08,Sep-08,4-Jan-13,null,4-Jan-13,"National University Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT01761370
NCT01759628,Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: H.pylori eradication,Change from Baseline liver function tests at Twelve weeks|Change of insulin resistance and lipid profile during the study period,Tehran University of Medical Sciences|Kashan University of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",91138 - KAUMS,Apr-12,Jun-13,Jun-13,3-Jan-13,null,13-Jun-13,"Gastroenterology clinic, Sina Hospital (Tehran) / Beheshti Hospital (Kashan), Tehran / Kashan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01759628
NCT01754714,Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group,EXPO,Completed,Has Results,Non Alcoholic Fatty Liver Disease,Drug: SAMe 1000 mg|Drug: SAMe 1500 mg|Drug: SAMe 2000 mg,"Methionine Elimination Half-life Measured in Blood.|Fasting Methionine Concentration of Average Methionine Concentration Versus Time Curve.|13 Carbon (Natural, Stable Isotope of Carbon) Methionine Breath Test|Hepatic Panel (Liver Laboratory Parameters)|Metabolic Panel (Metabolic Laboratory Parameters)|The Metabolic Clearance Rate Measured in the Blood.|Methionine Volume of Distribution at Week 7 (L)|Immunological/Anti-oxidant Panel (Immunological and Anti-oxidant Laboratory Parameters)|Fibrosis and Apoptosis Markers (Fibrosis and Apoptosis Laboratory Markers)|Area Under Curve (AUC) of Average Methionine Concentration Versus Time Curve",Abbott|PPD,All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 3,108,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,M13-397|2012-000975-18,Dec-12,Sep-14,Sep-14,21-Dec-12,19-Feb-16,19-Feb-16,"Site Reference ID 93914, Amiens, France|Site Reference ID 93895, Angers, France|Site Reference ID 93894, Bobigny, France|Site Reference ID 93913, Montpellier, France|Site Reference ID 93916, Nice, France|Site Reference ID 93915, Paris, France|Site Reference ID 93893, Paris, France|Site Reference ID 93896, Pessac, France|Site Reference ID 93953, Bonn, Germany|Site Reference ID 93954, Frankfurt, Germany|Site Reference ID 93935, Freiburg, Germany|Site Reference ID 93955, Halle, Germany|Site Reference ID 93917, Hannover, Germany|Site Reference ID 93933, Homburg, Germany|Site Reference ID 94015, Leipzig, Germany|Site Reference ID 93918, Mainz, Germany|Site Reference ID 94014, Ulm, Germany|Site reference ID/Investigator # 109455, Bydgoszcz, Poland|Site Reference ID 93958, Chorzow, Poland|Site Reference ID 93973, Krakow, Poland|Site Reference ID 93956, Lodz, Poland|Site Reference ID 93957, Myslowice, Poland|Site Reference ID 93974, Warsaw, Poland|Site Reference ID 93975, Wroclaw, Poland|Site reference ID ORG-000905, Krasnoyarsk, Russian Federation|Site reference ID ORG-000906, Moscow, Russian Federation|Site reference ID ORG-000900, Nizhniy Novgorod, Russian Federation|Site reference ID ORG-000907, Novosibirsk, Russian Federation|Site reference ID ORG-000903, Omsk, Russian Federation|Site reference ID ORG-000920, Rostov-on-Don, Russian Federation|Site reference ID ORG-000904, Samara, Russian Federation|Site reference ID ORG-000901, Stavropol, Russian Federation",,https://ClinicalTrials.gov/show/NCT01754714
NCT01747772,Sonoelastography: Ultrasound Method to Measure Liver Fibrosis,,Completed,Has Results,Chronic Liver Disease|Non-Alcoholic Fatty Liver Disease|Hepatitis C Virus (HCV) Coinfection|Hepatitis B Virus (HBV)|Drug-Induced Liver Injury,Device: Shear Wave Sonoelastography,Liver Elasticity Value Measured Using Sonoelastography (SE),Massachusetts General Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,180,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic,2009P002791,Feb-10,14-Feb-14,14-Feb-14,12-Dec-12,14-Jun-17,14-Jun-17,"Massachusetts General Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT01747772
NCT01720719,Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease,,Unknown status,No Results Available,Fatty Liver|Dyslipidemias|Diabetes Mellitus,Drug: atorvastatin|Drug: Vitamin E,Liver fat content(%)|Abdominal visceral fat area(cm2)|Abdominal subcutaneous fat area(cm2)|Lipid profiles|Liver enzymes|Glucose metabolism|Body weight|Anthropometric test|Muscle enzymes,Xin Gao|Pfizer|Fudan University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,120,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WS2334187,May-13,Dec-16,Dec-16,2-Nov-12,null,3-Feb-16,"Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01720719
NCT01712711,Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease,,Completed,Has Results,Non-alcoholic Fatty Liver Disease,Drug: H.pylori eradication,Liver Fat Content Change From Baseline to Six Weeks Post H.Pylori Treatment,Tehran University of Medical Sciences,All,18 Years to 45 Years   (Adult),Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",1391/7/24-579,Sep-12,Feb-13,Mar-13,23-Oct-12,6-May-13,28-Jun-18,"Gastroenterology clinic, Sina Hospital, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01712711
NCT01707914,Clinical Investigation on the Effects of Bayberry Juice Treatment in Adult Subjects With Features of Fatty Liver Disease,,Completed,No Results Available,Nonalcoholic Fatty Liver Disease,Dietary Supplement: Chinese bayberry juice|Dietary Supplement: placebo,Plasma lipids profile,Shaoguan University,All,18 Years to 25 Years   (Adult),Not Applicable,44,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",SGU-01|81172655,Jun-12,Oct-12,Nov-12,16-Oct-12,null,4-Dec-12,"The affiliated hospital of Shaoguan University, Shaoguan, Guangdong, China",,https://ClinicalTrials.gov/show/NCT01707914
NCT01703260,Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis,,Terminated,Has Results,Nonalcoholic Steatohapatitis,Drug: Roflumilast|Drug: Pioglitazone|Drug: Placebo,Amount of Serum Alanine Transaminase (ALT) at Baseline|Percent Change From Baseline in Serum ALT at Month 4|Amount of Serum Aspartate Transaminase (AST) at Baseline|Percent Change From Baseline in Serum AST at Month 4|Liver Fat Content at Baseline|Change From Baseline in Liver Fat Content at Month 4,AstraZeneca,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,20,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ROF-NASH_205|U1111-1129-5051,Jun-13,Sep-14,Sep-14,10-Oct-12,23-Feb-16,1-Feb-17,"Coronado, California, United States|Coronado, California, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01703260
NCT01696487,Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis,Dietary Supplement: High oral Fructose challenge (150g per day for 28 days),Gaps per 1000 intestinal epithelial cells assessed by confocal laser endomicroscopy,"Medical University of Vienna|State Government of Vienna, Austria (Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien)",All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,Fru1.0,Feb-12,Feb-13,Feb-14,1-Oct-12,null,28-Sep-15,"Medical University of Vienna, General Hospital of Vienna, Vienna, Austria",,https://ClinicalTrials.gov/show/NCT01696487
NCT01694849,Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH),,Completed,No Results Available,Non-Alcoholic Steatohepatitis (NASH),Drug: GFT505 80mg|Drug: GFT505 120mg|Drug: Placebo,"Percentage of responders defined by the disappearance of steatohepatitis without worsening of fibrosis|Percentage of responders, defined by the disappearance of steatohepatitis|NAS score (Non-alcoholic fatty liver disease Activity Score)|Stages of steatosis, hepatic activity|Stages of fibrosis|Area of fibrosis|Liver enzymes|Non-invasive markers of fibrosis and steatosis|Lipid parameters|Body weight|Insulin resistance|Inflammatory markers|Safety markers|Cardiovascular risk profile",Genfit|Naturalpha|Premier Research Group plc,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,270,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GFT505-212-7|2012-000295-42,Sep-12,Feb-15,Dec-15,27-Sep-12,null,14-Jan-16,"Site 920, Fresno, California, United States|Site 903, La Jolla, California, United States|Site 911, Aurora, Colorado, United States|Site 912, Gainesville, Florida, United States|Site 924, Atlanta, Georgia, United States|Site 917, Atlanta, Georgia, United States|Site 909, New Orleans, Louisiana, United States|Site 921, Worcester, Massachusetts, United States|Site 902, Detroit, Michigan, United States|Site 927, New York, New York, United States|Site 908, Durham, North Carolina, United States|Site 919, Philadelphia, Pennsylvania, United States|Site 916, Memphis, Tennessee, United States|Site 913, Fort Sam Houston, Texas, United States|Site 923, Houston, Texas, United States|Site 906, San Antonio, Texas, United States|Site 931, Salt Lake City, Utah, United States|Site 930, Charlottesville, Virginia, United States|Site 901, Richmond, Virginia, United States|Site 205, Brussels, Belgium|Site 201, Edegem, Belgium|Site 204, Gent, Belgium|Site 202, Haine-Saint-Paul, Belgium|Site 203, Leuven, Belgium|Site 106, Amiens, France|Site 102, Angers, France|Site 114, Clichy, France|Site 103, Lille, France|Site 113, Lyon, France|Site 111, Marseille, France|Site 108, Montpellier, France|Site 104, Nantes, France|Site 109, Nice, France|Site 112, Paris, France|Site 101, Paris, France|Site 107, Pessac, France|Site 405, Bonn, Germany|Site 404, Mainz, Germany|Site 507, Milano, Italy|Site 503, Palermo, Italy|Site 504, Roma, Italy|Site 501, Torino, Italy|Site 303, Amsterdam, Netherlands|Site 302, Nijmegen, Netherlands|Site 603, Bucharest, Romania|Site 601, Bucharest, Romania|Site 602, Bucharest, Romania|Site 703, Barcelona, Spain|Site 707, Majadahonda, Spain|Site 705, Malaga, Spain|Site 706, Santander, Spain|Site 701, Sevilla, Spain|Site 802, Camberley, United Kingdom|Site 808, Hull, United Kingdom|Site 801, Newcastle Upon Tyne, United Kingdom|Site 803, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01694849
NCT01680640,Investigation of Synbiotic Treatment in NAFLD,INSYTE,Recruiting,No Results Available,Non-Alcoholic Fatty Liver Disease,Dietary Supplement: Synbiotic|Dietary Supplement: Maltodextrin,"Change in biomarkers for NAFLD and change in liver fat|Change in adipose tissue inflammation, satiety and risk factors for type 2 diabetes.|Change in adipose tissue inflammation, satiety and risk factors for type 2 diabetes","University Hospital Southampton NHS Foundation Trust|National Institute for Health Research, United Kingdom",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,100,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",RHM MED1071,Dec-13,Oct-19,Oct-19,7-Sep-12,null,16-Nov-18,"Southamption General Hospital, Southampton, Hants, United Kingdom",,https://ClinicalTrials.gov/show/NCT01680640
NCT01680003,Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease,Hepar-P,Unknown status,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Hepar-P|Drug: Placebo for Hepar-P,"Improvement in serum aspartate aminotransferase and alanine aminotransferase levels|Histologic findings including degree of steatosis, lobular inflammation, hepatocellular ballooning and fibrosis and overall disease activity score",Nova Laboratories Sdn Bhd,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,50,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CT11-03,Sep-12,Oct-13,Dec-13,6-Sep-12,null,12-Apr-13,"Sultamah Bahiyah Hospital, Alor Setar, Kedah, Malaysia|Kuala Lumpur Hospital, Wilayah Persekutuan, Kuala Lumpur, Malaysia|Tengku Ampuan Afzan Hospital, Kuantan, Pahang, Malaysia|Queen Elizaberth Hospital, Kota Kinabalu, Sabah, Malaysia|Ampang Hospital, Selangor, Malaysia",,https://ClinicalTrials.gov/show/NCT01680003
NCT01679197,Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy,,Completed,Has Results,"Fatty Liver Disease, Nonalcoholic|Nonalcoholic Steatohepatitis|Lipodystrophy",Drug: Metreleptin,Liver Histopathology|Liver Fat by MRI and MR Spectroscopy|Liver Function Tests|Fasting Lipids|Fasting Glucose|Body Weight,University of Michigan|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"5 Years and older   (Child, Adult, Older Adult)",Phase 2,23,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCRU 2834|R01DK088114-02,8-Oct-12,13-Jul-16,13-Jul-16,5-Sep-12,14-Jun-17,14-Jun-17,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT01679197
NCT01677325,The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine,,Completed,No Results Available,NAFLD( Non-alcoholic Fatty Liver Disease ),Drug: Chinese herb (YiQiSanJu),The CT ratio of liver/spleen|BMI(Body Mass Index )|liver function|lipid profile|NEFA(nonesterified fatty acid)|HOMA index|adiponectin|IL-6(interleukin 6)|hs-CRP (C-reactive protein)|TNFα( tumor necrosis factor-α)|leptin,Fudan University,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,2006-65,Jan-07,Jan-07,Jan-08,3-Sep-12,null,5-Sep-12,,,https://ClinicalTrials.gov/show/NCT01677325
NCT01672866,"Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)",,Terminated,Has Results,Liver Fibrosis Due to NASH,Biological: Placebo|Biological: SIM,Change From Baseline in MQC on Liver Biopsy|Event Free Survival (EFS) Using Kaplan-Meier,Gilead Sciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,222,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GS-US-321-0105|2012-002488-88,5-Dec-12,2-Aug-16,29-Dec-16,27-Aug-12,27-Mar-19,27-Mar-19,"Mayo Clinic Hospital, Phoenix, Arizona, United States|Southern California Liver Centers, Coronado, California, United States|University of California, San Diego (UCSD), San Diego, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Miami Veterans Administration Healthcare System, Miami, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|University of Louisville, Louisville, Kentucky, United States|Tulane University, New Orleans, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Minnnesota Gastroenterology, PA, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|State University Of New York, Buffalo, New York, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|Duke University, Durham, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Clinical Research Institute, LLC, Arlington, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|St. Luke's Episcopal Hospital, Houston, Texas, United States|Alamo Clinical Research Associates, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Liver Institute of Virginia, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bucheon St. Marys Hospital, Richmond, Virginia, United States|Virginia Commonwealth University Health System, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|Hôpital Erasme, Brussels, Belgium|Université Catholique de Louvain, Bruxelles, Belgium|UZ Ghent, Gent, Belgium|University of Calgary, Calgary, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|London Health Science Center, London, Ontario, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Hopital Beaujon, Clichy, France|Hospital Saint-Antoine, Paris, France|Groupe Hospitalier Pitié- Salpétrière, Paris, France|CHU Strasbourg Hôpital Civil, Strasbourg, France|Medizinische Hochschule Hannover, Hannover, Germany|Gastroenterologisch-Hepatologisches Zentrum Kiel, Kiel, Germany|EUGASTRO GmbH, Leipzig, Germany|Azienda Ospedaliero-Universitaria di Modena Policlinico, Modena, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Fundacion De Investigacion, San Juan, Puerto Rico|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Donostia, San Sebastian, Spain|John Radcliffe Hospital, Headington, United Kingdom|The Royal London Hospital, London, United Kingdom|Royal Free Hospital, Pond Street, London, United Kingdom|King's College Hospital NHS Foundation Trust No. 1 Account, London, United Kingdom|Nottingham University Hospitals Queens Medica, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01672866
NCT01672879,"Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH",NASH,Terminated,Has Results,Liver Fibrosis Due to NASH,Biological: Placebo|Biological: SIM,Change From Baseline in Hepatic Venous Pressure Gradient (HVPG)|Event-Free Survival (EFS) Using Kaplan-Meier,Gilead Sciences,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,259,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GS-US-321-0106|2012-002489-11,29-Oct-12,26-Sep-16,3-Jan-17,27-Aug-12,27-Mar-19,27-Mar-19,"Mayo Clinic Hospital, Phoenix, Arizona, United States|Southern California Liver Centers, Coronado, California, United States|University of California, San Diego (UCSD), San Diego, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|University of Miami, Miami, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Indiana University School of Medicine, Division of Gastroenterology/Hepatology, Indianapolis, Indiana, United States|Iowa Digestive Disease Center, Clive, Iowa, United States|University of Louisville, Louisville, Kentucky, United States|Tulane University, New Orleans, Louisiana, United States|Mercy Medical Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Lahey Clinic, Burlington, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Michigan, United States|Minnnesota Gastroenterology, PA, Saint Paul, Minnesota, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|State University Of New York at Buffalo, Buffalo, New York, United States|North Shore University Health System, Manhasset, New York, United States|New York University, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University Gastroenterology, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Methodist University Hospital, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Clinical Research Institute, Arlington, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|St. Luke Episcopal Hospital, Houston, Texas, United States|Alamo Clinical Research Associates, San Antonio, Texas, United States|Intermountain Transplant Center, Murray, Utah, United States|University of Virginia Health Center, Charlottesville, Virginia, United States|Liver Institute of Virginia, Newport News, Virginia, United States|Digestive and Liver Disease Specialists, Norfolk, Virginia, United States|Bucheon St. Marys Hospital, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|University of Manitoba, Winnipeg, Manitoba, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|Toronto Liver Centre, Toronto, Ontario, Canada|Hôpital de la Croix Rousse, Lyon, France|Hospital Saint-Antoine, Paris, France|CHU Pitié-Salpêtrière, Paris, France|Fonds de Recherche Honoraires, Strasbourg, France|Gastroenterologisch-Hepatologisches Zentrum Kiel, Kiel, Germany|Eugastro Gmbh, Leipzig, Germany|Istituto Clinico Humanitas, Rozzano, Milano, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Fundacion De Investigacion, San Juan, Puerto Rico|Hospital Vall D´Hebron, Barcelona, Cataluna, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Royal Free Hospital, Pond Street, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|Nottingham University Hospitals Queen's Medical Centre, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01672879
NCT01654549,Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis,,Completed,Has Results,Non-alcoholic Fatty Liver Disease,Drug: H.pylori eradication,Liver Fat Content|Serum Alanine Aminotransferase Level|Serum Aspartate Aminotransferase Level|Fasting Serum Glucose|Serum Lipid Profile|Homeostasis Model Assessment-Insulin Resistance (HOMA-IR)|Anthropometric Measurements,Tehran University of Medical Sciences,All,18 Years to 45 Years   (Adult),Phase 2,40,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment",1391/3/27-573,Apr-12,Sep-12,Sep-12,31-Jul-12,21-Dec-12,28-Jun-18,"Gastroenterology clinic, Sina hospital., Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01654549
NCT01650181,Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis,,Completed,No Results Available,Liver Disease,Drug: Metformin|Dietary Supplement: Siliphos+ Selenium - Methionine + Alpha Lipoic Acid,Impact on biochemical and echosonographic parameters|Identify changes in anthropometric parameters,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 4,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",GAS-399-11/11/1,Nov-11,Mar-14,Jun-14,26-Jul-12,null,20-Aug-14,"Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT01650181
NCT01645852,A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection,,Completed,No Results Available,Nonalcoholic Fatty Liver Disease|Hepatic Steatosis|Steatohepatitis,Dietary Supplement: Optifast 800,"The effect of a low calorie diet on intra-operative blood loss, technical ease of hepatic transection, complication rates (including infectious complications), length of stay and mortality in patients undergoing liver surgery.|The effect of a low calorie diet on steatosis and steatohepatitis.|The mechanism of decreased steatosis in patients undergoing a low-calorie pre-op diet by measuring levels of expression of molecules involved in the de novo synthesis, hepatic uptake and degradation of lipids.",Dartmouth-Hitchcock Medical Center,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,65,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care,DMS 12052,Jun-12,Dec-16,Dec-16,20-Jul-12,null,8-Feb-17,"UMass Memorial Medical Center, Worcester, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Fletcher Allen Health Care, Burlington, Vermont, United States",,https://ClinicalTrials.gov/show/NCT01645852
NCT01638832,Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease,,Unknown status,No Results Available,Nonalcoholic Steatohepatitis (NASH),"Device: Transient Elastography (FibroScan), Echosens, Paris, France|Device: Controlled Attenuation Parameter (CAP), Echosens, Paris, France",Liver fibrosis scores I-IV (METAVIR)|Steatosis fibrosis scores I-III,Johann Wolfgang Goethe University Hospital,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,572,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,JWGUHMED1-005,Jun-12,Sep-13,Dec-13,12-Jul-12,null,12-Jul-12,"Klinikum der J. W. Goethe-Universität, Frankfurt am Main, Germany",,https://ClinicalTrials.gov/show/NCT01638832
NCT01634048,The Effect of Protein-enriched Diet on Body Composition and Appetite,ProteinRich,Completed,No Results Available,Overweight|Obese|Metabolic Syndrome|Non Alcoholic Fatty Liver Disease,"Dietary Supplement: High Protein, low calorie meal replacement","Change in lipid content of the liver (intrahepatocellular lipid)|Change in appetite regulation, measured by VAS, gut hormones and food intake.",Imperial College London,All,"25 Years to 70 Years   (Adult, Older Adult)",Not Applicable,35,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",12/LO/0592,Jul-12,May-15,May-15,6-Jul-12,null,21-Nov-16,"Imperial College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01634048
NCT01623024,Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis,,Unknown status,No Results Available,Non.Alcoholic Fatty Liver Disease,Drug: Vitamin D|Behavioral: Lifestyle counseling,"(a) improvement in NAS by at least 2 points spread across at least 2 of the NAS components or post-treatment NAS of 3 points or less, (b) at least 1 point improvement in the score for ballooning degeneration and (c) no worsening of the fibrosis score.|Changes in individual components of NAS score|Changes in intima-media thickness|Changes in liver fibrosis|Changes in insulin resistance",University of Palermo,All,"18 Years and older   (Adult, Older Adult)",Phase 3,200,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NAFLD-VITAMIN D 01,Sep-12,Sep-14,null,19-Jun-12,null,21-Jun-12,"Sezione di Gastroenterologia, Di.Bi.M.I.S. AOUP Paolo Giaccone, University of Palermo, Italy, Palermo, Italy",,https://ClinicalTrials.gov/show/NCT01623024
NCT01617772,"Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis",NALCAT,Recruiting,No Results Available,Non-alcoholic Steatohepatitis,Drug: Atorvastatin|Drug: L-Carnitine|Drug: Placebo,improvement in liver stiffness|improvement in liver enzyme levels|Adverse drug events,Tehran University of Medical Sciences,All,40 Years to 60 Years   (Adult),Phase 2,440,Other,Interventional,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",90-03-37-15428,1-Jan-16,Oct-19,Dec-19,12-Jun-12,null,11-May-18,"Pars Cohort Center, Shiraz, Fars, Iran, Islamic Republic of|Masoud Clinic, Tehran, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01617772
NCT01579162,Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation,Repro,"Active, not recruiting",No Results Available,"Hepatitis C, Chronic|Non-Alcoholic Fatty Liver Disease","Device: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)",Cholate Shunt Test|Intra-individual Reproducibility of the Cholate Tests|Correlation of Cholate Tests with Histological Fibrosis Stage,"HepQuant, LLC",All,"22 Years to 65 Years   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,HepQuant-001,Jan-12,Dec-18,Jun-19,17-Apr-12,null,7-Aug-18,"University of Colorado Hospital, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01579162
NCT01571063,Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D,,Completed,No Results Available,Non-alcoholic Steatohepatitis (NASH),Drug: Vitamin D3|Drug: Placebo,Change from Baseline in serum alanine aminotransferase levels at week 48,University of Zurich,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,22,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SASL 34,Jan-13,May-16,May-16,4-Apr-12,null,25-Oct-16,"University Hospital Zurich, Gastroenterology and Hepatology, Zurich, ZH, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland",,https://ClinicalTrials.gov/show/NCT01571063
NCT01556113,Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease,,Completed,No Results Available,"Non Alcoholic Fatty Liver Disease|Steatohepatitis|Hypertriglyceridemia|Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1",Other: Omega diet,reduction in hepatic fat fraction|reduction in triglycerides|lower ALT levels,Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),All,"10 Years to 19 Years   (Child, Adult)",Not Applicable,17,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1112009408|R01HD040787,Mar-12,Feb-17,Feb-17,16-Mar-12,null,28-Apr-17,"Yale School of Medicine, New Haven, Connecticut, United States",,https://ClinicalTrials.gov/show/NCT01556113
NCT01553500,Glucomannan Effects on Children With Non-alcoholic Fatty Liver Disease,GC-NASH,Completed,No Results Available,Metabolic Syndrome|Non Alcoholic Fatty Liver Disease|Insulin Resistance,Dietary Supplement: glucomannan|Behavioral: lifestyle intervention,Change from Baseline in lipid profile|Change from baseline in glycemic homeostasis|liver enzymes,Bambino Gesù Hospital and Research Institute,All,4 Years to 16 Years   (Child),Phase 2,66,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",OPBG_GLUCO_2010,Jun-11,Jun-13,Dec-13,14-Mar-12,null,2-Apr-14,"Bambino Gesù Children's Hospital and Research Institute, Rome, Italy",,https://ClinicalTrials.gov/show/NCT01553500
NCT01547910,Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Dietary Supplement: Fish Oil,Serum alanine transaminase level decrease min. 0.3 upper limit of normal|normalization of liver imaging on ultrasound|ALT and AST activity|Insulin resistance markers as Homa-IR|Fat and lean body mass measurements|Caloric intake including fat intake and sucrose intake,"Piotr Socha|Medical University of Bialystok|Medical University of Silesia|Pediatric Municipal Hospital of Rzeszow, Poland|Children's Memorial Health Institute, Poland",All,"6 Years to 19 Years   (Child, Adult)",Phase 2,76,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ChildrensMHIPoland,Aug-07,Mar-12,Apr-12,8-Mar-12,null,21-Aug-14,,,https://ClinicalTrials.gov/show/NCT01547910
NCT01548079,Ursodeoxycholic Acid in Bariatric Surgery,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease|Morbid Obesity,Drug: Ursodeoxycholic Acid (UDCA),Changes in regulators of lipid turnover|Changes in serum bile acids and lipids,"Sahlgrenska University Hospital, Sweden",All,25 Years to 60 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,UDCAINBS,Oct-08,Nov-09,May-10,8-Mar-12,null,3-Dec-13,,,https://ClinicalTrials.gov/show/NCT01548079
NCT01544751,Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin,,Unknown status,No Results Available,Nonalcoholic Fatty Liver Disease (NAFLD),Drug: Low dose metformin|Drug: Metformin|Drug: Atorvastatin,Number of Participants with improvement of liver hyperechogenicity|Number of Participants with amelioration of metabolic syndrome and HOMA-Index,Prof Antonino Belfiore|University Magna Graecia,All,18 Years to 55 Years   (Adult),Not Applicable,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010.42,Sep-11,Jun-15,Jun-15,6-Mar-12,null,28-May-14,"Endocrinology Unit, Catanzaro, Italy",,https://ClinicalTrials.gov/show/NCT01544751
NCT01529268,Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children,CyNCh,Completed,Has Results,Nonalcoholic Fatty Liver Disease (NAFLD),Drug: DR cysteamine bitartrate capsule|Other: DR cysteamine bitartrate placebo,Improvement in Nonalcoholic Fatty Liver Disease (NAFLD)|Change in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)|Steatosis: Patients With Improvement|Steatosis: Change in Score|Lobular Inflammation: Patients With Improvement|Lobular Inflammation: Change in Score|Hepatocellular Ballooning: Patients With Improvement|Hepatocellular Ballooning: Change in Score|Portal Inflammation: Patients With Improvement|Portal Inflammation: Change in Score|Fibrosis: Patients With Improvement|Fibrosis: Change in Stage|Resolution of NASH|Change in Serum Aminotransferase and Gamma-glutamyl Transpeptidase|Change in Weight (kg)|Change in Body-mass Index|Change in Body-mass Index Z-score|Change in Waist Circumference|Change in Fasting Serum Glucose|Change in Fasting Insulin|Change in HOMA-IR|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Change in Pediatric Quality of Life Inventory (PedsQL) Score|Reduction in MRI-determined Hepatic Fat Fraction,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Advancing Translational Science (NCATS)|National Cancer Institute (NCI)|Raptor Pharmaceuticals,All,8 Years to 17 Years   (Child),Phase 2|Phase 3,169,NIH|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NASH-CyNCh|U01DK061718|U01DK061728|U01DK061731|U01DK061732|U01DK061734|U01DK061737|U01DK061738|U01DK061730|U01DK061713,Jun-12,Mar-15,Sep-15,8-Feb-12,5-Sep-17,5-Sep-17,"University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago (NWU), Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|St. Louis University, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Texas Children's Hospital, Houston, Texas, United States|University of Washington, Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01529268
NCT01511523,Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD),,Unknown status,No Results Available,Non Alcoholic Fatty Liver Disease,Dietary Supplement: RGMA001|Dietary Supplement: Sugar Pill,Efficacy|Safety,"Biovil Research Group, LLC",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,40,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",BVL-001,Jan-12,Oct-12,Oct-12,18-Jan-12,null,16-Mar-12,"Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01511523
NCT01482065,"The Sleep, Liver Evaluation and Effective Pressure Study",SLEEP,Completed,Has Results,Non Alcoholic Fatty Liver Disease|Obstructive Sleep Apnea,Device: CPAP (ResMed S9 autoset CPAP),Cross Sectional Analysis of NAFLD Versus Sleep Apnea Severity Indices (AHI)|Liver Values|Analysis of Variance (ANOVA) in CPAP Versus No-CPAP Therapy on NAFLD|MRI Indices,Johns Hopkins University|ResMed Foundation,All,"21 Years and older   (Adult, Older Adult)",Phase 2,40,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NA_00048965|111481,Nov-11,Jul-15,Oct-15,30-Nov-11,4-Jan-17,4-Jan-17,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01482065
NCT01473875,Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102,,Terminated,No Results Available,Lysosomal Acid Lipase Deficiency|Wolman Disease,Drug: SBC-102,Overall survival|Survival rates at periodic intervals and median survival time.|Long-term safety of SBC-102 in children with growth failure due to LAL Deficiency,Alexion Pharmaceuticals,All,"Child, Adult, Older Adult",Phase 2|Phase 3,10,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LAL-CL05,Nov-11,Dec-14,Jan-15,17-Nov-11,null,20-Feb-17,"Hopital Necker Enfants Malades, Paris, France|St. Mary's Hospital, Central Manchester University Hospitals, Manchester, United Kingdom",,https://ClinicalTrials.gov/show/NCT01473875
NCT01466894,Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis,,Withdrawn,No Results Available,Nonalcoholic Steatohepatitis,Biological: IMM 124-E|Biological: Placebo,Safety outcome|MRI liver fat quantitation|ALT levels|Liver enzyme improvement|Lipid profile|HbA1c,Immuron Ltd.,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,0,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NASH-Immuron-002,Dec-12,Dec-13,Dec-13,8-Nov-11,null,6-Dec-12,,,https://ClinicalTrials.gov/show/NCT01466894
NCT01464801,Resveratrol in Patients With Non-alcoholic Fatty Liver Disease,LIRMOI3,Completed,No Results Available,Fatty Liver,Dietary Supplement: Resveratrol|Dietary Supplement: Placebo,Change in hepatic steatosis and inflammation|Assessment of tolerability and side-effects,"University of Aarhus|The Ministry of Science, Technology and Innovation, Denmark|Aarhus University Hospital",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,28,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",LIRMOI 3,Sep-11,Feb-15,Jun-15,4-Nov-11,null,15-Jun-15,"Aarhus University Hospital, Dept. of Hepatology and Gastroentology, Aarhus, Denmark",,https://ClinicalTrials.gov/show/NCT01464801
NCT01446276,Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease,,Completed,No Results Available,Obesity|Nonalcoholic Fatty Liver Disease,Dietary Supplement: Resveratrol|Other: Placebo,"Hepatic VLDL-TG secretion and peripheral VLDL-TG clearance|Basal and insulin stimulated free fatty acid (FFA) and glucose turnover|VLDL-TG oxidation|Body composition (fat mass, fat-free mass, percent fat, visceral fat mass)|lipoprotein lipase activity and fat cell size in abdominal and femoral adipose tissue biopsy|Baseline data","University of Aarhus|The Ministry of Science, Technology and Innovation, Denmark",Male,"25 Years to 65 Years   (Adult, Older Adult)",Not Applicable,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",M-20110172A,Nov-11,Apr-14,Apr-14,5-Oct-11,null,28-Apr-14,"Department of Endocrinology and Internal Medicine, Aarhus C, Denmark",,https://ClinicalTrials.gov/show/NCT01446276
NCT01431521,Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008),,Completed,Has Results,Non-alcoholic Fatty Liver Disease,Drug: MK-4074 200 mg|Drug: Placebo for MK-4074|Drug: Pioglitazone hydrochloride 30 mg|Drug: Placebo for pioglitazone hydrochloride,Percent Change From Baseline in Hepatic Fat|Number of Participants Experiencing One or More Adverse Events (AE)|Number of Participants Who Discontinued Study Drug Due to an AE|Percent Change From Baseline in Alanine Transaminase (ALT)|Percent Change From Baseline Aspartate Transaminase (AST),Merck Sharp & Dohme Corp.,All,18 Years to 60 Years   (Adult),Phase 1,31,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",4074-008,26-Oct-11,18-Sep-12,1-Oct-12,9-Sep-11,25-Mar-16,10-Sep-18,,,https://ClinicalTrials.gov/show/NCT01431521
NCT01418027,Combined Intensive and Conventional Exercise on Nonalcoholic Fatty Liver Disease (NAFLD),,Completed,No Results Available,Non-alcoholic Fatty Liver Disease (NAFLD),Other: Intensive exercise|Other: Conventional exercise,"Change of intrahepatic triglyceride contents|Change of body weight|Change of waist circumference|Change of body fat|Change of abdominal fat|Change of carotid intima-media thickness|Change of cardiovascular risk factors (Blood pressure, lipids, glucose)|Change of insulin resistance",Shanghai Jiao Tong University School of Medicine,All,"40 Years to 65 Years   (Adult, Older Adult)",Phase 3,220,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CCEMD011,Aug-11,Dec-13,Dec-13,16-Aug-11,null,1-Sep-14,"The First Hospital Affiliated to Xiamen University, Xiamen, China",,https://ClinicalTrials.gov/show/NCT01418027
NCT01406704,Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH,,Terminated,No Results Available,NASH (Non-alcoholic Steato-hepatitis),Drug: Rosiglitazone|Drug: alpha-lipoic acid|Drug: Rosiglitazone/alpha-lipoic acid,Histological evaluation|Biomechanical measurement,Seoul St. Mary's Hospital|GlaxoSmithKline,All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 4,26,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,KCMC-04-14,Jan-04,Dec-10,Dec-13,1-Aug-11,null,19-Aug-11,,,https://ClinicalTrials.gov/show/NCT01406704
NCT01399645,Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes,LIRAINS,Completed,No Results Available,Nonalcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Type 2 Diabetes,Drug: Liraglutide-metformin vs insulin-metformin,To determine liver fat fraction evolution induced by liraglutide and insulin,Centre hospitalier de l'Université de Montréal (CHUM)|Centre de Recherche du Centre Hospitalier de l'Université de Montréal|Diabetes Québec|Radiological Society of North America|Canadian Heads of Academic Radiology-GE Healthcare Development Award,All,"18 Years and older   (Adult, Older Adult)",Phase 2,35,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,CE09.159,May-11,Jun-14,Jun-14,22-Jul-11,null,27-Aug-14,"Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT01399645
NCT01384578,Pentoxiphylline and Vitamin E Versus Vitamin E in Patients With Non- Alcoholic Steatohepatitis,,Withdrawn,No Results Available,Non Alcoholic Steatohepatitis,Drug: pentoxiphylline and Vitamin E|Drug: Vitamin E,"histological outcome in the form of improvement or non- progression in hepatocyte injury and fibrosis (NAS score).|Response in form of anthropometry , HOMA-IR, fasting lipid profiles, biochemical response in form of normalization of ALT and AST levels and reduction in uric","Institute of Liver and Biliary Sciences, India",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,0,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",ILBS-NASH-02,Jul-11,Nov-13,Nov-13,29-Jun-11,null,12-Oct-15,"Institute of liver and Biliary Sciences, New Delhi, Delhi, India",,https://ClinicalTrials.gov/show/NCT01384578
NCT01373554,Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease,PMK-N01GI1,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Placebo|Drug: Oltipraz,"MRS|change in ALT, AST and total bilirubin|change in Cholesterol, Triglyceride|change in HOMA-IR|change in BMI|changes in NAS",PharmaKing,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PMK-N01GI1,May-11,Jun-13,Oct-13,15-Jun-11,null,10-Dec-13,"Inje University Ilsan Paik Hospital, Dahwa-dong, Ilsanseo-gu, Goyang-si, Gyeonggi-do, Korea, Republic of|NHUS Ilsan Hospital, Ilsan-ro Ilsan-donggu, Goyang-si, Korea, Republic of|Seoul National University Hospital, Daehak-ro Jongno-gu, Seoul, Korea, Republic of|Korea University Guro hospital, Gurodong-ro, Seoul, Korea, Republic of|Boramae Hospital, Sindaebang-dong Dongjak-gu, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01373554
NCT01371825,"Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency",,Completed,Has Results,Lysosomal Acid Lipase Deficiency|Wolman Disease,Drug: Sebelipase alfa (SBC-102),"Percentage Of Participants In The Primary Efficacy Analysis Set (PES) Surviving To 12 Months Of Age|Percentage Of Participants Surviving Beyond 12 Months Of Age|Median Age At Death|Change From Baseline To Months 12, 24, 36, 48, And 60 In Weight For Age (WFA) Percentiles|Number Of Participants With Stunting, Wasting, Or Underweight|Change From Baseline To Months 12, 24, 36, 48, And 60 In Serum Transaminases (ALT And AST)|Change From Baseline To Months 12, 24, 36, 48, And 60 In Serum Ferritin|Number Of Participants Achieving And Maintaining Transfusion-free Hemoglobin Normalization [TFHN]",Alexion Pharmaceuticals,All,up to 24 Months   (Child),Phase 2|Phase 3,9,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LAL-CL03,4-May-11,3-Jan-18,3-Jan-18,13-Jun-11,18-Apr-16,30-Jan-19,"Irvine, California, United States|Cairo, Egypt|Grenoble, France|Paris, France|Dublin, Ireland|London, United Kingdom|Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT01371825/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT01371825/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT01371825
NCT01371396,Effect of Dietary Macronutrient Composition,,Completed,No Results Available,Metabolic Syndrome|Non-alcoholic Fatty Liver Disease|Obesity,Other: Low-fat diet|Other: Low-carbohydrate diet,de novo lipogenesis|Dietary fatty acid clearance to liver|Adipose fatty acid flux,University of Texas Southwestern Medical Center,All,"20 Years to 65 Years   (Adult, Older Adult)",Not Applicable,24,Other,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,5RL-1DK081187,1-Sep-07,31-Dec-13,31-Dec-13,10-Jun-11,null,6-Feb-19,"Center for Human Nutrition, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01371396
NCT01355575,Rifaximin in Fatty Liver Disease,RiFL,Terminated,No Results Available,Nonalcoholic Fatty Liver Disease|NAFLD|Nonalcoholic Steatohepatitis,Drug: Rifaximin,Change in serum ALT levels|Change in insulin resistance|Change in hepatic triglyceride content,"Imperial College London|National Health Service, United Kingdom",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,15,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2010-021515-17|10/H0711/58|45706,May-11,Sep-12,Sep-12,18-May-11,null,17-Oct-12,"Liver Unit, St Mary's Hospital, Imperial College London, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01355575
NCT01354626,Dietary Protein and Hepatic Fat Accumulation,LiF-Pro,Completed,No Results Available,Hepatic Fat Accumulation|Nonalcoholic Fatty Liver Disease,Other: dietary protein|Other: low-protein,hepatic fat accumulation|Biomarkers of liver function/hepatic steatosis|Circulating cytokines|Postprandial lipid metabolism|Glucose homeostasis|Adipose tissue gene expression|Peripheral blood mononuclear cells gene expression (PBMC's).,Wageningen University,All,18 Years to 40 Years   (Adult),Not Applicable,29,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention,LiF-Pro,Aug-11,Mar-12,Mar-12,17-May-11,null,15-Mar-12,"Wageningen University, Division of Human Nutrition, Wageningen, Gelderland, Netherlands",,https://ClinicalTrials.gov/show/NCT01354626
NCT01327443,Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease,,Completed,No Results Available,Non Alcoholic Fatty Liver Disease,Behavioral: Weight loss|Behavioral: Exercise,NASH ( Non alcoholic steatohepatitis score) on liver biopsy|Liver Function Tests|DXA Scan|Ultrasonographical changes in liver echotexture,University of Missouri-Columbia,All,18 Years to 60 Years   (Adult),Not Applicable,17,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1142777,Oct-10,Sep-12,Oct-15,1-Apr-11,null,5-Oct-16,"University Hospital, Columbia, Missouri, United States",,https://ClinicalTrials.gov/show/NCT01327443
NCT01317576,Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!,,Completed,No Results Available,"Diabetes Mellitus, Type 2|Non-alcoholic Fatty Liver Disease|Obesity",Behavioral: Exercise intervention,"Proton Magnetic resonance spectroscopy to measure the reduction in liver fat content after a training intervention|Magnetic resonance spectroscopy to measure the ATP and Pi concentrations in the liver|13C-methionine breath test to measure hepatic mitochondrial function|Euglycemic-hyperinsulinemic clamp for measurement of insulin sensitivity and metabolic flexibility|Blood sampling to determine the concentration of cardiovascular risk factors in the blood before and after exercise|Peripheral arterial tonometry to measure endothelial function, as a marker for cardiovascular risk.|Echography of the heart to measure diastolic dysfunction|Fat biopsy to measure adipose tissue inflammatory markers and adipocyte size before and after training intervention|Muscle biopsy to measure muscle mitochondrial density, muscle mitochondrial function and muscle lipid metabolism",Bram Brouwers|Dutch Diabetes Research Foundation|Maastricht University Medical Center,Male,"40 Years to 70 Years   (Adult, Older Adult)",Not Applicable,81,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MEC 11-3-002,Mar-11,Nov-15,Nov-15,17-Mar-11,null,1-Mar-16,"Maastricht University, Maastricht, Limburg, Netherlands",,https://ClinicalTrials.gov/show/NCT01317576
NCT01306396,Effect of Fructose Reduction on Non-alcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome in Overweight Children,,Unknown status,No Results Available,Non-alcoholic Fatty Liver Disease,Behavioral: dietary intervention mainly focusing on fructose reduction,prevalence of fatty liver disease|changes in blood lipid concentrations|changes in blood pressure|changes in glucose metabolism|Changes in small intestinal bacterial overgrowth,University of Hohenheim,All,5 Years to 8 Years   (Child),Not Applicable,100,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,03105084 (IB),Apr-09,Dec-11,Dec-12,1-Mar-11,null,1-Mar-11,"University of Hohenheim, Dept. of Nutritional Medicine (180 a), Stuttgart, Baden-Württemberg, Germany",,https://ClinicalTrials.gov/show/NCT01306396
NCT01289639,Insulin Resistance in Non-alcoholic Fatty Liver Disease,,Terminated,Has Results,Fatty Liver,Drug: fenofibrate|Drug: pioglitazone|Drug: placebo,Liver/Spleen Ratio Measured as the Ratio in Hounsfield Units Between the Liver and the Spleen on Computed Tomography (CT) Scan|Change in Alanine Aminotransferase (ALT) Levels|Change in Liver/Spleen Ratio Measure by the Density Ratio in Hounsfield Units Between the Liver and the Spleen by CT|Change in Peripheral Insulin Sensitivity|Change in Intra-abdominal Fat Area by CT Scan|Change in Hepatic Insulin Sensitivity,VA Office of Research and Development,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,11,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",CDA-2-044-08S-2,Oct-05,Aug-13,Aug-14,4-Feb-11,20-Oct-14,17-Aug-17,"VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01289639
NCT01285362,Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease,Drug: Fish Oil Supplementation|Drug: Placebo Supplementation,Prevalence of normalized liver enzyme levels|Prevalence of insulin resistance attenuated,Columbia University|GlaxoSmithKline,All,"12 Years to 18 Years   (Child, Adult)",Not Applicable,8,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",AAAF0695,Mar-13,Sep-14,Sep-14,28-Jan-11,null,9-Mar-15,"Irving Clinical Research Center (GCRC) at Columbia University Medical Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01285362
NCT01281059,Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath Test,,Unknown status,No Results Available,NAFLD,Device: BreathID - Breath Test - 13C Octanoate,,Hadassah Medical Organization|Exalenz Bioscience LTD.,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,null,Other|Industry,Interventional,,0429-10-HMO-CTIL,Jan-11,null,null,21-Jan-11,null,28-Aug-12,"Hadassah Medical Organization, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01281059
NCT01279434,Vitamin E Versus Vitamin E Plus Pentoxiphyllin in Patients With Nonalcoholic Steatohepatitis: A Prospective Randomized Clinical Trial,,Withdrawn,No Results Available,Non Alcoholic Steatohepatitis,Drug: Vitamin E plus Pentoxiphyllin|Drug: Vitamin E,Improvement in hepatocyte injury and fibrosis (NAFLD Activity Score [NAS score])|Normalization of serum transaminases levels|Reduction in serum levels of proinflammatory cytokines (TNF-α and IL-6) and Malondialdehyde (MDA).|Improvement in HOMA-IR|No worsening of fibrosis,"Institute of Liver and Biliary Sciences, India",All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ILBS/DHPT/CT/006,Jan-12,Mar-12,Jun-12,19-Jan-11,null,28-May-15,"Institute of Liver & Biliary Sciences, New Delhi, Delhi, India",,https://ClinicalTrials.gov/show/NCT01279434
NCT01278056,The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis,DEFINE,Completed,No Results Available,Non-alcoholic Steatohepatitis|Increased Iron Storage / Disturbed Distribution,Drug: Exjade,"Safety and tolerability of deferasirox in all patients (Phase I)|Changes in liver histology in all patients (Phase II)|Phase I: e.g. changes in liver enzymes, serum ferritin, and hemoglobin levels|Phase II: e.g. changes in MRI and histology based assessment of hepatic steatosis, fibrosis and iron content","Crolll Gmbh|Estimate, GmbH|University of Magdeburg",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,5,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CICL670EDE08T,Mar-10,Mar-12,Jul-12,17-Jan-11,null,20-Jul-12,"Zollernalbklinikum, Balingen/Hechingen, Germany|Charité, Virchow Klinikum, Berlin, Germany|Klinikum der J. W. Goethe-Universität, Med. Klinik I, Frankfurt, Germany|Universitätsklinikum Halle, Klinik & Poliklinik für Innere Medizin I, Halle, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Universitätsklinikum Magdeburg, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Magdeburg, Germany|Universitätsklinikum Mainz, I. Medizinische Klinik und Poliklinik, Mainz, Germany|Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Med. I, Regensburg, Germany|Universitätsklinikum Tübingen, Medizinische Klinik IV, Tübingen, Germany",,https://ClinicalTrials.gov/show/NCT01278056
NCT01277094,A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease,,Completed,No Results Available,"Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD",Drug: Placebo|Drug: RO5093151,"Change of liver fat content measured by magnetic resonance spectroscopy (MRS)|Change in insulin resistance assessed by hyperinsulinemic euglycemic clamp|Change in endogenous glucose production assessed by hyperinsulinemic euglycemic clamp|Pharmacokinetic measures (max and min concentration, clearance, half-life, etc)|Safety (incidence and nature of adverse events)",Hoffmann-La Roche,All,"35 Years to 65 Years   (Adult, Older Adult)",Phase 1,82,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",BP25414,Apr-11,Mar-12,Mar-12,14-Jan-11,null,2-Nov-16,"Wien, Austria|Dusseldorf, Germany|Nuthetal, Germany|Tübingen, Germany",,https://ClinicalTrials.gov/show/NCT01277094
NCT01277237,The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease,,Completed,No Results Available,Non Alcoholic Fatty Liver Disease,Drug: Omacor|Drug: lactose tablet,Liver appearance on ultrasound|Liver function tests|hepatocyte mitochondrial function|Health-related Quality of Life,University of Edinburgh|NHS Lothian,All,"18 Years and older   (Adult, Older Adult)",Phase 3,50,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Edin2008-008275-34|2008-008275-34,Sep-10,Aug-12,Aug-12,14-Jan-11,null,23-Jan-14,"Royal Infirmary of Edinburgh, Edinburgh, Lothian, United Kingdom",,https://ClinicalTrials.gov/show/NCT01277237
NCT01269320,Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease,,Withdrawn,No Results Available,Nash,Drug: Femarelle,,Hadassah Medical Organization,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 4,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0172-10-HMO-CTIL,Jan-12,null,null,4-Jan-11,null,28-Aug-12,"Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01269320
NCT01265498,The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT),FLINT,Completed,Has Results,Nonalcoholic Fatty Liver Disease (NAFLD)|Nonalcoholic Steatohepatitis (NASH),Drug: obeticholic acid|Drug: placebo,Hepatic Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS)|Resolution of NASH Diagnosis|Fibrosis: Patient With Improvement|Fibrosis: Change in Score|Total NAFLD Activity Score: Change in Score|Hepatocellular Ballooning: Patients With Improvement|Hepatocellular Ballooning: Change in Score|Steatosis: Patients With Improvement|Steatosis: Change in Score|Lobular Inflammation: Patients With Improvement|Lobular Inflammation: Change in Score|Portal Inflammation: Patients With Improvement|Portal Inflammation: Change in Score|Change in Alanine Aminotransferase|Change in Asparate Aminotransferase|Change in Alkaline Phosphatase|Change in γ-glutamyl Transpeptidase|Change in Total Bilirubin|Change in Total Cholesterol|Change in HDL Cholesterol|Change in LDL Cholesterol|Change in Triglycerides|Change in Haemoglobin|Change in Haematocrit|Change in Mean Corpuscular Volume|Change in White Blood Cell Count|Change in Platelet Count|Change in Bicarbonate|Change in Calcium|Change in Phosphate|Change in Creatinine|Change in Uric Acid|Change in Albumin|Change in Total Protein|Change in Prothrombin Time|Change in International Normalised Ratio|Change in Fasting Serum Glucose|Change in Insulin|Change in HOMA-IR|Change in Glycated Haemoglobin A1c|Change in Weight|Change in Body-mass Index|Change in Waist Circumference|Change in Waist-to-hip Ratio|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Change in SF-36 Quality of Life Physical Component Summary|Change in SF-36 Quality of Life Mental Component Summary,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Phase 2,283,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NASH-FLINT (IND)|U01DK061730,Mar-11,Jan-14,Sep-14,23-Dec-10,21-Aug-15,6-Apr-18,"University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Indiana University, Indianapolis, Indiana, United States|St. Louis University, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01265498
NCT01264198,The Role of Resistance Training in Non Alcoholic Fatty Liver Disease,,Completed,No Results Available,NAFLD (Non-Alcoholic Fatty Liver Disease)|Resistance Training,Behavioral: Resistance Training,The HRI value will be reduced in the intervention arm as compared to the The The change in Hepato-Renal Index (HRI) evaluated by ultrasound (US).,Tel-Aviv Sourasky Medical Center,All,20 Years to 60 Years   (Adult),Not Applicable,82,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TASMC-10-RO-330-CTIL,Dec-10,Sep-12,Oct-12,21-Dec-10,null,27-Mar-14,"Tel Aviv Sourasky Medical center, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01264198
NCT01262326,Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease,Other: Calorie and Carbohydrate Restriction,Liver triglyceride content|Measures of hepatic and whole-body oxidation,University of Texas Southwestern Medical Center,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,012005-053,Jan-05,31-Dec-11,31-Dec-11,17-Dec-10,null,16-Nov-18,"UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT01262326
NCT01260246,Sitagliptin for the Treatment of Non-alcoholic Steatohepatitis in Patients With Type 2 Diabetes,,Terminated,No Results Available,Type 2 Diabetes|Nonalcoholic Steatohepatitis,Drug: sitagliptin|Drug: placebo,"To demonstrate improvement in liver disease (based on liver biopsy)with sitagliptin.|In individuals with NASH and DM2: To document the impact of sitagliptin therapy on adipocytokines, inflammatory markers, non-traditional cardiovascular risk factors, adipose distribution, and dyslipidemia.|In individuals with NASH and DM2: To delineate the effect of sitagliptin therapy on platelet aggregation and oxidative stress.|In individuals with NASH and DM2: To determine the correlation between changes in histology with changes in hepatic fat demonstrated by MRI and changes in fibrosis by Fibroscan.",Lawson Health Research Institute|The Physicians' Services Incorporated Foundation,All,"18 Years to 100 Years   (Adult, Older Adult)",Not Applicable,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",R-10-533|17389,Dec-10,Apr-15,Apr-15,15-Dec-10,null,14-Mar-17,"St. Joseph's Health Care, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01260246
NCT01245608,Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables.,PolyIran-L,Completed,No Results Available,Cardiovascular Diseases,Drug: Polypill,Major Cardiovascular Events|Side effects|Changes in liver enzyme levels|Changes in liver stiffness|Compliance|Fat deposition|All-cause Mortality,Tehran University of Medical Sciences|Golestan University of Medical Science|University of Birmingham,All,"50 Years and older   (Adult, Older Adult)",Phase 3,2400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,90-03-37-15582,Oct-11,Jan-18,Sep-18,22-Nov-10,null,15-Feb-19,"Golestan Cohort Center, Gonbad, Golestan, Iran, Islamic Republic of",,https://ClinicalTrials.gov/show/NCT01245608
NCT01244503,Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT),,Terminated,Has Results,Metabolic Syndrome|Nonalcoholic Fatty Liver Disease,Drug: Sodium Octanoate Breath Test,The Peak Value of the PDR (Percentage Dose Recovery of 13C) of OBT (Octanoate Breath Test)|Histology -NAS Scoring of Liver Biopsy,Virginia Commonwealth University|Exalenz Bioscience LTD.,All,"18 Years and older   (Adult, Older Adult)",Phase 2,61,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NASH-BID-FIS-808,Feb-11,May-12,Jun-12,19-Nov-10,28-Jul-15,28-Jul-15,"Baylor College of Medicine, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT01244503
NCT01237119,Liraglutide Efficacy and Action in Non-Alcoholic Steatohepatitis,LEAN,Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: Liraglutide|Other: Liraglutide-placebo,Liver Histological improvement|NAFLD Activity Score,University of Birmingham|Wellcome Trust|Novo Nordisk A/S,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,52,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HE2013|ISRCTN85774727,Aug-10,Jul-14,Jul-14,9-Nov-10,null,23-Mar-16,"NIHR BRU Centre for liver research, Queens Elizabeth University Hospital Birmingham, Birmingham, West Midlands, United Kingdom",,https://ClinicalTrials.gov/show/NCT01237119
NCT01210989,Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis,,Completed,No Results Available,Nonalcoholic Fatty Liver Disease,Drug: Phyllanthus urinaria|Drug: Placebo,Histologic NAFLD activity score|ALT normalization|Metabolic endpoints|Changes in magnetic resonance spectroscopy|Liver stiffness measurement|Biomarkers of NASH and liver fibrosis,Chinese University of Hong Kong,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NAFLD- Hepaguard,May-10,May-12,May-12,29-Sep-10,null,24-Feb-14,"Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China",,https://ClinicalTrials.gov/show/NCT01210989
NCT01208649,Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH),,Completed,No Results Available,Nonalcoholic Fatty Liver Disease,Drug: Exenatide,"histological activity of NASH (steatosis, necroinflammation, ballooning)|Liver fibrosis, as determined using the fibrosis score",Ruhr University of Bochum,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 4,13,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",H80-MC-O008,Jul-08,Sep-10,Sep-10,24-Sep-10,null,24-Sep-10,"Department of Medicine I; University Hospital St. Josef-Hospital, Bochum, Germany",,https://ClinicalTrials.gov/show/NCT01208649
NCT01205087,Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome,,Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: OKT3,"This clinical study is designed to evaluate the safety and the immune-modulatory effects of oral administration of the study drug anti-CD3 MAb to subjects with the metabolic syndrome.|This clinical study also will include evaluations for markers of efficacy, as described below.",Hadassah Medical Organization|NasVax Ltd,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,36,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,OKT3-NASH-HMO-CTIL,Sep-10,Dec-10,Apr-11,20-Sep-10,null,23-Jun-11,"Hadassah University Hospital, Liver Unit, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01205087
NCT01188083,Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis,Sweet Bev,Completed,No Results Available,Non-alcoholic Fatty-liver Disease,Dietary Supplement: Fructose Drink|Dietary Supplement: Glucose Drink,Hepatic Fat|Plasma Triglycerides,Emory University,All,"11 Years to 18 Years   (Child, Adult)",Not Applicable,53,Other,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",IRB00007471|Emory-Vos-SweetBev,Jun-09,Nov-12,Nov-12,25-Aug-10,null,21-Nov-13,"Emory Children's Center, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT01188083
NCT01167088,A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD),MARVEL,Terminated,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Mitoquinone mesylate|Drug: Placebo,"Percentage change in ALT (relative to baseline) at the end of the treatment period (Day 90) for MitoQ compared with placebo.|Absolute change in ALT level (relative to baseline) at end of treatment period for MitoQ compared with placebo|The percentage of participants whose ALT levels are in the normal range at the end of the treatment period.|The difference in the percentage and absolute rates of change in ALT levels between MitoQ and placebo.|The percentage and absolute change in AST at the end of the treatment period (relative to baseline) for MitoQ compared with placebo.|The change in HOMA-IR at the end of the treatment period (relative to baseline) for MitoQ compared with placebo.|The change in HbA1c at the end of the treatment period (relative to baseline) for MitoQ compared with placebo.|The percentage and absolute change in GGT and alkaline phosphatase at the end of the treatment period (relative to baseline) for MitoQ compared with placebo.|Areas under the ALT, AST, GGT and alkaline phosphatase curves from baseline to the end of the treatment period.|The change in markers of liver inflammation (leptin and adiponectin) at the end of the treatment period (relative to baseline) for MitoQ compared with placebo.|The change in biomarkers of mitochondrial function and oxidative damage (isoprostanes) at the end of the treatment period (relative to baseline) for MitoQ compared with placebo.|The change in blood pressure at the end of the treatment period (relative to baseline) for MitoQ compared with placebo.|The change in blood lipid profile at the end of the treatment period (relative to baseline) for MitoQ compared with placebo.|Incidence of adverse events|Clinically relevant deterioration in laboratory variables|Clinically relevant deterioration in vital signs|Clinically relevant deterioration in ECG parameters","Antipodean Pharmaceuticals, Inc.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,110,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MTQ-LD-001|2010-021368-13,Nov-10,Jun-11,Jul-11,22-Jul-10,null,1-Jun-11,"Freeman Hospital, Newcastle-upon-Tyne, United Kingdom",,https://ClinicalTrials.gov/show/NCT01167088
NCT01158066,Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification,,Unknown status,No Results Available,Coronary Artery Calcification,Procedure: CT Cardiac,Total calcium score measurement,Ziv Hospital,All,"45 Years to 75 Years   (Adult, Older Adult)",Not Applicable,120,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NAFLD and CAC,Aug-11,Jan-12,Mar-12,8-Jul-10,null,6-Apr-11,"Ziv medical center liver unit, Safed, Israel, Israel",,https://ClinicalTrials.gov/show/NCT01158066
NCT01154985,"Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)",,Completed,Has Results,Steatohepatitis,Drug: Placebo capsule|Drug: EPA-E 300 mg capsule,Histological Response Defined by Change From Baseline in Standardized Scoring of Liver Biopsies|Alanine Transaminase (ALT) Levels,"Mochida Pharmaceutical Company, Ltd.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,243,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MCH-02-001,Jun-10,Oct-12,Oct-12,1-Jul-10,20-Nov-14,20-Nov-14,"Mochida Investigative Site, Dothan, Alabama, United States|Mochida Investigative Site, Tucson, Arizona, United States|Mochida Investigative Site, Anaheim, California, United States|Mochida Investigative Site, Coronado, California, United States|Mochida Investigative Site, LaJolla, California, United States|Mochida Investigative Site, Los Angeles, California, United States|Mochida Investigative Site, San Diego, California, United States|Mochida Investigative Site, San Diego, California, United States|Mochida Investigative Site, Littleton, Colorado, United States|Mochida Investigative Site, Hialeah, Florida, United States|Mochida Investigative Site, Chicago, Illinois, United States|Mochida Investigative Site, Lexington, Kentucky, United States|Mochida Investigative Site, New Orleans, Louisiana, United States|Mochida Investigative Site, Chevy Chase, Maryland, United States|Mochida Investigative Site, Detroit, Michigan, United States|Mochida Investigative Site, Plymouth, Minnesota, United States|Mochida Investigative Site, Jackson, Mississippi, United States|Mochida Investigative Site, Tupelo, Mississippi, United States|Mochida Investigative Site, Plainview, New York, United States|Mochida Investigative Site, Asheville, North Carolina, United States|Mochida Investigative Site, Durham, North Carolina, United States|Mochida Investigative Site, Cincinnati, Ohio, United States|Mochida Investigative Site, Cincinnati, Ohio, United States|Mochida Investigative Site, Cleveland, Ohio, United States|Mochida Investigative Site, Providence, Rhode Island, United States|Mochida Investigative Site (2 sites), Germantown, Tennessee, United States|Mochida Investigative Site, Nashville, Tennessee, United States|Mochida Investigative Site, Houston, Texas, United States|Mochida Investigative Site (2 sites), Houston, Texas, United States|Mochida Investigative Site, San Antonio, Texas, United States|Mochida Investigative Site, Newport News, Virginia, United States|Mochida Investigative Site, Richmond, Virginia, United States|Mochida Investigative Site, Seattle, Washington, United States|Mochida Investigative Site, San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT01154985
NCT01147523,Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease,NAFLD,Completed,No Results Available,Fatty Liver|Steatohepatitis,Drug: Spironolactone/Vitamin E,Serum adipocytokines levels|Serum homocysteine levels|Liver histology|Insulin resistance|Hormonal profile|Serum biochemistry|Reactive Oxygen Metabolites (ROMs),Aristotle University Of Thessaloniki,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PolyzosKountouras,Jan-10,Nov-10,Dec-11,22-Jun-10,null,20-Jan-12,"Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT01147523
NCT01094158,Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis,Aramchol003,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis|Metabolic Syndrome,Drug: Aramchol|Drug: Placebo,"The difference between initial and final liver triglyceride concentration (measured by NMRS) comparing the Aramchol and placebo treated patients.|Comparing secondary variables of liver, metabolic and endothelial functions between the Aramchol and the placebo arms.","Galmed Medical Reserch|Tel-Aviv Sourasky Medical Center|Beilinson Hospital, Petach Tikva,Israel|Meir Medical Center|Kaplan Hospital ,Rehovot,Israel|Soroka Hospital,Beer Sheva,Israel|Hadassah Medical Organization|Hillel Yaffe Medical Center|Rambam Hospital, Haifa, Israel|The Lady Davis Carmel Medical Center|Holy Family Hospital, Nazareth, Israel|Ziv Hospital",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,60,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",Aramchol NAFLD Phase-II,Nov-10,Nov-11,Jan-12,26-Mar-10,null,31-Jan-12,"Soroka Medical Center, Beer Sheva, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Rambam, Haifa, Israel|The Lady Davis Carmel Medical Center, Haifa, Israel|Hadassah Ein Kerem M.C, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Holy Family HOSPITAL, Nazareth, Israel|Belinson,Rabin Medical Center, Petah Tikva, Israel|Kaplan M.C, Rehovot, Israel|Safed Ziv Hospital, Safed, Israel|The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT01094158
NCT01083992,Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD),,Unknown status,No Results Available,Non-Alcoholic Fatty Liver Disease,Drug: Galvus (vitagliptin)|Drug: Galvus + vitamin D,decrease in histological findings,Ziv Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NAFLD+ Vitamin D,Apr-12,Jan-13,Jun-13,10-Mar-10,null,28-Apr-11,"Ziv medical center liver unit, Safed, Israel, Israel",,https://ClinicalTrials.gov/show/NCT01083992
NCT01068444,The Efficacy and Safety of Pioglitazone in Patients With Nonalcoholic Steatohepatitis,,Recruiting,No Results Available,Hepatitis,Drug: Pioglitazone|Drug: placebo,Comparison between Pioglitazone and placebo groups in terms of steatosis and liver function tests|Evaluation of clinical safety of Pioglitazone|Comparison between Pioglitazone and placebo groups in terms of liver necroinflammation and fibrosis.,Kaohsiung Medical University Chung-Ho Memorial Hospital,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",KMUH-HB9608,Apr-09,Sep-18,Mar-19,15-Feb-10,null,8-Mar-18,"Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan",,https://ClinicalTrials.gov/show/NCT01068444
NCT01066364,Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis,,Unknown status,No Results Available,Nonalcoholic Steatohepatitis,Drug: Colesevelam Hcl,The primary outcome will be improvement in hepatic steatosis by liver MRI|Insulin sensitivity as determined by HOMA-IR|Serum ALT and AST values|Lipid profiles,"University of California, San Diego|Daiichi Sankyo, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,54,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",91491,Feb-10,Feb-12,Feb-12,10-Feb-10,null,10-Feb-10,"UCSD: Prevention Studies Clinic, La Jolla, California, United States|UCSD: Medical Center- Hillcrest, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT01066364
NCT01056133,Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH),,Completed,No Results Available,Non-alcoholic Fatty Liver Disease|Non-alcoholic Steatohepatitis,Other: Omega-3 capsules-Fish Oil,"Liver histology|Plasma and RBC fatty acid composition and PC:PE ratio|Blood biochemistry (blood sugar control, lipid profile, liver enzymes)|Intestinal microbiota|Plasma endotoxin|Plasma free choline|Bacterial DNA in plasma","Johane Allard|Canadian Institutes of Health Research (CIHR)|American College of Gastroenterology|University Health Network, Toronto",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,20,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,08-0874-A|CIHR Grant#89705|MOP-123459,Oct-09,Jan-15,Aug-15,26-Jan-10,null,12-May-16,"University Health Network, Toronto General Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT01056133
NCT01051219,Anti-Fibrotic Effects of Losartan In Nash Evaluation Study,FELINE,Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: Losartan,"The primary outcome will be change in Kleiner fibrosis score, [Kleiner DE et al Hepatology 2005], based on histological fibrosis stage (as judged by two independent blinded histopathologists from liver biopsies), from pre-treatment to end-of-study|Change in radiological (fibroscan) and serological (ELF) markers of fibrosis|change in NAFLD activity score (NAS)|comparison of ""responder rate"" - placebo versus intervention",Newcastle-upon-Tyne Hospitals NHS Trust|Newcastle University,All,"18 Years and older   (Adult, Older Adult)",Phase 3,45,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EME-08/43/15|ISRCTN,May-11,Nov-14,Dec-14,18-Jan-10,null,7-Oct-15,"Plymouth Hospitals NHS Trust, Plymouth, Devon, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Cambridge University NHS Foundation Trust, Cambridge, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Royal Liverpool & Broadgreen University Hospital, Liverpool, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Imperial College (St Mary's Site), London, United Kingdom|St George's Hospital, London, United Kingdom|Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom|Queens Medical Centre, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT01051219
NCT01047735,The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes,TRIABETES,"Active, not recruiting",No Results Available,Type 2 Diabetes Mellitus|Obesity,Procedure: Roux-en-Y Gastric Bypass Surgery|Procedure: Laparoscopic Adjustable Gastric Banding|Behavioral: Lifestyle Weight Loss Intervention,Feasibility of performing a randomized trial comparing two major types of bariatric surgery versus a lifestyle weight loss intervention (LWLI) induced by diet and increased physical activity in moderately obese patients with T2DM.|Preliminary information regarding the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss with diet and increased physical activity.,University of Pittsburgh|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,25 Years to 55 Years   (Adult),Not Applicable,60,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,RC1DK086037|R01DK095128-01,Sep-09,Feb-19,Feb-19,13-Jan-10,null,4-Apr-18,"Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01047735
NCT01045499,LAGB as a Treatment for Morbid Obesity in Adolescents,,Completed,No Results Available,Morbid Obesity|Obstructive Sleep Apnea Syndrome|Metabolic Syndrome|Insulin Resistance|Nonalcoholic Fatty Liver Disease,Device: Laparoscopic adjustable gastric banding (Allergan Lap Band),Percentage of excess weight loss (EWL),"Jeffrey L Zitsman, MD|Columbia University",All,"14 Years to 19 Years   (Child, Adult)",Not Applicable,137,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,AAAB1759,13-Sep-05,31-Jul-16,31-Jul-16,11-Jan-10,null,13-Feb-17,"Morgan Stanley Children's Hospital of NY Presbyterian, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT01045499
NCT01016418,Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease,,Completed,No Results Available,Nonalcoholic Steatohepatitis|Fatty Liver Disease,Dietary Supplement: Bovine colostrum powder,To determine the efficacy of BCP in improving liver enzyme levels in patients with NASH.|To determine the safety of the administration of oral BCP to patients with NASH.|To determine whether the administration of BCP will improve the metabolic syndrome in patients with NASH (namely insulin resistance).,Hadassah Medical Organization,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NASH Colostrum - HMO - CTIL,Jan-10,Jun-10,Aug-10,19-Nov-09,null,17-Sep-10,"Liver Unit, Hadassah, Ein Kerem, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01016418
NCT01006889,Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease,,Completed,Has Results,Nonalcoholic Fatty Liver Disease|Type 2 Diabetes Mellitus,Drug: Exenatide,"Hepatic Steatosis|A1c|Change in Anthropometric Variables (Weight).|Number of Severe Hypoglycemic (Glucose ≤40 mg/dL) Events.|Insulin Secretion (Hyperglycemic Clamp)|Percent Change From Baseline in Glucose Infusion (M Value) During Hyperglycemic Clamp|Lipid Profiles, Lipoprotein Analysis by NMR (LipoScience).|Change in Anthropometric Variables (BMI).","University of Florida|Amylin Pharmaceuticals, LLC.",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,24,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HSC20060167-2,Jan-08,Dec-09,Feb-10,3-Nov-09,29-Jul-16,28-Sep-16,"The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01006889
NCT01002547,Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment,VA NASH,Completed,Has Results,Nonalcoholic Steatohepatitis,Drug: pioglitazone-placebo|Drug: pioglitazone|Dietary Supplement: Vitamin E|Drug: Vitamin E-placebo,"Liver Histology (Kleiner's et al Criteria, Hepatology 2005)|Number of Participants With Resolution of NASH Without Worsening of Fibrosis|Mean Individual Histological Scores|Individual Histological Scores|Liver Fat by Magnetic Resonance Imaging and Spectroscopy (MRS).|Weight|Body Mass Index|Total Body Fat by DEXA|Plasma AST|Plasma ALT|Fasting Plasma Glucose|Fasting Plasma Insulin|Matsuda Index|Total Cholesterol|Triglycerides|HDL-cholesterol|LDL-cholesterol",VA Office of Research and Development,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,105,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",CLIN-015-08F|HSC20090401H|VA-ORD#GRANT00508571|610-2011,24-Jun-10,30-Sep-16,31-Dec-16,27-Oct-09,11-Sep-18,11-Sep-18,"North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States|South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT01002547
NCT00994682,University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial),,Completed,Has Results,Nonalcoholic Steatohepatitis|Nonalcoholic Fatty Liver Disease|Type 2 Diabetes Mellitus,Drug: Pioglitazone study drug|Drug: Placebo|Drug: Pioglitazone Open Label,"Liver Histology (Using Kleiner et al Criteria, Hepatology 2005)|Number of Participants With Resolution of NASH|Mean Individual Histological Scores|Individual Histological Scores|Liver Transaminases (AST and ALT).|Liver Fat by Magnetic Resonance and Spectroscopy (MRS).|Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)|Hepatic Insulin Sensitivity|Adipose Tissue Insulin Sensitivity|Skeletal Muscle Insulin Sensitivity|Body Mass Index (BMI)|Total Body Fat|Plasma Biomarkers Relevant to Hepatic Inflammation, Apoptosis and Fibrosis (Adiponectin).|Plasma Biomarkers Relevant to Hepatic Inflammation, Apoptosis and Fibrosis (CK-18).|Prevention of the Onset of T2DM and/or Reversal From IFG/IGT to NGT in Non-diabetics.|Osteoporotic Fractures|Molecular Pathways of Liver Glucose and Lipid Signaling; Inflammatory Pathways; Oxidative Stress; Other.|Bone Mineral Density",University of Florida|The University of Texas at San Antonio,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,176,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HSC20070654,Dec-08,Dec-14,Dec-14,14-Oct-09,5-Apr-17,5-Apr-17,"Bartter Research Unit, Audie L Murphy VA Hospital, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00994682
NCT00977730,The Effect of Protandim on Non-alcoholic Steatohepatitis,NASH,Completed,No Results Available,Non-Alcoholic Steatohepatitis,Dietary Supplement: Protandim|Dietary Supplement: Placebo,Change in NAS at study completion in the Protandim group compared to the placebo group.,"University of Colorado, Denver",All,"18 Years and older   (Adult, Older Adult)",Not Applicable,70,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",07-0848,Jul-08,Jul-11,Jul-11,16-Sep-09,null,5-Feb-13,"University of Colorado at Denver and Health Sciences Center, Denver, Colorado, United States",,https://ClinicalTrials.gov/show/NCT00977730
NCT00968747,Regulation of FGF21 by Nutritional Challenges,,"Active, not recruiting",No Results Available,Fasting|Non-alcoholic Fatty Liver Disease (NAFLD),Behavioral: Fasting|Behavioral: Diet|Dietary Supplement: oral carbohydrate challenge,Fibroblast Growth Factor 21 levels in serum and fat|Polymerase 1 and Transcript Release Factor levels in fat|Urine and serum ketosis|Hepatic fat content|change in serum triglyceride levels|change in glucose and insulin levels,Beth Israel Deaconess Medical Center,All,18 Years to 60 Years   (Adult),Not Applicable,40,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2009P-000073,Jul-09,31-Dec-19,30-Apr-20,31-Aug-09,null,26-Feb-19,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00968747
NCT00941642,Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease,,Unknown status,No Results Available,Non-Alcoholic Fatty Liver Disease,Drug: Lovaza|Drug: placebo control,To determine if Lovaza improves fibrosis and the NASH activity index.|To determine if Lovaza improves AST/ALT level and improves steatosis on biopsy.,Huntington Medical Research Institutes|GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 4,40,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"LOVAZA - NAFLD|IND # 105,085.",Sep-09,Sep-12,Sep-12,17-Jul-09,null,10-Jun-10,"HMRI - Liver Center, Pasadena, California, United States",,https://ClinicalTrials.gov/show/NCT00941642
NCT00928473,The Danish Childhood Obesity Biobank,,Recruiting,No Results Available,"Weight Loss|Obesity|Metabolic Syndrome|NAFLD, Non-alcoholic Fatty Liver Disease|Cardiovascular Diseases",Behavioral: Weightloss treatment program,"Weightloss, changes in blood parameters and in fatty liver developement.",Zealand University Hospital|University of Copenhagen|Steno Diabetes Center Copenhagen|Holbaek Sygehus,All,"2 Years to 100 Years   (Child, Adult, Older Adult)",Not Applicable,5000,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,250609,Jan-09,Dec-20,Dec-20,26-Jun-09,null,16-Jan-19,"The Children's Obesity Clinic, Paediatric department, University Hospital Holbæk, Region Zealand, Holbæk, Denmark",,https://ClinicalTrials.gov/show/NCT00928473
NCT00887393,Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates,,Completed,No Results Available,Morbid Obesity|Non-alcoholic Fatty Liver Disease,Other: low carbohydrate diet|Other: low-fat diet,Determine the efficacy of a low carbohydrate vs. a conventional low fat diet to reduce hepatic steatosis|Compare differences in weight loss with a 2 month hypocaloric conventional low fat vs. low carbohydrate diets in individuals who are candidates for laparoscopic Roux-en-Y gastric bypass surgery or adjustable laparoscopic banding surgery,University of Michigan|National Institutes of Health (NIH),All,18 Years to 55 Years   (Adult),Not Applicable,31,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,MCRU 2462,Apr-09,Sep-12,Dec-12,24-Apr-09,null,18-Jun-13,"University of Michigan Hospital, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00887393
NCT00885313,Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD),EDACN,Completed,No Results Available,Fatty Liver|Liver Fibrosis|Obesity|Metabolic Syndrome|Nonalcoholic Fatty Liver Disease,Drug: DHA250|Drug: DHA500|Drug: PLACEBO|Behavioral: Lifestyle intervention,Liver status by liver biopsy (steatosis and fibrosis)|Serum alanine transferase levels|Serum levels of triglycerides,Bambino Gesù Hospital and Research Institute,All,4 Years to 16 Years   (Child),Phase 1|Phase 2,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",1406-18-4,Mar-09,Apr-10,Mar-11,21-Apr-09,null,13-May-11,"Bambino Gesù Hospital and Research Institute, Rome, Italy",,https://ClinicalTrials.gov/show/NCT00885313
NCT00878592,Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity,,Terminated,No Results Available,Post Liver Transplantation Weight Gain|Post Liver Transplantation Obesity|Nonalcoholic Steatohepatitis,Behavioral: Dietary and life style modification,"waist circumference|weight, height (for BMI calculation)|skin fold thickness|survival rate|Co morbidity events|histological scores of necro-inflammation (Ishak score) and steatosis (Dixon's scale) of the implanted liver.",University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Not Applicable,null,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO08010154|non applicable,Oct-08,Jun-10,null,9-Apr-09,null,10-Oct-17,"Center for Liver Diseases, UPMC., Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00878592
NCT00870012,Treatment of Nonalcoholic Fatty Liver Disease With Probiotics and Prebiotics,,Completed,No Results Available,Nonalcoholic Fatty Liver Disease,Drug: Lepicol probiotic & prebiotic formula|Other: Simple lifestyle advice,"The primary endpoint is the reduction in hepatic triglyceride content from baseline to week 24.|The proportion of patients with normal ALT at week 24 will be determined. Normal ALT is defined according to Prati's cutoffs (≤30 IU/l in men and ≤19 IU/l in women).|The proportion of patients with impaired fasting glucose, diabetes, insulin resistance (estimated by the homeostasis model), hypertension, dyslipidemia and metabolic syndrome will be determined both at baseline and during each visit.|The changes in visceral fat will be determined by magnetic resonance imaging at the same session both at baseline and month 12.|The changes in liver fibrosis will be determined by transient elastography by Fibroscan both at baseline and month 12.|The percentage of total sequences of individual microbes will be calculated. In particular, the proportion of Firmicutes and Bacteroidetes will be compared between the two treatment arms.",Chinese University of Hong Kong,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor),NAFLD-GUT#2,Feb-09,Jan-12,Jan-12,26-Mar-09,null,24-Feb-14,"Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China",,https://ClinicalTrials.gov/show/NCT00870012
NCT00870077,A Pilot Study on Whey Protein Supplementation in Non Alcoholic Fatty Liver Disease,PROTOB,Completed,No Results Available,Non-alcoholic Fatty Liver Disease|Obesity,"Dietary Supplement: ProWHEY 94 CFM, SponserR",intrahepatic fat|glucose metabolism|body weight and body fat,University of Lausanne,All,18 Years to 50 Years   (Adult),Not Applicable,11,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Protobese,Apr-09,Dec-09,Apr-10,26-Mar-09,null,24-Feb-12,"Centre d'investigations cliniques ""cardiomet""/ CHUV, Lausanne, VD, Switzerland",,https://ClinicalTrials.gov/show/NCT00870077
NCT00868933,Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease,,Completed,No Results Available,Nonalcoholic Fatty Liver Disease,Other: Low glycemic index dietary intervention program|Other: simple lifestyle advice,Resolution of NAFLD by proton-magnetic resonance spectroscopy|Partial resolution of NAFLD|Visceral fat measurement|Liver fibrosis by transient elastography|Metabolic endpoints,Chinese University of Hong Kong,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,159,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),NAFLD-Diet,Feb-09,May-12,May-12,25-Mar-09,null,24-Feb-14,"Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China",,https://ClinicalTrials.gov/show/NCT00868933
NCT00856869,"Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers",,Completed,No Results Available,Hepatic Cirrhosis|Nonalcoholic Steatohepatitis,Drug: NRL972,"Clearance of NRL972 after a standard meal and while fasted in healthy volunteers, patients with NASH and patients with hepatic cirrhosis.|Adverse events and changes in physical findings from baseline|Effects of vital signs: blood pressure, pulse rate|Effects on electrocardiogram|Changes in haematology, clinical chemistry, urinalysis",Norgine,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 1|Phase 2,52,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NRL972-02/2003(ACPS),Aug-04,Feb-05,Apr-05,6-Mar-09,null,6-Mar-09,"UMHAPT St. Ivan Rilski's University Hospital, Sofia, Bulgaria",,https://ClinicalTrials.gov/show/NCT00856869
NCT00845845,Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH),,Terminated,Has Results,Nonalcoholic Steatohepatitis (NASH)|Hepatic Steatosis,Drug: Omega-3-acid ethyl esters (Lovaza)|Drug: Placebo,Omega-3 Fatty Acid Supplementation and Its Effect on Hepatic Steatosis and Other Factors Associated With the Development of Nonalcoholic Steatohepatitis (NASH)|Magnetic Resonance Imaging (MRI) as an Assessment of Hepatic Steatosis in Patients With Biopsy-proven Nonalcoholic Steatohepatitis (NASH),University of Illinois at Chicago,All,"18 Years and older   (Adult, Older Adult)",Phase 2,12,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2003-0601,Mar-06,Oct-10,Oct-10,18-Feb-09,24-Jul-13,24-Jul-13,"The University of Illinois Chicago, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00845845
NCT00842205,Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection,,Unknown status,No Results Available,Chronic HCV Infection|Nonalcoholic Steatohepatitis,Drug: pegylated interferon|Drug: Ribavarin,1. the relation between HO activity and basic virologic and histologic parameters in chronic HCV patients. 2. changes of HO activity within antiviral treatment 3. relation of HO gene polymorphisms to the course of disease|Relation of HO gene polymorphisms and UGT1A1*28 polymorphism.,"Charles University, Czech Republic|IGA MZ, Czech Republic",All,18 Years to 60 Years   (Adult),Not Applicable,150,Other,Interventional,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,IGA MZ CR NR9412-3,Jan-07,Jun-09,Dec-09,12-Feb-09,null,12-Feb-09,"Cetral Military Hospital, Prague, Czech Republic",,https://ClinicalTrials.gov/show/NCT00842205
NCT00820651,Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis,,Completed,No Results Available,Nonalcoholic Steatohepatitis|Insulin Resistance,Dietary Supplement: Diamel|Other: Placebo and lifestyle counseling,"The histological improvement (steatosis, necro-inflammatory activity and fibrosis) at 52 weeks (end of the treatment) as compared with pre-treatment liver biopsy.|Insulinresistance levels (HOMA-IR) at 52 weeks (end of the treatment), Aminotransferase levels at 52 weeks (end of the treatment), Body weight, Body Mass Index and waist circumference at 52 weeks (end of the treatment)",Catalysis SL,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 3,158,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",DIAMEL_NASH-09,Nov-09,Apr-12,Apr-12,12-Jan-09,null,26-Apr-12,"National Institute of Gastroenterology, Vedado, Havana, Cuba",,https://ClinicalTrials.gov/show/NCT00820651
NCT00819338,The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Dietary Supplement: Efamax,"Reduction of intrahepatic fat content as determined by magnetic resonance spectroscopy|Serum liver function tests, lipids, free fatty acids|Insulin resistance as assessed by HOMA-IR and Adipose Tissue Insulin Resistance Index|Liver saturated, monounsaturated and polyunsaturated fatty acid indexes as assessed by MR spectroscopy|Visceral obesity as quantified by MRI, and the adipose derived serum leptin and adiponectin|Primary assessment of the fibrotic and inflammatory status of the liver with serum TGF beta, TNF a, IL-6, IL-8, IL-8, IL-10|Further informative cytokine analyses: GM-CSF, IFN-G, IL-1B, IL-1RA, IL-2, IL-4, IL-5, MCP1|Compliance assessed by serum phospholipid fatty acids",University of Nottingham,All,"18 Years and older   (Adult, Older Adult)",Phase 2,58,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NottinghamNHST1|REC 08/H0403/14|R&D 08GA001,Jan-09,Mar-10,Mar-10,9-Jan-09,null,4-Jul-12,"Wolfson Digestive Diseases Centre, University Hospital, Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT00819338
NCT00816465,Safety and Efficacy of Hoodia Gordonii for Treatment of Non Alcoholic Fatty Liver Disease (NAFLD),,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease,Dietary Supplement: Hoodia gordonii|Other: Placebo,decreased insulin resistance|safety|reduced hepatic injury|reduced weight/BMI/abdominal circumference,Hadassah Medical Organization,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HoodiaNAFLD-HMO-CTIL,May-09,Jun-10,Aug-10,1-Jan-09,null,17-Sep-10,"Hadassah Medical Center, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT00816465
NCT00815009,Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease,NAFLD,Completed,No Results Available,Fatty Liver,Behavioral: Mod Fat/Low Processed Carb Diet and Moderate Exercise|Behavioral: Low Fat Diet and Moderate Exercise|Behavioral: Moderate Exercise Only,"NAFLD Activity Score (Percent liver steatosis, inflammation, and fibrosis)|Insulin resistance (IR)",San Antonio Military Medical Center,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,56,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C.2008.171,Oct-08,Mar-10,Dec-10,29-Dec-08,null,16-Jul-12,"San Antonio Military Medical Center, Fort Sam Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT00815009
NCT00808990,The Effect of Probiotics on Non Alcoholic Fatty Liver Disease,,Terminated,No Results Available,Liver Disease,Dietary Supplement: BioFemale,SIBO in NASH patients in both treated groups (probiotics treated versus placebo treated) will be evaluated by lactulose breath test|Lactulose breath test|FIBROMAX tests will assess severity of NAFLD in patients' group prior to treatment and post treatment|Fibromax test for the evaluation of NAFLD severity,Rabin Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 1,38,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,RMC085077CTIL|RMC local ID 5077,Feb-13,Aug-15,Sep-15,16-Dec-08,null,8-Apr-16,"Rabin Medical Center, Petach Tikva, Israel",,https://ClinicalTrials.gov/show/NCT00808990
NCT00799578,A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH),,Completed,Has Results,Fatty Liver,Drug: Cysteamine,Normalization or >50% of Serum ALT Levels From Baseline,"Joel Lavine|Raptor Pharmaceuticals Corp.|University of California, San Diego",All,"10 Years and older   (Child, Adult, Older Adult)",Phase 1|Phase 2,13,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07-1699,Oct-08,Jun-09,Jan-10,1-Dec-08,31-Jan-14,31-Jan-14,"University of California, San Diego School of Medicine General Clinic Research Center, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00799578
NCT00794716,Pharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD),,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis,Drug: NRL972,"The primary efficacy variable is the NRL972 fractional retention ratio for 10 and 30 minutes post-dose (C30/C10) for different populations with NAFLD.|Approximate overall clearance and t½ within 60 minutes of dosing with NRL972. Cmax, AUC(0-∞), and mean residence time derived from a non-compartmental analysis.",Norgine,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,125,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,NRL972-01/2007 (FLD),Jun-08,Mar-10,Nov-11,20-Nov-08,null,10-Jun-15,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00794716
NCT00771108,Exercise Dose and Nonalcoholic Fatty Liver Disease,ED,Completed,No Results Available,Non-alcoholic Fatty Liver Disease (NAFLD),Behavioral: exercise,"The effect of aerobic exercise on: Intrahepatic fat content|VLDL-triglyceride (TG) and VLDL-Apolipoprotein B (apoB) kinetics|Insulin action in liver (suppression of glucose production), muscle (stimulation of glucose uptake), and adipose tissue (suppression of lipolysis).|Plasma markers of inflammation|Potential cellular mechanisms responsible for changes in insulin action and inflammation",Washington University School of Medicine,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,33,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,06-0039|#5P30 DK052574 (NIH/DDRCC)|R01 DK37948 (NIH/NIDDK),May-06,Apr-11,Apr-11,13-Oct-08,null,7-Sep-11,"Washington University School of Medicine, St. Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00771108
NCT00760513,Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids,,"Active, not recruiting",No Results Available,Non-Alcoholic Fatty Liver Disease,Drug: OMACOR,Change in biomarkers for NAFLD and change in liver fat|Change in risk factors for cardiovascular disease and type 2 diabetes,"University Hospital Southampton NHS Foundation Trust|National Institute for Health Research, United Kingdom",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,100,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,25-12-59. (R&D: RHM MED 0836)|EudraCT number 2008-003766-26,Nov-09,Feb-19,Feb-19,26-Sep-08,null,18-Apr-18,"Southamption General Hospital, Southampton, Hants, United Kingdom",,https://ClinicalTrials.gov/show/NCT00760513
NCT00740610,"Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)",,Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: GS-9450|Drug: GS-9450 Placebo,Percentage of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities|Pharmacokinetics of GS-9450 and its metabolites|Change from baseline in alanine aminotransferase (ALT),Gilead Sciences,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,124,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",GS-US-228-0101,Aug-08,Aug-09,Sep-09,25-Aug-08,null,4-Feb-14,"Tucson, Arizona, United States|Fresno, California, United States|Fullerton, California, United States|San Diego, California, United States|San Mateo, California, United States|Lakewood, Colorado, United States|Washington, District of Columbia, United States|Jacksonville, Florida, United States|Atlanta, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Des Moines, Iowa, United States|Kansas City, Kansas, United States|Monroe, Louisiana, United States|New Orleans, Louisiana, United States|Ann Arbor, Michigan, United States|Troy, Michigan, United States|New York, New York, United States|Plainview, New York, United States|Syracuse, New York, United States|Asheville, North Carolina, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Clevleand, Ohio, United States|Providence, Rhode Island, United States|Dallas, Texas, United States|Galveston, Texas, United States|Irving, Texas, United States|Charlottesville, Virginia, United States|Falls Church, Virginia, United States|Richmond, Virginia, United States|Paris, France|Vandoeuvre les Nancy, France",,https://ClinicalTrials.gov/show/NCT00740610
NCT00736385,Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD),NAFLD,Terminated,Has Results,Fatty Liver,Drug: Glucophage (Metformin)|Drug: Placebo,"Study Endpoints Will Include Measurements of Insulin Sensitivity, Hepatic Insulin Clearance, and Altered Parameters of Lipid Metabolism, Changes in the Histological Features That Define NAFLD, and Quantitative Measurements of Visceral and Peripheral Fat.|Tests the Postulate That Metformin Will Improve Insulin Sensitivity in NAFLD. Also Test the Postulate That Improving IR (Insulin Resistance) With an Insulin Sensitizing Agent Will Improve Biochemical and Histological Features of NAFLD.|Determine if Metformin Improves the Altered Parameters of Lipid Metabolism as Compared to Placebo.|Measure the Differential Effects of IR and Lipid Metabolism on Peripheral Mononuclear Cell (PBMC) Inflammatory Response and the Associated Hepatocyte Mitochondrial Ultrastructure and Measures of Oxidative Stress",Manal Abdelmalek|Duke University,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 4,11,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Pro00006196|K23DK062116,Apr-09,Dec-12,Dec-12,15-Aug-08,26-Mar-15,7-Dec-16,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00736385
NCT00714129,"De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease",LINC,"Active, not recruiting",No Results Available,Non-alcoholic Fatty Liver Disease|Diabetes,Other: Dietary intervention (calorie restricted diet),"Stable isotopic and magnetic resonance measures to determine the changes in lipid and carbohydrate metabolism after dietary intervention|DEXA, insulin sensitivity and energy expenditure changes due to dietary intervention","University of California, San Francisco|Touro University|American Diabetes Association",All,18 Years to 60 Years   (Adult),Not Applicable,60,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science",R01DK078133-01|NIH R01DK078133-01A1|ADA 1-08-CR-56,Sep-07,Jun-20,Jun-20,14-Jul-08,null,20-Aug-18,"Touro University, Vallejo, California, United States",,https://ClinicalTrials.gov/show/NCT00714129
NCT00706537,Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH,,Completed,No Results Available,Non-Alcoholic Steatohepatitis(NASH),Drug: Active treatment|Drug: Placebo,"Urine 6-β-hydroxycortisol:cortisol ratio|Adverse event monitoring, physical examinations, sitting vital sign measurements (blood pressure and pulse rate), 12-lead ECGs, laboratory safety assessments.|PK for CP-945598 and its primary circulating metabolite|Breath ID® tests (methacetin and octanoate)|Soluble and exploratory biomarkers",Pfizer,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 1,9,Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",A5351053,Jul-08,Nov-08,Nov-08,27-Jun-08,null,13-Aug-09,"Pfizer Investigational Site, Anaheim, California, United States|Pfizer Investigational Site, Anaheim, California, United States|Pfizer Investigational Site, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT00706537
NCT00699036,Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH),,Unknown status,No Results Available,Nonalcoholic Steatohepatitis|Nonalcoholic Fatty Liver Disease,Drug: avandia|Drug: metformin|Drug: losartan,liver biopsy histologic improvement|serum transaminases,Brooke Army Medical Center,All,"18 Years and older   (Adult, Older Adult)",Phase 2,165,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C.2007.066,Apr-07,Jul-09,Aug-09,17-Jun-08,null,19-Jun-09,"Brooke Army Medical Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00699036
NCT00694746,Study of Fish Oil to Reduce ALT Levels in Adolescents,,Terminated,No Results Available,Non-alcoholic Fatty Liver Disease|Fatty Liver,Drug: Omega-3-acid ethyl esters|Drug: Placebo,"Efficacy parameters: Characterize the reduction in ALT levels.|Safety/compliance parameters: Describe the safety blood tests results, review of systems, and physical examination at baseline, mid point, and end of treatment, as well as identify adverse events and compliance parameters at study contacts.|Improvement in waist circumference, insulin and lipid indices, and other metabolic parameters.",Boston University|GlaxoSmithKline,All,13 Years to 17 Years   (Child),Phase 1,3,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",IIT40,Jun-08,Mar-14,Mar-14,10-Jun-08,null,29-Jan-16,"Boston University Medical Center, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00694746
NCT00681408,Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH),,Completed,No Results Available,Non-alcoholic Steatohepatitis|Fatty Liver,Drug: Omega 3 Fish Oil supplements|Drug: Placebo,"The Primary endpoint will be improvement in a composite score of histological injury as measured by the NASH Activity Score (NAS).|Measurement of anthropometric indices (weight, BMI, waist circumference)|Index of cardiorespiratory fitness determined by exercise tolerance (measured by lactate threshold on an exercise treadmill)|Hepatic fat content measured by magnetic resonance imaging|Changes in fasting plasma lipids, red cell fatty acid content, changes in anti-hyperlipidemia requirements, insulin sensitivity, and markers of inflammation including tumor necrosis factor and C-reactive protein",University of Virginia|National Center for Complementary and Integrative Health (NCCIH),All,"21 Years and older   (Adult, Older Adult)",Phase 2|Phase 3,41,Other|NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",12442|R21AT002901|IRB # 12442|GCRC: SHC003|Grant # 5R21AT2901-2,Mar-07,Aug-10,Aug-10,21-May-08,null,29-May-15,"University of Virginia School of Medicine, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00681408
NCT00681733,Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH),NASH,Unknown status,No Results Available,Metabolic Parameters and Liver Histology,Drug: Pioglitazone|Drug: Pentoxifylline,Improvement in metabolic profile and histology|Side effects,Govind Ballabh Pant Hospital,All,"18 Years to 65 Years   (Adult, Older Adult)",Not Applicable,20,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",drakchaudhary,Jan-07,Dec-08,Dec-08,21-May-08,null,21-May-08,"Dr. Barjesh Chander Sharma, New Delhi, India",,https://ClinicalTrials.gov/show/NCT00681733
NCT00680407,Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis,SyNCH,Completed,Has Results,Non-alcoholic Steatohepatitis,Other: Placebo|Drug: Silymarin 700 mg|Drug: Silymarin 420 mg,Efficacy - Improvement by at Least 2 Points in Histology (NAS)|Safety - Occurrence of a Dose-limiting Toxicity,Madaus Inc|University of Pennsylvania|University of North Carolina|Thomas Jefferson University|Beth Israel Deaconess Medical Center|Brooke Army Medical Center|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",Phase 2,78,Industry|Other|U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","U01AT003566-02|IND 105,461 (orig. IND 74,887)",Apr-08,Nov-12,Nov-12,20-May-08,29-Jan-16,29-Jan-16,"Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Brooke Army Medical Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00680407
NCT00678587,Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures,ELEVATE,Terminated,Has Results,Non-alcoholic Steatohepatitis|Chronic Liver Disease|HCV|NASH - Nonalcoholic Steatohepatitis|HIV Infection|Thrombocytopenia|Hepatitis C Virus|HBV|Human Immunodeficiency Virus|Liver Diseases|Hepatitis B Virus,Drug: Eltrombopag|Drug: Placebo,"Number of Participants With Chronic Liver Disease and Thrombocytopenia (Platelets <50 Gi/L) Who do Not Require a Platelet Transfusion Prior to, During, and up to 7 Days Following Elective Invasive Procedures|Number of Participants With a World Health Organization (WHO) Bleeding Score >=2 During and up to 7 Days Following Elective Invasive Procedures|Number of Participants With the Indicated Number of Platelet Transfusions Administered|Median Platelet Count at Screening; Days 1, 8, 15, 16-19; Procedure + 7, 14, 21, 30 Day Follow-up; Early Withdrawal; and Maximum Post-baseline|Number of Participants With the Indicated Platelet Count at Screening; Days 8 and 15; Procedure + 7, 14, 21, 30 Day Follow-up (FU); and Maximum Post-baseline|Number of Participants Experiencing an Adverse Event (AEs) and Serious Adverse Event (SAEs) Within the Indicated Category|Number of Participants With a Serious Adverse Event That Occurred in Greater Than One Participant|Number of Participants With the Indicated Event Relating to Vision|Number of Participants With Renal Function Abnormality|Number of Participants With a Clinically Significant Change in Electrocardiogram (ECG) Results|Pharmacokinetics (PK) of Eltrombopag, Steady State AUC(0-tau)|Pharmacokinetics (PK) of Eltrombopag, Cmax|Pharmacokinetics (PK) of Eltrombopag, t1/2|Pharmacokinetics (PK) of Eltrombopag, CL/F|Mean Number of Days Spent in the Hospital|Mean Number of Unscheduled Office Visits, Unscheduled Laboratory Tests, and Unscheduled Procedures",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 3,292,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TPL104054,Jun-08,Oct-09,Oct-09,15-May-08,8-Nov-10,12-Oct-18,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, New Orleans, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Burlington, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Valhalla, New York, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Hershey, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Charlottesville, Virginia, United States|GSK Investigational Site, Falls Church, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Capital Fefderal, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Derqui, Pilar, Buenos Aires, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Clermont Ferrand Cédex 1, France|GSK Investigational Site, Lyon Cedex 02, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Marseille, France|GSK Investigational Site, Montpellier, France|GSK Investigational Site, Nice, France|GSK Investigational Site, Paris Cedex 12, France|GSK Investigational Site, Paris Cedex 13, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Villejuif, France|GSK Investigational Site, Jaipur, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Avellino, Campania, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Bari, Puglia, Italy|GSK Investigational Site, San Giovanni Rotondo (FG), Puglia, Italy|GSK Investigational Site, Palermo, Sicilia, Italy|GSK Investigational Site, Padova, Veneto, Italy|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Chorzow, Poland|GSK Investigational Site, Lubin, Poland|GSK Investigational Site, Slupsk, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Saint-Petersburg, Russian Federation|GSK Investigational Site, Samara, Russian Federation|GSK Investigational Site, Smolensk, Russian Federation|GSK Investigational Site, Barakaldo, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Hospitalet de Llobregat, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Oviedo, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Valladolid, Spain|GSK Investigational Site, Douliou, Taiwan|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taoyuan, Taiwan",,https://ClinicalTrials.gov/show/NCT00678587
NCT00677521,A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD),,Terminated,No Results Available,Non-alcoholic Fatty Liver Disease,Drug: Acarbose,Improvement of hepatic steatosis as measured by proton magnetic resonance spectroscopy|Postprandial substrate metabolism reflected in the respiratory quotient (RQ) measured by indirect calorimetry,The Hospital for Sick Children,All,"10 Years to 18 Years   (Child, Adult)",Phase 2,1,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1000011557,Jan-07,Aug-08,Aug-08,14-May-08,null,19-Aug-13,"The Hospital for Sick Children, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00677521
NCT00668070,A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831,ASTER,Completed,No Results Available,Non-Alcoholic Steatohepatitis,Drug: ASP9831|Drug: Placebo,ALT,Astellas Pharma Inc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,114,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",9831-CL-0301|2007-002114-19,Apr-08,Oct-10,Oct-10,28-Apr-08,null,21-Mar-13,"Antwerp, Belgium|Brussels, Belgium|Gent, Belgium|La Louviere, Belgium|Leuven, Belgium|Brno-Bohunice, Czech Republic|Prague, Czech Republic|Praha, Czech Republic|Amiens Cedex 1, France|Angers cedex 9, France|Montpellier cedex 5, France|Paris Cedex 13, France|Paris, France|Pessac, France|Berlin, Germany|Essen, Germany|Frankfurt am Main, Germany|Mainz, Germany|Regensburg, Germany|Bucharest, Romania|Bucharest, Romania|Iasi, Romania|Timisoara, Romania|Basel, Switzerland|Bern, Switzerland|Zurich, Switzerland|Birmingham, United Kingdom|London, United Kingdom|Newcastle upon Tyne, United Kingdom|Nottingham, United Kingdom",,https://ClinicalTrials.gov/show/NCT00668070
NCT00666016,Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH),,Completed,No Results Available,Non-Alcoholic Steatohepatitis (NASH),Drug: TRO19622,"Mean change in ALT as assessed by an ANCOVA with the following covariates: treatment, gender, subject and time and a non parametric test (Conover-Salsburg).|Sustained reduction in ALT to either 50% of baseline or value < or equal to ULN. Sustained reduction serum AST and GGT.Clinical and laboratory safety.",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,35,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,WN29850|TRO19622 CL E Q 1159-1,Apr-08,Feb-09,Apr-09,24-Apr-08,null,22-Nov-16,"Hôpital Archet 2 - Pôle de Référence Hépatite C (Niveau -2) - 151, route Saint Antoine de Ginestière, Nice, France|Groupe Hospitalier Pitié-Salpétrière - Sce Hépato-Gastroentérologie - 47-83 Bd de l'Hôpital, Paris, France",,https://ClinicalTrials.gov/show/NCT00666016
NCT00658164,Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores,,Unknown status,No Results Available,Nonalcoholic Fatty Liver Disease,Other: Iron depletion treatment,"To determine in a 24 month controlled study whether iron depletion by phlebotomy improves insulin sensitivity, and thereby reduces hepatic steatosis and inflammation in subjects with nonalcoholic steatohepatitis|To assess the effect of iron depletion on glucose tolerance status. Glucose tolerance will be determined by OGTT in subjects without type 2 diabetes (T2D), and by HbA1c levels and the change in dosage of pharmacological therapy in those with T2D.","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 3,150,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,111.2007,Oct-07,Mar-09,null,14-Apr-08,null,14-Apr-08,"U.O. Medicina Interna 1/B, Milan, Italy",,https://ClinicalTrials.gov/show/NCT00658164
NCT00655018,Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD),VITENAFLD,Completed,No Results Available,Inflammation|Fibrosis|Insulin Resistance,Dietary Supplement: Vitamin treatment (alpha tocopherol plus ascorbic acid)|Dietary Supplement: Placebo,serum levels of aminotransferases|Liver histology (inflammation and fibrosis),Bambino Gesù Hospital and Research Institute,All,"3 Years to 20 Years   (Child, Adult)",Phase 2|Phase 3,90,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",VITENAFLD,Jan-03,Oct-06,Oct-06,9-Apr-08,null,9-Apr-08,"Dept. Of HepatoGastoEnterology and Nutrition, Liver Unit, Rome, Italy",,https://ClinicalTrials.gov/show/NCT00655018
NCT00650546,Role of Exenatide in NASH-a Pilot Study,NAFLD,Completed,Has Results,Nonalcoholic Fatty Liver Disease,Drug: Exenatide,Number of Patients With Improvement in Liver Histology After Treatment With Exenatide|Change in NAS,Indiana University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 99 Years   (Adult, Older Adult)",Phase 2|Phase 3,8,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,DK61737|U01DK061737,Aug-06,Aug-10,Aug-10,1-Apr-08,12-May-16,11-Apr-17,"Indiana University, Indianapolis, Indiana, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Fort Sam Houston, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00650546
NCT00641524,Evaluation of Phlebotomy as a Treatment for Non-alcoholic Fatty Liver Disease,,Completed,No Results Available,Non-alcoholic Fatty Liver Disease,Procedure: Phlebotomy,Severity of liver disease|Severity of metabolic disease,"University of Western Ontario, Canada",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,45,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,beatonclf,Jan-09,Dec-11,Dec-11,24-Mar-08,null,13-May-16,"London Health Sciences Centre, London, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00641524
NCT00633282,Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease,,Completed,No Results Available,Nonalcoholic Fatty Liver Disease,Behavioral: Life style intervention|Drug: pioglitazone|Drug: berberine,"Improved metabolic parameters(glucose, lipid, liver enzymes, etc.)|liver fat content|serum insulin|the ratio of withdrawing because of inefficiency",Xin Gao|Shanghai Jiao Tong University School of Medicine|Shanghai Municipal Science and Technology Commission|Fudan University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,184,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07JC14011,Mar-08,Aug-11,Aug-11,12-Mar-08,null,5-Jun-12,"Endocrinology and Metabolism Department, Zhongshan Hospital, Fudan University,, Shanghai, Shanghai, China|Department of Endocrinology and Metabolism,Shanghai Clinical Center of Diabetes,Shanghai Institute of Diabetes,The sixth people's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, China|Department of Endocrinology and Metabolism,The Fifth People's Hospital，Fudan University, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT00633282
NCT00596934,Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH),,Completed,Has Results,"Fatty Liver Disease, Nonalcoholic",Drug: metreleptin,Non-alcoholic Steatohepatitis Score as Determined by Liver Histopathology at 12 Months|Body Weight at 12 Months|Liver Fat Percentage by Magnetic Resonance Imaging (MRI - Dixon Method) at 12 Months|Liver Function Test: Alanine Aminotransferase (ALT) Values at 12 Months|Liver Function Test: Aspartate Aminotransferase (AST) Values at 12 Months|Fasting Glucose Value at 12 Months|Fasting Triglycerides Value at 12 Months|Insulin Resistance: Homeostatic Model Assessment (HOMA) at 12 Months,Elif Oral|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Michigan,Male,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,9,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R03DK074488|Protocol 2145 (MCRU)|Amylin Protocol 20050119|DRDA 643938K3,Feb-06,Mar-09,Mar-09,17-Jan-08,9-Dec-16,24-Nov-17,"University of Michigan, Ann Arbor, Michigan, United States",,https://ClinicalTrials.gov/show/NCT00596934
NCT00590161,Pentoxifylline in Patients With Nonalcoholic Steatohepatitis,,Completed,Has Results,Nonalcoholic Steatohepatitis,Drug: pentoxifylline (PTX)|Drug: placebo,Histological Improvement of at Least 2 Points in NAFLD Activity Score (NAS) on Liver Biopsy After One Year.,Case Western Reserve University|American College of Gastroenterology,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,55,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",R-1196 CWRU CRU,Dec-06,Jul-10,Dec-10,10-Jan-08,26-Sep-13,26-Sep-13,"Louis Stokes VA Medical Center, Cleveland, Ohio, United States|Metrohealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00590161
NCT00586885,Effects of Alanine in Patients With Nonalcoholic Steatohepatitis,,Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: L-alanine,"To assess the safety and tolerability of long-term L-alanine supplementation and the therapeutic efficacy of long-term L-alanine supplementation by evaluating liver biochemistry and histological findings.|Determine the effect of L-alanine on gene profiles, anti-oxidant response and inflammatory response in hepatocytes. Evaluate possible correlation between therapeutic efficacy and gene profiles altered by L-alanine supplementation","Keith D Lindor, M.D.|Ajinomoto USA, INC.|Mayo Clinic",All,"18 Years to 75 Years   (Adult, Older Adult)",Not Applicable,9,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,1753-03,Feb-04,Jun-06,Jun-06,7-Jan-08,null,11-Oct-12,"Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00586885
NCT00586911,Betaine in Patients With Nonalcoholic Steatohepatitis,,Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: Cystadane|Drug: Identical Placebo,"changes in degree of steatosis, necroinflammatory activity and fibrosis in liver biopsy.|Secondary end-points will be changes in liver test results and health related quality of life.",Mayo Clinic|University of Florida|Orphan Medical,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,26,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",458-00,Jan-03,Jun-06,Jun-06,7-Jan-08,null,8-Apr-15,"University of Florida at Gainesville, Gainesville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00586911
NCT00586313,Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.),NAFLD,Completed,Has Results,Non-alcoholic Fatty Liver Disease|Nonalcoholic Steatohepatitis,Device: Tru-cut biopsy|Procedure: Tru-cut,Median Total Specimen Length|The Number of Procedural Complications,Indiana University,All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,21,Other,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,0608-17,Jan-07,Jul-08,Jul-08,4-Jan-08,30-Nov-15,17-Oct-16,"University Hospital, Indianapolis, Indiana, United States",,https://ClinicalTrials.gov/show/NCT00586313
NCT00576667,An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes,,Terminated,No Results Available,Fatty Liver,Drug: Rimonabant|Drug: Placebo (for Rimonabant),Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS)|Change from baseline in hepatic fibrosis score|Change from baseline in serum hyaluronate (HA)|Change from baseline in hepatic transaminases (AST/ALT),Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,165,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC10143|2007-003013-14,Jan-08,Feb-09,Feb-09,19-Dec-07,null,18-May-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Cove, New South Wales, Australia|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Shangai, China|Sanofi-Aventis Administrative Office, Santafe de Bogota, Colombia|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Makati City, Philippines|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Geneva, Switzerland|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00576667
NCT00577148,An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes,,Terminated,No Results Available,Fatty Liver,Drug: Rimonabant|Drug: Placebo (for Rimonabant),Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS)|Change from baseline in hepatic fibrosis score|Change from baseline in serum hyaluronate and hepatic transaminases (AST/ALT),Sanofi,All,"18 Years and older   (Adult, Older Adult)",Phase 3,89,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EFC10144|2007-003013-14,Feb-08,Feb-09,Feb-09,19-Dec-07,null,18-May-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Cove, New South Wales, Australia|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Shangai, China|Sanofi-Aventis Administrative Office, Santafe de Bogota, Colombia|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Makati City, Philippines|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Geneva, Switzerland|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom",,https://ClinicalTrials.gov/show/NCT00577148
NCT00546455,"A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity",,Unknown status,No Results Available,Obesity|Insulin Resistance,Drug: Fenretinide|Drug: Placebo,"Assessment of the effect on insulin resistance|Assessment of the biochemical response in cholesterol, glucose and related blood tests.","University of California, San Diego",All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,120,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",61257,Dec-07,Feb-15,Apr-15,19-Oct-07,null,12-Feb-13,"University of California at San Diego Hospitals, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00546455
NCT00529204,"Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease",,Terminated,Has Results,Diabetes Complications|Fatty Liver,Drug: exenatide,"Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy|Changes in Components of Liver Histology at Baseline and Week 24 Including Steatosis, Inflammation and Fibrosis|Safety of Exenatide in Patients With NAFLD and Type 2 Diabetes","University of California, Davis|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company",All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,1,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,200715325|H80-MC-X006,Oct-07,Jul-09,Feb-10,14-Sep-07,22-Dec-14,20-Jun-17,"University of California Davis Medical Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT00529204
NCT00523562,"Effects of Macronutrients on Hepatic Lipids, Plasma Triglycerides, and Insulin Sensitivity",MACRONUTR,Completed,No Results Available,Metabolic Syndrome X|Liver Diseases,Other: diet intervention,plasma triglycerides|intra-hepatic lipids|insulin mediated glucose disposal|lipid oxidation|plasma beta-hydroxybutyrate|gene expression in skeletal muscle and adipose tissue,University of Lausanne,All,18 Years to 40 Years   (Adult),Not Applicable,41,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,protocol 140/04/CE/FBM,Jul-06,Apr-08,Jan-09,31-Aug-07,null,14-Jun-18,"Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland",,https://ClinicalTrials.gov/show/NCT00523562
NCT00509418,Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis,,Completed,No Results Available,Nonalcoholic Steatohepatitis,Dietary Supplement: Viusid|Other: Hypocaloric Diet with controlled exercise,"The histological improvement (steatosis, necro-inflammatory activity and fibrosis) at 24 weeks (end of the treatment).|Alanine aminotransferase levels (end of the treatment), δ-glutamyltransferase levels (end of the treatment), Body weight, Body Mass Index, Waist circumference (end of the treatment) Insulin resistance (HOMA) (end of the treatment)",Catalysis SL,All,18 Years to 60 Years   (Adult),Phase 3,60,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VIUNASH-07,Feb-07,Sep-07,Sep-07,31-Jul-07,null,12-Jan-09,"National Institute of Gastroenterology, Vedado, Havana, Cuba",,https://ClinicalTrials.gov/show/NCT00509418
NCT00501592,Study of INT-747 in Patients With Diabetes and Presumed NAFLD,,Completed,Has Results,"Diabetes Mellitus, Type II|Fatty Liver",Drug: INT-747|Drug: Placebo,Insulin Resistance and Glucose Homeostasis|Hepatocellular Function,Intercept Pharmaceuticals,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,64,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",747-203,Jul-07,Feb-09,Apr-09,16-Jul-07,27-Jan-12,20-Apr-12,"Profil Institute for Clinical Research, Inc., Chula Vista, California, United States|UC San Diego VAMC, San Diego, California, United States|Diabetes & Glandular Disease Research Associates, Inc., San Antonio, Texas, United States|Virginia Commonwelath University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00501592
NCT00492700,"A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis",FLIRT,Completed,No Results Available,Non Alcoholic Steatohepatitis,Drug: rosiglitazone,improvement in steatosis|improvement in transaminase levels; improvement/less worsening in necrosis and inflammatory activity and /or fibrosis,Association pour la Recherche sur les Maladies Hépatiques Virales,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,63,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,LIDO-Trials-01,Jan-03,null,null,27-Jun-07,null,27-Jun-07,"Service d'hépatogastroenérologie, Hôpital Pitié Salpêtrière, Paris, France",,https://ClinicalTrials.gov/show/NCT00492700
NCT00480922,Effects of a Low Glycemic Load Diet on Fatty Liver in Children,DELIVER,Completed,No Results Available,Hepatic Steatosis,Behavioral: Low glycemic load diet|Behavioral: Low fat diet,percent liver fat as determined by nMR spectroscopy|hepatic steatosis as measured by T1 weighted MRI images|visceral fat|liver function tests|measures of oxidative stress|measures of chronic inflammation|insulin resistance|serum lipids|blood pressure|insulin secretion|measures of glucose tolerance|adiponectin,Boston Children’s Hospital,All,8 Years to 17 Years   (Child),Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,07-03-0092 (completed),May-07,Dec-09,Dec-09,31-May-07,null,26-Aug-11,"Children's Hospital, Boston, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT00480922
NCT00470171,Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis,URSONASH,Completed,No Results Available,Serum Levels of ALAT Transaminases|Serum Markers for Fibrosis and Hepatic Inflammation,Drug: Ursodesoxycholic acid,A positive response is defined as a significantly larger decrease in average ALAT levels between the time of inclusion in the study and the end of the treatment for the ursodesoxycholic acid group as compared to the placebo group.,Axcan Pharma,All,"18 Years and older   (Adult, Older Adult)",Phase 2,98,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,URSONASH05-01|EudraCT n° : 2005-001931-31,Oct-05,Nov-08,Nov-08,7-May-07,null,3-Feb-09,"La Pitié Salpétrière Hospital, Paris, France",,https://ClinicalTrials.gov/show/NCT00470171
NCT00443079,A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH),,Completed,No Results Available,Fatty Liver,Drug: IdB 1016 (Siliphos),"Safety, as determined by laboratory and clinical assessment, during and after treatment|Tolerability, as determined by clinical assessment of side effects, during and after treatment|Efficacy, determined by serial measurement of serum aminotransferase levels before, during, and after treatment","University of California, San Diego|American College of Gastroenterology",All,"18 Years and older   (Adult, Older Adult)",Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,51117,Mar-07,Dec-09,Dec-09,5-Mar-07,null,25-Jun-10,"University of California, San Diego Medical Center, San Diego, California, United States",,https://ClinicalTrials.gov/show/NCT00443079
NCT00389376,Phase I Trial of Silymarin for Chronic Liver Diseases,SyNCH,Completed,No Results Available,Hepatitis C|Non-Alcoholic Fatty Liver Disease,Drug: Placebo|Drug: Silymarin,Adverse events,National Center for Complementary and Integrative Health (NCCIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Phase 1,56,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",U01AT003566-01|NIH grant # U01-AT0035661,Nov-06,Jan-08,Feb-08,18-Oct-06,null,20-Feb-08,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Graduate School of Public Health, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00389376
NCT00375349,Non Alcoholic Fatty Liver Disease Influence of Statin Therapy,,Withdrawn,No Results Available,Non-alcoholic Fatty Liver Disease (NAFLD),Procedure: Ultrasound to demonstrate existence of fatty liver,,Shaare Zedek Medical Center,All,"18 Years to 85 Years   (Adult, Older Adult)",Not Applicable,0,Other,Interventional,,20173CTIL,Sep-06,null,Sep-09,12-Sep-06,null,30-Sep-16,,,https://ClinicalTrials.gov/show/NCT00375349
NCT00323414,Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver,,Completed,Has Results,Fatty Liver,Drug: Polyunsaturated fatty acid (Opti-EPA)|Drug: Placebo,Number of Participants With Improvement of >= 2 Points in NAFLD Activity Score (NAS)|Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Values|Aspartate Amino Transferase (AST) Levels|Alanine Amino Transferase (ALT) Levels|Blood Glucose Levels|HbA1C Levels,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Phase 2,37,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DK61732|U01DK061732,Apr-06,Dec-11,Dec-11,9-May-06,23-Feb-18,23-Feb-18,"MetroHealth Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT00323414
NCT00303537,Metformin in Non-Alcoholic Fatty Liver Disease,,Unknown status,No Results Available,Fatty Liver,Drug: metformin,Grade of steatosis as judged by repeat biopsy|Grade of necroinflammation as judged by repeat biopsy|Liver density obtained by computer scan|Serum alanine transaminase (ALAT),"University Hospital, Aker|Merck Sharp & Dohme Corp.",All,"20 Years to 70 Years   (Adult, Older Adult)",Phase 2|Phase 3,90,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,AkerU3,Nov-04,null,Jun-08,17-Mar-06,null,2-Jul-07,"Haukeland Universitetssykehus, Bergen, Norway|Aker University Hospital, Oslo, Norway|Akershus University Hospital, Oslo, Norway|Universitetssykehuset i Nord-Norge, Tromsø, Norway",,https://ClinicalTrials.gov/show/NCT00303537
NCT00267670,Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH,,Completed,Has Results,Nonalcoholic Steatohepatitis|Liver Diseases,Drug: Pentoxifylline|Drug: Placebo,The Number of Participants With a 30% Reduction in Alanine Aminotransferase (ALT) Treated With Pentoxifylline (PTX) or Placebo for 12 Months.|The Effect of Pentoxifylline on Change in Tumor Necrosis Factor [TNF]-α Levels in Patients With NASH|Change in Serum Leptin Levels in Patients Treated With Pentoxifylline or Placebo for 12 Months|Change in Serum Adiponectin Levels in Patients Treated With Pentoxifylline or Placebo for 12 Months,Northwestern University,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2|Phase 3,26,Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB # 1347-001|GCRC Protocol #891,Mar-05,Sep-09,Sep-09,21-Dec-05,9-Sep-14,9-Sep-14,"Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00267670
NCT00266019,Weight Management in Nonalcoholic Steatohepatitis,,Completed,No Results Available,Fatty Liver,"Behavioral: Weight Management (diet, exercise, and behavior modification)",Liver histology score (NASH-Clinical Research Network [CRN] scoring system) at 48 weeks|Weight reduction at 48 weeks|Insulin sensitivity at 48 weeks|Liver function test at 48 weeks|Inflammatory markers and adipokine levels at 48 weeks|Quality of life at 48 weeks,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DK67363 (completed),Jan-05,null,Dec-07,15-Dec-05,null,13-Jan-10,"Rhode Island Hospital, Providence, Rhode Island, United States",,https://ClinicalTrials.gov/show/NCT00266019
NCT00262964,Obesity and Nonalcoholic Fatty Liver Disease,,Completed,Has Results,Non-alcoholic Fatty Liver Disease,Drug: Niacin|Drug: fenofibrate|Drug: placebo,Hepatic Insulin Sensitivity Index (HISI)|Percent Increase in Skeletal Muscle Insulin Sensitivity During Insulin Infusion.|Adipose Tissue Insulin Sensitivity|Hepatic Fat Content for Fenofibrate and Niacin Groups|Adipose Tissue Insulin Sensitivity in Fenofibrate and Niacin Groups|Change From Baseline in Skeletal Muscle Insulin Sensitivity|Change From Baseline in Hepatic Insulin Sensitivity Index|Very Low Density Lipoprotein - Triglyceride Production Rate|Change From Baseline in Very Low Density Lipoprotein Apolipoprotein B Production Rate|Change From Baseline in VLDL-Tg Clearance Rate|Change From Baseline in VLDL-Tg Production Rate|Change From Baseline in Very Low-density Lipoprotein Triglyceride Concentration,Washington University School of Medicine|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,18 Years to 45 Years   (Adult),Not Applicable,51,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,DK37948|R01DK037948,Oct-04,Dec-08,Dec-08,7-Dec-05,28-Jun-10,11-Jul-18,"Washington University School of Medicine, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT00262964
NCT00252499,Insulin Resistance in Non-alcoholic Fatty Liver Disease,,Terminated,Has Results,Fatty Liver|Insulin Resistance,Drug: rosiglitazone|Drug: fenofibrate|Drug: placebo for rosiglitazone|Drug: placebo for fenofibrate,Liver/Spleen Ratio at 6 Months|Change in Alanine Aminotransferase (ALT) Levels From Baseline to 6 Months|Change in the Liver Spleen Ratio by CT Scan From Baseline to 6 Months as a Measure of Fat in the Liver|Change in Peripheral Insulin Sensitivity From Baseline to 6 Months|Changes in Intra-abdominal Fat Area From Baseline to 6 Months|Change in Hepatic Insulin Sensitivity From Baseline to 6 Months,US Department of Veterans Affairs|VA Office of Research and Development,All,"18 Years to 80 Years   (Adult, Older Adult)",Not Applicable,13,U.S. Fed,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science",CDA-2-044-08S,Oct-05,Aug-10,Aug-10,11-Nov-05,11-Apr-14,20-Aug-14,"VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00252499
NCT00247117,Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD),,Unknown status,No Results Available,Liver Diseases,Drug: Metformin,histological and biochemical changes,Kaplan Medical Center,All,18 Years to 60 Years   (Adult),Not Applicable,15,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,037-2003,Jan-04,null,Aug-05,1-Nov-05,null,9-Oct-06,"Institute of Endocrinology, Kaplan Medical Center, Rehovot, Israel",,https://ClinicalTrials.gov/show/NCT00247117
NCT00244569,Development of a Breath Test for Monitoring Patients With Liver Disease,,Completed,No Results Available,Fatty Liver|Cirrhosis,Drug: 13C-Methacetin|Device: Breath ID Machine,The mean and standards of results obtained from the Breath ID system for each of the 3 groups of patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) will be compared by chi squared analysis.|A p value of 0.05 or less will be considered significant.|Receiver-operator curves will be developed to compare the results of the Breath ID to each histologic group of patients studied. A p value of 0.05 will be considered significant.,Virginia Commonwealth University|Oridion,All,"18 Years and older   (Adult, Older Adult)",Phase 3,120,Other|Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,OBID-2005-VCU,Sep-05,Apr-07,Apr-07,26-Oct-05,null,20-Mar-17,"Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00244569
NCT00230087,Iron Depletion Therapy for Type 2 DM and NAFLD,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease|Diabetes Mellitus,Procedure: blood donation,"Improved insulin sensitivity as determined by:(1) hyperinsulinemic euglycemic clamp method|(2) HOMA model- determined by the OGTT method|Change in serum aminotransferase levels Change in levels of serum, plasma and urinary markers of oxidative stress|Changes in intrahepatic and intraabdominal fat content as determined by CT scan|Change in serum levels of proinflammatory cytokines (ie IL-6, TnF-αR2)",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,15,NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DK 61728-S1 (completed),Sep-05,Jun-10,Jun-10,30-Sep-05,null,7-Nov-12,"University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00230087
NCT00230113,Effect of Omega-3 PUFA Supplementation in NAFLD Patients,,Completed,No Results Available,Non-Alcoholic Fatty Liver Disease,Dietary Supplement: Omega-3 fatty acid diet supplementation|Dietary Supplement: safflower oil,Reduction of intrahepatic fat content as determined by magnetic resonance spectroscopy|Change in serum aminotransferase levels Change in lipid profile Change in levels of proinflammatory cytokines|Change in insulin resistance determined by HOMA,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)",DK61728-S2,Sep-05,Jun-10,Jun-10,30-Sep-05,null,10-Jul-13,"University of Washington Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00230113
NCT00229255,Relation of Obesity With Frequency of Meals (MST 0557),,Completed,No Results Available,Obesity|Insulin Resistance|Fatty Liver,Other: high frequency of meals|Other: twice a day meals,"We will determine total body insulin sensitivity with the help of the hyperinsulinemic-euglycemic clamp. We will also assess hepatic steatosis by conducting MRI scans on our subjects.|Weight, waist and hip circumference, fasting glucose and insulin, serum ketones, lipids and lipoproteins including VLDL and apolipoprotien B100, liver function tests, serum adiponectin (marker for insulin resistance), and measures of hunger.",Rockefeller University|Cornell University,All,18 Years to 45 Years   (Adult),Not Applicable,22,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,MST-0557,Mar-05,Jun-09,Jun-09,29-Sep-05,null,1-Jun-12,"Rockefeller University Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT00229255
NCT00227110,Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH),,Completed,No Results Available,Nonalcoholic Steatohepatitis,Drug: Pioglitazone|Drug: Placebo,"Liver histology (Kleiner criteria, Hepatology 2005)|Liver fat content by MRS.|Double-tracer OGTT (EGP, glucose clearance).","The University of Texas Health Science Center at San Antonio|National Institutes of Health (NIH)|Takeda Pharmaceuticals North America, Inc.",All,"21 Years to 70 Years   (Adult, Older Adult)",Phase 4,55,Other|NIH|Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UTHSCSA IRB# 001-5014-331,Oct-02,Nov-05,Jan-06,27-Sep-05,null,14-Oct-09,"Audie L Murphy VA Hospital, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00227110
NCT00160407,Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH),,Completed,No Results Available,Fatty Liver|Hepatitis,Drug: Orlistat (Xenical)|Behavioral: 1400 kcal diet (30% fat),"The primary endpoint is weight loss leading to improvement in the global necroinflammatory and fibrosis scores on liver biopsies. A change of one point in the necroinflammatory grade or fibrosis stage will be considered statistically significant.|BMI,ALT,Serum free fatty acids,HOMA-IR (fasting insulin x fasting glucose/22.4)",St. Louis University|Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 4,50,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,12458|XEN185,Oct-03,null,Dec-06,12-Sep-05,null,20-Nov-07,"Saint Louis University, St. Louis, Missouri, United States|Brooke Army Medical Center, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00160407
NCT00152711,Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis,,Unknown status,No Results Available,Sleep Apnea Syndrome|Nonalcoholic Steatohepatitis,Device: nCPAP,,"University Hospital, Angers",All,"18 Years to 70 Years   (Adult, Older Adult)",Not Applicable,40,Other,Interventional,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PHRC 03-07,Sep-04,null,null,9-Sep-05,null,13-Feb-07,"University Hospital Angers, Angers, France",,https://ClinicalTrials.gov/show/NCT00152711
NCT00152815,Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions,,Terminated,No Results Available,HIV Infections|Fatty Liver,Drug: antioxidant vitamin E|Behavioral: weight reduction and exercise,"The change in grading of inflammation assessed by liver biopsy from month 0 to month 12 of the study|Liver histology for steatosis and fibrosis staging|Liver immuno-histochemistry for adducts of MDA: a product of LP|Alpha-smooth muscle actin (alpha-SMA): a marker of hepatic stellate cell activation|Transforming growth factor (TGF-beta): a pro-fibrogenic cytokine involved in fibrogenesis|Liver lipid peroxides and TNP-alpha|Liver steatosis and volume will be assessed by ultrasound|Liver enzymes and IR (HOMA and QUICKY) will also be measured|Lipid peroxides, TNF-alpha, vitamin E and C in plasma","Johane Allard|Ontario HIV Treatment Network|University Health Network, Toronto",All,"18 Years and older   (Adult, Older Adult)",Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,03-0297-B|ROGB139,Oct-03,Dec-10,Dec-10,9-Sep-05,null,19-Jul-13,"University Health Network, Toronto General Hospital, Toronto, Ontario, Canada",,https://ClinicalTrials.gov/show/NCT00152815
NCT00134303,Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity,,Unknown status,No Results Available,Obesity,Drug: Metformin,"Number of patients with histological amelioration of NASH after a period of 1 year|Number of patients with normalisation of ALT, steatosis on ultrasound after a period of 1 year","University Hospital, Ghent|Merck Sharp & Dohme Corp.",All,"Child, Adult, Older Adult",Phase 4,200,Other|Industry,Interventional,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",2005/045,Jun-05,Jul-15,Jul-15,24-Aug-05,null,5-Dec-14,"University Hospital Ghent, Ghent, Belgium",,https://ClinicalTrials.gov/show/NCT00134303
NCT00108589,S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis,,Completed,No Results Available,Hepatitis,Drug: S-adenosylmethionine,,US Department of Veterans Affairs|VA Office of Research and Development,Male,"18 Years and older   (Adult, Older Adult)",Phase 3,null,U.S. Fed,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,CLIN-014-03S,Jan-04,null,Dec-06,18-Apr-05,null,21-Jan-09,"VA Medical Center, Louisville, Kentucky, United States",,https://ClinicalTrials.gov/show/NCT00108589
NCT00099723,The Effect of a Probiotic on Hepatic Steatosis,,Terminated,No Results Available,Fatty Liver,Drug: VSL#3,MRI|Liver biopsy|Blood work,VSL Pharmaceuticals,All,"45 Years to 70 Years   (Adult, Older Adult)",Phase 1,30,Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,SS01305-01|R21AT001305-01,Oct-04,null,Dec-05,20-Dec-04,null,11-Feb-10,"Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00099723
NCT00068094,The Effect of Good Bacteria on Nonalcoholic Fatty Liver Disease in Diabetics,,Terminated,No Results Available,Fatty Liver|Hepatic Steatosis|Diabetes Mellitus|Liver Diseases,Drug: Probiotic-containing powder,,National Center for Complementary and Integrative Health (NCCIH),All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 1|Phase 2,30,NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,R21AT001305,Jul-05,null,Feb-06,9-Sep-03,null,18-Aug-06,"Johns Hopkins University, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00068094
NCT00063622,Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS),PIVENS,Completed,Has Results,Liver Diseases,Drug: Pioglitazone|Dietary Supplement: Vitamin E|Drug: Matching placebo,Number of Participants With Improvement in Non-alcoholic Fatty Liver Disease (NAFLD) Activity Defined by Change in Standardized Scoring of Liver Biopsies at Baseline and After 96 Weeks of Treatment.|Number of Participants With Improvement in Steatosis|Number of Participants With Improvement in Lobular Inflammation|Number of Participants With Improvement in Hepatocellular Ballooning|Number of Participants With Improvement in Fibrosis|Number of Participants With Resolution of Definite Nonalcoholic Steatohepatitis,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,"18 Years and older   (Adult, Older Adult)",Phase 3,247,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NASH - ADULT (IND)|U01DK061730,Jan-05,Jun-09,Sep-09,3-Jul-03,1-Aug-12,6-Apr-18,"University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Indiana University, Indianapolis, Indiana, United States|St. Louis University, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00063622
NCT00063635,Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC),TONIC,Completed,Has Results,Fatty Liver,Drug: Metformin|Dietary Supplement: Vitamin E|Drug: Matching placebo,Number of Participants With Sustained Reduction in Alanine Aminotransferase (ALT) to Either 50% of Baseline Value or < 40 IU/L|Change in Serum Aspartate Aminotransferase (AST)|Change in Nonalcoholic Fatty Liver Disease (NAFLD) Score (Histologic Feature Scores Determined by Standardized Scoring of Liver Biopsies) From Baseline at 96 Weeks of Treatment|Number of Participants With Improvement in Liver Fibrosis Score|Number of Participants With Improvement in Steatosis Score|Number of Participants With Improvement in Lobular Inflammation Score|Number of Participants With Improvement in Ballooning Degradation Score|Change in Body Mass Index|Change in Serum Vitamin E Levels|Change in Quality of Life (QOL) Scores- Physical Health|Change in QOL- Psychosocial Health,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),All,8 Years to 17 Years   (Child),Phase 3,173,NIH,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",NASH - PEDIATRICS (IND),Sep-05,Sep-09,Feb-10,3-Jul-03,27-Sep-12,27-Sep-12,"University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Indiana University, Indianapolis, Indiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|St. Louis University, St. Louis, Missouri, United States|Case Western Reserve University, Cleveland, Ohio, United States|Texas Children's Hospital, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT00063635
NCT00063232,Treating Nonalcoholic Steatohepatitis (NASH) With Metformin,,Completed,Has Results,Hepatitis,Drug: Metformin,"Change in the Histological NASH Activity Index at 48 Weeks Compared With Baseline (Number of Participants in Each Change Category)|Change in Serum Alanine Aminotransferase (ALT) Levels From Baseline (Number of Participants in Each Change Category)|Change in Insulin Sensitivity (Glucose Tolerance, Homeostatic Model Assessment of Insulin Resistence (HOMA-IR)) From Baseline",National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 2,28,NIH,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,030233|03-DK-0233,Jun-03,Mar-08,Mar-08,24-Jun-03,20-Jul-11,20-Jul-11,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00063232
NCT00062764,Treating Nonalcoholic Steatohepatitis With Pioglitazone,,Completed,Has Results,Hepatitis,Drug: Actos (Pioglitazone),Number of Patients With Improvement in Liver Histology|Number of Patients With Impaired Glucose Tolerance After Treatment|Mean Increase of Insulin Sensitivity Index|Average Increase in Weight After Treatment|Mean BMI Change,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"18 Years and older   (Adult, Older Adult)",Phase 2,18,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,030212|03-DK-0212,Jun-03,Feb-09,Feb-09,13-Jun-03,5-Apr-11,19-Dec-12,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00062764
NCT00013598,Treatment of Nonalcoholic Steatohepatitis With Pioglitazone,,Completed,No Results Available,Fatty Liver|Nonalcoholic Steatohepatitis,Drug: Pioglitazone,,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC),All,"Child, Adult, Older Adult",Phase 2,30,NIH,Interventional,Primary Purpose: Treatment,010130|01-DK-0130,Mar-01,null,Mar-04,26-Mar-01,null,4-Mar-08,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT00013598
